
<html lang="en"     class="pb-page"  data-request-id="e1540d45-d120-4ca9-9d9c-0cc276174a51"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-13;article:article:10.1021/acs.jmedchem.1c00099;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities" /></meta><meta name="dc.Creator" content="Christopher L.  Cioffi" /></meta><meta name="dc.Creator" content="Arun  Raja" /></meta><meta name="dc.Creator" content="Parthasarathy  Muthuraman" /></meta><meta name="dc.Creator" content="Aravindan  Jayaraman" /></meta><meta name="dc.Creator" content="Srinivasan  Jayakumar" /></meta><meta name="dc.Creator" content="Andras  Varadi" /></meta><meta name="dc.Creator" content="Boglarka  Racz" /></meta><meta name="dc.Creator" content="Konstantin  Petrukhin" /></meta><meta name="dc.Description" content="Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive dise..." /></meta><meta name="Description" content="Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive dise..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 17, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00099" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00099" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00099" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00099" /></link>
        
    
    

<title>Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00099" /></meta><meta property="og:title" content="Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0026.jpeg" /></meta><meta property="og:description" content="Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive disease resulting from the deposition of toxic fibrils in tissues that predominantly presents clinically as amyloid cardiomyopathy and peripheral polyneuropathy. Ligands that bind to and kinetically stabilize TTR tetramers prohibit their dissociation and may prevent ATTR onset. Drawing from clinically investigated AG10, we designed a constrained congener (14) that exhibits excellent TTR tetramer binding potency, prevents TTR aggregation in a gel-based assay, and possesses desirable pharmacokinetics in mice. Additionally, 14 significantly lowers murine serum retinol binding protein 4 (RBP4) levels despite a lack of binding at that protein’s all-trans-retinol site. We hypothesize that kinetic stabilization of TTR tetramers via 14 is allosterically hindering all-trans-retinol-dependent RBP4–TTR tertiary complex formation and that the compound could present ancillary therapeutic utility for indications treated with RBP4 antagonists, such as macular degeneration." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00099"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00099">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00099&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00099&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00099&amp;href=/doi/10.1021/acs.jmedchem.1c00099" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 9010-9041</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00093" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00158" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Christopher L. Cioffi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher L. Cioffi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#711219031802051e011914035f12181e1717183110120119025f141504"><span class="__cf_email__" data-cfemail="72111a001b01061d021a17005c111b1d14141b321311021a015c171607">[email protected]</span></a>. Phone: 518-694-7224.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+L.++Cioffi">Christopher L. Cioffi</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-0642-7905" title="Orcid link">https://orcid.org/0000-0003-0642-7905</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arun Raja</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arun Raja</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arun++Raja">Arun Raja</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Parthasarathy Muthuraman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Parthasarathy Muthuraman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Parthasarathy++Muthuraman">Parthasarathy Muthuraman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aravindan Jayaraman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aravindan Jayaraman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aravindan++Jayaraman">Aravindan Jayaraman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Srinivasan Jayakumar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Srinivasan Jayakumar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Srinivasan++Jayakumar">Srinivasan Jayakumar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andras Varadi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andras Varadi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andras++Varadi">Andras Varadi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Boglarka Racz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Boglarka Racz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Boglarka++Racz">Boglarka Racz</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Konstantin Petrukhin</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Konstantin Petrukhin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Ophthalmology, Columbia University Medical Center, New York, New York 10032, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3f545a4f0b7f5c4a525c115c50534a525d565e115a5b4a"><span class="__cf_email__" data-cfemail="563d3326621635233b357835393a233b343f3778333223">[email protected]</span></a>. Phone: 212-305-9040.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Konstantin++Petrukhin">Konstantin Petrukhin</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00099&amp;href=/doi/10.1021%2Facs.jmedchem.1c00099" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 9010–9041</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 17, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 January 2021</li><li><span class="item_label"><b>Published</b> online</span>17 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00099" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00099</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9010%26pageCount%3D32%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChristopher%2BL.%2BCioffi%252C%2BArun%2BRaja%252C%2BParthasarathy%2BMuthuraman%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D13%26contentID%3Dacs.jmedchem.1c00099%26title%3DIdentification%2Bof%2BTransthyretin%2BTetramer%2BKinetic%2BStabilizers%2BThat%2BAre%2BCapable%2Bof%2BInhibiting%2Bthe%2BRetinol-Dependent%2BRetinol%2BBinding%2BProtein%2B4-Transthyretin%2BInteraction%253A%2BPotential%2BNovel%2BTherapeutics%2Bfor%2BMacular%2BDegeneration%252C%2BTransthyretin%2BAmyloidosis%252C%2Band%2BTheir%2BCommon%2BAge-Related%2BComorbidities%26numPages%3D32%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9041%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00099"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">520</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00099" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;L. Cioffi&quot;},{&quot;first_name&quot;:&quot;Arun&quot;,&quot;last_name&quot;:&quot;Raja&quot;},{&quot;first_name&quot;:&quot;Parthasarathy&quot;,&quot;last_name&quot;:&quot;Muthuraman&quot;},{&quot;first_name&quot;:&quot;Aravindan&quot;,&quot;last_name&quot;:&quot;Jayaraman&quot;},{&quot;first_name&quot;:&quot;Srinivasan&quot;,&quot;last_name&quot;:&quot;Jayakumar&quot;},{&quot;first_name&quot;:&quot;Andras&quot;,&quot;last_name&quot;:&quot;Varadi&quot;},{&quot;first_name&quot;:&quot;Boglarka&quot;,&quot;last_name&quot;:&quot;Racz&quot;},{&quot;first_name&quot;:&quot;Konstantin&quot;,&quot;last_name&quot;:&quot;Petrukhin&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;9010-9041&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00099&quot;},&quot;abstract&quot;:&quot;Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive disease resulting from the deposition of toxic fibrils in tissues that predominantly presents clinically as amyloid cardiomyopathy and peripheral polyneuropathy. Ligands that bind to and kinetically stabilize TTR tetramers prohibit their dissociation and may prevent ATTR onset. Drawing from clinically investigated AG10, we designed a constrained congener (14) that exhibits excellent TTR tetramer binding potency, prevents TTR aggregation in a gel-based assay, and possesses desirable pharmacokinetics in mice. Additionally, 14 significantly lowers murine serum retinol binding protein 4 (RBP4) levels despite a lack of binding at that protein’s all-trans-retinol site. We hypothesize that kinetic stabilization of TTR tetramers via 14 is allosterically hindering all-trans-retinol-dependent RBP4–TTR tertiary complex formation a&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00099&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00099" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00099&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00099" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00099&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00099" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00099&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00099&amp;href=/doi/10.1021/acs.jmedchem.1c00099" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00099" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00099" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00099%26sid%3Dliteratum%253Aachs%26pmid%3D34138572%26genre%3Darticle%26aulast%3DCioffi%26date%3D2021%26atitle%3DIdentification%2Bof%2BTransthyretin%2BTetramer%2BKinetic%2BStabilizers%2BThat%2BAre%2BCapable%2Bof%2BInhibiting%2Bthe%2BRetinol-Dependent%2BRetinol%2BBinding%2BProtein%2B4-Transthyretin%2BInteraction%253A%2BPotential%2BNovel%2BTherapeutics%2Bfor%2BMacular%2BDegeneration%252C%2BTransthyretin%2BAmyloidosis%252C%2Band%2BTheir%2BCommon%2BAge-Related%2BComorbidities%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D13%26spage%3D9010%26epage%3D9041%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292541" title="Cavities">Cavities</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=290905" title="Kinetics">Kinetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dissociation of transthyretin (TTR) tetramers may lead to misfolding and aggregation of proamyloidogenic monomers, which underlies TTR amyloidosis (ATTR) pathophysiology. ATTR is a progressive disease resulting from the deposition of toxic fibrils in tissues that predominantly presents clinically as amyloid cardiomyopathy and peripheral polyneuropathy. Ligands that bind to and kinetically stabilize TTR tetramers prohibit their dissociation and may prevent ATTR onset. Drawing from clinically investigated AG10, we designed a constrained congener (<b>14</b>) that exhibits excellent TTR tetramer binding potency, prevents TTR aggregation in a gel-based assay, and possesses desirable pharmacokinetics in mice. Additionally, <b>14</b> significantly lowers murine serum retinol binding protein 4 (RBP4) levels despite a lack of binding at that protein’s all-<i>trans</i>-retinol site. We hypothesize that kinetic stabilization of TTR tetramers <i>via</i><b>14</b> is allosterically hindering all-<i>trans</i>-retinol-dependent RBP4–TTR tertiary complex formation and that the compound could present ancillary therapeutic utility for indications treated with RBP4 antagonists, such as macular degeneration.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In recent years, the circulating RBP4–TTR–all-<i>trans</i>-retinol transport complex has become a target for pharmacological intervention in ophthalmic diseases associated with enhanced accumulation of cytotoxic lipofuscin bisretinoids in the retina. Transport of all-<i>trans</i>-retinol (vitamin A, <b>1</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) from the liver to tissues, including the retina, involves a transport complex composed of retinol binding protein 4 (RBP4) and transthyretin (TTR, thyroxine binding prealbumin).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Reports indicate that prevention of ternary complex formation between all-<i>trans</i>-retinol, RBP4, and TTR can be achieved <i>via</i> selective antagonists that compete with all-<i>trans</i>-retinol for binding at RBP4.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3−7)</a> Prevention of holo-RBP4 (all-<i>trans</i>-retinol bound to RBP4) formation precludes complexation with TTR and subsequently leads to a lowering of serum RBP4 levels facilitated by rapid glomerular filtration of the protein due to its relatively low molecular weight (21 kDa).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Evidence suggests that pharmacological reduction of serum RBP4 levels induces a concomitant reduction in circulating all-<i>trans</i>-retinol that impedes ocular influx of the critical retinoid, resulting in a cessation of cytotoxic lipofuscin bisretinoid accumulation in the retina.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> This approach to modulate retinal lipofuscin bisretinoid production is hypothesized to slow the progression of geographic atrophy in dry age-related macular degeneration (AMD) and Stargardt disease patients. We have shown that potent and selective RBP4 antagonists disrupt holo-RBP4–TTR ternary complex formation <i>in vitro</i> and significantly reduce serum RBP4 levels <i>in vivo</i> in rodents and nonhuman primates.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref10 ref11">(4−7,10,11)</a> Furthermore, chronic oral administration of RBP4 antagonists in <i>Abca</i>4<sup>–/–</sup> knockout mice, a model of excessive lipofuscinogenesis that recapitulates the Stargardt disease phenotype, led to a reduction in retinal cytotoxic bisretinoid accumulation with an ancillary stabilization of complement system protein expression in the retinal pigment epithelium (RPE).<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Additional dosing studies in wild-type (WT) BALB/cJ mice revealed that RBP4 antagonist-induced reductions in circulating RBP4 levels correlated with partial reductions in bisretinoid precursor concentrations without disruption of visual cycle kinetics.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. All-<i>trans</i>-retinol (vitamin A) (<b>1</b>) and bispecific RBP4 antagonist–TTR tetramer kinetic stabilizer (±)-<b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To date, only selective all-<i>trans</i>-retinol-competitive antagonists of RBP4 have been reported to block the formation of a ternary complex with TTR and lead to a reduction in circulating RBP4 levels <i>in vivo</i>. While selective RBP4 antagonists can be a safe and effective bisretinoid-lowering therapy for a majority of dry AMD and Stargardt disease patients, this class of compounds may potentially be counterindicated for a fraction of macular degeneration patients who are predisposed to diseases associated with TTR aggregation,<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16">(12−16)</a> such as senile systemic amyloidosis (SSA).<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> Selective RBP4 antagonists would release unliganded TTR tetramer from the circulating holo-RBP4–TTR transport complex. This outcome may have serious implications as it has been previously suggested that in addition to transporting all-<i>trans</i>-retinol, the holo-RBP4–TTR complex may also serve to stabilize circulating TTR tetramers, as approximately 50% of TTR in circulation is bound to holo-RBP4.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Thus, the release of a significant pool of unliganded TTR tetramer induced by selective RBP4 antagonists may facilitate TTR amyloid fibril formation in susceptible individuals promoting TTR amyloidosis (ATTR)-related diseases. In an effort to address this potential liability, we recently identified and disclosed a series of potent RBP4 antagonists that also exhibit TTR tetramer kinetic stabilization activity. A standout analogue of this novel class of bispecific ligands, (±)-<b>2</b>, exhibited a favorable balance of <i>in vitro</i> RBP4 potency (RBP4 scintillation proximity assay (SPA) half-maximal inhibitory concentration (IC<sub>50</sub>) = 80 nM and homogeneous time-resolved fluorescence (HTRF-fluorescence resonance energy transfer (FRET)) assay IC<sub>50</sub> = 0.250 μM) and TTR potency (TTR fluorescence polarization (FP) assay IC<sub>50</sub> = 2.85 μM), which was found to induce a robust and sustained lowering of serum RBP4 levels (>80%) upon oral dosing in mice and was also capable of decreasing the formation of high-molecular-weight TTR aggregates in an <i>in vitro</i> gel-based TTR aggregation assay.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> These data suggest that (±)-<b>2</b> and its related analogues might hold promise as orally bioavailable therapeutics for the treatment of dry AMD and Stargardt disease that may also prevent potential ATTR comorbidities such as SSA in susceptible patients.</div><div class="NLM_p">Concurrent with our recently reported bispecific RBP4 antagonist–TTR tetramer kinetic stabilizer work, we also conducted a medicinal chemistry campaign that focused on the identification of novel, potent, and selective TTR tetramer kinetic stabilizers for the treatment of ATTR-related diseases. During the course of this ancillary drug discovery campaign, we sought to determine whether our newly designed TTR tetramer stabilizers were also capable of inducing concomitant reductions in serum RBP4 levels by potentially antagonizing the formation of the holo-RBP4–TTR complex.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> TTR Tetramer Kinetic Stabilizers</h3><div class="NLM_p">TTR is a 55 kDa homotetramer composed of four β-sheet-rich, 127-residue polypeptide monomers that is largely synthesized in the liver for secretion into the blood.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> TTR tetramers possess two high-affinity binding sites for the thyroid hormone thyroxine (T4, <b>3</b>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). However, less than 1% of circulating TTR carries T4, while another serum protein, thyroxine binding globulin (TBG), functions as its primary transporter in the blood.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> While TTR is not a primary carrier of T4 in the serum, it serves as the major transport protein for thyroxine in the central nervous system (CNS), where choroid plexus-derived TTR delivers T4 from the cerebrospinal fluid (CSF) to the choroid plexus and the brain.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Accumulating evidence suggests that TTR may play an auxiliary role in sequestering β-amyloid (Aβ) peptides within the CSF by promoting their clearance from the CNS to the periphery, potentially providing neuroprotective effects against Alzheimer’s disease.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Thyroid hormone thyroxine (T4) (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The quaternary structure of TTR is of a homotetramer principally formed between two dimers.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Formation of the structure begins with the association of two identical 127-residue β-sheet-rich polypeptide monomers that contain a total of eight antiparallel β-strands (denoted as β-strands A–H), with β-strand E presenting a short α-helix located at its terminus. The monomers associate <i>via</i> their edge β-strands (H-bond interactions involving the two edge β-strands H and F) yielding a dimer subunit, which further associates with a second dimer subunit in a back-to-back arrangement. The resulting dimer of dimer bears a large solvent channel, which passes between the two sheets and presents two identical <i>C</i><sub>2</sub>-symmetric binding sites for T4.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The TTR dimer–dimer interface is relatively weak and its dissociation is the rate-limiting step in the overall TTR tetramer dissociation process.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The free dimer subunits may subsequently further dissociate into monomers that could potentially proceed to misfold and oligomerize. Oligomerization can eventually lead to aggregation and formation of toxic amyloid fibrils, which underlies the pathophysiology of ATTR.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">Autosomal-dominant ATTR is a rare and progressive disease that involves severe organ damage due to the extracellular deposition of the aforementioned toxic TTR amyloid fibrils in tissues. The disease typically presents clinically as either TTR amyloid cardiomyopathy (ATTR-CM; can lead to arrhythmias, arterial fibrillation, and biventricular heart failure)<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> or peripheral polyneuropathy (ATTR-PN; can cause loss of sensation, tingling, numbness, or pain as well as damage to the autonomic nervous system)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and can arise from propathogenic monomers with inherited TTR mutations. Nonhereditary ATTR may emerge from wild-type TTR (WT-TTR) monomer misfolding in older individuals.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> There are at least 77 TTR mutations associated with familial ATTR diseases, and these variants influence amyloidogenicity by either (1) reducing the thermodynamic stability of the TTR tetramer (<i>i.e</i>., the monomers are less likely to associate into a TTR tetramer and are more likely to misfold into an amyloidogenic intermediate), (2) reducing the kinetic barrier for tetramer dissociation (the TTR tetramer with the variant dissociates at a faster rate than WT-TTR with a concomitant increase in monomer aggregation rate), or (3) both thermodynamically and kinetically destabilizing the TTR tetramer.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The kinetically stable but thermodynamically destabilized variant V30M<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> is predominantly associated with late-onset familial amyloid polyneuropathy (FAP) and is strongly pathogenic. The most common amyloidogenic TTR variant, V122I,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> presents at a relatively high frequency within the African-American population (approximately 3.4%) and is predominantly associated with familial amyloid cardiomyopathy (FAC). Its pathogenicity is attributed to its ability to kinetically destabilize the TTR tetramer and induce a dissociation rate that is approximately 2-fold faster than WT-TTR.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The L55P mutation both thermodynamically and kinetically destabilizes tetramer formation and can aggressively promote early-onset ATTR-CM and ATTR-PN.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Conversely, compound heterozygotes carrying a proamyloidogenic TTR mutation (<i>e.g</i>., V30M) and a disease-suppressing mutation that hyperstabilizes TTR tetramers, such as T119M or R104H,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> are reported to either develop a mild late-onset pathology or be completely protected against ATTR. The T119M variant kinetically stabilizes the TTR tetramer, whereas the R104H variant provides thermodynamic stability to the quaternary structure. This difference in mechanism of stabilization is crucial as the T119M variant is resistant to tetramer dissociation and aggregation and provides a greater level of protection against TTR aggregation <i>in vitro</i> relative to R104H. Finally, WT-TTR misfolding and aggregation that occur nongenetically with age are associated with SSA, a late-onset and prevalent form of ATTR that is estimated to affect 10–20% of individuals aged 80 years and older.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">Currently available Food and Drug Administration (FDA)-approved approaches for treating ATTR-CM and ATTR-PN include two treatments that reduce circulating TTR levels (the antisense oligonucleotide inotersen<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and the small interfering RNA (siRNA) patisiran<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a>) and the small molecule tafamidis (vyndaqel and vyndamax, <b>4</b>)<a onclick="showRef(event, 'ref35 ref36 ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38 ref39 ref40">(35−40)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) that binds to and stabilizes circulating TTR tetramers. Ligand binding at the T4 sites has been shown to kinetically stabilize TTR tetramers by increasing the dissociative energy barrier of the native tetrameric state. Due to the presence of two additional T4 transport proteins (TGB and albumin), the majority of TTR in circulation is not bound to TTR. Thus, drug discovery approaches to identify T4-competitive small molecules capable of kinetically stabilizing TTR tetramers have garnered significant interest as a therapeutic option for treating ATTR. Numerous structurally diverse scaffolds in addition to tafamidis have been reported to bind at the T4 site and stabilize TTR tetramers, and representatives of this class are highlighted in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. The two most advanced small molecule TTR tetramer stabilizers to date include the aforementioned FDA-approved tafamidis and clinically investigated AG10 (acoramidis, <b>5</b>).<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41−43)</a> Tafamidis has been approved for the treatment of FAP and ATTR-CM. A phase III study with 441 ATTR-CM patients showed that administration of the drug reduced the risk of death by 30% and the rate of cardiovascular-related hospitalizations by 32% compared to placebo controls.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> TTR stabilizer AG10 was reported to be well tolerated and demonstrated near-complete stabilization of TTR in a 28 day phase II proof-of-concept trial with ATTR-CM patients presenting symptomatic chronic heart failure.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Approximately 30% of patients with hereditary ATTR do not respond to tafamidis,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> indicating a need for exploring additional classes of TTR tetramer stabilizers. Phase III clinical trials with AG10 for the treatment of ATTR-CM and ATTR-PN are currently ongoing. In addition, the repurposed FDA-approved nonsteroidal anti-inflammatory drugs (NSAIDs) diflunisal (dolobid, <b>6</b>)<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and catechol-<i>O</i>-methyl transferase (COMT) inhibitor tolcapone (tasmar, <b>8</b>)<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> are also reported to exhibit TTR tetramer stabilization activity and have been investigated for clinical efficacy against ATTR-PN.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative examples of various reported TTR tetramer stabilizer structural classes that bind at the T4 binding site. This sample set of TTR tetramer stabilizers include tafamidis (<b>4</b>),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> AG10 (<b>5</b>),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> diflunisal (<b>6</b>),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> iododiflunisal (<b>7</b>),<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> tolcapone (<b>8</b>),<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> benzbromarone (<b>9</b>), diclofenac (<b>10</b>),<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a><i>N</i>-phenyl phenoxazine (<b>11</b>),<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> dibenzofuran (<b>12</b>),<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and bis-aryloxime ether (<b>13</b>).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The following compounds highlighted in the figure above are registered drugs for various indications: tafamidis (vyndaqel and vyndamax, <b>4</b>) for treating ATTR-PN, diflunisal (dolobid, <b>6</b>), an NSAID also used for ATTR, tolcapone (tasmar, <b>8</b>), a COMT inhibitor for treating Parkinson’s disease, benzbromarone (<b>9</b>), a uricosuric agent and noncompetitive inhibitor of xanthine oxidase previously shown by us to act as a potent TTR ligand,<a onclick="showRef(event, 'ref7 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref7 ref54 ref55">(7,54,55)</a> and diclofenac (voltaren, <b>10</b>), an NSAID to treat pain, inflammatory disorders, and dysmenorrhea.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Nature of the Holo-RBP4–TTR Protein–Protein Interaction (PPI)</h3><div class="NLM_p">RBP4 is a single domain protein that contains an N-terminal coil, eight antiparallel β-strands (denoted as β-strands A–H), and a short α-helix within close proximity to the C-terminus.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The all-<i>trans</i>-retinol binding cavity resides within the core of the protein and consists of an eight-stranded up-and-down β-barrel. Formation of the aforementioned transport complex requires that all-<i>trans</i>-retinol be initially bound to its respective RBP4 binding cavity as apo-RBP4 poorly associates with TTR. The reported Protein Data Bank (PDB) high-resolution holo-RBP4–TTR complex X-ray crystal structures <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB">1QAB</a><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> (RBP4–all-<i>trans</i>-retinol–TTR ternary complex) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BSZ">3BSZ</a><a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (RBP4–all-<i>trans</i>-retinol–TTR ternary complex bound to an anti-RBP Fab) show all-<i>trans</i>-retinol bound within its RBP4 binding cavity in a forward-facing pose (hand-in-glove-like fit) with its lipophilic β-ionone ring projecting into a vacuous hydrophobic and phenylalanine (Phe)-rich pocket located deep within the protein. The all-<i>trans</i>-retinol polyene chain traverses through a narrow β-barrel core region with the pendant terminal hydroxyl group projecting slightly out of the binding pocket and toward the solvent. These X-ray crystal structures show that the exterior RBP4 loops that surround the opening of the binding pocket (loops β3−β4 and β5−β6) present an interaction contact surface for docking with TTR.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Binding of all-<i>trans</i>-retinol to RBP4 induces conformational changes within these exterior loops that facilitate recognition of TTR, allowing holo-RBP4 to bind to TTR at a twofold axis of symmetry that is perpendicular to the T4 binding sites (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Furthermore, TTR features two equivalent sites for holo-RBP4 binding, providing a holo-RBP4 to TTR tetramer stoichiometry of 2:1. Finally, the structure of the holo-RBP4–TTR ternary complex fully encapsulates all-<i>trans</i>-retinol and conceals its binding site. However, the T4 binding sites are not occluded.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Quaternary structures of TTR with T4-bound, holo-RBP4, and the holo-RBP4–TTR ternary complexes. (A) Ribbon diagram of the quaternary homotetrameric structure of TTR with T4 (3) bound within its respective binding site (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ROX">2ROX</a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The two dimer subunits are each composed of two individual monomers (labeled A (blue-green), B (orange), C (light blue), and D (pink)). The dimers are associated back-to-back and present two <i>C</i><sub>2</sub> symmetrical T4 binding sites running through the center of the protein. The binding of T4 is shown in a ball and stick format (black). (B) Ribbon diagram of holo-RBP4 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RBP">1RBP</a>). Holo-RBP4 is shown as yellow and all-<i>trans</i>-retinol is depicted in a ball and stick format (black). (C) The holo-RBP4–TTR complex (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB">1QAB</a>) colored by chain and viewed from the front. The TTR tetramer is located at the center of the complex with two holo-RBP4 molecules (one holo-RBP4 molecule is shown as yellow and the other as light green) docked at a twofold axis of symmetry that is perpendicular to the T4 binding sites. All-<i>trans</i>-retinol is depicted in a ball and stick format (black), which is encapsulated by the complex and its binding site is blocked. The T4 binding site is not occluded.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both holo-RBP4 and TTR each contribute 21 amino acids to their respective PPI interface domains, which are both largely hydrophobic at their cores and hydrophilic at their peripheries.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The TTR amino acids Val-20, Trp79, Leu82, Ile84, Pro113, and Tyr114 from subunits B and C form a hydrophobic patch, which strongly associates with the complementary RBP4 hydrophobic patch composed of residues Trp67, Leu63, Leu64, Val69, Phe96, and Leu97. The resulting PPI involves a holo-RBP4 molecule simultaneously interacting with three TTR subunits (A–C)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Interacting hydrophilic residues from participating TTR subunit A are closer to the border of the contact surface of the protein. Four hydrogen bonds (H-bonds) between RBP4 and TTR subunit B also contribute to the PPI.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Notably, further stabilization of the complex is also achieved <i>via</i> a H-bond interaction between the hydroxyl group of all-<i>trans</i>-retinol and Gly83 of the TTR subunit B (EF loop).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PPI interaction surfaces between holo-RBP4 and TTR. (A) Close-up view of the holo-RBP4–TTR PPI (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB">1QAB</a>) colored by chain. Holo-RBP4 is shown as yellow and all-<i>trans</i>-retinol is depicted in a ball and stick format (black) and buried in the hydrophobic cavity of the RBP4 β-barrel. The alcohol moiety points toward the EF loop of TTR (subunit B) and engages in a H-bond interaction with Gly83. The TTR monomer subunits are labeled as A (blue-green), B (orange), C (light blue), and D (pink). The image shows how the loops β3−β4 and β5−β6 of holo-RBP4 provide a surface that fits into a crevice formed by the arrangement of three TTR subunits (A–C). (B) Molecular surface representation of holo-RBP4–TTR PPI that more clearly shows holo-RBP4 making contact with three TTR subunits (A–C) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB">1QAB</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The mechanism of action for selective all-<i>trans</i>-retinol-competitive RBP4 antagonists has been attributed to the significant and unfavorable conformational changes they induce in loops β3−β4 and β5−β6 that preclude facile association with the TTR PPI domain.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> We questioned whether ligands that bind at the T4 site of TTR could confer unfavorable changes to the protein’s PPI domain and allosterically antagonize its ability to associate with holo-RBP4 and disrupt complex formation. Such ligands could potentially induce serum RBP4 and all-<i>trans</i>-retinol reductions, thereby presenting RBP4 antagonist pharmacological activity with significant TTR tetramer stabilization capability. Prior to the work reported herein, TTR has not been considered as a drug target for indications that may be treated <i>via</i> RBP4 antagonists, such as Stargardt disease and dry AMD. Thus, such drugs may potentially prevent the formation of amyloid fibrils in patients who, in addition to dry AMD and Stargardt disease, may also carry proamyloidogenic mutations in the TTR gene.</div><div class="NLM_p">In our work reported herein, we initiated a structure-based drug design effort to identify a novel class of TTR tetramer kinetic stabilizers that would be assessed for their ability to both stabilize TTR tetramers <i>in vitro</i> and reduce circulating levels of RBP4 <i>in vivo</i>. We selected AG10 as a benchmark scaffold from which to develop a novel series of ligands as (1) the compound has been reported to effectively bind to and stabilize WT-TTR and the proamyloidogenic V122I-TTR variant and (2) the compound is also reported to be more potent and selective for stabilizing TTR tetramers in buffer and human serum than tafamidis, despite both compounds exhibiting similar TTR binding affinities (<i>K</i><sub>d</sub> for AG10 = 4.8 ± 1.9 nM; <i>K</i><sub>d</sub> for tafamidis = 4.4 ± 1.3 nM).<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Our primary goals were to identify novel chemical matter capable of (1) retaining or improving the observed <i>in vitro</i> TTR tetramer binding potency observed for AG10, (2) exhibiting suitable pharmacokinetics (PK) properties to allow for adequate TTR tetramer stabilization and prevention of aggregation <i>in vivo</i> upon oral administration, and (3) presenting a favorable absorption distribution metabolism and excretion (ADME) profile and no limiting off-target pharmacology that would preclude drug development. In addition, recently published phase I human PK data for AG10 revealed that the major metabolic pathway for the compound involves acyl glucuronidation of its carboxylic acid.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Thus, we also sought to include analogues within our sample set that may potentially circumvent this metabolic pathway, which is generally reported to be associated with increased incidences of idiosyncratic toxicity.</div><div class="NLM_p">We utilized the X-ray crystallographic data PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> in our structure-based drug design efforts, which shows AG10 occupying both T4 binding sites of V122I-TTR tetramer (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). AG10 was reported to bind to V122I-TTR with negative cooperativity (<i>K</i><sub>d<sub>1</sub></sub> = 4.8 nM, <i>K</i><sub>d<sub>2</sub></sub> = 314 nM).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The <i>C</i><sub>2</sub> symmetrical T4 binding sites are subdivided into inner and outer binding cavities containing three pairs of halogen binding pockets (HBP1, HBP1′, HBP2, HBP2′, HBP3, and HBP3′) that the iodine atoms of thyroxine occupy. Within the innermost region of the T4 binding cavity, residues Ser117 and Ser117′ engage in bridging H-bond interactions with a resident structural water molecule. These residues are within close proximity to the T4 inner binding cavity HBP3 and HBP3′ pockets. The lipophilic HBP2 and HBP2′ pockets are located between the inner and outer binding cavities, and the HBP1 and HBP1′ pockets are housed near the outer region of the binding cavity. The ionizable residues Lys15/Lys15′ and Glu54/Glu54′ reside near the periphery of the T4 binding site opening.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0007.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray crystallographic structure showing AG10 (<b>5</b>) bound to V122I-TTR (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a>). (A) Ribbon diagram of the quaternary homotetrameric structure of TTR with AG10 bound in the T4 binding sites with both symmetry-related binding conformations shown. The TTR dimers are shown as dimer subunits A and B, and each monomer subunit of the tetramer (labeled 1–4) is shown with its secondary structural elements and colored differently. The monomer components of dimer A are shown in cyan (monomer 1) and orange (monomer 2). The monomer components of dimer B are shown in pink (monomer 3) and yellow (monomer 4). The dimers are associated back-to-back creating a large channel through the center of the tetramer that presents two <i>C</i><sub>2</sub> symmetrical T4 binding sites. AG10 is shown in stick format (gray). (B) TTR tetramer kinetic stabilizer AG10 is shown in a ball and stick format (dark gray), with contacting residues labeled and illustrated in stick format (white). The binding pose of AG10 (<b>5</b>) positions the benzoic acid motif bent out of the plane with the rest of the molecule in a nearly orthogonal orientation. (C) Ligand interaction diagram of AG10 (shown as blue) derived from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a>, which features the HBPs with their associated localized amino acids. The diagram further illustrates key binding interactions observed in the X-ray crystallographic data, including pivotal H-bonds and salt-bridge interactions. The pyrazole head group of AG10 projects deep within the inner binding cavity of the T4 binding pocket where it engages in two H-bond interactions with Ser117 and Ser117′. The pyrazole 3,5-dimethyl groups of AG10 occupy HBP3 and HBP3′. The aliphatic chain of AG10 comes in contact with the residues lining HBP2/HBP2′. The fluorine atom of AG10 projects into a hydrophobic region of HBP1 in the outer T4 binding cavity. The carboxylic acid of AG10 is sandwiched between Lys15 and Lys15′. The H-bond interactions are depicted as blue dashed lines, with the atomic distances labeled in angstrom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The occupancy of AG10 within the T4 site involves a forward binding mode, with the 3,5-dimethyl-1<i>H</i>-pyrazole group projecting deep within the inner cavity where it engages in two H-bond interactions with Ser117 and Ser117′ (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B,C).<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> The two pyrazole methyl groups occupy the neighboring HBP3 and HBP3′ pockets, and the <i>n</i>-propyloxy linker resides within the center of the binding site channel where it makes van der Waals contacts with the residues lining HBP2 and HBP2′. The fluorine atom of the benzoic acid fragment projects toward the lipophilic HBP1 pocket (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B,C),<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> while the carboxylic acid is positioned in close proximity to the opening of the T4 binding site where it is sandwiched between the two symmetry-related ε-amino groups of Lys15 and Lys15′. The interactions between the carboxylic acid of AG10 and Lys15/Lys15′ induce partial closure of the T4 binding site opening and effectively shield the compound from the solvent.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a></div><div class="NLM_p">The reported isothermal titration calorimetry (ITC) thermograms for tafamidis and AG10 show that although both compounds present similar changes in Gibbs free energy of binding (Δ<i>G</i>, where Δ<i>G</i> = Δ<i>H</i> – <i>T</i>Δ<i>S</i>) (Δ<i>G</i> for AG10 = −11.34 kcal/mol; Δ<i>G</i> for tafamidis = −11.34 kcal/mol), the compounds differed significantly with regard to their relative enthalpic and entropic contributions.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> The binding of AG10 was found to be largely enthalpically driven (Δ<i>H</i> = −13.60 kcal/mol and <i>T</i>Δ<i>S</i> = −2.26 kcal/mol), while tafamidis demonstrated equal enthalpic and entropic contributions to binding (Δ<i>H</i> = −5.00 kcal/mol and <i>T</i>Δ<i>S</i> = 6.39 kcal/mol). The larger enthalpic contribution for AG10 is attributed to the H-bond interactions between its pyrazole head group and Ser117 and Ser117′, which are not present for tafamidis. Importantly, these additional H-bond interactions of AG10 with Ser117 and Ser117′ appear to mimic the direct H-bond interaction observed between these two residues in the T119M-TTR disease-suppressing variant.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> The Ser117 and Ser117′ residues of T119M-TTR are within close proximity (∼2.8 Å) to form an intramolecular H-bond interaction between them. This pivotal H-bond interaction helps to draw the dimer subunits closer and fortifies the aggregate molecular interactions between them. This is hypothesized to significantly increase in the T119M-TTR dimer–dimer dissociation energy barrier, thus providing superior kinetic stabilization relative to WT-TTR quaternary structure, which does not contain this key Ser117/Ser117′ H-bond interaction. Indeed, the T119M variant displays a 40-fold slower dissociation rate relative to WT-TTR. Thus, the ability of AG10 to mimic this critical Ser117/Ser117′ binding interaction of T119-TTR may explain why it demonstrates superior potency to tafamidis with regard to stabilizing TTR tetramers in buffer and human serum despite exhibiting a similar binding affinity.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a></div><div class="NLM_p">Our medicinal chemistry strategy utilized the X-ray crystallographic data of PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a> to construct a computational docking model that would assist with the design of novel scaffolds with the goal of (1) maintaining the pivotal H-bond interactions with Ser117/Ser117′ and key van der Waals interactions observed for AG10 and (2) potentially improving entropic contributions to binding by reducing the number of rotatable bonds and conformational flexibility presented by AG10. The model was generated with Molecular Operating Environment (MOE) 2020.09 (Chemical Computing Group, Inc., Montreal, Quebec, Canada, <a href="http://www.chemcomp.com" class="extLink">http://www.chemcomp.com</a>) and utilized the protein structure preparation tool followed by Protonate3D, as implemented in MOE. Our initial docking analysis involved piperazine analogue <b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), a novel and conformationally constrained congener of AG10, and the data generated was primarily used to determine whether the proposed compound was predicted to have good docking orientations by positioning it within the T4 binding cavity relative to AG10. The docking model images shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> present AG10 and <b>14</b> bound with one-half of the <i>C</i><sub>2</sub>-symmetric T4 binding site removed to visualize the binding poses and interactions for the compounds. The model predicted that <b>14</b> would exhibit good convergence with AG10 in the T4 binding site, as evidenced in the observed calculated root-mean-square deviation (RMSD) value of 1.7 Å. <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B,C shows compound <b>14</b> presenting a similar binding pose as AG10 in the T4 site, with both compounds exhibiting a forward binding mode projecting their respective 3,5-dimethyl-1<i>H</i>-pyrazole head groups into the inner binding cavity and oriented orthogonally. The 3,5-dimethyl-1<i>H</i>-pyrazole of <b>14</b> is proposed to reside within the inner T4 binding cavity, where it is predicted to engage in a H-bond interaction with Ser117 and van der Waals interactions between its methyl group and HBP3 in a similar manner to AG10. Our docking model also predicts that the piperazine ring serves as a suitable replacement for the <i>n</i>-propyloxy linker, as it is shown to effectively place the 3,5-dimethyl-1<i>H</i>-pyrazole head group within the T4 inner binding cavity while also presenting the benzoic acid in an optimal position to engage in electrostatic interactions with Lys15 and Lys15′ residing near the opening of the binding site. Finally, our model also shows the fluorine atom of <b>14</b> positioned to occupy HBP1 in a similar manner to the AG10 aryl fluoride (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0008.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Putative binding mode of piperazine compound <b>14</b> within the T4 binding site. (A) Proposed TTR tetramer kinetic stabilizer <b>14</b>, which contains a piperazine core. (B) Overlay of docked poses of piperazine <b>14</b> (magenta) and AG10 (orange) within the TTR T4 binding cavity using PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a> (obtained from the Protein Data Bank); contacting residues are labeled and illustrated in stick format; H-bond interactions are depicted as blue dashed lines. (C) Molecular surface with the overlay of docked poses of piperazine <b>14</b> (magenta) and AG10 (orange) within the TTR T4 binding cavity using PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a>. The protein surface is colored by hydrophobicity (green) and hydrophilicity (purple) using contact preferences; contacting residues are labeled and illustrated in stick format; H-bond interactions are depicted as blue dashed lines. (D) Legend for the ligand interaction diagrams in the binding pose using MOE. (MOE) 2020.09 (Chemical Computing Group, Inc., Montreal, Quebec, Canada, <a href="http://www.chemcomp.com" class="extLink">http://www.chemcomp.com</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As outlined in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, our medicinal chemistry plan focused on exploring the aforementioned computational docking results as we conducted structure–activity relationship (SAR) campaigns that focused on three key regions of lead AG10 and piperazine <b>14</b>. This included exploring the SAR of (1) alternative conformationally constrained cyclic core linkers, (2) isosteres and replacements for the 3,5-dimethyl-1<i>H</i>-pyrazole “head group region”, and (3) variation of substituents and substitution patterns on benzoic acid “bottom-group region” appendage. Based on our docking model, we designed and synthesized illustrative examples of constrained analogues of AG10 that initially incorporated a piperazine linker and later included fused bicyclic and spirocyclic piperazine ring isosteres. We subsequently investigated the SAR of a series of analogues that featured a 3,5-dimethyl-1<i>H</i>-pyrazole head group with a piperazine core linker while presenting differing benzoic acid substituents. Previously reported SAR campaigns for AG10 suggest that positioning the carboxylic acid meta to its <i>n</i>-propyloxy linker was optimal for electrostatic binding interactions with the Lys15 and Lys15′ residues residing near the periphery of the T4 binding site opening. Thus, we fixed the carboxylic acid at the same position for our series of analogues while exploring alternative substituents and substitution patterns to the fluorine of AG10. We also explored the SAR of a small set of isosteres and replacements for the 3,5-dimethyl-1<i>H</i>-pyrazole head group of AG10, which projects deep into the T4 binding site and engages in H-bond interactions with Ser117 and Ser117′. Finally, we investigated the SAR effects of a carboxylic acid replacement and bioisostere that could mitigate or circumvent potential undesirable acyl glucuronidation metabolism.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0009.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Medicinal chemistry work plan for the identification of novel and conformationally constrained TTR tetramer kinetic stabilizers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthetic route for a series of substituted 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoic acid analogues (<b>14</b>, <b>20a</b>–<b>i</b>), highlighted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, begins with a palladium(0)-catalyzed amination between <i>tert</i>-butyl piperazine-1-carboxylate (<b>15</b>) and a corresponding substituted methyl bromobenzoate. The resulting aryl amines (<b>16a</b>–<b>j</b>) were <i>N</i>-Boc-deprotected with trifluoroacetic acid (TFA) in dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>) at 0 °C, yielding <b>17a</b>–<b>j</b>. Amines <b>17a</b>–<b>j</b> were subsequently alkylated with 3-chloropentane-2,4-dione to give dione intermediates <b>18b</b>–<b>j</b><i>in situ</i>, which then underwent condensation with hydrazine hydrate (N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O) to provide the respective dimethyl pyrazoles <b>19a</b>–<b>j</b> in one pot (the exception to this sequence was dione <b>18a</b>, which was isolated). The methyl esters of <b>19a</b>–<b>j</b> were hydrolyzed with anhydrous lithium hydroxide (LiOH), and the lithium carboxylate salts were carefully neutralized with 2 N aqueous hydrochloric acid (HCl) to yield the desired carboxylic acids <b>14</b> and <b>20a</b>–<b>i</b>. Compound <b>14</b> was subsequently converted to the bis-hydrochloride salt <b>14a</b><i>via</i> treatment with a solution of 2 N HCl in diethyl ether (Et<sub>2</sub>O).</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0013.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) substituted methyl bromobenzoate, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos), Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub>), cesium carbonate (Cs<sub>2</sub>CO<sub>3</sub>), 1,4-dioxane, stirred at reflux for 16 h under an atmosphere of N<sub>2</sub> or heated in a sealed vessel at 110 °C, 16 h; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temperature (rt), 3 h; (c) 3-chloropentane-2,4-dione, <i>N</i>,<i>N</i>-diisopropylethylamine (<i>i</i>-Pr<sub>2</sub>NEt), tetrahydrofuran (THF), 0 °C to rt, 16 h; (d) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (64–65% in H<sub>2</sub>O), THF, rt, 1 h; (e) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 3 h; (ii) 2 N aqueous HCl; (f) 2 N HCl in Et<sub>2</sub>O, 0 °C to rt, 3 h.</p></p></figure><div class="NLM_p">The iodo analogue of <b>14</b> (<b>26</b>) was prepared <i>via</i> the route depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The synthesis begins with a nucleophilic substitution reaction (S<sub>N</sub>Ar) displacement between methyl 3-fluoro-4-nitrobenzoate and <b>15</b>, proving intermediate <b>21</b>. Aryl nitro compound <b>21</b> was readily hydrogenated to the corresponding aniline <b>22</b>, which was subsequently converted to the aryl iodide <i>via</i> a Sandmeyer reaction involving 0.25 N aqueous sulfuric acid (H<sub>2</sub>SO<sub>4</sub>), H<sub>2</sub>O, and potassium iodide (KI). The Sandmeyer reaction conditions served to produce the desired conversion to the aryl iodide as well as induce removal of the Boc group in one pot, affording <b>23</b> directly from <b>22</b>. Construction of the 3,5-dimethyl-1<i>H</i>-pyrazole head group was conducted in the same manner outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The desired iodo-substituted benzoic acid <b>26</b> was achieved upon hydrolysis of ethyl ester <b>25</b> and neutralization of the resulting lithium carboxylate salt with 2 N aqueous HCl.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0014.jpeg" id="gr2" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 3-fluoro-4-nitrobenzoate, potassium carbonate (K<sub>2</sub>CO<sub>3</sub>), CH<sub>3</sub>CN, 60 °C, 16 h; (b) H<sub>2</sub> (1 atm pressure), 10%Pd/C, CH<sub>3</sub>OH, rt, 24 h; (c) (i) 0.25 N aqueous H<sub>2</sub>SO<sub>4</sub>, sodium nitrite (NaNO<sub>2</sub>), H<sub>2</sub>O, 0 °C, 30 min; (ii) KI, urea, rt, 1 h; (d) 3-chloropentane-2,4-dione, <i>i</i>-Pr<sub>2</sub>NEt, THF, 0 °C to rt, 16 h; (e) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (64–65% in H<sub>2</sub>O), THF, rt, 1 h; (f) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 3 h; (ii) 2 N aqueous HCl.</p></p></figure><div class="NLM_p">Fused bicyclic and spirocyclic piperazine ring isostere analogues of <b>14</b> (<b>32</b>, (±)-<b>38</b>, and <b>44</b>) were prepared and their corresponding syntheses are shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The preparation of each analogue of this sample set began with a palladium(0)-catalyzed amination between the corresponding <i>N</i>-Boc-protected piperazine ring isostere (<i>tert</i>-butyl (3a<i>R</i>,6a<i>S</i>)-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-2(1<i>H</i>)-carboxylate (<b>27</b>), (±)-<i>tert</i>-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate ((±)-<b>33</b>), and <i>tert</i>-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (<b>39</b>)) and methyl 3-bromo-4-fluorobenzoate. TFA-promoted <i>N</i>-Boc deprotection followed by 3,5-dimethyl-1<i>H</i>-pyrazole construction was conducted using the same three-step process as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. LiOH-mediated hydrolysis of the corresponding methyl esters followed by neutralization of the lithium carboxylate salts with 2 N aqueous HCl provided the desired piperazine ring isostere analogues <b>32</b>, (±)-<b>38</b>, and <b>44</b>.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0015.jpeg" id="gr3" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl (3a<i>R</i>,6a<i>S</i>)-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-2(1<i>H</i>)-carboxylate (<b>27</b>), (±)-<i>tert</i>-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate ((±)-<b>33</b>), or <i>tert</i>-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (<b>39</b>), methyl 3-bromo-4-fluorobenzoate, X-Phos, Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, sealed vessel at 110 °C, 16 h; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 3 h; (c) 3-chloropentane-2,4-dione, <i>i</i>-Pr<sub>2</sub>NEt, THF, 0 °C to rt, 16 h; (d) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (64–65% in H<sub>2</sub>O), THF, rt, 1 h; (e) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 3 h; (ii) 2 N aqueous HCl.</p></p></figure><div class="NLM_p">The previously described dione intermediate 3-(4-(2,4-dioxopentan-3-yl)piperazin-1-yl)-4-fluorobenzoate (<b>18a</b>) also afforded a handle for the construction of isoxazole <b>46</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), an analogue bearing a 3,5-dimethyl-1<i>H</i>-pyrazole head group isostere. Condensation of <b>18a</b> with hydroxyl amine hydrochloride (NH<sub>2</sub>OH·HCl) provided methyl 3-(4-(3,5-dimethylisoxazol-4-yl)piperazin-1-yl)-4-fluorobenzoate (<b>45</b>), which was hydrolyzed with anhydrous LiOH followed by neutralization with 2 N aqueous HCl to give the final product 3-(4-(3,5-dimethylisoxazol-4-yl)piperazin-1-yl)-4-fluorobenzoic acid (<b>46</b>).</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0016.jpeg" id="gr4" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>2</sub>OH·HCl, CH<sub>3</sub>OH, rt, 16 h; (b) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 1 h; (ii) 2 N aqueous HCl.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> presents the routes starting with aryl piperazine intermediate <b>17a</b> that enabled the preparation of both tetrazole head group analogue <b>48</b> and 2-trifluoromethylphenyl head group analogue <b>50</b>. Treatment of <b>17a</b> with cyanogen bromide (CNBr) at 0 °C in THF in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (<i>i</i>-Pr<sub>2</sub>NEt) afforded an intermediary cyanopiperazine, which underwent cycloaddition with sodium azide (NaN<sub>3</sub>) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) at 120 °C to give tetrazole <b>47</b>. Subsequent LiOH saponification of the methyl ester of <b>47</b> and neutralization of the lithium carboxylate salt with 2 N aqueous HCl gave the desired tetrazole <b>48</b>. The preparation of 2-trifluoromethylphenyl analogue <b>50</b> began with a palladium(0)-catalyzed amination between <b>17a</b> and 1-bromo-2-(trifluoromethyl)benzene to give methyl ester intermediate <b>49</b>. The aforementioned saponification and neutralization process was conducted with <b>49</b> affording the desired 2-trifluoromethylphenyl head group analogue <b>50</b>.</div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0017.jpeg" id="gr5" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) CNBr, <i>i</i>-Pr<sub>2</sub>NEt, THF, 0 °C to rt, 1 h, (ii) ammonium chloride (NH<sub>4</sub>Cl), NaN<sub>3</sub>, DMF, 120 °C, 12 h; (b) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 1 h; (ii) 2 N aqueous HCl; (c) 1-bromo-2-(trifluoromethyl)benzene, X-Phos, Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, sealed vessel, 110 °C, 16 h; (d) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 1 h; (ii) 2 N aqueous HCl.</p></p></figure><div class="NLM_p">The preparation of the homologated variant of <b>14</b>, analogue <b>52</b>, is shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. A sodium triacetoxyborohydride (NaBH(OAc)<sub>3</sub>)-mediated reductive amination between amine <b>17a</b> and 3-methyl-1<i>H</i>-pyrazole-4-carbaldehyde provided methyl ester <b>51</b>, which upon saponification and subsequent 2 N aqueous HCl neutralization provided the desired homologated analogue <b>52</b>.</div><figure id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0018.jpeg" id="gr6" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-methyl-1<i>H</i>-pyrazole-4-carbaldehyde, NaBH(OAc)<sub>3</sub>, acetic acid (HOAc), 1,2-dichloroethane, 60 °C, 12 h; (b) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 3 h; (ii) 2 N aqueous HCl.</p></p></figure><div class="NLM_p">Replacement of the carboxylic acid of <b>14</b> with a primary carboxamide (<b>53</b>) and the bioisostere tetrazole (<b>54</b>) was also explored (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Production of primary carboxamide <b>53</b> involved amide bond formation between ammonium chloride and <b>14</b> using the peptide coupling agent <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HBTU). The bioisostere tetrazole <b>54</b> was furnished from <b>53</b> using tetrachlorosilane-sodium azide (NaN<sub>3</sub>). Tetrachlorosilane-mediated dehydration of primary carboxamide <b>53</b> afforded the corresponding nitrile <i>in situ</i>, which underwent 1,3-dipolar cycloaddition with NaN<sub>3</sub> to afford tetrazole <b>54</b> in one pot.</div><figure id="sch7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0019.jpeg" id="gr7" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>4</sub>Cl, HBTU, <i>i</i>-Pr<sub>2</sub>NEt, DMF, rt, 18 h; (b) NaN<sub>3</sub>, tetrachlorosilane, CH<sub>3</sub>CN, 80 °C, 18 h.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16072" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16072" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure–Activity Relationships</h3><div class="NLM_p">Compound binding potency (IC<sub>50</sub> values) of novel compounds for unliganded TTR tetramers isolated from human plasma was measured using an established fluorescence polarization assay designed for TTR kinetic stabilizers.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The assay measured competitive displacement of a fluorescent probe (fluorescein isothiocyanate (FITC) coupled to a diclofenac analogue <i>via</i> a PEGylated linker) from TTR.</div><div class="NLM_p">The less favorable entropic binding energy observed with the reported ITC thermogram of AG10 relative to tafamidis (AG10 <i>T</i>Δ<i>S</i> = −2.26 kcal/mol; tafamidis <i>T</i>Δ<i>S</i> = 6.39 kcal/mol)<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> may potentially be attributed to the conformational flexibility of the <i>n</i>-propyloxy core linker, which contains five rotatable bonds. Thus, our initial goal was to prepare a conformationally constrained congener of AG10 by installing a piperazine ring as a replacement for the <i>n</i>-propyloxy linker. We hoped to potentially further improve potency relative to AG10 by maintaining its key enthalpic contributions to binding while ameliorating a putative entropic penalty by reducing the number of rotatable bonds within the molecule’s linker region. Indeed, piperazine <b>14</b> did exhibit excellent potency at TTR (TTR FP IC<sub>50</sub> = 220 nM) that was approximately 2-fold better than tafamidis (TTR FP IC<sub>50</sub> = 410 nM) and comparable to that of AG10 (TTR FP IC<sub>50</sub> = 160 nM) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. TTR FP and RBP4 SPA <i>In Vitro</i> Assay Data for Piperazine-Containing TTR Tetramer Kinetic Stabilizers Bearing Various Benzoic Acid Substituents (Bottom-Group Region SAR)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0020.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0021.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values for the TTR FP assay obtained in the presence of a fixed, 25 μM concentration of fluorescein isothiocyanate (FITC)-coupled TTR FP probe.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values for the RBP4 SPA assay obtained in the presence of a fixed, 10 nM concentration of <sup>3</sup>H-retinol.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub> values for the HTRF assay obtained in the presence of 1 μM concentration of retinol.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">For compounds tested multiple times (more than twice), the IC<sub>50</sub> data is represented as the mean ± standard deviation (SD). For those compounds that were only tested twice, the IC<sub>50</sub> data is shown as the mean of two independent experiments and not as the mean ± standard deviation.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">ND, not determined.</p></div></div><div></div></div><div class="NLM_p">With <b>14</b> in hand, we next sought to explore the SAR effects of varying the substituents and substitution patterns of the benzoic acid bottom-group motif. We prepared a focused sample set of follow-up analogues to <b>14</b> that replaced its <i>para</i>-fluorine atom with alternative groups that might better occupy the neighboring HBP1 pocket, stabilize a putative forward binding pose, and potentially further improve potency (<b>20a</b>–<b>e</b>). The HBP1 pocket, and its twofold symmetry-related HBP1′ pocket, resides near the outer binding cavity and is occupied by one of the iodine atoms of T4. They are hydrophobic and are composed of residues Leu17, Thr106, and Val121 as well as the methylene groups of Lys15 and Glu54. Our docking model predicted that the fluorine of <b>14</b> would project toward HBP1 in a similar manner as the fluorine of AG10. Therefore, we sought to initially explore this region of the scaffold to see if substituents other than fluorine could lead to improved potency <i>via</i> better HBP1 occupancy and more robust van der Waals binding interactions. To that end, our initial sample set included substituents that were larger and more lipophilic than fluorine (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). With the exception of des-fluoro analogue <b>20a</b> (TTR FP IC<sub>50</sub> = 780 nM), all of the analogues of this sample set were well tolerated and exhibited potencies within a twofold range of <b>14</b>. Indeed, para-substituted analogues <b>20b</b>–<b>e</b> are equipotent to <b>14</b>. We also replaced the fluorine of <b>14</b> with the larger, more lipophilic, and halogen bond-donating iodine that is featured on T4 (<b>26</b>), and this analogue was also found to be an active TTR ligand within our portfolio, exhibiting comparable potency relative to the parent fluoro compound <b>14</b> and AG10 (<b>26</b> TTR FP IC<sub>50</sub> = 190 nM). We plan to follow up on this emerging SAR and test future analogues presenting larger and more sterically bulky substituents (<i>e.g</i>., isopropyl, <i>tert-</i>butyl, cyclopropyl, cyclobutyl, <i>etc</i>.) and polar substituents (<i>i.e</i>., oxetane, nitrile, <i>etc</i>.) to further probe the capacity of HBP1 and to determine if such substituents can lead to more potent scaffolds within our series.</div><div class="NLM_p">The improved potency observed for several analogues within our series relative to tafamidis may suggest the compounds’ benefit from increased enthalpic contributions to binding <i>via</i> putative H-bonds between their respective pyrazole head groups and Ser117/Ser117′ in a similar manner as AG10, which would be consistent with the binding pose of <b>14</b> predicted by our computational docking model. The lack of further improvement in potency for the series relative to AG10 may be attributed to several factors. For example, potential entropic benefits for binding gained may be slightly offset by subtle adverse changes to enthalpic contributions. It is possible that the more electron-rich amino pyrazole head group of our series presents a slightly weaker H-bond-donating group relative to the pyrazole of AG10, which could affect the strength of the Ser117/Ser117′ H-bond interaction. Furthermore, replacing the aryl ether of AG10 with the aryl amine for our compounds may alter the p<i>K</i><sub>a</sub> of the carboxylic acid and modulate the strength of its interactions with Lys15/Lys15′. Additionally, our piperazine-containing scaffolds may be unable to attain a fully suitable bioactive conformation to allow for the optimal pyrazole head group and/or carboxylic acid bottom-group binding interactions due to the reduced flexibility of the core. The increased rigidity imposed by the piperazine core may actually not confer a significant entropic benefit and may prevent optimal occupancy required for fortified H-bond, van der Waals, and hydrophobic effect contributions. Alternatively, it may also be possible that the potencies exhibited by AG10 and <b>14</b> and <b>26</b> may simply represent the upper limit for ligand binding affinity at the T4 site.</div><div class="NLM_p">We next investigated whether moving the fluorine of <b>14</b> from the para position relative to the carboxylic acid to the corresponding ortho and meta positions would have an effect on TTR potency (<b>20f</b>–<b>h</b>). Interestingly, the SAR for this group demonstrated a preference for fluorine substitution para to the carboxylic acid. The ortho-fluorinated analogue <b>20f</b> (TTR FP IC<sub>50</sub> = 550 nM) exhibited a >2-fold loss in potency relative to <b>14</b>, while the alternate ortho-substituted fluorinated analogue <b>20g</b> exhibited a greater loss in potency (∼6.5-fold) (TTR FP IC<sub>50</sub> = 1.44 μM). The <i>meta</i>-fluoro analogue <b>20h</b> (TTR FP IC<sub>50</sub> = 620 nM) was nearly equipotent with <b>20f</b>. The relatively modest decrease in potency observed for <b>20f</b> and <b>20h</b> may be attributed to their respective fluorine atoms being unable to optimally project into and fully occupy the HBP1′ or HBP1 pocket, potentially leading to weaker van der Waals interactions and destabilized binding poses. Contrarily, the substitution pattern of <b>20g</b> may potentially project the fluorine atom into an area that does not allow it to occupy either HBP1 or HBP1′ and/or engage in any favorable binding interactions, thus leading to the more significant loss in potency exhibited. Finally, we prepared and tested the disubstituted analogue <b>20i</b> that incorporated a methyl group ortho (2-position) to the carboxylic acid, which could serve as a potential blocking group to hinder a possible acyl glucuronidation metabolic pathway. Gratifyingly, the compound was active and exhibited good potency (TTR FP IC<sub>50</sub> = 600 nM). As previously stated, uridine 5′-diphospho-glucuronosyltransferase (UGT) acyl glucuronidation has been identified as the predominant metabolic pathway of AG10.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> As acyl glucuronidation is reported to be associated with an increased incidence of idiosyncratic toxicity,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> the diminishment or elimination of this metabolic pathway should be considered during the early stages of drug discovery to potentially remove or hinder the probability of encountering this liability. Although AG10 has been found to be safe and well tolerated clinically, we wanted to investigate early-stage analogues that may potentially hinder an acyl glucuronidation metabolic pathway for our series. Thus, the introduction of a methyl group within close proximity to the nucleophilic carboxylate moiety was anticipated to sterically encumber and reduce its accessibility to UGT and the UDP-glucuronic acid cofactor, potentially impairing or prohibiting acyl glucuronidation.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Future metabolite profiling and structural elucidation studies will be conducted to investigate whether <b>14</b> and/or <b>20i</b> are subject to acyl glucuronidation <i>in vivo</i> and if there are significant differences observed with regard to the extent of this type of metabolism between the two analogues.</div><div class="NLM_p">In addition to TTR binding, we also tested our compounds, together with tafamidis and AG10, in the <i>in vitro</i> RBP4 scintillation proximity (SPA) assay, which is used to measure binding potency of all-<i>trans</i>-retinol-competitive ligands at RBP4. Neither tafamidis, AG10, nor any of our novel TTR ligands exhibited activity at RBP4 in this assay (RBP4 SPA IC<sub>50</sub> for all compounds tested >3 μM). We also tested our most potent TTR ligands in the RBP4–TTR HTRF assay,<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3−7)</a> which is typically used to determine the all-<i>trans</i>-retinol-competitive RBP4 antagonist potency for inhibiting the holo-RBP4–TTR complex formation. Interestingly, despite a lack of activity in the RBP4 SPA assay, we did observe activity in the RBP4–TTR HTRF assay for some of the compounds tested from this portfolio. Tafamidis, AG10, <b>14</b>, <b>20b</b>, <b>20d</b>, <b>20e</b>, and <b>26</b> were all found to exhibit single-digit to submicromolar IC<sub>50</sub> potency values in this assay, providing evidence that the compounds are also capable of hindering holo-RBP4–TTR complexation. Interestingly, compound <b>20i</b> exhibited very weak activity in this assay, despite presenting TTR potency that is comparable to the aforementioned HTRF-active compounds.</div><div class="NLM_p">We next explored the SAR effects of a focused sample set of three piperazine ring isostere core linker analogues (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The (3a<i>S</i>,6a<i>S</i>)-octahydropyrrolo[3,4-<i>c</i>]pyrrole fused bicyclic analogue <b>32</b> exhibited an order of magnitude loss in potency relative to <b>14</b> (TTR FP IC<sub>50</sub> = 2.82 μM), while racemic 2,7-diazaspiro[4.4]nonane (±)-<b>38</b> was found to be 5-fold less potent (TTR FP IC<sub>50</sub> = 1.08 μM). 2,6-Diazaspiro[3.3]heptane <b>44</b> was inactive at TTR. None of the piperazine isostere analogues demonstrated activity in the <i>in vitro</i> RBP4 SPA assay. The diminishment in potency or complete loss of activity for these compounds could be attributed to either the longer lengths or unfavorable geometries (or both) of the linkers, which prohibited the formation of compatible binding poses within the T4 site. Due to their poor binding at TTR, these compounds were not profiled for activity in the RBP4–TTR HTRF assay.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. TTR FP and RBP4 SPA <i>In Vitro</i> Assay Data for Conformationally Constrained Piperazine Isostere TTR Tetramer Kinetic Stabilizer Analogues (Core Scaffold Region SAR)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0022.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">TTR FP<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">RBP4 SPA<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">>3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char=".">2.82</td><td class="colsep0 rowsep0" align="char" char=".">>3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(±)-38</b></td><td class="colsep0 rowsep0" align="char" char=".">1.08</td><td class="colsep0 rowsep0" align="char" char=".">>3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values for the TTR FP assay obtained in the presence of a fixed, 25 μM concentration of fluorescein isothiocyanate (FITC)-coupled TTR FP probe.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values for the RBP4 SPA assay obtained in the presence of a fixed, 10 nM concentration of <sup>3</sup>H-retinol.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">For compounds tested multiple times (more than twice), the IC<sub>50</sub> data is represented as the mean ± standard deviation. For those compounds that were only tested twice, the IC<sub>50</sub> data is shown as the mean of two independent experiments and not as the mean ± standard deviation.</p></div></div></div><div class="NLM_p">A concise exploration of 3,5-dimethyl-1<i>H</i>-pyrazole head group SAR for analogue <b>14</b> was also conducted (<b>46</b>, <b>48</b>, <b>50</b>, and <b>52</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Previous reports indicate very tight SAR for this region as exchanging the methyl groups of the 3,5-dimethyl-1<i>H</i>-pyrazole of AG10 (<b>5</b>) with ethyl groups or methylation of one of the pyrazole nitrogen atoms was not well tolerated.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Thus, we prepared a focused sample set that was designed to further probe the nature of the T4 inner binding cavity. Replacement of the 3,5-dimethyl-1<i>H</i>-pyrazole of <b>14</b> with a 3,5-dimethylisoxazole ring (<b>46</b>) was not well tolerated and leads to a >20-fold loss in potency (TTR FP IC<sub>50</sub> = 5.3 μM). This observation may be attributed to the installation of a poorer H-bond-accepting isoxazole ring system, which may have led to significantly weaker putative H-bonds with Ser117 and Ser117′ relative to <b>14</b>. Incorporation of a tetrazole group (<b>48</b>) led to a complete loss in TTR activity, which may be attributed to (1) the contrasting polarity of the tetrazole with the hydrophobic macromolecular interior of the inner T4 binding site and/or (2) the lack of pendant methyl groups to occupy the adjacent HBP3 and HBP3′ pockets. Interestingly, replacing the 3,5-dimethyl-1<i>H</i>-pyrazole of <b>14</b> with a 2-trifluoromethylphenyl head group (<b>50</b>) also led to a diminishment in potency (TTR FP IC<sub>50</sub> = 1.7 μM), though not as severe as was observed for isoxazole <b>46</b> and tetrazole <b>48</b>. The 2-trifluoromethylphenyl head group of <b>50</b> is significantly more hydrophobic than the 3,5-dimethyl-1<i>H</i>-pyrazole, and it is incapable of H-bond interactions with Ser117 and Ser117′. Furthermore, the X-ray crystal structure PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a> indicates that there is insufficient space between the symmetry-related side chains of Ser117 to accommodate the size of the 2-trifluoromethylphenyl ring. We speculate that the relatively moderate loss in potency observed for <b>50</b> may be due to an alternative binding pose similar to that reported for TTR stabilizer <b>12</b>,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> which could involve the benzoic acid of <b>50</b> projecting inward and toward HPB3 and Ser117, while the 2-trifluoromethylphenyl ring is positioned closer to the opening of the binding site where it may engage HPB2 and/or HBP3. It is unclear at this time as to why this compound exhibits moderate potency and we plan to obtain an X-ray crystal structure of it cocrystallized with TTR to determine its mode of binding. The 3-methyl-1<i>H</i>-pyrazol-4-yl analogue <b>52</b> was found to be inactive.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. TTR FP and RBP4 SPA <i>In Vitro</i> Assay Data for TTR Tetramer Kinetic Stabilizer Analogues Bearing 3,5-Dimethyl-1<i>H</i>-pyrazole Replacements (Head Group Region SAR)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0023.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0024.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values for the TTR FP assay obtained in the presence of a fixed, 25 μM concentration of fluorescein isothiocyanate (FITC)-coupled TTR FP probe.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values for the RBP4 SPA assay obtained in the presence of a fixed, 10 nM concentration of <sup>3</sup>H-retinol.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">For compounds tested multiple times (more than twice), the IC<sub>50</sub> data is represented as the mean ± standard deviation. For those compounds that were only tested twice, the IC<sub>50</sub> data is shown as the mean of two independent experiments and not as the mean ± standard deviation.</p></div></div><div></div></div><div class="NLM_p">We then examined two replacements for the carboxylic acid of <b>14</b>, which included primary carboxamide <b>53</b> and the bioisostere tetrazole <b>54</b>. Carboxamide <b>53</b> exhibited good potency and was approximately 3-fold less potent than <b>14</b>. This is presumably due to the fact that the primary carboxamide, although capable of serving as a H-bond donor and acceptor that can form strong charge-reinforced H-bonds with Lys15/Lys15′ and Glu54/Glu54′, is nonionizable and unable to engage in stronger electrostatic interactions that the carboxylic acid of <b>14</b> is capable of. The tetrazole of <b>54</b> is ionizable at physiological pH and serves as a suitable bioisostere of the carboxylic acid, thus likely allowing it to participate in similar electrostatic interactions with Lys15/Lys15′, which may explain why it is equipotent with <b>14</b>. As an additional beneficial attribute, the tetrazole of <b>54</b> may also serve to potentially hinder acyl glucuronidation. Interestingly, despite conferring TTR potency and selectivity that is comparable to <b>14</b> (TTR FP IC<sub>50</sub> = 0.26 nM; RBP4 SPA IC<sub>50</sub> > 3 μM), tetrazole <b>54</b> exhibited an approximate 10-fold loss in potency in the RBP4–TTR HTRF assay (RBP4–TTR HTRF IC<sub>50</sub> = 9.58 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. TTR FP and RBP4 SPA <i>In Vitro</i> Assay Data for Primary Carboxamide and Tetrazole TTR Tetramer Kinetic Stabilizer Analogues (Bottom-Group Region SAR)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0025.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">TTR FP<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">RBP4 SPA<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">RBP4–TTR HTRF<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">0.845</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="char" char=".">0.67</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">>3</td><td class="colsep0 rowsep0" align="left">9.58</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values for the TTR FP assay obtained in the presence of a fixed, 25 μM concentration of fluorescein isothiocyanate (FITC)-coupled TTR FP probe.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values for the RBP4 SPA assay obtained in the presence of a fixed, 10 nM concentration of <sup>3</sup>H-retinol.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub> values for the HTRF assay obtained in the presence of a 1 μM concentration of retinol.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">For compounds tested multiple times (more than twice), the IC<sub>50</sub> data is represented as the mean ± standard deviation. For those compounds that were only tested twice, the IC<sub>50</sub> data is shown as the mean of two independent experiments and not as the mean ± standard deviation.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">ND, not determined.</p></div></div></div><div class="NLM_p">We next evaluated our most potent compounds from our SAR campaign for their corresponding ADME properties. The <i>in vitro</i> pharmacological profiles presented in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> show that all of the compounds possess excellent kinetic aqueous solubility in phosphate-buffered saline (PBS) (pH = 7.4), excellent microsomal stability with low intrinsic clearance (CL<sub>int</sub>) values across multiple species, and suitable % plasma protein binding (PPB) values that largely indicate relatively low fraction unbound in human, rat, and mouse. Compound <b>14</b> emerged from this collection as the lead because it was among the most potent in the series that presented the best cytochrome P450 (CYP) inhibition profile. Further analysis of <b>14</b> revealed that the compound did not demonstrate any limiting off-target pharmacology at the human ether-a-go-go (hERG) channel (hERG IC<sub>50</sub> > 30 μM; five-point dose–response (<i>n</i> = 2), electrophysiological patch-clamp (QPatch) assay) or at the nuclear peroxisome proliferator-activated receptor-γ receptor (PPARγ) (PPARγ EC<sub>50</sub> > 30 μM). PPARγ agonists may potentially induce adverse effects, which include risk for fluid retention, weight gain, bone loss, and congestive heart failure.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Our previously reported RBP4 antagonist <b>BPN-14136</b> (structure not shown)<a onclick="showRef(event, 'ref5 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref5 ref10 ref11">(5,10,11)</a> was found to exhibit modest agonist activity for the receptor (PPARγ IC<sub>50</sub> = 3.6 μM in the agonist-induced corepressor NCoR release assay). Due to the fact that <b>14</b> shares some structural complementarity with <b>BPN-14136</b> and with reported PPARγ agonists, we surveilled our novel TTR tetramer kinetic stabilizer series for this undesirable off-target pharmacology.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vitro</i> ADME Profile for Selected TTR Tetramer Kinetic Stabilizer Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center">microsomal CL<sub>int</sub> (mL/(min mg))<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="4" align="center">liver microsomal stability (% remaining at 30 min)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">%PPB<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">TTR FP IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">solubility (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">H</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">M</th><th class="colsep0 rowsep0" align="center">monkey</th><th class="colsep0 rowsep0" align="center">HLM</th><th class="colsep0 rowsep0" align="center">RLM</th><th class="colsep0 rowsep0" align="center">MLM</th><th class="colsep0 rowsep0" align="center" char=".">monkey LM</th><th class="colsep0 rowsep0" align="center" char=".">predicted half-life<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (H, R, M, monkey)</th><th class="colsep0 rowsep0" align="center">CYP inhibition (% inhibition at 10 μM) 2C9, 2C19, 2D6, 3A4</th><th class="colsep0 rowsep0" align="center">H</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">M</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left"><b>14</b></td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">0.22</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">184.5</td><td class="colsep0 rowsep0" rowspan="4" colspan="4" align="left"><0.0231</td><td class="colsep0 rowsep0" rowspan="4" align="left">93</td><td class="colsep0 rowsep0" rowspan="4" align="left">98</td><td class="colsep0 rowsep0" rowspan="4" align="left">102</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">94</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">>60 min for all species</td><td class="colsep0 rowsep0" align="left">2C9—10.4%</td><td class="colsep0 rowsep0" rowspan="4" align="left">83</td><td class="colsep0 rowsep0" rowspan="4" align="left">97</td><td class="colsep0 rowsep0" rowspan="4" align="left">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19—3.1%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6—8.1%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4—(−)2.2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left"><b>20b</b></td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">0.30</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">200</td><td class="colsep0 rowsep0" rowspan="4" colspan="4" align="left"><0.0231</td><td class="colsep0 rowsep0" rowspan="4" align="left">108</td><td class="colsep0 rowsep0" rowspan="4" align="left">101</td><td class="colsep0 rowsep0" rowspan="4" align="left">102</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">102</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">>60 min for all species</td><td class="colsep0 rowsep0" align="left">2C9—1.4%</td><td class="colsep0 rowsep0" rowspan="4" align="left">75</td><td class="colsep0 rowsep0" rowspan="4" align="left">78</td><td class="colsep0 rowsep0" rowspan="4" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19—4.2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6—8.0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4—19.6%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left"><b>20d</b></td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">0.21</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">200</td><td class="colsep0 rowsep0" rowspan="4" colspan="4" align="left"><0.0231</td><td class="colsep0 rowsep0" rowspan="4" align="left">101</td><td class="colsep0 rowsep0" rowspan="4" align="left">101</td><td class="colsep0 rowsep0" rowspan="4" align="left">97.5</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">96.7</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">>60 min for all species</td><td class="colsep0 rowsep0" align="left">2C9—17.1%</td><td class="colsep0 rowsep0" rowspan="4" align="left">86</td><td class="colsep0 rowsep0" rowspan="4" align="left">91</td><td class="colsep0 rowsep0" rowspan="4" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19—2.3%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6—5.9%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4—14.8%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left"><b>20c</b></td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">0.26</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">200</td><td class="colsep0 rowsep0" rowspan="4" colspan="4" align="left"><0.0231</td><td class="colsep0 rowsep0" rowspan="4" align="left">97.8</td><td class="colsep0 rowsep0" rowspan="4" align="left">96.6</td><td class="colsep0 rowsep0" rowspan="4" align="left">96</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">100</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">>60 min for all species</td><td class="colsep0 rowsep0" align="left">2C9—56.2%</td><td class="colsep0 rowsep0" rowspan="4" align="left">97</td><td class="colsep0 rowsep0" rowspan="4" align="left">97</td><td class="colsep0 rowsep0" rowspan="4" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19—0.06%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6—7.34%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4—(−)5.2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left"><b>20e</b></td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">0.20</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">200</td><td class="colsep0 rowsep0" rowspan="4" colspan="4" align="left"><0.0231</td><td class="colsep0 rowsep0" rowspan="4" align="left">103</td><td class="colsep0 rowsep0" rowspan="4" align="left">104</td><td class="colsep0 rowsep0" rowspan="4" align="left">98</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">100</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">>60 min for all species</td><td class="colsep0 rowsep0" align="left">2C9—25.2%</td><td class="colsep0 rowsep0" rowspan="4" align="left">91</td><td class="colsep0 rowsep0" rowspan="4" align="left">89</td><td class="colsep0 rowsep0" rowspan="4" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19—1.85%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6—10.0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4—19.5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left"><b>20i</b></td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">0.60</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">200</td><td class="colsep0 rowsep0" rowspan="4" colspan="4" align="left"><0.0231</td><td class="colsep0 rowsep0" rowspan="4" align="left">90</td><td class="colsep0 rowsep0" rowspan="4" align="left">105</td><td class="colsep0 rowsep0" rowspan="4" align="left">96</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">95.2</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">>60 min for all species</td><td class="colsep0 rowsep0" align="left">2C9—1.1%</td><td class="colsep0 rowsep0" rowspan="4" align="left">87</td><td class="colsep0 rowsep0" rowspan="4" align="left">93</td><td class="colsep0 rowsep0" rowspan="4" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19—(−)3.0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6—9.2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4—31.7%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left"><b>54</b></td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">0.26</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">200</td><td class="colsep0 rowsep0" rowspan="4" colspan="4" align="left">H = 0.0184; R, M, monkey <0.0231</td><td class="colsep0 rowsep0" rowspan="4" align="left">71.4</td><td class="colsep0 rowsep0" rowspan="4" align="left">98.2</td><td class="colsep0 rowsep0" rowspan="4" align="left">91.5</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">95.7</td><td class="colsep0 rowsep0" rowspan="4" align="char" char=".">H = 75.4 min; R, M, monkey <60 min</td><td class="colsep0 rowsep0" align="left">2C9—26.3%</td><td class="colsep0 rowsep0" rowspan="4" align="left">92</td><td class="colsep0 rowsep0" rowspan="4" align="left">94</td><td class="colsep0 rowsep0" rowspan="4" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19—(−)4.8%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6—0.8%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4—18.9%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Kinetic solubility measured in PBS (pH = 7.4). When the observed mean solubility is greater than 200 μM, the mean value is adjusted to the maximum assay concentration, which is 200 μM.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Microsomal intrinsic clearance (CL<sub>int</sub>); H, human; R, rat; M, mouse; cyno, cynomolgus monkey.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Liver microsomal metabolic stability, % of parent drug remaining after a 30 min incubation in the presence of the microsomes; HLM, human liver microsomes; RLM, rat liver microsomes; MLM, mouse liver microsomes; monkey LM, monkey liver microsomes. %Remaining values shown as higher than 100% may be potentially attributed to error.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">When the calculated half-life is longer than the duration of the experiment, the half-life is expressed as greater than the longest incubation time.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">%PPB, plasma protein binding; H, human; R, rat; M, mouse.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Analogue <b>14</b> Inhibits Formation of High-Molecular-Weight Forms of TTR</h3><div class="NLM_p">The ability of TTR ligands to act as kinetic stabilizers of TTR tetramers can be assessed <i>in vitro</i> using a low pH-induced TTR aggregation sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) assay.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> A 72 h incubation of TTR tetramers at pH = 4.0 initiates its dissociation into monomeric intermediates that misassemble and oligomerize into amyloid fibrils and other high-molecular-weight forms.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> To confirm the ability of analogue <b>14</b> to act as a kinetic stabilizer of TTR tetramers, we tested its ability to suppress low pH-mediated TTR aggregate formation using the previously published protocol. Tafamidis was used as a positive control in the aggregation experiments. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, following 72 h of incubation of TTR tetramers with dimethyl sulfoxide (DMSO) at pH = 4 at 37 °C, the amount of high-molecular-weight forms of TTR is greatly increased in comparison to the DMSO control incubated for 72 h at pH = 7.5. Consistent with its ability to act as a kinetic TTR stabilizer, treatment with analogue <b>14</b> (50 μM) as well as with tafamidis (50 μM), significantly inhibited the formation of high-molecular-weight forms of TTR (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). Higher intensities of the TTR monomer and dimer bands in samples treated with <b>14</b> and tafamidis when compared to that of DMSO correlated with a corresponding reduction in TTR aggregates induced by <b>14</b> and tafamidis. Quantification of Western blot band intensities established a 3.1-fold reduction in the amount of aggregates in the presence of <b>14</b>, while a 3.0-fold reduction was induced by tafamidis (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). Significant increase in the dimer band intensities and appreciable increase in the intensity of TTR monomer bands conferred by <b>14</b> and tafamidis were associated with inhibition of the low pH-induced TTR aggregate formation (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C,D). The results of the conducted aggregation experiments confirmed that <b>14</b> can act as a TTR tetramer kinetic stabilizer.</div><figure id="fig9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0010.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Analogue <b>14</b> reduces the formation of high-molecular-weight TTR forms in the acid-induced aggregation assay. TTR protein (5 μg) was aggregated using acetate buffer (pH = 4.0) and incubated for 72 h at 37 °C. TTR tetramer concentration during the incubation was 9 μM. After incubation in the presence of DMSO, 50 μM tafamidis, and 50 μM <b>14</b> and cross-linking with glutaraldehyde, samples were subjected to SDS-PAGE followed by Western blot analysis of TTR. The representative blot of at least three independent experiments is presented (A). Bar graphs represent the pixel volume means ± SD of the scanned bands on the immunoblots in arbitrary units for TTR high-molecular-weight aggregates (B), dimers (C), and monomers (D). Statistical significance was determined by one-way analysis of variance (ANOVA) with the Holm–Šidák <i>post hoc</i> test; *, <i>p</i> ≤ 0.05; **, <i>p</i> ≤ 0.01; ***, <i>p</i> ≤ 0.001; ****, <i>p</i> ≤ 0.0001 compared to TTR aggregation + DMSO group (pH 4.0); <sup>#</sup>, <i>p</i> ≤ 0.05; <sup>##</sup>, <i>p</i> ≤ 0.01; <sup>###</sup>, <i>p</i> ≤ 0.001; <sup>####</sup>, <i>p</i> ≤ 0.0001 compared to TTR without aggregation group (pH = 7.5).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vivo</i> Activity: PK Characteristics of <b>14</b> in Mice</h3><div class="NLM_p">The PK properties of <b>14</b> were determined <i>via</i> studies conducted with CD-1 male mice (2 mg/kg intravenous (IV) and 5 mg/kg oral (PO)) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The compound exhibited a favorable plasma clearance (0.354 L/(h kg)) and a good half-life of 5.08 h. Rapid oral absorption was observed (<i>T</i><sub>max</sub> = 0.42 h) with a maximal concentration (<i>C</i><sub>max</sub>) of 1563 ng/mL. Compound <b>14</b> presented a low volume of distribution (<i>V</i><sub>ss</sub> = 2.19 L/kg), good overall exposure (area under the curve (AUC)<sub>INF</sub> was 16 073 h ng/mL), and excellent oral bioavailability (%<i>F</i> = 103%). The observed slightly >100% oral bioavailability for <b>14</b> may be the result of its low plasma clearance and potential nonlinear pharmacokinetics over the dose range tested or it may be due in part to enterohepatic recycling.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. <i>In Vivo</i> PK Data for Analogue <b>14</b> Following IV and PO Administration in CD-1 Mice<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="("><i>C</i><sub>0</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="(">CL<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (L/(h kg))</th><th class="colsep0 rowsep0" align="center" char="("><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (h)</th><th class="colsep0 rowsep0" align="center" char="("><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="(">AUC<sub>last</sub><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a> (h ng/mL)</th><th class="colsep0 rowsep0" align="center" char="(">AUC<sub>INF</sub><a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (h ng/mL)</th><th class="colsep0 rowsep0" align="center">%<i>F</i><a class="ref internalNav" href="#t6fn10" aria-label="j">j</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char="(">1622 (267)</td><td class="colsep0 rowsep0" align="char" char="(">0.354 (0.139)</td><td class="colsep0 rowsep0" align="char" char="(">5.08 (0.814)</td><td class="colsep0 rowsep0" align="char" char="(">2.18 (0.585)</td><td class="colsep0 rowsep0" align="char" char="(">6214 (2321)</td><td class="colsep0 rowsep0" align="char" char="(">6242 (2303)</td><td class="colsep0 rowsep0" align="left">NA</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="left" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="("><i>C</i><sub>max</sub><a class="ref internalNav" href="#t6fn8" aria-label="h">h</a> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="("><i>T</i><sub>max</sub><a class="ref internalNav" href="#t6fn9" aria-label="i">i</a> (h)</th><th class="colsep0 rowsep0" align="center" char="("><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (h)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> (mL/kg)</th><th class="colsep0 rowsep0" align="center" char="(">AUC<sub>last</sub><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a> (h ng/mL)</th><th class="colsep0 rowsep0" align="center" char="(">AUC<sub>INF</sub><a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (h ng/mL)</th><th class="colsep0 rowsep0" align="center" char="(">%<i>F</i><a class="ref internalNav" href="#t6fn10" aria-label="j">j</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char="(">1563 (115)</td><td class="colsep0 rowsep0" align="char" char="(">0.42 (0.14)</td><td class="colsep0 rowsep0" align="char" char="(">5.38 (0.624)</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="(">16 040 (2778)</td><td class="colsep0 rowsep0" align="char" char="(">16 073 (2783)</td><td class="colsep0 rowsep0" align="char" char="(">103 (17.8)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Data are represented as the mean with standard deviation in parentheses (mean (SD)). Dosing groups consisted of three drug naïve adult male CD-1 mice. IV administration: test article was administered at the 2 mg/kg dose; test article vehicle = 3% dimethylacetamide (DMA)/45% poly(ethylene glycol) 300 (PEG300)/12% ethanol/40% sterile water; PO administration: test article was administered at the 5 mg/kg dose, vehicle = 2% Tween 80 in 0.9% saline.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Observed initial concentration of compound in blood at time zero.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Total body clearance.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Apparent half-life of the terminal phase of elimination of compound from blood.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Volume of distribution at steady state.</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">Area under the blood concentration <i>versus</i> time curve from 0 to the last time point that the compound was quantifiable in blood.</p></div><div class="footnote" id="t6fn7"><sup><sup>g</sup></sup><p class="last">Area under the blood concentration <i>versus</i> time curve from 0 to infinity.</p></div><div class="footnote" id="t6fn8"><sup><sup>h</sup></sup><p class="last">Maximum observed concentration of compound in blood.</p></div><div class="footnote" id="t6fn9"><sup><sup>i</sup></sup><p class="last">Time of maximum observed concentration of compound in blood.</p></div><div class="footnote" id="t6fn10"><sup><sup>j</sup></sup><p class="last">Bioavailability; <i>F</i> = (AUC<sub>INFpo</sub> × dose<sub>iv</sub>)/AUC<sub>INFiv</sub> × dose<sub>po</sub>.</p></div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>In Vivo</i> Activity: RBP4-Lowering and PK–Pharmacodynamics (PD) Correlations of Analogue <b>14</b> in Mouse</h3><div class="NLM_p">Taking into account that the levels of serum RBP4 depend on formation of the RBP4–TTR–all-<i>trans</i>-retinol complex in circulation, we wanted to establish that a selective TTR tetramer binding ligand can allosterically antagonize the retinol-dependent RBP4–TTR interaction and potentially be capable of reducing circulating RBP4 levels <i>in vivo</i>. We evaluated the effect of a single oral dose of <b>14</b> on dynamics of serum RBP4 levels in mice (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). After a single 25 mg/kg oral dose of <b>14</b>, a maximal 66% reduction in serum RBP4 levels was observed 2 h following the dose administration (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). Given that T4 and synthetic TTR ligands may stimulate the secretion of certain TTR forms,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> we assessed the effect of oral administration of <b>14</b> on circulating levels of transthyretin. No changes in serum TTR levels in response to <b>14</b> dosing were noted (data not shown). The dynamics of serum RBP4 changes induced by <b>14</b> demonstrated a very good correlation between the presence of the compound in circulation after oral dosing (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B) and a reduction in serum RBP4. The maximal RBP4 reduction seen at the 1 and 2 h time points correlated very well with rapid oral absorption (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) that led to the high concentration of <b>14</b> in the blood at time points of the maximal serum RBP4 reduction. Compound clearance by 24 h matches well with the lack of the PD response at this time point.</div><figure id="fig10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0011.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Pharmacokinetic and pharmacodynamic properties of 14 in mice. (A) Serum RBP4 levels following a single 25 mg/kg oral administration of <b>14</b>. (B) Blood compound levels following administration of a single oral 5 mg/kg dose of <b>14</b>. Data are presented as means ± SD. Three mice per treatment group were used in the PK–PD study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To test whether members of the general class of TTR ligands may be able to reduce serum RBP4, we conducted a series of single oral dose experiments in Balb/c mice with established TTR tetramer stabilizers (tafamidis and AG10) as well as with our new analogues <b>14</b>, <b>20c</b>, and <b>20e</b>. Analogues <b>20c</b> and <b>20e</b> were chosen as they exhibited equivalent potency to <b>14</b> in the TTR FP assay and exhibited similar ADME profiles relative to <b>14</b>. A bis-hydrochloric salt of <b>14</b> (<b>14a</b>) was used in these experiments due to an observed improved solubility in the dosing vehicle (0.9% NaCl, 2% Tween 80). Despite variability in baseline levels of serum RBP4 between study groups, all tested compounds induced a significant reduction in circulating levels of RBP4 in comparison to the vehicle (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Analogue <b>14a</b> showed superior RBP4-lowering efficacy in comparison to AG10 and tafamidis (81% serum RBP4 reduction at the 6 h time point), while tafamidis seems to have a longer duration of action (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). We plan to obtain PK data for analogues <b>20e</b>, <b>20c</b>, and <b>14a</b> to generate PK–PD correlations in a similar manner to <b>14</b>. Given that we and others previously established a very good correlation between pharmacological reduction of serum RBP4 and efficacy in the <i>Abca</i>4<sup>–/–</sup> mouse model of enhanced retinal lipofuscinogenesis,<a onclick="showRef(event, 'ref10 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref10 ref68 ref69">(10,68,69)</a> our RBP4-lowering data for TTR ligands may indicate that members of a general class of TTR tetramer stabilizers could have utility in treating retinal diseases associated with accumulation of RPE lipofuscin.</div><figure id="fig11" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0012.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effect of TTR ligands on circulating levels of serum RBP4 in Balb/c mice. Serum RBP4 levels were measured following a single oral administration of (A) AG10, (B) tafamidis, (C) <b>14a</b>, (D) <b>20e</b>, and (E) <b>20c</b>. Percent changes of serum RBP4 in comparison to the baseline levels (100%) are shown in (F) for test compounds as well as for the dosing vehicle (0.9% NaCl, 2% Tween 80). The oral dose was 25 mg/kg for AG10, <b>14a</b>, <b>20e</b>, and <b>20c</b>; the tafamidis dose was 50 mg/kg. Data represented as the mean ± SD. Three to eight mice per compound treatment group were used in the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is currently unclear how <b>14</b> and other TTR ligands inhibit RBP4–TTR–all-<i>trans</i>-retinol complex formation, which seems to be the likely cause of serum RBP4-lowering. Indeed, tafamidis, AG10, <b>14</b>, and <b>20e</b> were all found to exhibit good potency in the RBP4–TTR HTRF assay, providing evidence that the compounds are in fact hindering complex formation. One possible mechanism of action may be that the binding of kinetic stabilizers such as <b>14</b> at the T4 site causes conformational changes to occur within the distal PPI interface domain that are unfavorable for holo-RBP4 association. For example, the aforementioned TTR residues Ile84, Val-20, and Ala-81 play pivotal roles in the formation of the PPI interface domain and mutations involving TTR Ile84 have deleterious consequences with regard to complex formation with holo-RBP4.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The <i>K</i><sub>d</sub> for the holo-RBP–TTR complex is approximately 0.4 μM, whereas the I84S mutation results in negligible TTR affinity for holo-RBP4 and abrogates complex formation.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Indeed, individuals expressing variants of TTR whereby Ile84 is replaced with either Ser or Asn have substantially lowered plasma concentrations of RBP4.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> It may be possible that ligand binding at the T4 site causes a conformational shift that impedes Ile84 and/or other residues within the TTR hydrophobic patch from facilitating docking to holo-RBP4, in much the same manner as RBP4 antagonist prevents loops β3−β4 and β5−β6 to adopt favorable conformations that promote association with the PPI domain of TTR. The emerging RBP4–TTR HTRF SAR is also intriguing. Of the compounds tested in this assay, the two that were found to be the least potent (methylated analogue <b>20i</b> and tetrazole <b>54</b>) present either a steric blocking group ortho to or a bioisosteric replacement of the carboxylic acid of <b>14</b>. We plan to determine if <b>20i</b>, carboxamide <b>53</b>, and tetrazole <b>54</b> also induce a significant lowering of serum RBP4 in mice and we will generate additional amide analogues and isosteres of <b>53</b>, carboxylic acid isosteres of <b>14</b>, and analogues of <b>20i</b> featuring various blocking substituents beyond a methyl group to further probe TTR FP and RBP4–TTR HTRF SAR effects.</div><div class="NLM_p">It may also be possible that in addition to binding at the T4 site, compound <b>14</b> may also be binding at another-to-be-determined site on TTR and/or RBP4 that results in antagonism of holo-RBP4–TTR complex formation. We plan to address questions concerning the putative mechanism of action for holo-RBP4–TTR complex disruption by <b>14</b><i>via</i> conducting a series of studies designed to further elucidate the nature of the compound’s mode(s) of binding. This includes the generation of an X-ray crystal structure of TTR cocrystallized with <b>14</b> to confirm that the compound is binding within the T4 site in the pose predicted by our docking model. Such data, coupled with saturation transfer difference (STD) nuclear magnetic resonance (NMR) experiments,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> may also allow us to determine if <b>14</b> binding at the T4 site imparts conformational changes within the TTR hydrophobic patch and PPI domain that disfavor association with holo-RBP4. An X-ray crystal structure may also determine if <b>14</b> is binding at any other potential sites at TTR in addition to the T4 binding site. We also plan to conduct ITC studies with <b>14</b>. Generation of ITC data with <b>14</b> and TTR will help elucidate the relative magnitude of enthalpic and entropic contributions to binding for <b>14</b> relative to tafamidis and AG10, which could guide subsequent drug design campaigns for the series. Furthermore, we will also conduct ITC studies with <b>14</b> and RBP4 to probe whether the compound is potentially disrupting the holo-RBP4–TTR complex formation <i>via</i> binding to an allosteric site on the protein that overlaps with or is located separately from the all-<i>trans</i>-retinol orthosteric binding site. Such potential mechanisms of allosteric binding at RBP4 may not be detected with our RBP4 SPA binding assay if they do not disrupt all-<i>trans</i>-retinol binding.</div><div class="NLM_p last">In general, our current data proves that there is a very good PK–PD relationship between <b>14</b> exposure and serum RBP4-lowering activity in mice. In our previous work, we proved a direct correlation between serum RBP4-lowering induced by different classes of selective RBP4 antagonists and bisretinoid-lowering efficacy in the <i>Abca</i>4<sup>–/–</sup> mouse model of Stargardt disease.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Based on the very good <i>in vivo</i> RBP4-lowering activity exhibited by <b>14</b> and its bis-hydrochloride salt <b>14a</b>, it is expected that this compound will be efficacious in suppressing the formation of cytotoxic lipofuscin bisretinoids in the retina, and studies with the <i>Abca</i>4<sup>–/–</sup> mouse model are ongoing. The data presented herein justifies further evaluation of selective TTR ligands as a class of potential therapeutics for the treatment of Stargardt disease, dry AMD, and other conditions characterized by enhanced accumulation of lipofuscin in the retina.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01312" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01312" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Inherited Stargardt disease and dry AMD are the forms of macular degeneration that may potentially be treated by pharmacological inhibition of lipofuscin bisretinoid synthesis in the retina. Only one class of compounds, competitive antagonists of all-<i>trans</i>-retinol binding to RBP4, was currently known to block the all-<i>trans</i>-retinol-dependent RBP4–TTR interaction and reduce cytotoxic bisretinoid production in the animal models of excessive lipofuscin accumulation. However, the use of selective RBP4 antagonists may not be optimal in patients who, in addition to macular degeneration, may also be predisposed to genetic or sporadic forms of ATTR. The holo-RBP4–TTR interaction stabilizes a portion of TTR tetramers circulating in the bloodstream, thus preventing formation of TTR amyloid fibrils and ATTR. Selective RBP4 antagonists release the TTR tetramer from the serum holo-RBP4–TTR complex, and the release of a pool of unliganded TTR may be associated with destabilization of TTR tetramers. We hypothesized that ligands that selectively bind to TTR and not to RBP4 may also be capable of allosterically antagonizing all-<i>trans</i>-retinol-dependent RBP4–TTR ternary complex formation. Such selective TTR ligands may induce a desired partial reduction in serum RBP4 levels required for inhibition of lipofuscin bisretinoid synthesis in the retina while simultaneously providing adequate TTR tetramer kinetic stabilization. To the best of our knowledge, prior to the work reported herein, TTR had not been considered as a drug target for mechanisms or indications that may be treated <i>via</i> selective RBP4 antagonists. In the reported work, we sought to identify novel TTR tetramer kinetic stabilizers that may also demonstrate robust RBP4-lowering capability <i>in vivo</i>. We utilized a TTR computational docking model derived from reported X-ray crystallographic data (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a>) and SAR for clinically investigated AG10 to enable our structure-based drug design campaign. Our goal was to identify novel and conformationally constrained compounds that could provide favorable TTR tetramer kinetic stabilization. We initially prepared piperazine ring core linker congener <b>14</b>, which was found to exhibit excellent potency at TTR (TTR FP IC<sub>50</sub> = 220 nM). Our computational docking model derived from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a> provided insights into the molecular determinants responsible for the high-affinity <b>14</b> exhibits toward the TTR. Follow-up analogues of <b>14</b> included a focused sample set containing alternately substituted benzoic acid appendages as well as analogues that explored SAR effects with alternative pyrazole head groups. Compound <b>14</b> emerged as a lead upon conclusion of our SAR and ADME profiling campaigns and was found to possess excellent PK characteristics in mouse. Analogue <b>14</b> significantly decreases the formation of TTR high-molecular-weight aggregates in a manner comparable to tafamidis in an <i>in vitro</i> TTR aggregation assay, proving its activity as a TTR kinetic stabilizer. Furthermore, the compound and its bis-hydrochloride salt induced robust and sustained lowering of serum RBP4 levels upon oral dosing in mice. As previously stated, it is currently unclear how the TTR kinetic stabilizers studied in this work are inhibiting RBP4–TTR–all-<i>trans</i>-retinol complex formation, and future studies will be conducted to help gain a better understanding of these observations. However, the current data suggests that they may be efficacious in suppressing the formation of cytotoxic lipofuscin bisretinoids in the retina while preventing possible TTR amyloid fibril formation. This justifies evaluation of selective TTR tetramer ligands as a class of potential therapeutics for Stargardt disease, dry AMD, and other conditions characterized by enhanced accumulation of lipofuscin in the retina, especially in patients who are also prone to ATTR comorbidities such as sporadic SSA or hereditary TTR amyloidosis. Studies with <b>14</b> in the <i>Abca</i>4<sup>–/–</sup> mouse model are ongoing, and the data will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34236" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34236" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Fluorescence Polarization TTR Tetramer Binding Assay</h3><div class="NLM_p last">Binding potency (IC<sub>50</sub> values) of novel compounds for unliganded TTR tetramers isolated from human plasma (Clabiochem-Millipore, cat. no. 52957) was measured using an established fluorescence polarization assay designed for TTR kinetic stabilizers.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The assay measured competitive displacement of a fluorescent probe (fluorescein isothiocyanate (FITC) coupled to a diclofenac analogue <i>via</i> a PEGylated linker) by a novel compound from TTR. The FITC probe was synthesized at LeadGen Labr, LLC, using the reported route by Alhamadsheh and co-workers.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Each well contained 200 nM of TTR and 100 nM of FITC probe in the FP buffer (10 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.01% of 3-(3-cholamidopropyl)dimethylammonio-1-propanesulfonate (CHAPS), 0.01% Prionex) along with test compounds. Nonspecific binding was determined in the presence of 500 μM unlabeled diclofenac (Sigma-Aldrich). Reactions with test compounds were incubated overnight at 4 °C, and FP was measured on a Spectramax M5e plate reader (Molecular Devices).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> TTR Aggregation Assay</h3><div class="NLM_p last">The ability of test compounds to prevent TTR aggregation was evaluated under the acidic conditions that favor TTR aggregation and fibril formation.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> A 2 μL solution of 167 μM human TTR (ACRO Biosystems #H5223) was incubated with 7 μL of 50 mM sodium acetate (pH = 4.0) (Sigma-Aldrich # S7545), and 100 mM KCl (Sigma-Aldrich # S5405) in the presence or absence of 1 μL of TTR inhibitor for 72 h at 37 °C. At the end of the incubation, 3.5 μL of a 500 mM sodium phosphate (Sigma-Aldrich #S5136) buffer (pH = 8.0) was added to each sample for neutralization and 0.6 μL of 5% CHAPS (Sigma-Aldrich #C5070) as a detergent to prevent reassociation of protein. The cross-linking was performed by adding 1.5 μL of 5% glutaraldehyde solution (Sigma-Aldrich # G6257). After 4 min, the reaction was stopped by the addition of 2.5 μL of freshly made 5% sodium borohydride (NaBH<sub>4</sub>). Samples were subjected to TTR Western blotting with prealbumin antibodies (1:500; Dako #A0002). Band intensity for TTR monomer and TTR aggregates was quantified from scanned images of the blots.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>In Vitro</i> Binding of Compounds to RBP4</h3><div class="NLM_p last">Compound binding to RBP4 was assessed in the radiometric scintillation proximity (SPA) assay that was previously described.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> The assay measured competitive displacement of radiolabeled [<sup>3</sup>H]-all-<i>trans</i>-retinol from native RBP4 purified from human urine (Fitzgerald, 30R-AR022L). The protein was biotinylated using the EZ-link Sulfo-NHS-LC-Biotinylation kit from ThermoFisher (Cat #21335) as recommended by the manufacturer. Binding assays were implemented in a final volume of 100 μL in SPA buffer (1× PBR, pH 7.4, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.1% BRA, 0.5% CHAPS). The assay reaction included a radioligand, 10 nM [<sup>3</sup>H]-all-<i>trans</i>-retinol (48.7 Ci/mmol; PerkinElmer, Waltham, MA), along with the 0.3 mg/well streptavidin-PVT beads (PerkinElmer, RPNQ0006) and 50 nM biotinylated human RBP4. Unlabeled retinol (Sigma-Aldrich, cat # 95144) at 20 μM was added to control wells to assess a nonspecific binding. Radioactivity counts were measured using CHAMELEON plate reader (Hidex Oy, Turku, Finland) after 16 h of incubation at rt with mild shaking.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Assessment of Antagonistic Activity in the HTRF RBP4–TTR Interaction Assay</h3><div class="NLM_p last">The ability of analogues to act as antagonists of all-<i>trans</i>-retinol-dependent RBP4–TTR interaction was measured in the homogeneous time-resolved fluorescence (HTRF) assay. Untagged TTR (Calbiochem, cat # 529577) and maltose-binding protein-tagged RBP4 expressed in <i>Escherichia coli</i> were used in this assay. HTRF Cryptate labeling kit from CisBio (Cisbio, cat # 62EUSPEA, Bedford, MA) was used to label TTR with Eu<sup>3+</sup> cryptate. The assay was performed in a final assay volume of 16 μL in the buffer that contained 10 mM Tris–HCl (pH = 7.5), 1 mM dithiothreitol (DTT), 0.05% NP-40, 0.05% Prionex, 6% glycerol, and 400 mM KF. Other components of the reaction mix included 60 nM of MBP-RBP4, 5 nM of TTR-Eu, 26.7 nM of anti-MBP antibody conjugated with d2 (Cisbio, cat # 61MBPDAA), and 1 μM of all-<i>trans</i>-retinol (Sigma-Aldrich, cat # 95144). All of the reactions were performed under dim red light in the dark. The plates were read in the SpectraMax M5e Multimode Plate Reader (Molecular Devices, Sunnyvale, CA) after the overnight incubation at 4 °C. Fluorescence was excited at 337 nm; emission was measured at 668 and 620 nm with a 75 μs counting delay. The HTRF signal was expressed as the ratio of fluorescence intensity: Flu<sub>668</sub>/Flu<sub>620</sub> × 10 000.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Animal Care and Use Statement</h3><div class="NLM_p last">Information regarding <i>in vivo</i> experimental protocols is located within the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00099/suppl_file/jm1c00099_si_004.pdf" class="ext-link">Supporting Information</a> section. All of the protocols used for the <i>in vivo</i> experiments disclosed are in compliance with the U.S. Department of Agriculture’s (USDA) Animal Welfare Act (nine CFR parts 1–3); the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, National Academy Press, Washington, DC, 1996; and the National Institutes of Health, Office of Laboratory Animal Welfare. Whenever possible, procedures in this study are designed to avoid or minimize discomfort, distress, and pain to animals.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Docking Models</h3><div class="NLM_p last">PDB structures were prepared for molecular docking experiments using the protein structural preparation tool followed by Protonate3D, as implemented in the Molecular Operating Environment (MOE) 2020.09 (Chemical Computing Group, Inc., Montreal, Quebec, Canada, <a href="http://www.chemcomp" class="extLink">http://www.chemcomp</a>.com). Ligand structures were built with MOE and minimized using the MM-FF94x force field until a root-mean-square deviation (RMSD) gradient of 0.05 kcal/(mol Å) was reached. In the first step for protein preparation, we preprocessed the structure using the standard protocol, which included the assigning of bond orders, the adding of hydrogens, the creating of disulfide bonds, and the prediction of the structural protonation state at a physiological pH of 7.4. The structure was subjected to a short energy minimization routine to relax it using the Amber 99 force field as implemented in MOE. The following standard parameters were selected: receptor van der Waals scaling, 0.50; ligand van der Waals scaling, 0.50; and a maximum of 20 poses per ligand. The best docking pose for <b>14</b> was selected based on the lowest RMSD value, which was 1.7 Å.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Chemistry</h3><div class="NLM_p">All reactions were performed under a dry atmosphere of nitrogen unless otherwise specified. Indicated reaction temperatures refer to the reaction bath, while room temperature (rt) is noted as 25 °C. Commercial-grade reagents and anhydrous solvents were used as received from vendors, and no attempts were made to purify or dry these components further. Removal of solvents under reduced pressure was accomplished with a Buchi rotary evaporator at approximately 28 mmHg pressure using a Teflon-linked KNF vacuum pump. The measurement of pH for neutralizations or acidifications was measured with Hydrion pH paper (MicroEssential Lab). Thin-layer chromatography (TLC) was performed using 1 in. × 3 in. Analtech no. 02521 silica gel plates with a fluorescent indicator. Visualization of TLC plates was made by observation with either short-wave UV light (254 nm lamp), 10% phosphomolybdic acid in ethanol, or in iodine vapors. Preparative thin-layer chromatography was performed using Analtech, 20 × 20 cm<sup>2</sup>, 1000 μm preparative TLC plates. Flash column chromatography was carried out using a Teledyne Isco CombiFlash Companion Unit and a Biotage Selekt System with Teledyne Isco RediSep Rf and Biotage Sfär silica gel columns. If needed, products were purified by reverse-phase chromatography, using a Teledyne Isco CombiFlash Companion Unit and a Biotage Selekt System with a RediSep Gold C18 reverse-phase column. Proton NMR spectra were obtained on a 400 MHz Varian nuclear magnetic resonance spectrometer. Chemical shifts (δ) are reported in parts per million (ppm), and coupling constant (<i>J</i>) values are given in hertz, with the following spectral pattern designations: s, singlet; d, doublet; t, triplet, q, quartet; quint, quintet; m, multiplet; dd, doublet of doublets; dt, doublet of triplets; dq; doublet of quartets; br, broad signal. Tetramethylsilane was used as an internal reference. Peak listing, multiplicity designations, and coupling constant calculations were conducted using Mnova v.14 software (Mestrelab Research). Carbon NMR spectra were obtained on a 500 MHz Bruker AV III nuclear magnetic resonance spectrometer, and tetramethylsilane was used as an internal reference. Fluorine NMR spectra were obtained on a 400 MHz Bruker AV III nuclear magnetic resonance spectrometer. Any melting points provided are uncorrected and were obtained using a Stanford Research Systems OptiMelt melting point apparatus (MPA100) with an automated melting point system. Mass spectroscopic analyses were performed using electrospray ionization (ESI) on a Waters AQUITY UPLC MS triple quadrapole mass spectrometer. High-pressure liquid chromatography (HPLC) purity analysis was performed using a Waters Breeze2 HPLC system with binary solvent systems A and B using a gradient elusion [A, H<sub>2</sub>O with 0.1% formic acid; B, CH<sub>3</sub>CN with 0.1% formic acid] and flow rate = 0.5 mL/min, with UV detection at 254 nm (system equipped with a photodiode array (PDA) detector). An ACQUITY UPLC BEH C18 column, 130 Å, 1.7 μm, 2.1 mm × 50 mm, was used. High-resolution mass spectrometry (HRMS) analysis was performed using an Agilent 6530 Accurate-Mass Q-TOF. All final compounds tested for <i>in vitro</i> and <i>in vivo</i> biological testing were purified to ≥95% purity, and these purity levels were measured by both <sup>1</sup>H NMR and HPLC.</div><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzoic Acid (<b>14</b>)</h4><div id="s0044" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 2.00 g, 10.7 mmol) and methyl 3-bromo-4-fluorobenzoate (2.25 g, 9.65 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (10.0 g, 30.6 mmol), X-Phos (0.600 g, 1.25 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.555 g, 0.536 mmol) were then added, and the mixture was stirred reflux for 16 h under an atmosphere of N<sub>2</sub>. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% ethyl acetate (EtOAc) in hexanes) to give <i>tert</i>-butyl 4-(2-fluoro-5-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16a</b>) as a brown oil (3.0 g, 83%). The material was used as is in the next step: ESI MS <i>m</i>/<i>z</i> 339 [M + H]<sup>+</sup>.</div></div><div id="s0045" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(2-fluoro-5-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16a</b>, 3.00 g, 8.87 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (6.7 mL, 87.5 mmol), and the resulting solution was stirred at rt for 16 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 4-fluoro-3-(piperazin-1-yl)benzoate (<b>17a</b>) as a white solid (1.20 g, 57%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.85 (br, 1H), 7.72–7.69 (m, 1H), 7.63–7.60 (m, 1H), 7.21–7.04 (m, 1H), 3.87 (s, 3H), 3.35 (s, 8H); ESI MS <i>m</i>/<i>z</i> 239 [M + H]<sup>+</sup>.</div></div><div id="s0046" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 4-fluoro-3-(piperazin-1-yl)benzoate (<b>17a</b>, 1.20 g, 5.03 mmol) in anhydrous THF (10 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (0.9 mL, 5.16 mmol) and 3-chloropentane-2,4-dione (0.67 mL, 5.96 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to give methyl 3-(4-(2,4-dioxopentan-3-yl)piperazin-1-yl)-4-fluorobenzoate (<b>18a</b>) as a brown oil (0.600 g, 35%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.64–7.62 (m, 2H), 7.06–7.01 (m, 1H), 3.86 (s, 1H), 3.31–3.09 (m, 4H), 3.09–3.05 (m, 4H), 2.27 (s, 1H), 2.24 (s, 6H); ESI MS <i>m</i>/<i>z</i> 337 [M + H]<sup>+</sup>.</div></div><div id="s0047" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-(4-(2,4-dioxopentan-3-yl)piperazin-1-yl)-4-fluorobenzoate (<b>18a</b>, 0.500 g, 1.48 mmol) in CH<sub>3</sub>OH (10 mL) was added N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.2 mL, 2.67 mmol, 64–65% solution in H<sub>2</sub>O), and the resulting mixture was stirred at rt for 1 h. The mixture was then concentrated under reduced pressure, and the resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to give methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzoate (<b>19a</b>) as a brown solid (0.420 g, 85%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67–7.63 (m, 2H), 7.04–7.01 (m, 1H), 3.86 (s, 1H), 3.16–3.15 (m, 4H), 3.15–3.11 (m, 4H), 2.24 (s, 6H); ESI MS <i>m</i>/<i>z</i> 333 [M + H]<sup>+</sup>.</div></div><div id="s0048" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Step E</h5><div class="NLM_p last">To a solution of methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzoate (<b>19a</b>, 0.420 g, 1.26 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (91 mg, 3.79 mmol). The reaction mixture was stirred at rt for 16 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzoic acid (<b>14</b>) as a white solid (0.390 g, 97%): melting point = 220–222 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.53–7.55 (m, 2H, H<sub>1</sub> and H<sub>2</sub>), 7.23–7.18 (dt, <i>J</i> = 12, 3.2 Hz, 1H, H<sub>3</sub>), 3.04 (m, 4H, H<sub>4</sub>), 3.01 (m, 4H, H<sub>5</sub>), 2.10 (s, 6H, H<sub>6</sub>); <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 128.7, 121.7, 124.1, 124.0, 120.2, 120.2, 116.3, 116.2; <sup>19</sup>F NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ −116.0 (s, F); ESI MS <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>; HRMS (ESI<sup>+</sup>) C<sub>16</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub> calcd [M + H]<sup>+</sup> = 319.1565, observed [M + H]<sup>+</sup> = 319.1562; combustion analysis (%C, H, N): calcd for C<sub>16</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>·0.5H<sub>2</sub>O·0.5HCl: %C = 55.61; %H = 5.98; %N = 16.21; found: %C = 55.88; %H = 5.74; %N = 15.97; HPLC >99% (AUC), <i>t</i><sub>R</sub> = 11.5 min.</div></div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzoic Acid Bis-hydrochloride (<b>14a</b>)</h4><div id="s0077" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Step A</h5><div class="NLM_p last">To a solution of 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzoic acid (<b>14</b>, 0.700 g, 2.20 mmol) in anhydrous Et<sub>2</sub>O (5 mL) at 0 °C was slowly added a 2 N HCl solution in Et<sub>2</sub>O dropwise (11.0 mL, 22.0 mmol), and the pH of the mixture was observed at approximately pH = 2 (monitored with Hydrion pH paper). The mixture was then stirred at rt for 3 h, and the Et<sub>2</sub>O was removed under reduced pressure. The resulting material was triturated with Et<sub>2</sub>O and dried under reduced pressure to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzoic acid bis-hydrochloride (<b>14a</b>) as a white solid (0.800 g, 93%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.63 (m, 2H), 7.29 (dt, <i>J</i> = 8.8 Hz, 3.2 Hz, 1H), 3.26 (m, 8H), 2.39 (s, 6H); <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.0, 159.1, 157.1, 140.0, 139.2, 128.1, 124.8, 120.8, 116.9, 52.2, 50.0, 10.8; ESI MS <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>; HRMS (ESI<sup>+</sup>) C<sub>16</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub> calcd [M + H]<sup>+</sup> = 319.1565, observed [M + H]<sup>+</sup> = 319.1561; combustion analysis (%C, H, N, Cl): calcd for C<sub>16</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>2</sub>·1.2H<sub>2</sub>O·2.0HCl: %C = 46.54; %H = 5.71; %N = 13.57; %Cl = 17.17; found: %C = 46.57; %H = 5.52; %N = 13.39; %Cl = 16.97; HPLC >99% (AUC), <i>t</i><sub>R</sub> = 11.4 min.</div></div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoic Acid (<b>20a</b>)</h4><div id="s0049" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 3.46 g, 18.5 mmol) and methyl 3-bromobenzoate (2.0 g, 9.30 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (1.04 g, 3.19 mmol), X-Phos (0.600 g, 1.25 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.621 g, 0.600 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–20% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16b</b>) as a brown solid (0.440 g, 14%). The material was used as is in the next step: ESI MS <i>m</i>/<i>z</i> 321 [M + H]<sup>+</sup>.</div></div><div id="s0050" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16b</b>, 0.430 g, 1.34 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (3.0 mL, 39.2 mmol), and the resulting solution was stirred at rt for 16 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give crude methyl 3-(piperazin-1-yl)benzoate (<b>17b</b>) as a white solid (0.292 g, >99%, crude): ESI MS <i>m</i>/<i>z</i> 221 [M + H]<sup>+</sup>.</div></div><div id="s0051" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 3-(piperazin-1-yl)benzoate (<b>17b</b>, 0.290 g, 1.32 mmol) in anhydrous THF (5 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (1.2 mL, 6.88 mmol) and 3-chloropentane-2,4-dione (0.44 mL, 3.90 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of methyl 3-(4-(2,4-dioxopentan-3-yl)piperazin-1-yl)benzoate (<b>18b</b>) (monitored by liquid chromatography-mass spectrometry (LC-MS); ESI MS <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.26 mL, 3.15 mmol, 64–65% solution in H<sub>2</sub>O) was then added, and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoate as a brown solid (<b>19b</b>) along with an inseparable and uncharacterized impurity (0.280 g, 67%, impure): ESI MS <i>m</i>/<i>z</i> 315 [M + H]<sup>+</sup>.</div></div><div id="s0052" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoate (<b>19b</b>, 0.130 g, 0.413 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (49.5 mg, 2.06 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoic acid (<b>20a</b>) as a white solid (7.8 mg, 6.2%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.48 (s, 1H), 7.36 (m, 2H), 7.23 (m, 1H), 3.23 (m, 4H), 3.04 (m, 4H), 2.14 (s, 6H); ESI MS <i>m</i>/<i>z</i> 301 [M + H]<sup>+</sup>; HPLC >99% (AUC), <i>t</i><sub>R</sub> = 10.7 min.</div></div></div><div id="sec5_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-methoxybenzoic Acid (<b>20b</b>)</h4><div id="s0053" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 0.911 g, 4.89 mmol) and methyl 3-bromo-4-methoxybenzoate (1.0 g, 4.08 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (2.6 g, 7.97 mmol), X-Phos (0.230 g, 0.482 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.124 g, 0.120 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(2-methoxy-5-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16c</b>) as a light yellow solid (1.40 g, 98%): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.68 (d, <i>J</i> = 8.0 Hz, 1H), 7.51 (s, 1H), 7.04 (d, <i>J</i> = 8.4 Hz, 1H), 3.93 (s, 3H), 3.82 (s, 3H), 3.53 (brs, 4 h), 2.98 (brs, 4 h), 1.41 (s, 9H): ESI MS <i>m</i>/<i>z</i> 351 [M + H]<sup>+</sup>.</div></div><div id="s0054" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(2-methoxy-5-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16c</b>, 1.4 g, 3.99 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (5.0 mL, 65.33 mmol), and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give crude methyl 4-methoxy-3-(piperazin-1-yl)benzoate (<b>17c</b>) as a brown oil (0.650 g, 65%, crude): ESI MS <i>m</i>/<i>z</i> 251 [M + H]<sup>+</sup>.</div></div><div id="s0055" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 4-methoxy-3-(piperazin-1-yl)benzoate (<b>17c</b>, 0.650 g, 2.59 mmol) in anhydrous THF (10 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (1.4 mL, 8.03 mmol) and 3-chloropentane-2,4-dione (0.6 mL, 5.32 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>18c</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 349 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.26 mL, 3.15 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-methoxybenzoate (<b>19c</b>) along with an inseparable and uncharacterized impurity (0.100 g, 11%, crude): ESI MS <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>.</div></div><div id="s0056" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-methoxybenzoate (<b>19c</b>, 0.100 g, 0.290 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (34.0 mg, 1.41 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-methoxybenzoic acid (<b>20b</b>) as a white solid (38.0 mg, 39%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.58 (dd, <i>J</i> = 8.4 Hz, 2.0 Hz, 1H), 7.44 (d, <i>J</i> = 2.0 Hz, 1H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 3.83 (s, 3H), 2.99 (s, 8H), 2.08 (s, 6H); ESI MS <i>m</i>/<i>z</i> 331 [M + H]<sup>+</sup>; HPLC 94.6% (AUC), <i>t</i><sub>R</sub> = 10.2 min.</div></div></div><div id="sec5_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-methylbenzoic Acid (<b>20c</b>)</h4><div id="s0057" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 0.978 g, 5.26 mmol) and methyl 3-bromo-4-methylbenzoate (1.0 g, 4.36 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (2.8 g, 8.59 mmol), X-Phos (0.248 g, 0.520 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.136 g, 0.131 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(5-(methoxycarbonyl)-2-methylphenyl)piperazine-1-carboxylate (<b>16d</b>) as a brown solid (0.600 g, 41%). The material was used as is in the next step: ESI MS <i>m</i>/<i>z</i> 335 [M + H]<sup>+</sup>.</div></div><div id="s0058" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(5-(methoxycarbonyl)-2-methylphenyl)piperazine-1-carboxylate (<b>16d</b>, 0.600 g, 1.79 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (5.0 mL, 65.3 mmol), and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 4-methyl-3-(piperazin-1-yl)benzoate (<b>17d</b>) as a white solid (0.300 g, 71%, crude): ESI MS <i>m</i>/<i>z</i> 235 [M + H]<sup>+</sup>.</div></div><div id="s0059" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 4-methyl-3-(piperazin-1-yl)benzoate (<b>17d</b>, 0.300 g, 1.28 mmol) in anhydrous THF (10 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (0.74 mL, 4.24 mmol) and 3-chloropentane-2,4-dione (0.30 mL, 2.66 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>18d</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 333 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.14 mL, 1.68 mmol, 64–65% solution in H<sub>2</sub>O) was then added, and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-methylbenzoate (<b>19d</b>) as a brown oil along with an inseparable and uncharacterized impurity (0.100 g, 23%, crude): ESI MS <i>m</i>/<i>z</i> 329 [M + H]<sup>+</sup>.</div></div><div id="s0060" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-methylbenzoate (<b>19d</b>, 0.100 g, 0.304 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (24.0 mg, 1.00 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-methylbenzoic acid (<b>20c</b>) as a white solid (31.0 mg, 32%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.57 (d, <i>J</i> = 1.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.27 (d, <i>J</i> = 8.0 Hz, 1H), 3.01 (m, 4H), 2.90 (m, 4H), 2.46 (s, 3H), 2.12 (s, 6H); ESI MS <i>m</i>/<i>z</i> 315 [M + H]<sup>+</sup>; HPLC >99% (AUC), <i>t</i><sub>R</sub> = 11.2 min.</div></div></div><div id="sec5_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-(trifluoromethyl)benzoic Acid (<b>20d</b>)</h4><div id="s0061" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 0.700 g, 3.75 mmol) and methyl 3-bromo-4-(trifluoromethyl)benzoate (0.957 g, 3.38 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (3.6 g, 11.04 mmol), X-Phos (0.212 g, 0.444 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.192 g, 0.186 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(5-(methoxycarbonyl)-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate (<b>16e</b>) as a brown oil (0.450 g, 31%). The material was used as is in the next step: ESI MS <i>m</i>/<i>z</i> 389 [M + H]<sup>+</sup>.</div></div><div id="s0062" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(5-(methoxycarbonyl)-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate (<b>16e</b>, 0.450 g, 1.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (3.0 mL, 39.2 mmol), and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 3-(piperazin-1-yl)-4-(trifluoromethyl)benzoate (<b>17e</b>) as a white solid (0.350 g, >99%, crude): ESI MS <i>m</i>/<i>z</i> 289 [M + H]<sup>+</sup>.</div></div><div id="s0063" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 3-(piperazin-1-yl)-4-(trifluoromethyl)benzoate (<b>17e</b>, 0.350 g, 1.21 mmol) in anhydrous THF (10 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (1.0 mL, 5.74 mmol) and 3-chloropentane-2,4-dione (0.40 mL, 3.54 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>18e</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 387 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.20 mL, 1.82 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-(trifluoromethyl)benzoate (<b>19e</b>) as a brown oil (0.150 g, 32%): ESI MS <i>m</i>/<i>z</i> 383 [M + H]<sup>+</sup>.</div></div><div id="s0064" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-(trifluoromethyl)benzoate (<b>19e</b>, 0.130 g, 0.34 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (81 mg, 3.38 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-(trifluoromethyl)benzoic acid (<b>20d</b>) as an amorphous white solid (79.0 mg, 63%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.99 (s, 1H), 7.84 (d, <i>J</i> = 8.4 Hz, 1H), 7.78 (d, <i>J</i> = 8.4 Hz, 1H), 2.97 (m, 4H), 2.94 (m, 4H), 2.11 (s, 6H); ESI MS <i>m</i>/<i>z</i> 369 [M + H]<sup>+</sup>; HPLC 98.7% (AUC), <i>t</i><sub>R</sub> = 11.9 min.</div></div></div><div id="sec5_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-Chloro-3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoic Acid (<b>20e</b>)</h4><div id="s0065" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 0.700 g, 3.75 mmol) and methyl 3-bromo-4-chlorobenzoate (0.844 g, 3.38 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (3.6 g, 11.04 mmol), X-Phos (0.212 g, 0.44 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.192 g, 0.186 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(2-chloro-5-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16f</b>) as a yellow oil (0.800 g, 60%): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.71 (s, 1H), 7.68–7.66 (m, 1H), 7.54 (d, <i>J</i> = 8.0 Hz, 1H), 3.88 (s, 3H), 3.58 (brs, 4H), 3.02 (brs, 4H), 1.46 (s, 9H); ESI MS <i>m</i>/<i>z</i> 355 [M + H]<sup>+</sup>.</div></div><div id="s0066" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(2-chloro-5-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16f</b>, 0.700 g, 1.97 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (5.0 mL, 65.33 mmol), and the resulting solution was stirred at rt for 16 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 4-chloro-3-(piperazin-1-yl)benzoate (<b>17f</b>) as a white solid (0.450 g, 89%, crude): ESI MS <i>m</i>/<i>z</i> 255 [M + H]<sup>+</sup>.</div></div><div id="s0067" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 4-chloro-3-(piperazin-1-yl)benzoate (<b>17f</b>, 0.200 g, 0.787 mmol) in anhydrous THF (10 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (0.7 mL, 4.01 mmol) and 3-chloropentane-2,4-dione (0.26 mL, 2.38 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>18f</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 353 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.1 mL, 1.18 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 4-chloro-3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoate (<b>19f</b>) as a brown oil (80.0 mg, 29%): ESI MS <i>m</i>/<i>z</i> 349 [M + H]<sup>+</sup>.</div></div><div id="s0068" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Step D</h5><div class="NLM_p last">To a solution of methyl 4-chloro-3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoate (<b>19f</b>, 80.0 mg, 0.23 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (55.0 mg, 2.29 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 4-chloro-3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)benzoic acid (<b>20e</b>) as an amorphous white solid (30.0 mg, 39%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.66 (s, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 1H), 7.51 (d, <i>J</i> = 10.8 Hz, 1H), 3.04 (brs, 8H), 2.12 (s, 6H); ESI MS <i>m</i>/<i>z</i> 335 [M + H]<sup>+</sup>; HPLC 98.0% (AUC), <i>t</i><sub>R</sub> = 11.5 min.</div></div></div><div id="sec5_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-2-fluorobenzoic Acid (<b>20f</b>)</h4><div id="s0069" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 0.700 g, 3.75 mmol) and methyl 3-bromo-2-fluorobenzoate (0.787 g, 3.38 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (3.6 g, 11.04 mmol), X-Phos (0.212 g, 0.444 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.192 g, 0.186 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(2-fluoro-3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16g</b>) as a yellow oil (1.0 g, 78%): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.47–7.45 (m, 1H), 7.31–7.27 (m, 1H), 7.19 (t, <i>J</i> = 8.0 Hz, 1H), 3.87 (s, 3H), 3.56 (brs, 4H), 3.02 (brs, 4H), 1.45 (s, 9H); ESI MS <i>m</i>/<i>z</i> 339 [M + H]<sup>+</sup>.</div></div><div id="s0070" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(2-fluoro-3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16g</b>, 1.0 g, 2.95 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (5.0 mL, 65.33 mmol), and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 2-fluoro-3-(piperazin-1-yl)benzoate (<b>17g</b>) as a brown oil (0.600 g, 85%, crude): ESI MS <i>m</i>/<i>z</i> 239 [M + H]<sup>+</sup>.</div></div><div id="s0071" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 2-fluoro-3-(piperazin-1-yl)benzoate (<b>17g</b>, 300 mg, 1.26 mmol) in anhydrous THF (3 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (0.5 mL, 2.52 mmol) and 3-chloropentane-2,4-dione (0.3 mL, 2.52 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>18g</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 337 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.16 mL, 1.89 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-2-fluorobenzoate (<b>19g</b>) as a brown oil (0.160 g, 38%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.79 (brs, 1H), 7.40–7.36 (m, 1H), 7.32–7.28 (m, 1H), 7.21–7.17 (m, 1H), 3.81 (s, 3H), 3.05–3.00 (m, 8H), 2.11 (s, 6H); ESI MS <i>m</i>/<i>z</i> 333 [M + H]<sup>+</sup>.</div></div><div id="s0072" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-2-fluorobenzoate (<b>19g</b>, 0.150 g, 0.451 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (0.108 g, 4.50 mmol). The reaction mixture was stirred at rt for 16 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-2-fluorobenzoic acid (<b>20f</b>) as an amorphous white solid (90.0 mg, 63%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.29 (m, 1H), 7.19 (m, 1H), 7.12 (t, <i>J</i> = 9.6 Hz, 1H), 3.03 (br, 8H), 2.12 (s, 6H); ESI MS <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>; HPLC 98.3% (AUC), <i>t</i><sub>R</sub> = 10.3 min.</div></div></div><div id="sec5_7_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 5-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-2-fluorobenzoic Acid (<b>20g</b>)</h4><div id="s0073" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 0.700 g, 3.75 mmol) and methyl 5-bromo-2-fluorobenzoate (0.787 g, 3.38 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (3.6 g, 11.04 mmol), X-Phos (0.212 g, 0.44 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.192 g, 0.186 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(4-fluoro-3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16h</b>) as a yellow oil (1.05 g, 83%). The material was used as is in the next step: ESI MS <i>m</i>/<i>z</i> 339 [M + H]<sup>+</sup>.</div></div><div id="s0074" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(4-fluoro-3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16h</b>, 1.2 g, 3.55 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (5.0 mL, 65.33 mmol), and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 2-fluoro-5-(piperazin-1-yl)benzoate (<b>17h</b>) as a white solid (0.540 g, 64%, crude): ESI MS <i>m</i>/<i>z</i> 239 [M + H]<sup>+</sup>.</div></div><div id="s0075" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 2-fluoro-5-(piperazin-1-yl)benzoate (<b>17h</b>, 0.300 g, 1.26 mmol) in anhydrous THF (3 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (0.5 mL, 2.87 mmol) and 3-chloropentane-2,4-dione (0.30 mL, 2.66 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>18h</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 337 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.16 mL, 1.89 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 5-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-2-fluorobenzoate (<b>19h</b>) as a brown oil along with an inseparable and uncharacterized impurity (0.140 g, 33%, crude): ESI MS <i>m</i>/<i>z</i> 333 [M + H]<sup>+</sup>.</div></div><div id="s0076" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> Step D</h5><div class="NLM_p last">To a solution of methyl 5-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-2-fluorobenzoate (<b>19h</b>, 0.140 g, 0.421 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL) and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (99.4 mg, 4.15 mmol). The reaction mixture was stirred at rt for 16 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 5-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-2-fluorobenzoic acid (<b>20g</b>) as an amorphous white solid (75.0 mg, 56%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.29 (m, 1H), 7.19 (m, 1H), 7.12 (t, <i>J</i> = 9.6 Hz, 1H), 3.13 (br, 4H), 2.99 (br, 4H), 2.10 (s, 6H); ESI MS <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>; HPLC >99% (AUC), <i>t</i><sub>R</sub> = 10.6 min.</div></div></div><div id="sec5_7_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-5-fluorobenzoic Acid (<b>20h</b>)</h4><div id="s0078" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 0.700 g, 3.75 mmol) and methyl 3-bromo-5-fluorobenzoate (0.787 g, 3.38 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (3.6 g, 11.04 mmol), X-Phos (0.212 g, 0.44 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.192 g, 0.186 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(3-fluoro-5-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16i</b>) as a brown oil (0.800 g, 70%): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.39 (s, 1H), 7.08 (d, <i>J</i> = 8.4 Hz, 1H), 6.97 (d, <i>J</i> = 12.0 Hz, 1H), 3.87 (s, 3H), 3.56 (brs, 4 h), 3.26 (brs, 4 h), 1.45 (s, 9H): ESI MS <i>m</i>/<i>z</i> 339 [M + H]<sup>+</sup>.</div></div><div id="s0079" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(3-fluoro-5-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>16i</b>, 0.800 g, 2.37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (3.0 mL, 39.20 mmol), and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 3-fluoro-5-(piperazin-1-yl)benzoate (<b>17i</b>) as an off-white solid (0.540 g, 96%, crude): ESI MS <i>m</i>/<i>z</i> 239 [M + H]<sup>+</sup>.</div></div><div id="s0080" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 3-fluoro-5-(piperazin-1-yl)benzoate (<b>17i</b>, 0.500 g, 2.09 mmol) in anhydrous THF (10 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (1.0 mL, 5.74 mmol) and 3-chloropentane-2,4-dione (0.545 mL, 4.83 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>18i</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 337 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.26 mL, 3.15 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-5-fluorobenzoate (<b>19i</b>) as a brown oil along with an inseparable and uncharacterized impurity (0.230 g, 33%, crude): ESI MS <i>m</i>/<i>z</i> 337 [M + H]<sup>+</sup>.</div></div><div id="s0081" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-5-fluorobenzoate (<b>19i</b>, 0.230 g, 0.692 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (0.166 g, 6.93 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-5-fluorobenzoic acid (<b>20h</b>) as an amorphous off-white solid (90.0 mg, 41%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.28 (s, 1H), 6.99 (m, 2H), 3.24 (m, 4H), 2,98 (m, 4H), 2.10 (s, 6H); ESI MS <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>; HPLC 97.6% (AUC), <i>t</i><sub>R</sub> = 11.3 min.</div></div></div><div id="sec5_7_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 5-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluoro-2-methylbenzoic Acid (<b>20i</b>)</h4><div id="s0082" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Step A</h5><div class="NLM_p last">A mixture of <i>tert-</i>butyl piperazine-1-carboxylate (<b>15</b>, 0.771 g, 4.13 mmol) and methyl 5-bromo-4-fluoro-2-methylbenzoate (0.930 g, 3.76 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (3.70 g, 11.35 mmol), X-Phos (0.213 g, 0.446 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.218 g, 0.211 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(2-fluoro-5-(methoxycarbonyl)-4-methylphenyl)piperazine-1-carboxylate (<b>16j</b>) as a brown oil (0.260 g, 18%). The material was used as is in the next step: ESI MS <i>m</i>/<i>z</i> 353 [M + H]<sup>+</sup>.</div></div><div id="s0083" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 4-(2-fluoro-5-(methoxycarbonyl)-4-methylphenyl)piperazine-1-carboxylate (<b>16j</b>, 0.250 g, 1.34 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (3.0 mL, 39.20 mmol), and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 4-fluoro-2-methyl-5-(piperazin-1-yl)benzoate (<b>17j</b>) as a brown oil (0.160 g, 47%, crude): ESI MS <i>m</i>/<i>z</i> 253 [M + H]<sup>+</sup>.</div></div><div id="s0084" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 4-fluoro-2-methyl-5-(piperazin-1-yl)benzoate (<b>17j</b>, 0.150 g, 0.594 mmol) in anhydrous THF (5 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (0.54 mL, 3.10 mmol) and 3-chloropentane-2,4-dione (0.20 mL, 1.77 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>18j</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 351 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.5 mL, 5.95 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 5-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluoro-2-methylbenzoate (<b>19j</b>) as a brown oil along with an inseparable and uncharacterized impurity (0.140 g, 68%, crude): ESI MS <i>m</i>/<i>z</i> 347 [M + H]<sup>+</sup>.</div></div><div id="s0085" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Step D</h5><div class="NLM_p last">To a solution of methyl 5-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluoro-2-methylbenzoate (<b>19j</b>, 0.140 g, 0.404 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (48.3 mg, 2.02 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 5-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluoro-2-methylbenzoic acid (<b>20i</b>) as an amorphous off-white solid (14.6 mg, 11%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.52 (d, <i>J</i> = 8.4 Hz, 1H), 7.13 (d, <i>J</i> = 13.2 Hz, 1H), 3.04 (br, 8H), 2.45 (s, 1H), 2.13 (s, 6H); ESI MS <i>m</i>/<i>z</i> 333 [M + H]<sup>+</sup>; HPLC 98.7% (AUC), <i>t</i><sub>R</sub> = 11.6 min.</div></div></div><div id="sec5_7_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-iodobenzoic Acid (<b>26</b>)</h4><div id="s0086" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Step A</h5><div class="NLM_p last">A mixture of <i>tert</i>-butyl piperazine-1-carboxylate (<b>15</b>, 1.05 g, 5.63 mmol), ethyl 3-fluoro-4-nitrobenzoate (1.0 g, 4.69 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.3 g, 9.38 mmol) in anhydrous CH<sub>3</sub>CN (20 mL) was heated at 60 °C for 16 h under an atmosphere of N<sub>2</sub>. The mixture was then allowed to cool to rt and concentrated under reduced pressure. The resulting residue was diluted with H<sub>2</sub>O (50 mL), and the aqueous mixture was extracted with EtOAc (3 × 75 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–15% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(5-(ethoxycarbonyl)-2-nitrophenyl)piperazine-1-carboxylate (<b>21</b>) as an orange oil (1.6 g, 90%): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.89–7.87 (m, 2H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 4.38 (q, 2H), 3.54 (brs, 4H), 3.08 (brs, 4H), 1.42 (s, 9H), 1.37 (t, <i>J</i> = 6.8 Hz, 3H); ESI MS <i>m</i>/<i>z</i> 380 [M + H]<sup>+</sup>.</div></div><div id="s0087" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> Step B</h5><div class="NLM_p last">A mixture of <i>tert</i>-butyl 4-(5-(ethoxycarbonyl)-2-nitrophenyl)piperazine-1-carboxylate (<b>21</b>, 1.6 g, 4.21 mmol) and Pd/C (10% w/w, 0.160 g) in anhydrous EtOH (30 mL) was stirred at rt under an atmosphere of H<sub>2</sub> gas <i>via</i> balloon (1 atm of pressure) for 24 h. The mixture was filtered through a pad of CELITE pad with repeat rinsing using anhydrous EtOH. The filtrate was concentrated under reduced pressure, and the resulting crude residue was chromatographed over silica gel (0–25% EtOAc in hexanes) to give <i>tert</i>-butyl 4-(2-amino-5-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>22</b>) as a white solid (1.3 g, 88%): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.60 (s, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 6.77 (d, <i>J</i> = 8.0 Hz, 1H), 5.30 (brs, 2H), 4.24 (q, 2H), 3.57 (brs, 4H), 2.89 (brs, 4H), 1.43 (s, 9H), 1.30 (t, <i>J</i> = 6.8 Hz, 3H): ESI MS <i>m</i>/<i>z</i> 350 [M + H]<sup>+</sup>.</div></div><div id="s0088" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> Step C</h5><div class="NLM_p last">A mixture of <i>tert</i>-butyl 4-(2-amino-5-(ethoxycarbonyl)phenyl)piperazine-1-carboxylate (<b>22</b>, 0.500 g, 1.43 mmol) dissolved in 3 N aqueous H<sub>2</sub>SO<sub>4</sub> (5.7 mL, 0.25 M) was cooled to 0 °C. A solution of NaNO<sub>2</sub> (0.108 g, 1.57 mmol) in H<sub>2</sub>O (10 mL) was added dropwise slowly at 0 °C over a period of 30 min. A solution of KI (0.356 mg, 2.15 mmol) and urea (17.2 mg, 0.29 mmol) in H<sub>2</sub>O (5 mL) was subsequently added, and the resulting mixture was continued to stir at 0 °C for an additional 1 h. The mixture was then quenched <i>via</i> addition of 10% NaHCO<sub>3</sub> (50 mL) and extracted with ethyl acetate (3 × 50 mL). The organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and cooled to 0 °C. TFA (3 mL, 39.2 mmol) was added, and the resulting solution was stirred for 3 h, gradually warming to rt. The mixture was concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated NaHCO<sub>3</sub> solution, and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give crude ethyl 4-iodo-3-(piperazin-1-yl)benzoate (<b>23</b>) as a brown oil, which was carried forward as is without further purification (0.300 g, 58%, crude): ESI MS <i>m</i>/<i>z</i> 361[M + H]<sup>+</sup>.</div></div><div id="s0089" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> Step D</h5><div class="NLM_p last">To a 0 °C cooled solution of crude ethyl 4-iodo-3-(piperazin-1-yl)benzoate (<b>23</b>, 0.300 g, 0.83 mmol) in THF (6 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (0.75 mL, 4.30 mmol) and 3-chloropentane-2,4-dione (0.28 mL, 2.48 mmol) simultaneously, and the resulting solution was stirred at rt for 16 h. Upon <i>in situ</i> formation of <b>24</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 459 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.5 mL, 5.95 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give ethyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-iodobenzoate (<b>25</b>) as a brown oil, which was carried forward as is without further purification (0.200 g, 53%, crude).</div></div><div id="s0090" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> Step E</h5><div class="NLM_p last">To a solution of ethyl 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-iodobenzoate (<b>25</b>, 0.200 g, 0.44 mmol) in EtOH (4 mL), THF (4 mL) and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (0.105 g, 4.38 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The resulting aqueous mixture was diluted with H<sub>2</sub>O (10 mL) and acidified with 2 N HCl to pH 3. The mixture was extracted with EtOAc (3 × 50 mL), and the combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-iodobenzoic acid (<b>26</b>) as an off-white solid (80.0 mg, 43%): <sup>1</sup>H NMR (acetone-<i>d</i><sub>6</sub>, 400 MHz) δ 7.95 (d, <i>J</i> = 8.0 Hz, 1H), 7.58 (s, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 2H), 3.12–3.10 (m, 4H), 3.03–2.98 (m, 4H), 2.11 (s, 6H); ESI MS <i>m</i>/<i>z</i> 427 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_7_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 3-((3a<i>R</i>,6a<i>S</i>)-5-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)hexahydropyrrolo[3,4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl)-4-fluorobenzoic Acid (<b>32</b>)</h4><div id="s0091" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> Step A</h5><div class="NLM_p last">A mixture of <i>tert</i>-butyl (3a<i>R</i>,6a<i>S</i>)-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-2(1<i>H</i>)-carboxylate (<b>27</b>, 1.0 g, 4.71 mmol) and methyl 3-bromo-4-fluorobenzoate (1.0 g, 4.29 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (4.17 g, 12.8 mmol), X-Phos (0.240 g, 0.503 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.248 g, 0.240 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl (3a<i>R</i>,6a<i>S</i>)-5-(2-fluoro-5-(methoxycarbonyl)phenyl)hexahydropyrrolo[3,4-<i>c</i>]pyrrole-2(1<i>H</i>)-carboxylate (<b>28</b>) as a brown oil (0.400 g, 26%): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.37–7.35 (m, 2H), 7.14–7.08 (m, 1H), 3.88 (s, 3H), 3.61 (brs, 4H), 3.36–3.29 (m, 4H), 3.03 (brs, 2H), 1.38 (s, 9H); ESI MS <i>m</i>/<i>z</i> 365 [M + H]<sup>+</sup>.</div></div><div id="s0092" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl (3a<i>R</i>,6a<i>S</i>)-5-(2-fluoro-5-(methoxycarbonyl)phenyl)hexahydropyrrolo[3,4-<i>c</i>]pyrrole-2(1<i>H</i>)-carboxylate (<b>28</b>, 0.390 g, 1.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (5.0 mL, 65.33 mmol), and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 4-fluoro-3-((3a<i>R</i>,6a<i>S</i>)-hexahydropyrrolo[3,4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl)benzoate (<b>29</b>) as a brown solid (0.220 mg, 78%, crude): ESI MS <i>m</i>/<i>z</i> 265 [M + H]<sup>+</sup>.</div></div><div id="s0093" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 4-fluoro-3-((3a<i>R</i>,6a<i>S</i>)-hexahydropyrrolo[3,4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl)benzoate (<b>29</b>, 0.210 g, 0.79 mmol) in anhydrous THF (10 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (0.73 mL, 4.19 mmol) and 3-chloropentane-2,4-dione (0.27 mL, 2.39 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of diketone <b>30</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 337 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.26 mL, 3.15 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-((3a<i>R</i>,6a<i>S</i>)-5-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)hexahydropyrrolo[3,4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl)-4-fluorobenzoate (<b>31</b>) as a brown oil along with an inseparable and uncharacterized impurity (0.100 g, 35%, crude): ESI MS <i>m</i>/<i>z</i> 359 [M + H]<sup>+</sup>.</div></div><div id="s0094" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-((3a<i>R</i>,6a<i>S</i>)-5-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)hexahydropyrrolo[3,4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl)-4-fluorobenzoate (<b>31</b>, 60.0 mg, 0.16 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (20.0 mg, 0.84 mmol). The reaction mixture was stirred at rt for 3 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-((3a<i>R</i>,6a<i>S</i>)-5-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)hexahydropyrrolo[3,4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl)-4-fluorobenzoic acid (<b>32</b>) as an amorphous off-white solid (4.8 mg, 8.7%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.40 (m, 2H), 7.16 (m, 1H), 3.60 (m, 2H), 3.20 (m, 2H), 3.01 (m, 2H), 2.88 (m, 4H), 2.11 (s, 6H); ESI MS <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>; HPLC 95.4% (AUC), <i>t</i><sub>R</sub> = 11.0 min.</div></div></div><div id="sec5_7_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> (±)-3-(7-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2,7-diazaspiro[4.4]nonan-2-yl)-4-fluorobenzoic Acid ((±)-<b>38</b>)</h4><div id="s0095" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> Step A</h5><div class="NLM_p last">A mixture of (±)-<i>tert</i>-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate ((±)-<b>33</b>, 1.07 g, 4.72 mmol) and methyl 3-bromo-4-fluorobenzoate (1.0 g, 4.29 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (4.16 g, 12.84 mmol), X-Phos (240 mg, 0.51 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.217 g, 0.21 mmol) were then added, and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give (±)-<i>tert</i>-butyl 7-(2-fluoro-5-(methoxycarbonyl)phenyl)-2,7-diazaspiro[4.4]nonane-2-carboxylate ((±)-<b>34</b>) as a yellow solid (0.480 g, 30%): <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.33–7.31 (m, 2H), 7.12–7.07 (m, 1H), 3.84 (s, 3H), 3.56–3.44 (m, 2H), 3.42–3.27 (m, 6H), 1.99–1.91 (m, 4H), 1.42 (s, 9H); ESI MS <i>m</i>/<i>z</i> 379 [M + H]<sup>+</sup>.</div></div><div id="s0096" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of (±)-<i>tert</i>-butyl 7-(2-fluoro-5-(methoxycarbonyl)phenyl)-2,7-diazaspiro[4.4]nonane-2-carboxylate ((±)-<b>34</b>, 0.470 g, 1.24 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (3.0 mL, 39.20 mmol), and the resulting solution was stirred at rt for 16 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure (±)-methyl 4-fluoro-3-(2,7-diazaspiro[4.4]nonan-2-yl)benzoate ((±)-<b>35</b>) as a white solid (0.340 g, 99%, crude): ESI MS <i>m</i>/<i>z</i> 279 [M + H]<sup>+</sup>.</div></div><div id="s0097" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of (±)-methyl 4-fluoro-3-(2,7-diazaspiro[4.4]nonan-2-yl)benzoate ((±)-<b>35</b>, 0.340 g, 1.22 mmol) in anhydrous THF (10 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (1.1 mL, 6.31 mmol) and 3-chloropentane-2,4-dione (0.40 mL, 3.66 mmol) simultaneously, and the resulting solution was stirred for 16 h under a N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of (±)-<b>36</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 377 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.62 mL, 12.23 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture was continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give (±)-methyl 3-(7-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)-2,7-diazaspiro[4.4]nonan-2-yl)-4-fluorobenzoate ((±)-<b>37</b>) as a brown oil (65.0 mg, 14%, crude): ESI MS <i>m</i>/<i>z</i> 373 [M + H]<sup>+</sup>.</div></div><div id="s0098" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> Step D</h5><div class="NLM_p last">To a solution of (±)-methyl 3-(7-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)-2,7-diazaspiro[4.4]nonan-2-yl)-4-fluorobenzoate ((±)-<b>37</b>, 60.0 mg, 0.16 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (19.2 mg, 0.81 mmol). The reaction mixture was stirred at rt for 16 h and concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL) and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give (±)-3-(7-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)-2,7-diazaspiro[4.4]nonan-2-yl)-4-fluorobenzoic acid ((±)-<b>38</b>) as an amorphous white solid (10.5 mg, 18%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.25 (m, 2H), 7.14 (m, 1H), 3.46 (m, 4H), 3.02 (m, 2H), 2.99 (m, 2H), 2.11 (s, 6H), 1.94–1.87 (m, 4); ESI MS <i>m</i>/<i>z</i> 359 [M + H]<sup>+</sup>; HPLC 97.3% (AUC), <i>t</i><sub>R</sub> = 11.3 min.</div></div></div><div id="sec5_7_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 3-(6-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-4-fluorobenzoic Acid (<b>44</b>)</h4><div id="s0099" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> Step A</h5><div class="NLM_p last">A mixture of <i>tert</i>-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (<b>39</b>, 1.0 g, 5.04 mmol) and methyl 3-bromo-4-fluorobenzoate (2.25 g, 9.65 mmol) in anhydrous 1,4-dioxane (50 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (4.17 g, 12.79 mmol), X-Phos (0.240 g, 0.50 mmol) and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (0.248 g, 0.24 mmol) were then added and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool to rt and then concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give <i>tert</i>-butyl 6-(2-fluoro-5-(methoxycarbonyl)phenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (<b>40</b>) as a brown oil (1.34 g, 76%): <sup>1</sup>H NMR (acetone-<i>d</i><sub>6</sub>, 400 MHz) δ 7.39–7.35 (m, 1 H), 7.11–7.05 (m, 2 H), 4.13 (s, 3 H), 4.12–4.09 (m, 4 H), 3.85–3.78 (m, 4 H), 1.37 (s, 9 H); ESI MS <i>m</i>/<i>z</i> 351 [M + H]<sup>+</sup>.</div></div><div id="s0100" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> Step B</h5><div class="NLM_p last">To a 0 °C cooled solution of <i>tert</i>-butyl 6-(2-fluoro-5-(methoxycarbonyl)phenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (<b>40</b>, 1.30 g, 3.71 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was added TFA (5.0 mL, 65.33 mmol) and the resulting solution was stirred at rt for 3 h while gradually warming to rt. The mixture was then concentrated under reduced pressure and diluted with H<sub>2</sub>O (30 mL), basified with saturated aqueous NaHCO<sub>3</sub> solution (50 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was triturated with Et<sub>2</sub>O and filtered to give pure methyl 4-fluoro-3-(2,6-diazaspiro[3.3]heptan-2-yl)benzoate (<b>41</b>) as a brown oil (0.600 g, 65%, crude): ESI MS <i>m</i>/<i>z</i> 251 [M + H]<sup>+</sup>.</div></div><div id="s0101" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> Step C</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 4-fluoro-3-(2,6-diazaspiro[3.3]heptan-2-yl)benzoate (<b>41</b>, 0.600 g, 1.65 mmol) in anhydrous THF (5 mL) were added <i>i</i>-Pr<sub>2</sub>NEt (1.37 mL, 7.89 mmol) and 3-chloropentane-2,4-dione (0.55 mL, 4.91 mmol) simultaneously and the resulting solution was stirred for 16 h under N<sub>2</sub> atmosphere while gradually warming to rt. Upon <i>in situ</i> formation of <b>42</b> (monitored by LC-MS; ESI MS <i>m</i>/<i>z</i> 349 [M + H]<sup>+</sup>), N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (0.82 g, 16.5 mmol, 64–65% solution in H<sub>2</sub>O) was then added and the mixture continued to stir at rt for an additional 1 h. The mixture was then diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(6-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-4-fluorobenzoate (<b>43</b>) as a brown oil (0.100 g, 18%): ESI MS <i>m</i>/<i>z</i> 345 [M + H]<sup>+</sup>.</div></div><div id="s0102" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> Step D</h5><div class="NLM_p last">To a solution of methyl 3-(6-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-4-fluorobenzoate (<b>43</b>, 51.0 mg, 0.14 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL) and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (17.0 mg, 0.70 mmol). The reaction mixture was stirred at rt for 16 h and was concentrated under reduced pressure. The aqueous layer was then diluted with H<sub>2</sub>O (30 mL) and neutralized to approximately pH = 7 with 2 N aqueous HCl (monitored with Hydrion pH paper). The aqueous mixture was extracted with EtOAc (3 × 50 mL), and the combined organic solution was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(6-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-4-fluorobenzoic acid (<b>44</b>) as an amorphous white solid (13.0 mg, 26%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.31 (m, 1H), 7.17 (t, <i>J</i> = 9.2 Hz, 1H), 7.7 (d, <i>J</i> = 8.4 Hz, 1H), 4.09 (m, 4H), 3.96 (m, 4H), 2.10 (s, 6H); ESI MS <i>m</i>/<i>z</i> 331 [M + H]<sup>+</sup>; HPLC 98.8% (AUC), <i>t</i><sub>R</sub> = 10.7 min.</div></div></div><div id="sec5_7_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 3-(4-(3,5-Dimethylisoxazol-4-yl)piperazin-1-yl)-4-fluorobenzoic Acid (<b>46</b>)</h4><div id="s0103" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> Step A</h5><div class="NLM_p last">To a solution of methyl 3-(4-(2,4-dioxopentan-3-yl)piperazin-1-yl)-4-fluorobenzoate (<b>18a</b>, 80.0 mg, 0.23 mmol) in CH<sub>3</sub>OH (2 mL) was added NH<sub>2</sub>OH·HCl (32.0 mg, 0.47 mmol), and the resulting solution was stirred at rt for 16 h. The mixture was concentrated under reduced pressure, and the resulting residue was chromatographed over silica gel (0–50% EtOAc in hexanes) to give methyl 3-(4-(3,5-dimethylisoxazol-4-yl)piperazin-1-yl)-4-fluorobenzoate (<b>45</b>) as a brown solid (20.1 mg, 25%); ESI MS <i>m</i>/<i>z</i> 334 [M + H]<sup>+</sup>.</div></div><div id="s0104" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> Step B</h5><div class="NLM_p last">To a solution of methyl 3-(4-(3,5-dimethylisoxazol-4-yl)piperazin-1-yl)-4-fluorobenzoate (<b>45</b>, 8.1 mg, 0.023 mmol) in CH<sub>3</sub>OH (1 mL), THF (1 mL), and H<sub>2</sub>O (0.5 mL) was added anhydrous LiOH (2.7 mg, 0.11 mmol). The reaction mixture was stirred at rt for 1 h and then concentrated under reduced pressure. The aqueous layer was diluted with H<sub>2</sub>O (15 mL) and neutralized with 2 N aqueous HCl. The aqueous mixture was extracted with EtOAc (3 × 10 mL), and the combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(3,5-dimethylisoxazol-4-yl)piperazin-1-yl)-4-fluorobenzoic acid (<b>46</b>) as a white solid (2.5 mg, 34%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.71–7.59 (m, 1H), 7.19–7.10 (m, 2H), 3.18–3.3.17 (m, 4H), 3.12–3.11 (m, 4H), 2.38 (s, 3H), 2.25 (s, 3H); ESI MS <i>m</i>/<i>z</i> 320 [M + H]<sup>+</sup>; HPLC 96.8% (AUC), <i>t</i><sub>R</sub> = 13.7 min.</div></div></div><div id="sec5_7_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 3-(4-(2<i>H</i>-Tetrazol-5-yl)piperazin-1-yl)-4-fluorobenzoic Acid (<b>48</b>)</h4><div id="s0105" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> Step A</h5><div class="NLM_p last">To a 0 °C cooled solution of methyl 4-fluoro-3-(piperazin-1-yl)benzoate (<b>17a</b>, 0.200 g, 0.84 mmol) and <i>i</i>-Pr<sub>2</sub>NEt (0.5 mL, 2.52 mmol) in THF (3 mL) was added CNBr (0.106 g, 1.01 mmol), and the mixture was stirred for 1 h while gradually warming to rt. The mixture was concentrated under reduced pressure, and the residue was dissolved in DMF (3 mL). To this solution were added NH<sub>4</sub>Cl (0.449 g, 8.4 mmol) and NaN<sub>3</sub> (0.546 g, 8.4 mmol), and the resulting mixture was heated at 120 °C for 12 h. The mixture was then allowed to cool to rt, diluted with H<sub>2</sub>O (10 mL), and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give methyl 3-(4-(2<i>H</i>-tetrazol-5-yl)piperazin-1-yl)-4-fluorobenzoate (<b>47</b>) (0.160 g, 62%), which was taken into the next step as is without purification: ESI MS <i>m</i>/<i>z</i> 307 [M + H]<sup>+</sup>.</div></div><div id="s0106" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> Step B</h5><div class="NLM_p last">To a solution of methyl 3-(4-(2<i>H</i>-tetrazol-5-yl)piperazin-1-yl)-4-fluorobenzoate (<b>47</b>, 0.160 g, 0.52 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (0.125 g, 5.2 mmol), and the resulting mixture was stirred at rt for 1 h. The mixture was then concentrated under reduced pressure, and the aqueous layer was diluted with H<sub>2</sub>O (15 mL) and acidified to pH = 3 with 2 N aqueous HCl. The aqueous mixture was then extracted with EtOAc (3 × 10 mL), and the combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 3-(4-(2<i>H</i>-tetrazol-5-yl)piperazin-1-yl)-4-fluorobenzoic acid (<b>48</b>) as a white solid (80.2 mg, 53%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.59 (m, 2H), 7.25 (dd, <i>J</i> = 7.6, 3.6 Hz, 1H), 3.52 (br, 4H), 3.14 (br, 4H); ESI MS <i>m</i>/<i>z</i> 293 [M + H]<sup>+</sup>; HPLC 98.3% (AUC), <i>t</i><sub>R</sub> = 11.3 min.</div></div></div><div id="sec5_7_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 4-Fluoro-3-(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)benzoic Acid (<b>50</b>)</h4><div id="s0107" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> Step A</h5><div class="NLM_p last">A mixture of methyl 4-fluoro-3-(piperazin-1-yl)benzoate (<b>17a</b>, 0.200 g, 0.84 mmol) and 1-bromo-2-(trifluoromethyl)benzene (0.263 g, 1.17 mmol) in anhydrous 1,4-dioxane (10 mL) was degassed with N<sub>2</sub> for 5 min. Cs<sub>2</sub>CO<sub>3</sub> (0.816 g, 2.50 mmol), X-Phos (79.1 mg, 0.16 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (73.2 mg, 0.08 mmol) were then added, and the reaction mixture was stirred at reflux for 16 h under an atmosphere of N<sub>2</sub>. The mixture was allowed to cool to rt and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–30% EtOAc in hexanes) to give methyl 4-fluoro-3-(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)benzoate (<b>49</b>) (30.2 mg, 9%) as a brown solid: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.69–7.63 (m, 3H), 7.61–7.60 (m, 1H), 7.52–7.41 (m, 1H), 7.08–7.03 (m, 2H), 3.88 (m, 3H), 3.25–3.23 (m, 4H), 3.10–3.08 (m, 4H); ESI MS <i>m</i>/<i>z</i> 383 [M + H]<sup>+</sup>.</div></div><div id="s0108" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> Step B</h5><div class="NLM_p last">To a solution of methyl 4-fluoro-3-(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)benzoate (<b>49</b>, 30.0 mg, 0.78 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (9 mg, 0.39 mmol). The mixture was stirred at rt for 1 h and then concentrated under reduced pressure. The aqueous layer was diluted with H<sub>2</sub>O (10 mL) and acidified to pH = 3 with 2 N aqueous HCl. The aqueous mixture was extracted with EtOAc (3 × 10 mL), and the combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 4-fluoro-3-(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)benzoic acid (<b>50</b>) as a white solid (15.2 mg, 53%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.76–7.72 (m, 2H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.52–7.50 (m, 1H), 7.42 (d, <i>J</i> = 8.0 Hz, 1H), 7.23 (m, 1H), 7.10 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 3.26 (m, 4H), 3.11 (m, 4H); ESI MS <i>m</i>/<i>z</i> 369 [M + H]<sup>+</sup>; HPLC 96.7% (AUC), <i>t</i><sub>R</sub> = 16.0 min.</div></div></div><div id="sec5_7_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 4-Fluoro-3-(4-((3-methyl-1<i>H</i>-pyrazol-5-yl)methyl)piperazin-1-yl)benzoic Acid (<b>52</b>)</h4><div id="s0109" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> Step A</h5><div class="NLM_p last">A solution of methyl 4-fluoro-3-(piperazin-1-yl)benzoate (<b>17a</b>, 0.200 g, 0.84 mmol) and 3-methyl-1<i>H</i>-pyrazole-5-carbaldehyde (0.111 g, 1.0 mmol) in 1,2-dichloroethane (5 mL) and HOAc (0.01 mL, 0.17 mmol) was stirred at rt for 1 h. NaBH(OAc)<sub>3</sub> (0.267 g, 1.26 mmol) was then added, and the mixture was stirred for 12 h at 60 °C. The mixture was then allowed to cool to rt and diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The organic mixture was washed with saturated aqueous NaHCO<sub>3</sub> (10 mL), H<sub>2</sub>O (10 mL), and brine. The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give methyl 4-fluoro-3-(4-((3-methyl-1<i>H</i>-pyrazol-5-yl)methyl)piperazin-1-yl)benzoate (<b>51</b>) as a white solid (0.210 g, 76%): ESI MS <i>m</i>/<i>z</i> 333 [M + H]<sup>+</sup>.</div></div><div id="s0110" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> Step B</h5><div class="NLM_p last">To a solution of methyl 4-fluoro-3-(4-((3-methyl-1<i>H</i>-pyrazol-5-yl)methyl)piperazin-1-yl)benzoate (<b>51</b>, 0.200 g, 0.60 mmol) in CH<sub>3</sub>OH (4 mL), THF (4 mL), and H<sub>2</sub>O (2 mL) was added anhydrous LiOH (144.5 mg, 6.0 mmol), and the resulting mixture was stirred at rt for 3 h. The mixture was concentrated under reduced pressure, and the resulting aqueous layer was diluted with H<sub>2</sub>O (10 mL) and neutralized with 2 N aqueous HCl. The aqueous mixture was then extracted with EtOAc (13 × 10 mL), and the combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 4-fluoro-3-(4-((3-methyl-1<i>H</i>-pyrazol-5-yl)methyl)piperazin-1-yl)benzoic acid (<b>52</b>) as a white solid (0.120 g, 63%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.50–7.46 (m, 2H), 7.33 (s, 1H), 7.13 (dd, <i>J</i> = 8.8, 4.0 Hz, 1H), 3.30 (s, 2H), 2.95 (br, 4H), 2.45 (br, 4H), 2.12 (s, 3H); ESI MS <i>m</i>/<i>z</i> 319 [M + H]<sup>+</sup>; HPLC 98.7% (AUC), <i>t</i><sub>R</sub> = 10.2 min.</div></div></div><div id="sec5_7_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 3-(4-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzamide (<b>53</b>)</h4><div id="s0111" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> Step A</h5><div class="NLM_p last">To a mixture of 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzoic acid (<b>14</b>, 0.100 g, 0.314 mmol), HBTU (0.178 g, 0.471 mmol), and <i>i</i>-Pr<sub>2</sub>NEt (0.218 mL, 1.26 mmol) in DMF (4 mL) was added NH<sub>4</sub>Cl (16.7 mg, 0.314 mmol). The resulting solution was stirred at rt for 18 h under an atmosphere of N<sub>2</sub>. The mixture was diluted with H<sub>2</sub>O (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with H<sub>2</sub>O (3 × 20 mL) and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude residue was chromatographed over silica gel (0–80% EtOAc in hexanes) to give 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzamide (<b>53</b>) as a white solid (71.7 mg, 72%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (br, 1H), 7.94 (bs, 1H), 7.54-7,48 (m, 2H), 7.31 (s, 1H), 7.14 (m, 1H), 3.06–3.01 (m, 8H), 2.10 (s, 6H); ESI MS <i>m</i>/<i>z</i> 318 [M + H]<sup>+</sup>; HPLC >99% (AUC), <i>t</i><sub>R</sub> = 10.5 min.</div></div></div><div id="sec5_7_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 1-(3,5-Dimethyl-1<i>H</i>-pyrazol-4-yl)-4-(2-fluoro-5-(2H-tetrazol-5-yl)phenyl)piperazine (<b>54</b>)</h4><div id="s0112" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> Step A</h5><div class="NLM_p last">A mixture of 3-(4-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)piperazin-1-yl)-4-fluorobenzamide (<b>53</b>, 0.180 g, 0.526 mmol), NaN<sub>3</sub> (0.142 g, 0.375 mmol), and tetrachlorosilane (98.5 mg, 0.579 mmol) in CH<sub>3</sub>CN (4 mL) was stirred at 80 °C for 18 h in a sealed vessel. The reaction mixture was allowed to cool to rt and diluted with saturated NaHCO<sub>3</sub> (5 mL). The aqueous mixture was extracted with CHCl<sub>3</sub> (3 × 50 mL), and the combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was chromatographed over silica gel (0–10% CH<sub>3</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give 1-(3,5-dimethyl-1<i>H</i>-pyrazol-4-yl)-4-(2-fluoro-5-(2H-tetrazol-5-yl)phenyl)piperazine (<b>54</b>) as a white solid (60.3 mg, 30%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.69 (m, 1H), 7.67 (m, 1H), 7.36–7. (dd, <i>J</i> = 4, 8.4 Hz, 1H); 3.12 (m, 4H), 3.09 (m, 4H), 2.13 (s, 6H); ESI MS <i>m</i>/<i>z</i> 343 [M + H]<sup>+</sup>; HPLC >99% (AUC), <i>t</i><sub>R</sub> = 11.1 min.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i116"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00099" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00099?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00099</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">TTR in vitro assay information, RBP4 <i>in vitro</i> assay information, mouse PK information, serum RBP4 measurement information, <i>in vitro</i> ADME assay information, general chemistry information, and spectroscopic and analytical data for compounds <b>14</b> (<sup>1</sup>H NMR, <sup>13</sup>C NMR, <sup>19</sup>F NMR, MS, HRMS, and HPLC), <b>20c</b>, and <b>20e</b> (<sup>1</sup>H NMR, MS, and HPLC) and all of the remaining biologically tested compounds (HPLC), and molecular formula strings for biologically tested compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00099/suppl_file/jm1c00099_si_004.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00099/suppl_file/jm1c00099_si_004.pdf">jm1c00099_si_004.pdf (2.93 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00099" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82031" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82031" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher L. Cioffi</span> - <span class="hlFld-Affiliation affiliation">Departments
of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-0642-7905" title="Orcid link">https://orcid.org/0000-0003-0642-7905</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4d2e253f243e39223d25283f632e24222b2b240d2c2e3d253e63282938"><span class="__cf_email__" data-cfemail="85e6edf7ecf6f1eaf5ede0f7abe6eceae3e3ecc5e4e6f5edf6abe0e1f0">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Konstantin Petrukhin</span> - <span class="hlFld-Affiliation affiliation">Department
of Ophthalmology, Columbia University Medical
Center, New York, New York 10032, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#98f3fde8acd8fbedf5fbb6fbf7f4edf5faf1f9b6fdfced"><span class="__cf_email__" data-cfemail="adc6c8dd99edced8c0ce83cec2c1d8c0cfc4cc83c8c9d8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arun Raja</span> - <span class="hlFld-Affiliation affiliation">Departments
of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Parthasarathy Muthuraman</span> - <span class="hlFld-Affiliation affiliation">Departments
of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aravindan Jayaraman</span> - <span class="hlFld-Affiliation affiliation">Departments
of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Srinivasan Jayakumar</span> - <span class="hlFld-Affiliation affiliation">Departments
of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York 12208, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andras Varadi</span> - <span class="hlFld-Affiliation affiliation">Department
of Ophthalmology, Columbia University Medical
Center, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Boglarka Racz</span> - <span class="hlFld-Affiliation affiliation">Department
of Ophthalmology, Columbia University Medical
Center, New York, New York 10032, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8688-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Research reported in this publication was supported by the National Eye Institute of the National Institutes of Health under Award Number R01EY028549. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This project has been funded in whole or in part with Federal funds from the National Eye Institute, the National Institutes of Health, the Department of Health and Human Services, NIH Grant R01EY028549 (to K.P. and C.L.C.). This study was supported by NIH Grant P30 EY019007 (Core Support for Vision Research) and unrestricted funds from the Research to Prevent Blindness (New York, NY) to the Department of Ophthalmology, Columbia University.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">β-amyloid</p></td></tr><tr><td class="NLM_term"><i>Abca</i>4</td><td class="NLM_def"><p class="first last">ATP-binding cassette, subfamily A (ABC), member 4</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, elimination</p></td></tr><tr><td class="NLM_term">AMD</td><td class="NLM_def"><p class="first last">age-related macular degeneration</p></td></tr><tr><td class="NLM_term">Arg</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">Asn</td><td class="NLM_def"><p class="first last">asparagine</p></td></tr><tr><td class="NLM_term">ATTR</td><td class="NLM_def"><p class="first last">transthyretin amyloidosis</p></td></tr><tr><td class="NLM_term">ATTR-CM</td><td class="NLM_def"><p class="first last">transthyretin amyloidosis cardiomyopathy</p></td></tr><tr><td class="NLM_term">ATTR-PN</td><td class="NLM_def"><p class="first last">transthyretin amyloidosis polyneuropathy</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">CH<sub>2</sub>Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">CH<sub>3</sub>CN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">CH<sub>3</sub>OH</td><td class="NLM_def"><p class="first last">methyl alcohol</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">Cs<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">cesium carbonate</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">%<i>F</i></td><td class="NLM_def"><p class="first last">% oral bioavailability</p></td></tr><tr><td class="NLM_term">FAC</td><td class="NLM_def"><p class="first last">familial amyloid cardiomyopathy</p></td></tr><tr><td class="NLM_term">FAP</td><td class="NLM_def"><p class="first last">familial amyloid neuropathy</p></td></tr><tr><td class="NLM_term">FITC</td><td class="NLM_def"><p class="first last">fluorescein isothiocyanate</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluorescence polarization</p></td></tr><tr><td class="NLM_term">Glu</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">Gly</td><td class="NLM_def"><p class="first last">glycine</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour(s)</p></td></tr><tr><td class="NLM_term">HBP</td><td class="NLM_def"><p class="first last">halogen binding pocket</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">(2-(1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O</td><td class="NLM_def"><p class="first last">hydrazine hydrate</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go channel</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>SO<sub>4</sub></td><td class="NLM_def"><p class="first last">sulfuric acid</p></td></tr><tr><td class="NLM_term"><i>i</i>-Pr<sub>2</sub>NEt</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">Ile</td><td class="NLM_def"><p class="first last">isoleucine</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">Leu</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">LiOH</td><td class="NLM_def"><p class="first last">lithium hydroxide</p></td></tr><tr><td class="NLM_term">Lys</td><td class="NLM_def"><p class="first last">lysine</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minutes</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">NaBH<sub>4</sub></td><td class="NLM_def"><p class="first last">sodium borohydride</p></td></tr><tr><td class="NLM_term">NaBH(OAc)<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium triacetoxyborohydride</p></td></tr><tr><td class="NLM_term">NaN<sub>3</sub></td><td class="NLM_def"><p class="first last">sodium azide</p></td></tr><tr><td class="NLM_term">NaNO<sub>2</sub></td><td class="NLM_def"><p class="first last">sodium nitrite</p></td></tr><tr><td class="NLM_term">NH<sub>4</sub>Cl</td><td class="NLM_def"><p class="first last">ammonium chloride</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub></td><td class="NLM_def"><p class="first last">Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct</p></td></tr><tr><td class="NLM_term">Phe</td><td class="NLM_def"><p class="first last">phenylalanine</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">oral</p></td></tr><tr><td class="NLM_term">PPARγ</td><td class="NLM_def"><p class="first last">nuclear peroxisome proliferator-activated receptor-γ</p></td></tr><tr><td class="NLM_term">%PPB</td><td class="NLM_def"><p class="first last">% plasma protein binding</p></td></tr><tr><td class="NLM_term">RBP4</td><td class="NLM_def"><p class="first last">retinol binding protein-4</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">RPE</td><td class="NLM_def"><p class="first last">retinal pigment epithelium</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">Ser</td><td class="NLM_def"><p class="first last">serine</p></td></tr><tr><td class="NLM_term">SPA</td><td class="NLM_def"><p class="first last">scintillation proximity assay</p></td></tr><tr><td class="NLM_term">SSA</td><td class="NLM_def"><p class="first last">senile systemic amyloidosis</p></td></tr><tr><td class="NLM_term">STD NMR</td><td class="NLM_def"><p class="first last">saturation transfer difference nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">TBG</td><td class="NLM_def"><p class="first last">thyroxine binding globulin</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">Thr</td><td class="NLM_def"><p class="first last">threonine</p></td></tr><tr><td class="NLM_term">TTR</td><td class="NLM_def"><p class="first last">transthyretin</p></td></tr><tr><td class="NLM_term">Trp</td><td class="NLM_def"><p class="first last">tryptophan</p></td></tr><tr><td class="NLM_term">Tyr</td><td class="NLM_def"><p class="first last">tyrosine</p></td></tr><tr><td class="NLM_term">T4</td><td class="NLM_def"><p class="first last">thyroxine</p></td></tr><tr><td class="NLM_term">Val</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr><tr><td class="NLM_term">X-Phos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i119">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 70 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprasadarao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSousa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, J. B.</span></span> <span> </span><span class="NLM_article-title">The transfer of retinol from serum retinol-binding protein to cellular retinol-binding protein is mediated by a membrane receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">3336</span>– <span class="NLM_lpage">3342</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.6.3336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1074%2Fjbc.273.6.3336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=9452451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVylsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=3336-3342&author=M.+Sundaramauthor=A.+Sivaprasadaraoauthor=M.+M.+DeSousaauthor=J.+B.+Findlay&title=The+transfer+of+retinol+from+serum+retinol-binding+protein+to+cellular+retinol-binding+protein+is+mediated+by+a+membrane+receptor&doi=10.1074%2Fjbc.273.6.3336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The transfer of retinol from serum retinol-binding protein to cellular retinol-binding protein is mediated by a membrane receptor</span></div><div class="casAuthors">Sundaram, Manickavasagam; Sivaprasadarao, Adipu; DeSousa, Monica M.; Findlay, John B. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3336-3342</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The hypothesis that the cellular uptake of retinol involves the specific interaction of a plasma membrane receptor with serum retinol-binding protein (RBP) at the extracellular surface followed by ligand transfer to cytoplasmic cellular retinol-binding protein (CRBP) has been investigated.  The exptl. system consisted of the [3H]retinol-RBP complex, Escherichia coli-expressed recombinant apo-CRBP contg. the 10 amino acid long streptavidin-binding peptide sequence at its C terminus (designated as CRBP-Strep) and permeabilized human placental membranes.  [3H]Retinol transfer from RBP to CRBP-Strep was monitored by measuring the radioactivity assocd. with CRBP-Strep retained by an immobilized streptavidin resin.  Using this assay system, we have demonstrated that optimal retinol uptake is achieved with holo-RBP, the membrane receptor and apo-CRBP.  The effects are specific: other binding proteins, including β-lactoglobulin and serum albumin, despite their ability to bind retinol, failed to substitute for either RBP or apo-CRBP.  The process is facilitated by membranes contg. the native receptor suggesting that this protein is an important component in the transfer mechanism.  Taken together, the data suggest that the RBP receptor, through specific interactions with the binding proteins, participates (either directly or via assocd. proteins) in the mechanism which mediates the transfer of retinol from extracellular RBP to intracellular CRBP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNh_R1TkPFLbVg90H21EOLACvtfcHk0lgosUUrR_OEZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVylsro%253D&md5=4d9faf55fbd5b90e27d2e7a4c946252a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.6.3336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.6.3336%26sid%3Dliteratum%253Aachs%26aulast%3DSundaram%26aufirst%3DM.%26aulast%3DSivaprasadarao%26aufirst%3DA.%26aulast%3DDeSousa%26aufirst%3DM.%2BM.%26aulast%3DFindlay%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520transfer%2520of%2520retinol%2520from%2520serum%2520retinol-binding%2520protein%2520to%2520cellular%2520retinol-binding%2520protein%2520is%2520mediated%2520by%2520a%2520membrane%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D3336%26epage%3D3342%26doi%3D10.1074%2Fjbc.273.6.3336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ter-Stepanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Vitamin A Transport Mechanism of the Multitransmembrane Cell-Surface Receptor STRA6</span>. <i>Membranes</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.3390/membranes5030425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fmembranes5030425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=26343735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGksrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=425-453&author=R.+Kawaguchiauthor=M.+Zhongauthor=M.+Kassaiauthor=M.+Ter-Stepanianauthor=H.+Sun&title=Vitamin+A+Transport+Mechanism+of+the+Multitransmembrane+Cell-Surface+Receptor+STRA6&doi=10.3390%2Fmembranes5030425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin A transport mechanism of the multitransmembrane cell-surface receptor STRA6</span></div><div class="casAuthors">Kawaguchi, Riki; Zhong, Ming; Kassai, Miki; Ter-Stepanian, Mariam; Sun, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Membranes (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">425-453</span>CODEN:
                <span class="NLM_cas:coden">MBSEB6</span>;
        ISSN:<span class="NLM_cas:issn">2077-0375</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Vitamin A has biol. functions as diverse as sensing light for vision, regulating stem cell differentiation, maintaining epithelial integrity, promoting immune competency, regulating learning and memory, and acting as a key developmental morphogen.  Vitamin A derivs. have also been used in treating human diseases.  If vitamin A is considered a drug that everyone needs to take to survive, evolution has come up with a natural drug delivery system that combines sustained release with precise and controlled delivery to the cells or tissues that depend on it.  This "drug delivery system" is mediated by plasma retinol binding protein (RBP), the principle and specific vitamin A carrier protein in the blood, and STRA6, the cell-surface receptor for RBP that mediates cellular vitamin A uptake.  The mechanism by which the RBP receptor absorbs vitamin A from the blood is distinct from other known cellular uptake mechanisms.  This review summarizes recent progress in elucidating the fundamental mol. mechanism mediated by the RBP receptor and multiple newly discovered catalytic activities of this receptor, and compares this transport system with retinoid transport independent of RBP/STRA6.  How to target this new type of transmembrane receptor using small mols. in treating diseases is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLm6WqwKJAWbVg90H21EOLACvtfcHk0lgosUUrR_OEZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGksrbP&md5=331d8bcb759d5565992f3ba9df925fd3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3390%2Fmembranes5030425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmembranes5030425%26sid%3Dliteratum%253Aachs%26aulast%3DKawaguchi%26aufirst%3DR.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DKassai%26aufirst%3DM.%26aulast%3DTer-Stepanian%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DVitamin%2520A%2520Transport%2520Mechanism%2520of%2520the%2520Multitransmembrane%2520Cell-Surface%2520Receptor%2520STRA6%26jtitle%3DMembranes%26date%3D2015%26volume%3D5%26spage%3D425%26epage%3D453%26doi%3D10.3390%2Fmembranes5030425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2885</span>– <span class="NLM_lpage">2891</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.bmcl.2014.04.089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=24835984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2885-2891&author=Y.+Wangauthor=R.+Connorsauthor=P.+Fanauthor=X.+Wangauthor=Z.+Wangauthor=J.+Liuauthor=F.+Kayserauthor=J.+C.+Medinaauthor=S.+Johnstoneauthor=H.+Xuauthor=S.+Thibaultauthor=N.+Walkerauthor=M.+Connauthor=Y.+Zhangauthor=Q.+Liuauthor=M.+P.+Grilloauthor=A.+Motaniauthor=P.+Cowardauthor=Z.+Wang&title=Structure-assisted+discovery+of+the+first+non-retinoid+ligands+for+Retinol-Binding+Protein+4&doi=10.1016%2Fj.bmcl.2014.04.089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4</span></div><div class="casAuthors">Wang, Yingcai; Connors, Richard; Fan, Pingchen; Wang, Xiaodong; Wang, Zhongyu; Liu, Jiwen; Kayser, Frank; Medina, Julio C.; Johnstone, Sheree; Xu, Haoda; Thibault, Stephen; Walker, Nigel; Conn, Marion; Zhang, Ying; Liu, Qingxiang; Grillo, Mark P.; Motani, Alykhan; Coward, Peter; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2885-2891</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Retinol-Binding Protein 4 (RBP4) is a plasma protein that transports retinol (vitamin A) from the liver to peripheral tissues.  This Letter highlights our efforts in discovering the first, to our knowledge, non-retinoid small mols. that bind to RBP4 at the retinol site and reduce serum RBP4 levels in mice, by disrupting the interaction between RBP4 and transthyretin (TTR), a plasma protein that binds RBP4 and protects it from renal excretion.  Potent compds. were discovered and optimized quickly from high-throughput screen (HTS) hits utilizing a structure-based approach.  Inhibitor co-crystal X-ray structures revealed unique disruptions of RBP4-TTR interactions by our compds. through induced loop conformational changes instead of steric hindrance exemplified by fenretinide.  When administered to mice, A1120, a representative compd. in the series, showed concn.-dependent retinol and RBP4 lowering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq0W6CwH_asbVg90H21EOLACvtfcHk0lj8Eunn9gSh8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFGgu74%253D&md5=21bf540e2cc853aa9395f4cfafbec1f0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.089%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DConnors%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKayser%26aufirst%3DF.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DConn%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGrillo%26aufirst%3DM.%2BP.%26aulast%3DMotani%26aufirst%3DA.%26aulast%3DCoward%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructure-assisted%2520discovery%2520of%2520the%2520first%2520non-retinoid%2520ligands%2520for%2520Retinol-Binding%2520Protein%25204%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2885%26epage%3D2891%26doi%3D10.1016%2Fj.bmcl.2014.04.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cywin, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7731</span>– <span class="NLM_lpage">7757</span>, <span class="refDoi"> DOI: 10.1021/jm5010013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5010013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGht7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7731-7757&author=C.+L.+Cioffiauthor=N.+Dobriauthor=E.+E.+Freemanauthor=M.+P.+Conlonauthor=P.+Chenauthor=D.+G.+Staffordauthor=D.+M.+Schwarzauthor=K.+C.+Goldenauthor=L.+Zhuauthor=D.+B.+Kitchenauthor=K.+D.+Barnesauthor=B.+Raczauthor=Q.+Qinauthor=E.+Michelottiauthor=C.+L.+Cywinauthor=W.+H.+Martinauthor=P.+G.+Pearsonauthor=G.+Johnsonauthor=K.+Petrukhin&title=Design%2C+synthesis%2C+and+evaluation+of+nonretinoid+retinol+binding+protein+4+antagonists+for+the+potential+treatment+of+atrophic+age-related+macular+degeneration+and+Stargardt+disease&doi=10.1021%2Fjm5010013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Nonretinoid Retinol Binding Protein 4 Antagonists for the Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease</span></div><div class="casAuthors">Cioffi, Christopher L.; Dobri, Nicoleta; Freeman, Emily E.; Conlon, Michael P.; Chen, Ping; Stafford, Douglas G.; Schwarz, Daniel M. C.; Golden, Kathy C.; Zhu, Lei; Kitchen, Douglas B.; Barnes, Keith D.; Racz, Boglarka; Qin, Qiong; Michelotti, Enrique; Cywin, Charles L.; Martin, William H.; Pearson, Paul G.; Johnson, Graham; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7731-7757</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Accumulation of lipofuscin in the retina is assocd. with pathogenesis of atrophic age-related macular degeneration and Stargardt disease.  Lipofuscin bisretinoids (exemplified by N-retinylidene-N-retinylethanolamine) seem to mediate lipofuscin toxicity.  Synthesis of lipofuscin bisretinoids depends on the influx of retinol from serum to the retina.  Compds. antagonizing the retinol-dependent interaction of retinol-binding protein 4 (RBP4) with transthyretin in the serum would reduce serum RBP4 and retinol and inhibit bisretinoid formation.  The authors recently showed that I, a potent carboxylic acid based RBP4 antagonist, can significantly reduce lipofuscin bisretinoid formation in the retinas of Abca4-/- mice.  As part of the NIH Blueprint Neurotherapeutics Network project the authors undertook the in vitro exploration to identify novel conformationally flexible and constrained RBP4 antagonists with improved potency and metabolic stability.  The authors also demonstrate that upon acute and chronic dosing in rats, II, a potent cyclopentyl fused pyrrolidine antagonist, reduced circulating plasma RBP4 protein levels by approx. 60%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUF22isGQmYbVg90H21EOLACvtfcHk0lhLI5Tm7zGXQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGht7bF&md5=b1b0f386ddb1766db11e2495e8e1c0b6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm5010013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5010013%26sid%3Dliteratum%253Aachs%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DDobri%26aufirst%3DN.%26aulast%3DFreeman%26aufirst%3DE.%2BE.%26aulast%3DConlon%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DStafford%26aufirst%3DD.%2BG.%26aulast%3DSchwarz%26aufirst%3DD.%2BM.%26aulast%3DGolden%26aufirst%3DK.%2BC.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DBarnes%26aufirst%3DK.%2BD.%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DMichelotti%26aufirst%3DE.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520nonretinoid%2520retinol%2520binding%2520protein%25204%2520antagonists%2520for%2520the%2520potential%2520treatment%2520of%2520atrophic%2520age-related%2520macular%2520degeneration%2520and%2520Stargardt%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7731%26epage%3D7757%26doi%3D10.1021%2Fjm5010013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cywin, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Bicyclic [3.3.0]-octahydrocyclopenta[c]pyrrolo antagonists of retinol binding protein 4: potential treatment of atrophic age-related macular degeneration and Stargardt disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5863</span>– <span class="NLM_lpage">5888</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00423</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyqs7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5863-5888&author=C.+L.+Cioffiauthor=B.+Raczauthor=E.+E.+Freemanauthor=M.+P.+Conlonauthor=P.+Chenauthor=D.+G.+Staffordauthor=D.+M.+Schwarzauthor=L.+Zhuauthor=D.+B.+Kitchenauthor=K.+D.+Barnesauthor=N.+Dobriauthor=E.+Michelottiauthor=C.+L.+Cywinauthor=W.+H.+Martinauthor=P.+G.+Pearsonauthor=G.+Johnsonauthor=K.+Petrukhin&title=Bicyclic+%5B3.3.0%5D-octahydrocyclopenta%5Bc%5Dpyrrolo+antagonists+of+retinol+binding+protein+4%3A+potential+treatment+of+atrophic+age-related+macular+degeneration+and+Stargardt+disease&doi=10.1021%2Facs.jmedchem.5b00423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease</span></div><div class="casAuthors">Cioffi, Christopher L.; Racz, Boglarka; Freeman, Emily E.; Conlon, Michael P.; Chen, Ping; Stafford, Douglas G.; Schwarz, Daniel M. C.; Zhu, Lei; Kitchen, Douglas B.; Barnes, Keith D.; Dobri, Nicoleta; Michelotti, Enrique; Cywin, Charles L.; Martin, William H.; Pearson, Paul G.; Johnson, Graham; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5863-5888</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonists of retinol-binding protein 4 (RBP4) impede ocular uptake of serum all-trans retinol (1) and have been shown to reduce cytotoxic bisretinoid formation in the retinal pigment epithelium (RPE), which is assocd. with the pathogenesis of both dry age-related macular degeneration (AMD) and Stargardt disease.  Thus, these agents show promise as a potential pharmacotherapy by which to stem further neurodegeneration and concomitant vision loss assocd. with geog. atrophy of the macula.  We previously disclosed the discovery of a novel series of nonretinoid RBP4 antagonists, represented by bicyclic [3.3.0]-octahydrocyclopenta[c]pyrrolo analog 4.  We describe herein the utilization of a pyrimidine-4-carboxylic acid fragment as a suitable isostere for the anthranilic acid appendage of 4, which led to the discovery of standout antagonist 33.  Analog 33 possesses exquisite in vitro RBP4 binding affinity and favorable drug-like characteristics and was found to reduce circulating plasma RBP4 levels in vivo in a robust manner (>90%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXHKHv5GfUDrVg90H21EOLACvtfcHk0lhLI5Tm7zGXQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyqs7fL&md5=6360017d9a35d984c99b22be38df8acb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00423%26sid%3Dliteratum%253Aachs%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DFreeman%26aufirst%3DE.%2BE.%26aulast%3DConlon%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DStafford%26aufirst%3DD.%2BG.%26aulast%3DSchwarz%26aufirst%3DD.%2BM.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DBarnes%26aufirst%3DK.%2BD.%26aulast%3DDobri%26aufirst%3DN.%26aulast%3DMichelotti%26aufirst%3DE.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DBicyclic%2520%255B3.3.0%255D-octahydrocyclopenta%255Bc%255Dpyrrolo%2520antagonists%2520of%2520retinol%2520binding%2520protein%25204%253A%2520potential%2520treatment%2520of%2520atrophic%2520age-related%2520macular%2520degeneration%2520and%2520Stargardt%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5863%26epage%3D5888%26doi%3D10.1021%2Facs.jmedchem.5b00423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaner, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and preclinical efficacy of novel nonretinoid antagonists of retinol-binding protein 4 in the mouse model of hepatic steatosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5470</span>– <span class="NLM_lpage">5500</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00352</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00352" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlKru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5470-5500&author=C.+L.+Cioffiauthor=B.+Raczauthor=A.+Varadiauthor=E.+E.+Freemanauthor=M.+P.+Conlonauthor=P.+Chenauthor=L.+Zhuauthor=D.+B.+Kitchenauthor=K.+D.+Barnesauthor=W.+H.+Martinauthor=P.+G.+Pearsonauthor=G.+Johnsonauthor=W.+S.+Blanerauthor=K.+Petrukhin&title=Design%2C+synthesis%2C+and+preclinical+efficacy+of+novel+nonretinoid+antagonists+of+retinol-binding+protein+4+in+the+mouse+model+of+hepatic+steatosis&doi=10.1021%2Facs.jmedchem.9b00352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis</span></div><div class="casAuthors">Cioffi, Christopher L.; Racz, Boglarka; Varadi, Andras; Freeman, Emily E.; Conlon, Michael P.; Chen, Ping; Zhu, Lei; Kitchen, Douglas B.; Barnes, Keith D.; Martin, William H.; Pearson, Paul G.; Johnson, Graham; Blaner, William S.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5470-5500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Retinol-binding protein 4 (RBP4) serves as a transporter for all-trans-retinol (1) in the blood, and it has been proposed to act as an adipokine.  Elevated plasma levels of the protein have been linked to diabetes, obesity, cardiovascular diseases, and nonalcoholic fatty liver disease (NAFLD).  Recently, adipocyte-specific overexpression of RBP4 was reported to cause hepatic steatosis in mice.  We previously identified an orally bioavailable RBP4 antagonist that significantly lowered RBP4 serum levels in Abca4-/- knockout mice with concomitant normalization of complement system protein expression and redn. of bisretinoid formation within the retinal pigment epithelium.  We describe herein the discovery of novel RBP4 antagonists 48 and 59, which reduce serum RBP4 levels by >80% in mice upon acute oral dosing.  Furthermore, 59 demonstrated efficacy in the transgenic adi-hRBP4 murine model of hepatic steatosis, suggesting that RBP4 antagonists may also have therapeutic utility for the treatment of NAFLD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqump9JRd0bHrVg90H21EOLACvtfcHk0libEcHaSGW-3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlKru7Y%253D&md5=26e23f630afb5dacf84b942fcda8a834</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00352%26sid%3Dliteratum%253Aachs%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DFreeman%26aufirst%3DE.%2BE.%26aulast%3DConlon%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DBarnes%26aufirst%3DK.%2BD.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DBlaner%26aufirst%3DW.%2BS.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520preclinical%2520efficacy%2520of%2520novel%2520nonretinoid%2520antagonists%2520of%2520retinol-binding%2520protein%25204%2520in%2520the%2520mouse%2520model%2520of%2520hepatic%2520steatosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5470%26epage%3D5500%26doi%3D10.1021%2Facs.jmedchem.9b00352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthuraman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of bispecific antagonists of retinol binding protein 4 that stabilize transthyretin tetramers: scaffolding hopping, optimization, and preclinical pharmacological evaluation as a potential therapy for two common age-related comorbidities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11054</span>– <span class="NLM_lpage">11084</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00996</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00996" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11054-11084&author=C.+L.+Cioffiauthor=P.+Muthuramanauthor=A.+Rajaauthor=A.+Varadiauthor=B.+Raczauthor=K.+Petrukhin&title=Discovery+of+bispecific+antagonists+of+retinol+binding+protein+4+that+stabilize+transthyretin+tetramers%3A+scaffolding+hopping%2C+optimization%2C+and+preclinical+pharmacological+evaluation+as+a+potential+therapy+for+two+common+age-related+comorbidities&doi=10.1021%2Facs.jmedchem.0c00996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities</span></div><div class="casAuthors">Cioffi, Christopher L.; Muthuraman, Parthasarathy; Raja, Arun; Varadi, Andras; Racz, Boglarka; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11054-11084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Accumulation of cytotoxic lipofuscin bisretinoids may contribute to atrophic age-related macular degeneration (AMD) pathogenesis.  Retinal bisretinoid synthesis depends on the influx of serum all-trans-retinol delivered via a tertiary retinol binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex.  We previously identified selective RBP4 antagonists that dissoc. circulating RBP4-TTR-retinol complexes, reduce serum RBP4 levels, and inhibit bisretinoid synthesis in models of enhanced retinal lipofuscinogenesis.  However, the release of TTR by selective RBP4 antagonists may be assocd. with TTR tetramer destabilization and, potentially, TTR amyloid formation.  We describe herein the identification of bispecific RBP4 antagonist-TTR tetramer kinetic stabilizers.  Standout analog I possesses suitable potency for both targets, significantly lowers mouse plasma RBP4 levels, and prevents TTR aggregation in a gel-based assay.  This new class of bispecific compds. may be esp. important as a therapy for dry AMD patients who have another common age-related comorbidity, senile systemic amyloidosis, a nongenetic disease assocd. with wild-type TTR misfolding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobBY7AXQ-snrVg90H21EOLACvtfcHk0libEcHaSGW-3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslCltr7P&md5=2aa161b0000d797b71c4e08f2a6f57f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00996%26sid%3Dliteratum%253Aachs%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DMuthuraman%26aufirst%3DP.%26aulast%3DRaja%26aufirst%3DA.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520bispecific%2520antagonists%2520of%2520retinol%2520binding%2520protein%25204%2520that%2520stabilize%2520transthyretin%2520tetramers%253A%2520scaffolding%2520hopping%252C%2520optimization%252C%2520and%2520preclinical%2520pharmacological%2520evaluation%2520as%2520a%2520potential%2520therapy%2520for%2520two%2520common%2520age-related%2520comorbidities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11054%26epage%3D11084%26doi%3D10.1021%2Facs.jmedchem.0c00996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radu, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nusinowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata, N. L.</span></span> <span> </span><span class="NLM_article-title">Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4393</span>– <span class="NLM_lpage">43401</span>, <span class="refDoi"> DOI: 10.1167/iovs.05-0820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1167%2Fiovs.05-0820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=16303925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnit1GgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=4393-43401&author=R.+A.+Raduauthor=Y.+Hanauthor=T.+V.+Buiauthor=S.+Nusinowitzauthor=D.+Bokauthor=J.+Lichterauthor=K.+Widderauthor=G.+H.+Travisauthor=N.+L.+Mata&title=Reductions+in+serum+vitamin+A+arrest+accumulation+of+toxic+retinal+fluorophores%3A+a+potential+therapy+for+treatment+of+lipofuscin-based+retinal+diseases&doi=10.1167%2Fiovs.05-0820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases</span></div><div class="casAuthors">Radu Roxana A; Han Yun; Bui Tam V; Nusinowitz Steven; Bok Dean; Lichter Jay; Widder Ken; Travis Gabriel H; Mata Nathan L</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4393-401</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  Excessive accumulation of lipofuscin is observed in numerous degenerative retinal diseases.  A toxic vitamin A-based fluorophore (A2E) present within lipofuscin has been implicated in the death of RPE and photoreceptor cells.  Here, we used an animal model that manifests accelerated lipofuscin accumulation (ABCA4-/- mutant) to evaluate the efficacy of a therapeutic approach based on reduction of serum retinol.  METHODS:  N-(4-hydroxyphenyl)retinamide (HPR) potently and reversibly reduces serum retinol.  The interaction of HPR with retinol binding protein (RBP) and transthyretin was studied by spectrofluorometry and size-exclusion chromatography.  To assess the effects of HPR on visual cycle retinoids and A2E biosynthesis, HPR was chronically administered to ABCA4-/- mice.  Mice were evaluated using biochemical, electrophysiological, and morphologic techniques.  RESULTS:  Administration of HPR to ABCA4-/- mice caused immediate, dose-dependent reductions in serum retinol and RBP.  Chronic administration produced commensurate reductions in visual cycle retinoids and arrested accumulation of A2E and lipofuscin autofluorescence in the RPE.  Physiologically, HPR treatment caused modest delays in dark adaptation.  Chromophore regeneration kinetics, light sensitivity of photoreceptors, and phototransduction processes were normal.  Histologic examinations showed no alteration of retinal cytostructure or morphology.  CONCLUSIONS:  These findings demonstrate the vitamin A-dependent nature of A2E biosynthesis and validate a novel therapeutic approach with potential to halt the accumulation of lipofuscin fluorophores in the eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcST_ie98itsIvcsfMJQC1ZdfW6udTcc2eaOP6xVbhK2Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnit1GgtQ%253D%253D&md5=dc425883e9829eab910c9cf96a9d5fe6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1167%2Fiovs.05-0820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.05-0820%26sid%3Dliteratum%253Aachs%26aulast%3DRadu%26aufirst%3DR.%2BA.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DBui%26aufirst%3DT.%2BV.%26aulast%3DNusinowitz%26aufirst%3DS.%26aulast%3DBok%26aufirst%3DD.%26aulast%3DLichter%26aufirst%3DJ.%26aulast%3DWidder%26aufirst%3DK.%26aulast%3DTravis%26aufirst%3DG.%2BH.%26aulast%3DMata%26aufirst%3DN.%2BL.%26atitle%3DReductions%2520in%2520serum%2520vitamin%2520A%2520arrest%2520accumulation%2520of%2520toxic%2520retinal%2520fluorophores%253A%2520a%2520potential%2520therapy%2520for%2520treatment%2520of%2520lipofuscin-based%2520retinal%2520diseases%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2005%26volume%3D46%26spage%3D4393%26epage%3D43401%26doi%3D10.1167%2Fiovs.05-0820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dobri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moiseyev, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allikmets, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparrow, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1167/iovs.12-10050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1167%2Fiovs.12-10050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23211825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjt1eqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=85-95&author=N.+Dobriauthor=Q.+Qinauthor=J.+Kongauthor=K.+Yamamotoauthor=Z.+Liuauthor=G.+Moiseyevauthor=J.+X.+Maauthor=R.+Allikmetsauthor=J.+R.+Sparrowauthor=K.+Petrukhin&title=A1120%2C+a+nonretinoid+RBP4+antagonist%2C+inhibits+formation+of+cytotoxic+bisretinoids+in+the+animal+model+of+enhanced+retinal+lipofuscinogenesis&doi=10.1167%2Fiovs.12-10050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis</span></div><div class="casAuthors">Dobri, Nicoleta; Qin, Qiong; Kong, Jian; Yamamoto, Kazunori; Liu, Zhao; Moiseyev, Gennadiy; Ma, Jian-xing; Allikmets, Rando; Sparrow, Janet R.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-95</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">PURPOSE. Excessive accumulation of lipofuscin is assocd. with pathogenesis of atrophic age-related macular degeneration (AMD) and Stargardt disease.  Pharmacol. inhibition of the retinol-induced interaction of retinol-binding protein 4 (RBP4) with transthyretin (TTR) in the serum may decrease the uptake of serum retinol to the retina and reduce formation of lipofuscin bisretinoids.  We evaluated in vitro and in vivo properties of the new nonretinoid RBP4 antagonist, A1120.  METHODS. RBP4 binding potency, ability to antagonize RBP4-TTR interaction, and compd. specificity were analyzed for A1120 and for the prototypic RBP4 antagonist fenretinide.  A1120 ability to inhibit RPE65-mediated isomerohydrolase activity was assessed in the RPE microsomes.  The in vivo effect of A1120 administration on serum RBP4, visual cycle retinoids, lipofuscin bisretinoids, and retinal visual function was evaluated using a combination of biochem. and electrophysiol. techniques.  RESULTS. In comparison to fenretinide, A1120 did not act as a RARα agonist, while exhibiting superior in vitro potency in RBP4 binding and RBP4-TTR interaction assays.  A1120 did not inhibit isomerohydrolase activity in the RPE microsomes.  A1120 dosing in mice induced 75% redn. in serum RBP4, which correlated with redn. in visual cycle retinoids and ocular levels of lipofuscin fluorophores.  A1120 dosing did not induce changes in kinetics of dark adaptation.  CONCLUSIONS. A1120 significantly reduces accumulation of lipofuscin bisretinoids in the Abca4-/- animal model.  This activity correlates with redn. in serum RBP4 and visual cycle retinoids confirming the mechanism of action for A1120.  In contrast to fenretinide, A1120 does not act as a RARα agonist indicating a more favorable safety profile for this nonretinoid compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCuxjzXex7aLVg90H21EOLACvtfcHk0lgdzOE8S5a-sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjt1eqs70%253D&md5=3a605e4dc084a06e325ccdd14ec48886</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1167%2Fiovs.12-10050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.12-10050%26sid%3Dliteratum%253Aachs%26aulast%3DDobri%26aufirst%3DN.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMoiseyev%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DJ.%2BX.%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DSparrow%26aufirst%3DJ.%2BR.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DA1120%252C%2520a%2520nonretinoid%2520RBP4%2520antagonist%252C%2520inhibits%2520formation%2520of%2520cytotoxic%2520bisretinoids%2520in%2520the%2520animal%2520model%2520of%2520enhanced%2520retinal%2520lipofuscinogenesis%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2013%26volume%3D54%26spage%3D85%26epage%3D95%26doi%3D10.1167%2Fiovs.12-10050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allikmets, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">11574</span>– <span class="NLM_lpage">11588</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.002062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1074%2Fjbc.RA118.002062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=29871924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGltLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=11574-11588&author=B.+Raczauthor=A.+Varadiauthor=J.+Kongauthor=R.+Allikmetsauthor=P.+G.+Pearsonauthor=G.+Johnsonauthor=C.+L.+Cioffiauthor=K.+Petrukhin&title=A+non-retinoid+antagonist+of+retinol-binding+protein+4+rescues+phenotype+in+a+model+of+Stargardt+disease+without+inhibiting+the+visual+cycle&doi=10.1074%2Fjbc.RA118.002062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle</span></div><div class="casAuthors">Racz, Boglarka; Varadi, Andras; Kong, Jian; Allikmets, Rando; Pearson, Paul G.; Johnson, Graham; Cioffi, Christopher L.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11574-11588</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A primary pathol. defect in the heritable eye disorder Stargardt disease is excessive accumulation of cytotoxic lipofuscin bisretinoids in the retina.  Age-dependent accumulation of lipofuscin in the retinal pigment epithelium (RPE) matches the age-dependent increase in the incidence of the atrophic (dry) form of age-related macular degeneration (AMD) and therefore may be one of several pathogenic factors contributing to AMD progression.  Lipofuscin bisretinoid synthesis in the retina depends on the influx of serum retinol from the circulation into the RPE.  Formation of the tertiary retinol-binding protein 4 (RBP4)-transthyretin-retinol complex in the serum is required for this influx.  Herein, we report the pharmacol. effects of the non-retinoid RBP4 antagonist, BPN-14136.  BPN-14136 dosing in the Abca4-/- mouse model of increased lipofuscinogenesis significantly reduced serum RBP4 levels and inhibited bisretinoid synthesis, and this inhibition correlated with a partial redn. in visual cycle retinoids such as retinaldehydes serving as bisretinoid precursors.  BPN-14136 administration at doses inducing maximal serum RBP4 redn. did not produce changes in the rate of the visual cycle, consistent with minimal changes in dark adaptation.  Abca4-/- mice exhibited dysregulation of the complement system in the retina, and BPN-14136 administration normalized the retinal levels of proinflammatory complement cascade components such as complement factors D and H, C-reactive protein, and C3.  We conclude that BPN-14136 has several beneficial characteristics, combining inhibition of bisretinoid synthesis and redn. in retinaldehydes with normalization of the retinal complement system.  BPN-14136, or a similar compd., may be a promising drug candidate to manage Stargardt disease and dry AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCSqbHhwE9BLVg90H21EOLACvtfcHk0liGCW83AfqMoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGltLfE&md5=65f2b1f8433dede41cc2a6c181cc92a9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.002062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.002062%26sid%3Dliteratum%253Aachs%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DA%2520non-retinoid%2520antagonist%2520of%2520retinol-binding%2520protein%25204%2520rescues%2520phenotype%2520in%2520a%2520model%2520of%2520Stargardt%2520disease%2520without%2520inhibiting%2520the%2520visual%2520cycle%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26spage%3D11574%26epage%3D11588%26doi%3D10.1074%2Fjbc.RA118.002062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Comparative pharmacokinetics and pharmacodynamics of the advanced retinol-binding protein 4 antagonist in dog and cynomolgus monkey</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0228291</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0228291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1371%2Fjournal.pone.0228291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31978148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFCqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=B.+Raczauthor=A.+Varadiauthor=P.+G.+Pearsonauthor=K.+Petrukhin&title=Comparative+pharmacokinetics+and+pharmacodynamics+of+the+advanced+retinol-binding+protein+4+antagonist+in+dog+and+cynomolgus+monkey&doi=10.1371%2Fjournal.pone.0228291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacokinetics and pharmacodynamics of the advanced Retinol-Binding Protein 4 antagonist in dog and cynomolgus monkey</span></div><div class="casAuthors">Racz, Boglarka; Varadi, Andras; Pearson, Paul G.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0228291</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Accumulation of lipofuscin bisretinoids in the retina contributes to pathogenesis of macular degeneration.  Retinol-Binding Protein 4 (RBP4) antagonists reduce serum retinol concns. thus partially reducing retinol delivery to the retina which decreases bisretinoid synthesis.  BPN-14136 is a novel RBP4 antagonist with good in vitro potency and selectivity and optimal rodent pharmacokinetic (PK) and pharmacodynamic (PD) characteristics.  To select a non-rodent species for regulatory toxicol. studies, we conducted PK and PD evaluation of BPN-14136 in dogs and non-human primates (NHP).  PK properties were detd. following oral and i.v. administration of BPN-14136 in beagle dogs and cynomolgus monkeys.  Dynamics of plasma RBP4 redn. in response to compd. administration was used as a PD marker.  BPN-14136 exhibited favorable PK profile in both species.  Dose-normalized exposure was significantly higher in NHP than in dog.  Baseline concns. of RBP4 were considerably lower in dog than in NHP, reflecting the atypical reliance of canids on non-RBP4 mechanisms of retinoid trafficking.  Oral administration of BPN-14136 to NHP induced a strong 99% serum RBP4 redn.  Dynamics of RBP4 lowering in both species correlated with compd. exposure.  Despite adequate PK and PD characteristics of BPN-14136 in dog, reliance of canids on non-RBP4 mechanisms of retinoid trafficking precludes evaluation of on-target toxicities for RBP4 antagonists in this species.  Strong RBP4 lowering combined with good PK attributes and high BPN-14136 exposure achieved in NHP, along with the biol. of retinoid trafficking that is similar to that of humans, support the choice of NHP as a non-rodent safety species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ufYb9IqvXbVg90H21EOLACvtfcHk0liGCW83AfqMoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFCqtrc%253D&md5=45fb390c994eeb5138a90d33a020afba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0228291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0228291%26sid%3Dliteratum%253Aachs%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DComparative%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520the%2520advanced%2520retinol-binding%2520protein%25204%2520antagonist%2520in%2520dog%2520and%2520cynomolgus%2520monkey%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0228291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotrina, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsequell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Barbero, J.</span></span> <span> </span><span class="NLM_article-title">Insights on the interaction between transthyretin and Aβ in solution. A saturation transfer difference (STD) NMR analysis of the role of iododiflunisal</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5749</span>– <span class="NLM_lpage">5758</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00428</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00428" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Kntrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5749-5758&author=A.+Gimenoauthor=L.+M.+Santosauthor=M.+Alemiauthor=J.+Rivasauthor=D.+Blasiauthor=E.+Y.+Cotrinaauthor=J.+Llopauthor=G.+Valenciaauthor=I.+Cardosoauthor=J.+Quintanaauthor=G.+Arsequellauthor=J.+Jimenez-Barbero&title=Insights+on+the+interaction+between+transthyretin+and+A%CE%B2+in+solution.+A+saturation+transfer+difference+%28STD%29+NMR+analysis+of+the+role+of+iododiflunisal&doi=10.1021%2Facs.jmedchem.7b00428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Insights on the Interaction between Transthyretin and Aβ in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal</span></div><div class="casAuthors">Gimeno, Ana; Santos, Luis M.; Alemi, Mobina; Rivas, Josep; Blasi, Daniel; Cotrina, Ellen Y.; Llop, Jordi; Valencia, Gregorio; Cardoso, Isabel; Quintana, Jordi; Arsequell, Gemma; Jimenez-Barbero, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5749-5758</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several strategies against Alzheimer disease (AD) are directed toward targeting Aβ-peptides.  The ability of transthyretin (TTR) to bind Aβ-peptides and the pos. effect exerted by some TTR stabilizers for modulating the TTR-Aβ interaction have been previously studied.  Here, key structural features of the interaction between TTR and Aβ(12-28) peptide, the essential recognition element of Aβ, have been unraveled by STD-NMR spectroscopy methods in soln.  Mol. aspects related with the role of the TTR stabilizer, iododiflunisal (IDIF), on the TTR-Aβ complex were also examd.  The NMR results, assisted by mol. modeling protocols, provided a structural model for the TTR-Aβ interaction, as well as for the ternary complex formed in the presence of IDIF.  This basic structural information could be relevant for providing light on the mechanisms involved in the ameliorating effects of AD symptoms obsd. in AD/TTR± animal models after IDIF treatment and eventually for designing new mols. toward AD therapeutic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYFHzRMCro1rVg90H21EOLACvtfcHk0lhDs5ADa6Qoaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Kntrw%253D&md5=8e4c5275309c8d1129655c6d30a9c82d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00428%26sid%3Dliteratum%253Aachs%26aulast%3DGimeno%26aufirst%3DA.%26aulast%3DSantos%26aufirst%3DL.%2BM.%26aulast%3DAlemi%26aufirst%3DM.%26aulast%3DRivas%26aufirst%3DJ.%26aulast%3DBlasi%26aufirst%3DD.%26aulast%3DCotrina%26aufirst%3DE.%2BY.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DValencia%26aufirst%3DG.%26aulast%3DCardoso%26aufirst%3DI.%26aulast%3DQuintana%26aufirst%3DJ.%26aulast%3DArsequell%26aufirst%3DG.%26aulast%3DJimenez-Barbero%26aufirst%3DJ.%26atitle%3DInsights%2520on%2520the%2520interaction%2520between%2520transthyretin%2520and%2520A%25CE%25B2%2520in%2520solution.%2520A%2520saturation%2520transfer%2520difference%2520%2528STD%2529%2520NMR%2520analysis%2520of%2520the%2520role%2520of%2520iododiflunisal%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5749%26epage%3D5758%26doi%3D10.1021%2Facs.jmedchem.7b00428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jesus, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaz, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faria, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brito, R. M.</span></span> <span> </span><span class="NLM_article-title">A new folding kinetic mechanism for human transthyretin and the influence of the amyloidogenic V30M mutation</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>, <span class="NLM_elocation-id">1428</span> <span class="refDoi"> DOI: 10.3390/ijms17091428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fijms17091428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2qsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&author=C.+S.+Jesusauthor=Z.+L.+Almeidaauthor=D.+C.+Vazauthor=T.+Q.+Fariaauthor=R.+M.+Brito&title=A+new+folding+kinetic+mechanism+for+human+transthyretin+and+the+influence+of+the+amyloidogenic+V30M+mutation&doi=10.3390%2Fijms17091428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A new folding kinetic mechanism for human transthyretin and the influence of the amyloidogenic V30M mutation</span></div><div class="casAuthors">Jesus, Catarina S. H.; Almeida, Zaida L.; Vaz, Daniela C.; Faria, Tiago Q.; Brito, Rui M. M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1428/1-1428/19</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Protein aggregation into insol. amyloid fibrils is the hallmark of several neurodegenerative diseases, chief among them Alzheimer's and Parkinson's.  Although caused by different proteins, these pathologies share some basic mol. mechanisms with familial amyloidotic polyneuropathy (FAP), a rare hereditary neuropathy caused by amyloid formation and deposition by transthyretin (TTR) in the peripheral and autonomic nervous systems.  Among the amyloidogenic TTR mutations known, V30M-TTR is the most common in FAP.  TTR amyloidogenesis (ATTR) is triggered by tetramer dissocn., followed by partial unfolding and aggregation of the low conformational stability monomers formed.  Thus, tetramer dissocn. kinetics, monomer conformational stability and competition between refolding and aggregation pathways do play a crit. role in ATTR.  Here, we propose a new model to analyze the refolding kinetics of WT-TTR and V30M-TTR, showing that at pH and protein concns. close to physiol., a two-step mechanism with a unimol. first step followed by a second-order second step adjusts well to the exptl. data.  Interestingly, although sharing the same kinetic mechanism, V30M-TTR refolds at a much slower rate than WT-TTR, a feature that may favor the formation of transient species leading to kinetic partition into amyloidogenic pathways and, thus, significantly increasing the probability of amyloid formation in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM2hUOB2t2mbVg90H21EOLACvtfcHk0lhDs5ADa6Qoaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2qsrfL&md5=298a1ca1f946455376bbccf958d5c69b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3390%2Fijms17091428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms17091428%26sid%3Dliteratum%253Aachs%26aulast%3DJesus%26aufirst%3DC.%2BS.%26aulast%3DAlmeida%26aufirst%3DZ.%2BL.%26aulast%3DVaz%26aufirst%3DD.%2BC.%26aulast%3DFaria%26aufirst%3DT.%2BQ.%26aulast%3DBrito%26aufirst%3DR.%2BM.%26atitle%3DA%2520new%2520folding%2520kinetic%2520mechanism%2520for%2520human%2520transthyretin%2520and%2520the%2520influence%2520of%2520the%2520amyloidogenic%2520V30M%2520mutation%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2016%26volume%3D17%26doi%3D10.3390%2Fijms17091428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damrauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argulian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbyn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerraty, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kember, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vleck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abul-Husn, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirinos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loos, R. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirugo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadkarni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rader, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, R.</span></span> <span> </span><span class="NLM_article-title">Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of african or hispanic/latino ancestry</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">2191</span>– <span class="NLM_lpage">2202</span>, <span class="refDoi"> DOI: 10.1001/jama.2019.17935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1001%2Fjama.2019.17935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31821430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyqu7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2019&pages=2191-2202&author=S.+M.+Damrauerauthor=K.+Chaudharyauthor=J.+H.+Choauthor=L.+W.+Liangauthor=E.+Argulianauthor=L.+Chanauthor=A.+Dobbynauthor=M.+A.+Guerratyauthor=R.+Judyauthor=J.+Kayauthor=R.+L.+Kemberauthor=M.+G.+Levinauthor=A.+Sahaauthor=T.+Van+Vleckauthor=S.+S.+Vermaauthor=J.+Weaverauthor=N.+S.+Abul-Husnauthor=A.+Barasauthor=J.+A.+Chirinosauthor=B.+Drachmanauthor=E.+E.+Kennyauthor=R.+J.+F.+Loosauthor=J.+Narulaauthor=J.+Overtonauthor=J.+Reidauthor=M.+Ritchieauthor=G.+Sirugoauthor=G.+Nadkarniauthor=D.+J.+Raderauthor=R.+Do&title=Association+of+the+V122I+hereditary+transthyretin+amyloidosis+genetic+variant+with+heart+failure+among+individuals+of+african+or+hispanic%2Flatino+ancestry&doi=10.1001%2Fjama.2019.17935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of Aafrican or Hispanic/Latino ancestry</span></div><div class="casAuthors">Damrauer, Scott M.; Chaudhary, Kumardeep; Cho, Judy H.; Liang, Lusha W.; Argulian, Edgar; Chan, Lili; Dobbyn, Amanda; Guerraty, Marie A.; Judy, Renae; Kay, Jenna; Kember, Rachel L.; Levin, Michael G.; Saha, Aparna; Van Vleck, Tielman; Verma, Shefali S.; Weaver, JoEllen; Abul-Husn, Noura S.; Baras, Aris; Chirinos, Julio A.; Drachman, Brian; Kenny, Eimear E.; Loos, Ruth J. F.; Narula, Jagat; Overton, John; Reid, Jeffrey; Ritchie, Marylyn; Sirugo, Giorgio; Nadkarni, Girish; Rader, Daniel J.; Do, Ron</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2191-2202</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance Hereditary transthyretin (TTR) amyloid cardiomyopathy (hATTR-CM) due to the TTR V122I variant is an autosomal-dominant disorder that causes heart failure in elderly individuals of African ancestry.  The clin. assocns. of carrying the variant, its effect in other African ancestry populations including Hispanic/Latino individuals, and the rates of achieving a clin. diagnosis in carriers are unknown. objective To assess the assocn. between the TTR V122I variant and heart failure and identify rates of hATTR-CM diagnosis among carriers with heart failure. design, setting, and participants Cross-sectional anal. of carriers and noncarriers of TTR V122I of African ancestry aged 50 years or older enrolled in the Penn Medicine Biobank between 2008 and 2017 using electronic health record data from 1996 to 2017.  Case-control study in participants of African and Hispanic/Latino ancestry with and without heart failure in the Mount Sinai BioMe Biobank enrolled between 2007 and 2015 using electronic health record data from 2007 to 2018. exposuresTTR V122I carrier status. main outcomes and measures The primary outcome was prevalent heart failure.  The rate of diagnosis with hATTR-CM among TTR V122I carriers with heart failure was measured. results The cross-sectional cohort included 3724 individuals of African ancestry with a median age of 64 years (interquartile range, 57-71); 1755 (47%) were male, 2896 (78%) had a diagnosis of hypertension, and 753 (20%) had a history of myocardial infarction or coronary revascularization.  There were 116 TTR V122I carriers (3.1%); 1121 participants (30%) had heart failure.  The case-control study consisted of 2307 individuals of African ancestry and 3663 Hispanic/Latino individuals; the median age was 73 years (interquartile range, 68-80), 2271 (38%) were male, 4709 (79%) had a diagnosis of hypertension, and 1008 (17%) had a history of myocardial infarction or coronary revascularization.  There were 1376 cases of heart failure.  TTR V122I was assocd. with higher rates of heart failure (cross-sectional cohort: n = 51/116 TTR V122I carriers [44%], n = 1070/3608 noncarriers [30%], adjusted odds ratio, 1.7 [95% CI, 1.2-2.4], P = .006; case-control study: n = 36/1376 heart failure cases [2.6%], n = 82/4594 controls [1.8%], adjusted odds ratio, 1.8 [95% CI, 1.2-2.7], P = .008).  Ten of 92 TTR V122I carriers with heart failure (11%) were diagnosed as having hATTR-CM; the median time from onset of symptoms to clin. diagnosis was 3 years. conclusions and relevance Among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks, the TTR V122I genetic variant was significantly assocd. with heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJWp0hnVGqZrVg90H21EOLACvtfcHk0ljl9vGiW0tiMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyqu7jN&md5=9f32e51a320407644e54901b78d0c15e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjama.2019.17935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2019.17935%26sid%3Dliteratum%253Aachs%26aulast%3DDamrauer%26aufirst%3DS.%2BM.%26aulast%3DChaudhary%26aufirst%3DK.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DLiang%26aufirst%3DL.%2BW.%26aulast%3DArgulian%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DL.%26aulast%3DDobbyn%26aufirst%3DA.%26aulast%3DGuerraty%26aufirst%3DM.%2BA.%26aulast%3DJudy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DJ.%26aulast%3DKember%26aufirst%3DR.%2BL.%26aulast%3DLevin%26aufirst%3DM.%2BG.%26aulast%3DSaha%26aufirst%3DA.%26aulast%3DVan%2BVleck%26aufirst%3DT.%26aulast%3DVerma%26aufirst%3DS.%2BS.%26aulast%3DWeaver%26aufirst%3DJ.%26aulast%3DAbul-Husn%26aufirst%3DN.%2BS.%26aulast%3DBaras%26aufirst%3DA.%26aulast%3DChirinos%26aufirst%3DJ.%2BA.%26aulast%3DDrachman%26aufirst%3DB.%26aulast%3DKenny%26aufirst%3DE.%2BE.%26aulast%3DLoos%26aufirst%3DR.%2BJ.%2BF.%26aulast%3DNarula%26aufirst%3DJ.%26aulast%3DOverton%26aufirst%3DJ.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DRitchie%26aufirst%3DM.%26aulast%3DSirugo%26aufirst%3DG.%26aulast%3DNadkarni%26aufirst%3DG.%26aulast%3DRader%26aufirst%3DD.%2BJ.%26aulast%3DDo%26aufirst%3DR.%26atitle%3DAssociation%2520of%2520the%2520V122I%2520hereditary%2520transthyretin%2520amyloidosis%2520genetic%2520variant%2520with%2520heart%2520failure%2520among%2520individuals%2520of%2520african%2520or%2520hispanic%252Flatino%2520ancestry%26jtitle%3DJAMA%26date%3D2019%26volume%3D322%26spage%3D2191%26epage%3D2202%26doi%3D10.1001%2Fjama.2019.17935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellotti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Arias, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallaina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obici, L.</span></span> <span> </span><span class="NLM_article-title">A narrative review of the role of transthyretin in health and disease</span>. <i>Neurol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1007/s40120-020-00217-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs40120-020-00217-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=33001386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FlvFOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=395-402&author=M.+A.+Lizauthor=T.+Coelhoauthor=V.+Bellottiauthor=M.+I.+Fernandez-Ariasauthor=P.+Mallainaauthor=L.+Obici&title=A+narrative+review+of+the+role+of+transthyretin+in+health+and+disease&doi=10.1007%2Fs40120-020-00217-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A Narrative Review of the Role of Transthyretin in Health and Disease</span></div><div class="casAuthors">Liz Marcia Almeida; Coelho Teresa; Bellotti Vittorio; Bellotti Vittorio; Fernandez-Arias Maria Isabel; Mallaina Pablo; Obici Laura</div><div class="citationInfo"><span class="NLM_cas:title">Neurology and therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-402</span>
        ISSN:<span class="NLM_cas:issn">2193-8253</span>.
    </div><div class="casAbstract">Transthyretin (TTR) is a tetrameric transport protein highly conserved through vertebrate evolution and synthesized in the liver, choroid plexus, and retinal pigment epithelium.  TTR transports the thyroid hormone thyroxine and the retinol-binding protein (RBP) bound to retinol (vitamin A).  Mutations in TTR are associated with inherited transthyretin amyloidosis (ATTRv), a progressive, debilitating disease that is ultimately fatal and is characterized by misfolding of TTR and aggregation as amyloid fibrils, predominantly leading to cardiomyopathy or polyneuropathy depending on the particular TTR mutation.  Transthyretin amyloid cardiomyopathy can also occur as an age-related disease caused by misfolding of wild-type TTR.  Apart from its transport role, little is known about possible additional physiological functions of TTR.  Evidence from animal model systems in which TTR has been disrupted via gene knockout is adding to our cumulative understanding of TTR function.  There is growing evidence that TTR may have a role in neuroprotection and promotion of neurite outgrowth in response to injury.  Here, we review the literature describing potential roles of TTR in neurobiology and in the pathophysiology of diseases other than ATTR amyloidosis.  A greater understanding of these processes may also contribute to further clarification of the pathology of ATTR and the effects of potential therapies for TTR-related conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUOc90fHQzQae0F5ixvZgXfW6udTcc2eaAgpmYraXFtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FlvFOkuw%253D%253D&md5=d1d3ee1375a086677381ab96ddf1353a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40120-020-00217-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40120-020-00217-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiz%26aufirst%3DM.%2BA.%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DBellotti%26aufirst%3DV.%26aulast%3DFernandez-Arias%26aufirst%3DM.%2BI.%26aulast%3DMallaina%26aufirst%3DP.%26aulast%3DObici%26aufirst%3DL.%26atitle%3DA%2520narrative%2520review%2520of%2520the%2520role%2520of%2520transthyretin%2520in%2520health%2520and%2520disease%26jtitle%3DNeurol.%2520Ther.%26date%3D2020%26volume%3D9%26spage%3D395%26epage%3D402%26doi%3D10.1007%2Fs40120-020-00217-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taboada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraiva, M. J.</span></span> <span> </span><span class="NLM_article-title">Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Human Transthyretin Leu55Pro</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1935</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)64469-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2FS0002-9440%2810%2964469-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=12414539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD38XptV2gurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2002&pages=1935-1948&author=M.+M.+Sousaauthor=R.+Fernandesauthor=J.+A.+Palhaauthor=A.+Taboadaauthor=P.+Vieiraauthor=M.+J.+Saraiva&title=Evidence+for+Early+Cytotoxic+Aggregates+in+Transgenic+Mice+for+Human+Transthyretin+Leu55Pro&doi=10.1016%2FS0002-9440%2810%2964469-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro</span></div><div class="casAuthors">Sousa, Monica Mendes; Fernandes, Rui; Palha, Joana Almeida; Taboada, Ana; Vieira, Paulo; Saraiva, Joao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1935-1948</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Familial amyloidotic polyneuropathy (FAP) is a lethal autosomal dominant disorder characterized by systemic extracellular deposition of transthyretin (TTR) amyloid fibrils.  Several groups have generated transgenic mice carrying human TTR Val30Met, the most common mutation in FAP.  To study amyloidogenicity and cytotoxicity of different TTRs, the authors produced transgenic mice expressing human TTR Leu55Pro, one of the most aggressive FAP-related mutations.  TTR deposition and presence of amyloid fibrils was investigated and compared to animals carrying the human TTR Val30Met gene kept under the same conditions.  Deposition in a C57BL/6J background (TTR-Leu55Pro mice) and in a TTR-null background [TTR-Leu55Pro X TTR-knockout (KO) mice] was compared.  Animals in a C57BL/6J background presented early (1 to 3 mo) nonfibrillar TTR deposition but amyloid was absent.  In a TTR-null background, presence of amyloid fibrils was detected starting at 4 to 8 mo with a particular involvement of the gastrointestinal tract and skin.  This data suggested that TTR homotetramers are more prone to fibril formation than TTR murine wild-type/human mutant heterotetramers.  The nature of the deposited material was further investigated by immunocytochem.  Both amorphous aggregates and small TTR fibrils were present in TTR-Leu55Pro X TTR-KO transgenics.  The authors obsd. that these TTR deposits mimic the toxic effect of TTR deposits in FAP: animals with TTR deposition, present approx. twofold increased levels of nitrotyrosine in sites related to deposition.  The TTR-Leu55Pro X TTR-KO mice here described are an important tool for the dual purpose of investigating factors involved in amyloidogenesis and in cytotoxicity of deposited TTR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSteyHj6slmLVg90H21EOLACvtfcHk0lgJLk0MK13J_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptV2gurw%253D&md5=5596a3628ee339d3d0b3778ad478cc06</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2964469-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252964469-0%26sid%3Dliteratum%253Aachs%26aulast%3DSousa%26aufirst%3DM.%2BM.%26aulast%3DFernandes%26aufirst%3DR.%26aulast%3DPalha%26aufirst%3DJ.%2BA.%26aulast%3DTaboada%26aufirst%3DA.%26aulast%3DVieira%26aufirst%3DP.%26aulast%3DSaraiva%26aufirst%3DM.%2BJ.%26atitle%3DEvidence%2520for%2520Early%2520Cytotoxic%2520Aggregates%2520in%2520Transgenic%2520Mice%2520for%2520Human%2520Transthyretin%2520Leu55Pro%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2002%26volume%3D161%26spage%3D1935%26epage%3D1948%26doi%3D10.1016%2FS0002-9440%2810%2964469-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connors, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span> <span> </span><span class="NLM_article-title">Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy</span>. <i>Amyloid</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.3109/13506129.2011.574354059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3109%2F13506129.2011.574354059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=21838471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BC3Mjmt1Sqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=157-159&author=L.+H.+Connorsauthor=G.+Dorosauthor=F.+Samauthor=A.+Badieeauthor=D.+C.+Seldinauthor=M.+Skinner&title=Clinical+features+and+survival+in+senile+systemic+amyloidosis%3A+comparison+to+familial+transthyretin+cardiomyopathy&doi=10.3109%2F13506129.2011.574354059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy</span></div><div class="casAuthors">Connors L H; Doros G; Sam F; Badiee A; Seldin D C; Skinner M</div><div class="citationInfo"><span class="NLM_cas:title">Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0Q70bhE16Pxcr74wzj5o5fW6udTcc2eaUktw1Hx-txrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mjmt1Sqsg%253D%253D&md5=a5979dec60667c1df1cd9b609be2c148</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3109%2F13506129.2011.574354059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F13506129.2011.574354059%26sid%3Dliteratum%253Aachs%26aulast%3DConnors%26aufirst%3DL.%2BH.%26aulast%3DDoros%26aufirst%3DG.%26aulast%3DSam%26aufirst%3DF.%26aulast%3DBadiee%26aufirst%3DA.%26aulast%3DSeldin%26aufirst%3DD.%2BC.%26aulast%3DSkinner%26aufirst%3DM.%26atitle%3DClinical%2520features%2520and%2520survival%2520in%2520senile%2520systemic%2520amyloidosis%253A%2520comparison%2520to%2520familial%2520transthyretin%2520cardiomyopathy%26jtitle%3DAmyloid%26date%3D2011%26volume%3D18%26spage%3D157%26epage%3D159%26doi%3D10.3109%2F13506129.2011.574354059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buxbaum, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruberg, F. L.</span></span> <span> </span><span class="NLM_article-title">Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1038/gim.2016.200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2Fgim.2016.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=28102864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFygsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=733-742&author=J.+N.+Buxbaumauthor=F.+L.+Ruberg&title=Transthyretin+V122I+%28pV142I%29*+cardiac+amyloidosis%3A+an+age-dependent+autosomal+dominant+cardiomyopathy+too+common+to+be+overlooked+as+a+cause+of+significant+heart+disease+in+elderly+African+Americans&doi=10.1038%2Fgim.2016.200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans</span></div><div class="casAuthors">Buxbaum, Joel N.; Ruberg, Frederick L.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">733-742</span>CODEN:
                <span class="NLM_cas:coden">GEMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1098-3600</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the identification of a valine-to-isoleucine substitution at position 122 (TTR V122I; pV142I) in the transthyretin (TTR)-derived fibrils extd. from the heart of a patient with late-onset cardiac amyloidosis, it has become clear that the amyloidogenic mutation and the disease occur almost exclusively in individuals of identifiable African descent.  In the United States, the amyloidogenic allele frequency is 0.0173 and is carried by 3.5% of community-dwelling African Americans.  Genotyping across Africa indicates that the origin of the allele is in the West African countries that were the major source of the slave trade to North America.  At autopsy, the allele was found to be assocd. with cardiac TTR amyloid deposition in all the carriers after age 65 years; however, the clin. penetrance varies, resulting in substantial heart disease in some carriers and few symptoms in others.  The allele has been found in 10% of African Americans older than age 65 with severe congestive heart failure.  At this time there are potential forms of therapy in clin. trials.  The combination of a highly accurate genetic test and the potential for specific therapy demands a greater awareness of this autosomal dominant, age-dependent cardiac disease in the cardiol. community.  Genet Med advance online publication 19 Jan. 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMWF8ztYOPfbVg90H21EOLACvtfcHk0lgMRmZ-VZQC6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFygsLfO&md5=edf1f2a43c2c58b8ea6e8e8d35156d05</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fgim.2016.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgim.2016.200%26sid%3Dliteratum%253Aachs%26aulast%3DBuxbaum%26aufirst%3DJ.%2BN.%26aulast%3DRuberg%26aufirst%3DF.%2BL.%26atitle%3DTransthyretin%2520V122I%2520%2528pV142I%2529%252A%2520cardiac%2520amyloidosis%253A%2520an%2520age-dependent%2520autosomal%2520dominant%2520cardiomyopathy%2520too%2520common%2520to%2520be%2520overlooked%2520as%2520a%2520cause%2520of%2520significant%2520heart%2520disease%2520in%2520elderly%2520African%2520Americans%26jtitle%3DGenet.%2520Med.%26date%3D2017%26volume%3D19%26spage%3D733%26epage%3D742%26doi%3D10.1038%2Fgim.2016.200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buxbaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koziol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, L. H.</span></span> <span> </span><span class="NLM_article-title">Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity</span>. <i>Amyloid</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1080/13506120802525285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1080%2F13506120802525285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=19065297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=255-261&author=J.+Buxbaumauthor=J.+Koziolauthor=L.+H.+Connors&title=Serum+transthyretin+levels+in+senile+systemic+amyloidosis%3A+effects+of+age%2C+gender+and+ethnicity&doi=10.1080%2F13506120802525285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity</span></div><div class="casAuthors">Buxbaum, Joel; Koziol, James; Connors, Lawreen H.</div><div class="citationInfo"><span class="NLM_cas:title">Amyloid</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">AIJIET</span>;
        ISSN:<span class="NLM_cas:issn">1350-6129</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Serum transthyretin (TTR) levels are reduced in familial amyloidotic polyneuropathy (FAP).  A single study of patients with senile systemic amyloidosis (SSA) in Sweden found that those individuals also had a significantly lower mean serum TTR concn. than age- and gender-matched controls.  To det. if the same phenomenon prevailed in an ethnically more heterogeneous population, we compared the serum TTR levels, as detd. by ELISA, in 45 documented SSA patients with congestive heart failure, 20 AL patients with congestive heart failure and population controls.  Serum TTR concns. in the controls were influenced in a statistically significant manner by age, gender and ethnicity.  Although it is unlikely that such differences are clin. relevant, they must be considered when assessing the meaning of serum TTR concns. in any clin. defined population.  The serum concns. in patients with SSA did not differ from age, gender and ethnically matched controls or from a group of AL patients with significant clin. cardiac involvement.  We also compared TTR concns. in 12 African-Americans carrying the TTR V122I allele with those in 826 African-Americans who were homozygous wild type at the TTR locus.  The TTR V122I carriers had significantly lower serum TTR concns. than appropriate controls even though the majority of such individuals had not reached the age of clin. or anat. risk, i.e. over 60.  Thus, as in carriers of other TTR mutations the serum TTR level is lower than normal, despite having a much later appearance of clin. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqOXYzo0LtebVg90H21EOLACvtfcHk0lgMRmZ-VZQC6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7%252FJ&md5=10845b18a6d76cd65b736b7e9b6c6eb0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1080%2F13506120802525285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13506120802525285%26sid%3Dliteratum%253Aachs%26aulast%3DBuxbaum%26aufirst%3DJ.%26aulast%3DKoziol%26aufirst%3DJ.%26aulast%3DConnors%26aufirst%3DL.%2BH.%26atitle%3DSerum%2520transthyretin%2520levels%2520in%2520senile%2520systemic%2520amyloidosis%253A%2520effects%2520of%2520age%252C%2520gender%2520and%2520ethnicity%26jtitle%3DAmyloid%26date%3D2008%26volume%3D15%26spage%3D255%26epage%3D261%26doi%3D10.1080%2F13506120802525285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, D. S.</span></span> <span> </span><span class="NLM_article-title">Retinol-binding protein: the transport protein for vitamin A in human plasma</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2025</span>– <span class="NLM_lpage">2044</span>, <span class="refDoi"> DOI: 10.1172/JCI105889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1172%2FJCI105889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=5675424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaF1cXltVeju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1968&pages=2025-2044&author=M.+Kanaiauthor=A.+Razauthor=D.+S.+Goodman&title=Retinol-binding+protein%3A+the+transport+protein+for+vitamin+A+in+human+plasma&doi=10.1172%2FJCI105889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Retinol-binding protein; the transport protein for vitamin A in human plasma</span></div><div class="casAuthors">Kanai, Masamitsu; Raz, Amiram; Goodman, DeWitt S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2025-44</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">Retinol-binding protein (RBP) was isolated from human plasma following i.v. administration of retinol-15-14C and purified by Cohn fractionation and gel filtration chromatog.  Purified RBP exhibited α1 mobility on electrophoresis and a mol. wt. of 21,000-22,000.  There appeared to be one retinol binding site per RBP mol.  RBP solns. were fluorescent and exhibited uv absorption max. at 330 and 280 mμ.  No fatty acid or fatty acyl chains were present in RBP.  RBP concn. in normal plasma was 3-4 mg./100 ml.  RBP circulated as a complex with another larger protein with prealbumin electrophoretic mobility, separable on gel electrophoresis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBfuGmG0Ac3bVg90H21EOLACvtfcHk0liLFg3cPrR60g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXltVeju7s%253D&md5=61318c230fa0e3d2b625d61ff29207e4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI105889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI105889%26sid%3Dliteratum%253Aachs%26aulast%3DKanai%26aufirst%3DM.%26aulast%3DRaz%26aufirst%3DA.%26aulast%3DGoodman%26aufirst%3DD.%2BS.%26atitle%3DRetinol-binding%2520protein%253A%2520the%2520transport%2520protein%2520for%2520vitamin%2520A%2520in%2520human%2520plasma%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1968%26volume%3D47%26spage%3D2025%26epage%3D2044%26doi%3D10.1172%2FJCI105889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangerter, F. W.</span></span> <span> </span><span class="NLM_article-title">On the labelling of oxidized cell surface membranes by acyl hydrazides</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>557</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1016/0005-2736(79)90333-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2F0005-2736%2879%2990333-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaL3cXltlOmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=557&publication_year=1979&pages=354-362&author=R.+R.+Randoauthor=F.+W.+Bangerter&title=On+the+labelling+of+oxidized+cell+surface+membranes+by+acyl+hydrazides&doi=10.1016%2F0005-2736%2879%2990333-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">On the labeling of oxidized cell surface membranes by acyl hydrazides</span></div><div class="casAuthors">Rando, Robert R.; Bangerter, Faan Wen</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">557</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-62</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    </div><div class="casAbstract">The covalent modification of bovine erythrocyte membranes by first oxidizing cell surface sugars followed by the covalent coupling of the oxidized components with hydrazides was investigated.  The aldehydic groups were introduced either chem., by mild periodate oxidn., or enzymically with galactose oxidase.  The periodate (0.1 mM) and galactose oxidase (50 units) oxidns. were complete at 5 and 240 min, resp., in phosphate-buffered saline (pH 7.4) at 30° using 2 × 109 cells/mL.  The rates of hydrazone formation between the oxidatively generated aldehyde groups and α-acethydrazide-3H also were measured (pH 7.4) at 30°.  The reactions with the periodate and galactose oxidase-treated cells went to completion in 1.5 and 6 h, resp.  Aniline had a marked catalytic effect on these rates.  With 5 mM aniline under the same conditions, the periodate-treated cells reacted to completion with acethydrazide in 30 min and the galactose oxidase-treated cells in 40 min.  As expected, although the rates of α-acethydrazide-3H incorporation were increased with aniline, the extents of the reaction were not.  Finally, the stability of the hydrazone linkages were measured.  The hydrazone bonds formed when the galactose oxidase-treated cells were reacted with acethydrazide were completely stable at 30° for 24 h, whereas those formed from the periodate-treated cells were not.  In the latter case roughly 50% of the membrane-bound hydrazone linkages were lost after 6 h at 30°.  The remaining 50%, however, were stable to cleavage.  Thus, these sites are clearly heterogeneous in nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJCs-XBuLGLVg90H21EOLACvtfcHk0liLFg3cPrR60g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXltlOmuw%253D%253D&md5=a85e15cf8071ae57170105918d08e31e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0005-2736%2879%2990333-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2736%252879%252990333-X%26sid%3Dliteratum%253Aachs%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DBangerter%26aufirst%3DF.%2BW.%26atitle%3DOn%2520the%2520labelling%2520of%2520oxidized%2520cell%2520surface%2520membranes%2520by%2520acyl%2520hydrazides%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D1979%26volume%3D557%26spage%3D354%26epage%3D362%26doi%3D10.1016%2F0005-2736%2879%2990333-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraiva, M. J.</span></span> <span> </span><span class="NLM_article-title">Transthyretin: a multifaceted protein</span>. <i>Biomol. Concepts</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1515/bmc-2013-0038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1515%2Fbmc-2013-0038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=25372741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKmurbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=45-54&author=M.+Vieiraauthor=M.+J.+Saraiva&title=Transthyretin%3A+a+multifaceted+protein&doi=10.1515%2Fbmc-2013-0038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin: a multifaceted protein</span></div><div class="casAuthors">Vieira, Marta; Saraiva, Maria Joao</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecular Concepts</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">BCIOB8</span>;
        ISSN:<span class="NLM_cas:issn">1868-5021</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">A review.  Transthyretin is a highly conserved homotetrameric protein, mainly synthesized by the liver and the choroid plexus of brain.  The carrier role of TTR is well-known; however, many other functions have emerged, namely in the nervous system.  Behavior, cognition, neuropeptide amidation, neurogenesis, nerve regeneration, axonal growth and 14-3-3ζ metab. are some of the processes where TTR has an important role.  TTR aggregates are responsible for many amyloidosis such as familial amyloidotic polyneuropathy and cardiomyopathy.  Normal TTR can also aggregate and deposit in the heart of old people and in preeclampsia placental tissue.  Differences in TTR levels have been found in several neuropathologies, but its neuroprotective role, until now, was described in ischemia and Alzheimer's disease.  The aim of this review is to stress the relevance of TTR, besides its well-known role on transport of thyroxine and retinol-binding protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyXcOGE6oRy7Vg90H21EOLACvtfcHk0liLFg3cPrR60g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKmurbE&md5=5dfaf06a6cb8a0394d17d1586aa6a1e8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1515%2Fbmc-2013-0038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fbmc-2013-0038%26sid%3Dliteratum%253Aachs%26aulast%3DVieira%26aufirst%3DM.%26aulast%3DSaraiva%26aufirst%3DM.%2BJ.%26atitle%3DTransthyretin%253A%2520a%2520multifaceted%2520protein%26jtitle%3DBiomol.%2520Concepts%26date%3D2014%26volume%3D5%26spage%3D45%26epage%3D54%26doi%3D10.1515%2Fbmc-2013-0038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kassem, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, J. E.</span></span> <span> </span><span class="NLM_article-title">Role of transthyretin in thyroxine transfer from cerebrospinal fluid to brain and choroid plexus</span>. <i>Am. J. Physiol.: Regul., Integr. Comp. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">R1310</span>– <span class="NLM_lpage">R1315</span>, <span class="refDoi"> DOI: 10.1152/ajpregu.00789.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1152%2Fajpregu.00789.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=16825415" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2006&pages=R1310-R1315&author=N.+A.+Kassemauthor=R.+Deaneauthor=M.+B.+Segalauthor=J.+E.+Preston&title=Role+of+transthyretin+in+thyroxine+transfer+from+cerebrospinal+fluid+to+brain+and+choroid+plexus&doi=10.1152%2Fajpregu.00789.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.00789.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.00789.2005%26sid%3Dliteratum%253Aachs%26aulast%3DKassem%26aufirst%3DN.%2BA.%26aulast%3DDeane%26aufirst%3DR.%26aulast%3DSegal%26aufirst%3DM.%2BB.%26aulast%3DPreston%26aufirst%3DJ.%2BE.%26atitle%3DRole%2520of%2520transthyretin%2520in%2520thyroxine%2520transfer%2520from%2520cerebrospinal%2520fluid%2520to%2520brain%2520and%2520choroid%2520plexus%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Regul.%252C%2520Integr.%2520Comp.%2520Physiol.%26date%3D2006%26volume%3D291%26spage%3DR1310%26epage%3DR1315%26doi%3D10.1152%2Fajpregu.00789.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, Â.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liz, M. A.</span></span> <span> </span><span class="NLM_article-title">Transthyretin neuroprotection in Alzheimer’s disease is dependent on proteolysis</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.neurobiolaging.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=28780366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ems7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2017&pages=10-14&author=C.+S.+Silvaauthor=J.+Eiraauthor=C.+A.+Ribeiroauthor=%C3%82.+Oliveiraauthor=M.+M.+Sousaauthor=I.+Cardosoauthor=M.+A.+Liz&title=Transthyretin+neuroprotection+in+Alzheimer%E2%80%99s+disease+is+dependent+on+proteolysis&doi=10.1016%2Fj.neurobiolaging.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin neuroprotection in Alzheimer's disease is dependent on proteolysis</span></div><div class="casAuthors">Silva, Catarina S.; Eira, Jessica; Ribeiro, Carlos A.; Oliveira, Angela; Sousa, Monica M.; Cardoso, Isabel; Liz, Marcia A.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-14</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The deposition of amyloid β peptide (Aβ) in the hippocampus is one of the major hallmarks of Alzheimer's disease, a neurodegenerative disorder characterized by memory loss and cognitive impairment.  The modulation of Aβ levels in the brain results from an equil. between its prodn. from the amyloid precursor protein and removal by amyloid clearance proteins, which might occur via enzymic (Aβ-degrading enzymes) or nonenzymic (binding/transport proteins) reactions.  Transthyretin (TTR) is one of the major Aβ-binding proteins acting as a neuroprotector in AD.  In addn., TTR cleaves Aβ peptide in vitro.  In this work, we show that proteolytically active TTR, and not the inactive form of the protein, impacts on Aβ fibrillogenesis, degrades neuronal-secreted Aβ, and reduces Aβ-induced toxicity in hippocampal neurons.  Our data demonstrate that TTR proteolytic activity is required for the neuroprotective effect of the protein constituting a putative novel therapeutic target for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpThmsCU6e4d7Vg90H21EOLACvtfcHk0lhtv8PFjG8dQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ems7%252FM&md5=3fc23516ebc342634546e4a855c15b75</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DC.%2BS.%26aulast%3DEira%26aufirst%3DJ.%26aulast%3DRibeiro%26aufirst%3DC.%2BA.%26aulast%3DOliveira%26aufirst%3D%25C3%2582.%26aulast%3DSousa%26aufirst%3DM.%2BM.%26aulast%3DCardoso%26aufirst%3DI.%26aulast%3DLiz%26aufirst%3DM.%2BA.%26atitle%3DTransthyretin%2520neuroprotection%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520is%2520dependent%2520on%2520proteolysis%26jtitle%3DNeurobiol.%2520Aging%26date%3D2017%26volume%3D59%26spage%3D10%26epage%3D14%26doi%3D10.1016%2Fj.neurobiolaging.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gião, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saavedra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotrina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsequell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, I.</span></span> <span> </span><span class="NLM_article-title">Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for alzheimer’s disease</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>, <span class="NLM_elocation-id">2075</span> <span class="refDoi"> DOI: 10.3390/ijms21062075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fijms21062075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVejsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&author=T.+Gi%C3%A3oauthor=J.+Saavedraauthor=E.+Cotrinaauthor=J.+Quintanaauthor=J.+Llopauthor=G.+Arsequellauthor=I.+Cardoso&title=Undiscovered+roles+for+transthyretin%3A+from+a+transporter+protein+to+a+new+therapeutic+target+for+alzheimer%E2%80%99s+disease&doi=10.3390%2Fijms21062075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for Alzheimer's disease</span></div><div class="casAuthors">Giao, Tiago; Saavedra, Joana; Cotrina, Ellen; Quintana, Jordi; Llop, Jordi; Arsequell, Gemma; Cardoso, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, resp., has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids.  Still, this protein has managed to stay in the spotlight as it has been assigned new and varied functions.  In this review, we cover knowledge on novel TTR functions and the cellular pathways involved, spanning from neuroprotection to vascular events, while emphasizing its involvement in Alzheimer's disease (AD).  We describe details of TTR as an amyloid binding protein and discuss its interaction with the amyloid Aβ peptides, and the proposed mechanisms underlying TTR neuroprotection in AD.  We also present the importance of translating advances in the knowledge of the TTR neuroprotective role into drug discovery strategies focused on TTR as a new target in AD therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqKLQRIz_CCrVg90H21EOLACvtfcHk0lhtv8PFjG8dQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVejsLbP&md5=2c3668a3205d852c73a34efd8df805a8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3390%2Fijms21062075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21062075%26sid%3Dliteratum%253Aachs%26aulast%3DGi%25C3%25A3o%26aufirst%3DT.%26aulast%3DSaavedra%26aufirst%3DJ.%26aulast%3DCotrina%26aufirst%3DE.%26aulast%3DQuintana%26aufirst%3DJ.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DArsequell%26aufirst%3DG.%26aulast%3DCardoso%26aufirst%3DI.%26atitle%3DUndiscovered%2520roles%2520for%2520transthyretin%253A%2520from%2520a%2520transporter%2520protein%2520to%2520a%2520new%2520therapeutic%2520target%2520for%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26doi%3D10.3390%2Fijms21062075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, P. E.</span></span> <span> </span><span class="NLM_article-title">Kinetic analysis of the multistep aggregation pathway of human transthyretin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E6201</span>– <span class="NLM_lpage">E6208</span>, <span class="refDoi"> DOI: 10.1073/pnas.1807024115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1073%2Fpnas.1807024115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=29915031" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E6201-E6208&author=X.+Sunauthor=H.+J.+Dysonauthor=P.+E.+Wright&title=Kinetic+analysis+of+the+multistep+aggregation+pathway+of+human+transthyretin&doi=10.1073%2Fpnas.1807024115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1807024115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1807024115%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DDyson%26aufirst%3DH.%2BJ.%26aulast%3DWright%26aufirst%3DP.%2BE.%26atitle%3DKinetic%2520analysis%2520of%2520the%2520multistep%2520aggregation%2520pathway%2520of%2520human%2520transthyretin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3DE6201%26epage%3DE6208%26doi%3D10.1073%2Fpnas.1807024115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruberg, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M. S.</span></span> <span> </span><span class="NLM_article-title">Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2872</span>– <span class="NLM_lpage">2891</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2019.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.jacc.2019.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31171094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2hs7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=2872-2891&author=F.+L.+Rubergauthor=M.+Groganauthor=M.+Hannaauthor=J.+W.+Kellyauthor=M.+S.+Maurer&title=Transthyretin+amyloid+cardiomyopathy%3A+JACC+state-of-the-art+review&doi=10.1016%2Fj.jacc.2019.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin Amyloid Cardiomyopathy</span></div><div class="casAuthors">Ruberg, Frederick L.; Grogan, Martha; Hanna, Mazen; Kelly, Jeffery W.; Maurer, Mathew S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2872-2891</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin (TTR) or pre-albumin.  Characteristic patterns of echocardiog. and cardiac magnetic resonance can strongly suggest the disease but are not diagnostic.  The diagnosis can be made with noninvasive nuclear imaging when there is no evidence of a monoclonal protein.  Amyloid fibril formation results from a destabilizing mutation in hereditary ATTR amyloidosis (hATTR) or from an aging-linked process in wild-type ATTR amyloidosis (wtATTR).  Recent studies have suggested that up to 10% to 15% of older adults with HF may have unrecognized wtATTR.  Assocd. features, including carpal tunnel syndrome and lumbar spinal stenosis, raise suspicion and may afford a means for early diagnosis.  Previously treatable only by organ transplantation, pharmaceutical therapy that slows or halts ATTR-CM progression and favorably affects clin. outcomes is now available.  Early recognition remains essential to afford the best treatment efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFK5Abf8-PzLVg90H21EOLACvtfcHk0lhqlBx-_Ln2Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2hs7nE&md5=451b455f9dff555f9602116d7da03cb1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2019.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2019.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DRuberg%26aufirst%3DF.%2BL.%26aulast%3DGrogan%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DMaurer%26aufirst%3DM.%2BS.%26atitle%3DTransthyretin%2520amyloid%2520cardiomyopathy%253A%2520JACC%2520state-of-the-art%2520review%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2019%26volume%3D73%26spage%3D2872%26epage%3D2891%26doi%3D10.1016%2Fj.jacc.2019.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokochi, T.</span></span> <span> </span><span class="NLM_article-title">Transthyretin cardiac amyloidosis: an update on diagnosis and treatment</span>. <i>ESC Heart Fail.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1139</span>, <span class="refDoi"> DOI: 10.1002/ehf2.12518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fehf2.12518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31553132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvFGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1128-1139&author=H.+Yamamotoauthor=T.+Yokochi&title=Transthyretin+cardiac+amyloidosis%3A+an+update+on+diagnosis+and+treatment&doi=10.1002%2Fehf2.12518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin cardiac amyloidosis: an update on diagnosis and treatment</span></div><div class="casAuthors">Yamamoto Hiroyuki; Yokochi Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">ESC heart failure</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1128-1139</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Transthyretin cardiac amyloidosis (ATTR-CA) demonstrates progressive, potentially fatal, and infiltrative cardiomyopathy caused by extracellular deposition of transthyretin-derived insoluble amyloid fibrils in the myocardium.  Two distinct types of transthyretin (wild type or variant) become unstable, and misfolding forms aggregate, resulting in amyloid fibrils.  ATTR-CA, which has previously been underrecognized and considered to be rare, has been increasingly recognized as a cause of heart failure with preserved ejection fraction among elderly persons.  With the advanced technology, the diagnostic tools have been improving for cardiac amyloidosis.  Recently, the efficacy of several disease-modifying agents focusing on the amyloidogenic process has been demonstrated.  ATTR-CA has been changing from incurable to treatable.  Nevertheless, there are still no prognostic improvements due to diagnostic delay or misdiagnosis because of phenotypic heterogeneity and co-morbidities.  Thus, it is crucial for clinicians to be aware of this clinical entity for early diagnosis and proper treatment.  In this mini-review, we focus on recent advances in diagnosis and treatment of ATTR-CA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAmyb6j8k9Er0AGQpJZWpJfW6udTcc2eY2RJRAXZcaJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvFGlsw%253D%253D&md5=ae2e5096c74f15b8d8b37954cad3d8eb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fehf2.12518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fehf2.12518%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DYokochi%26aufirst%3DT.%26atitle%3DTransthyretin%2520cardiac%2520amyloidosis%253A%2520an%2520update%2520on%2520diagnosis%2520and%2520treatment%26jtitle%3DESC%2520Heart%2520Fail.%26date%3D2019%26volume%3D6%26spage%3D1128%26epage%3D1139%26doi%3D10.1002%2Fehf2.12518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waddington-Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botteman, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amass, L.</span></span> <span> </span><span class="NLM_article-title">Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">34</span> <span class="refDoi"> DOI: 10.1186/s13023-019-1000-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1186%2Fs13023-019-1000-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30736835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3cfgslChsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&author=M.+Waddington-Cruzauthor=H.+Schmidtauthor=M.+F.+Bottemanauthor=J.+A.+Carterauthor=M.+Stewartauthor=M.+Hoppsauthor=S.+Falletauthor=L.+Amass&title=Epidemiological+and+clinical+characteristics+of+symptomatic+hereditary+transthyretin+amyloid+polyneuropathy%3A+a+global+case+series&doi=10.1186%2Fs13023-019-1000-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series</span></div><div class="casAuthors">Waddington-Cruz Marcia; Waddington-Cruz Marcia; Schmidt Hartmut; Botteman Marc F; Carter John A; Stewart Michelle; Hopps Markay; Fallet Shari; Amass Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016.  Approximately 18% of the cases were from countries where ATTR-PN is traditionally considered to be endemic (i.e., Portugal, Japan, and Sweden).  East Asia (Japan, China, Taiwan, and South Korea) contributed a sizeable combined proportion (37.0%, n = 200) with Japan (n = 92) and China (n = 71) being the primary contributors.  The most common genotypes among the 65 genotypes represented in the sample were Val30Met (47.6%), Ser77Tyr (10%), Ala97Ser (6.5%), and Phe64Leu (4.4%).  Cases with genotypes other than the aforementioned four had the lowest ages at onset (mean 49.2 [standard deviation {SD} 21.0; inter-quartile range {IQR}14.7]) and diagnosis (mean 53.4 [SD 21.0; IQR 14.7]).  Conversely, Phe64Leu mean age of onset was 67.5 (SD 8.8; IQR 5.2) and mean age of diagnosis was 71.3 (SD 8.8; IQR 5.4).  The prevalence of upper and lower limb involvement at the time of diagnosis (67 and 41%) observed across all cases is consistent with the typical presentation of ATTR-PN.  Other notable findings at the time of diagnosis included a high rate of impotence among the Ala97Ser cases versus all others (67% vs. 21%) and a high rate of non-motor visual symptoms (i.e., visual opacities and glaucoma) in the Ser77Tyr cases versus all others (93% vs. 16%).  Though comparisons were made descriptively and were hindered by inconsistency of reporting across the cases, these findings support the notion that ATTR-PN is a more phenotypically and geographically variable disease than is typically considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR14vDbvZsWtj0SWnHPWbmmfW6udTcc2ea4b9eXFkq-Z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfgslChsw%253D%253D&md5=882869e7aea9845f237864c82ecad74d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2Fs13023-019-1000-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13023-019-1000-1%26sid%3Dliteratum%253Aachs%26aulast%3DWaddington-Cruz%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DBotteman%26aufirst%3DM.%2BF.%26aulast%3DCarter%26aufirst%3DJ.%2BA.%26aulast%3DStewart%26aufirst%3DM.%26aulast%3DHopps%26aufirst%3DM.%26aulast%3DFallet%26aufirst%3DS.%26aulast%3DAmass%26aufirst%3DL.%26atitle%3DEpidemiological%2520and%2520clinical%2520characteristics%2520of%2520symptomatic%2520hereditary%2520transthyretin%2520amyloid%2520polyneuropathy%253A%2520a%2520global%2520case%2520series%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2019%26volume%3D14%26doi%3D10.1186%2Fs13023-019-1000-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamerlan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S. S. A.</span></span> <span> </span><span class="NLM_article-title">Diagnostic and treatment approaches involving transthyretin in amyloidogenic diseases</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">2982</span> <span class="refDoi"> DOI: 10.3390/ijms20122982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fijms20122982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&author=G.+Y.+Parkauthor=A.+Jamerlanauthor=K.+H.+Shimauthor=S.+S.+A.+An&title=Diagnostic+and+treatment+approaches+involving+transthyretin+in+amyloidogenic+diseases&doi=10.3390%2Fijms20122982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnostic and treatment approaches involving transthyretin in amyloidogenic diseases</span></div><div class="casAuthors">Park, Gil Yong; Jamerlan, Angelo; Shim, Kyu Hwan; An, Seong Soo A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2982</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Transthyretin (TTR) is a thyroid hormone-binding protein which transports thyroxine from the bloodstream to the brain.  The structural stability of TTR in tetrameric form is crucial for maintaining its original functions in blood or cerebrospinal fluid (CSF).  The altered structure of TTR due to genetic mutations or its deposits due to aggregation could cause several deadly diseases such as cardiomyopathy and neuropathy in autonomic, motor, and sensory systems.  The early diagnoses for hereditary amyloid TTR with cardiomyopathy (ATTR-CM) and wild-type amyloid TTR (ATTRwt) amyloidosis, which result from amyloid TTR (ATTR) deposition, are difficult to distinguish due to the close similarities of symptoms.  Thus, many researchers investigated the role of ATTR as a biomarker, esp. its potential for differential diagnosis due to its varying pathogenic involvement in hereditary ATTR-CM and ATTRwt amyloidosis.  As a result, the detection of ATTR became valuable in the diagnosis and detn. of the best course of treatment for ATTR amyloidoses.  Assessing the extent of ATTR deposition and genetic anal. could help in detg. disease progression, and thus survival rate could be improved following the detn. of the appropriate course of treatment for the patient.  Here, the perspectives of ATTR in various diseases were presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBFDKPVBDBo7Vg90H21EOLACvtfcHk0liYyyyckR703g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGlur4%253D&md5=69716e62707a004ec2c260166d6a6154</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3390%2Fijms20122982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20122982%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DG.%2BY.%26aulast%3DJamerlan%26aufirst%3DA.%26aulast%3DShim%26aufirst%3DK.%2BH.%26aulast%3DAn%26aufirst%3DS.%2BS.%2BA.%26atitle%3DDiagnostic%2520and%2520treatment%2520approaches%2520involving%2520transthyretin%2520in%2520amyloidogenic%2520diseases%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26doi%3D10.3390%2Fijms20122982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanus, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudas, L. J.</span></span> <span> </span><span class="NLM_article-title">Reduced levels of retinyl esters and vitamin A in human renal cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2774</span>– <span class="NLM_lpage">2781</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=11289161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVSksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2774-2781&author=X.+Guoauthor=D.+M.+Nanusauthor=A.+Ruizauthor=R.+R.+Randoauthor=D.+Bokauthor=L.+J.+Gudas&title=Reduced+levels+of+retinyl+esters+and+vitamin+A+in+human+renal+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced levels of retinyl esters and vitamin A in human renal cancers</span></div><div class="casAuthors">Guo, Xiaojia; Nanus, David M.; Ruiz, Alberto; Rando, Robert R.; Bok, Dean; Gudas, Lorraine J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2774-2781</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. and preclin. studies suggest that retinoids can inhibit the growth of a small percentage of human renal cancers (RCs), although the majority of RCs both in vitro and in vivo are retinoid resistant.  Our recent studies indicate that the metab. of retinol to retinyl esters is greatly reduced in human carcinoma cell lines of the oral cavity, skin, and breast as compared with their normal epithelial counterparts, suggesting that human carcinoma cells are retinoid deficient relative to normal epithelial cells.  We considered whether retinoid resistance in RCs was related to an abnormality in retinoid metab.  The metab. of [3H]retinol and of [3H]retinoic acid (RA) was examd. in RC cell lines and normal human kidney (NK) epithelial cells cultured in media, in RA, or in RA plus IFN-α.  The expression of LRAT (lecithin:retinol acyltransferase) was assessed by Northern and Western anal.  Retinol and retinyl ester levels were detd. in tissue samples of normal human kidney and renal cell carcinoma.  NK cells esterified all of the 50 nM [3H]retinol in which they were cultured.  In contrast, six of the seven RC cell lines metabolized only trace amts. of [3H]retinol to [3H]retinyl esters.  Consistent with this relative lack of [3H]retinol esterification by the tumor cells, the tumor cells exhibited LRAT transcripts of aberrantly low sizes relative to those in normal epithelial cells.  Moreover, the NK cells expressed abundant levels of LRAT protein by Western anal., whereas the RC cells did not express LRAT protein.  When samples of human kidney tumor tissue were compared with samples of normal kidney tissue from patients who had undergone surgery for primary RC, the normal kidney tissues contained much higher levels of retinol and retinyl esters (approx. 0.5-2 μg/g wet wt.) than the tumor tissues in all seven patients examd.  Culture of the RC lines in IFN-α plus all-trans-RA, a combination therapy used clin., resulted in higher intracellular levels of [3H]retinol and [3H]retinyl esters.  The metab. of [3H]RA was also examd. in these RC lines vs. NK cells.  Although the NK epithelial cells metabolized [3H]RA, the majority of the RC lines metabolized [3H]RA at a much slower rate.  Most of the RC lines metabolized only 10-30% of the 50 nM [3H]RA over 6 h of culture.  These data indicate that RCs both in vitro and in vivo are retinol and retinyl ester deficient relative to the normal human kidney, and they suggest that the aberrant differentiation of the neoplastic renal cells results in part from a defect in retinoid metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtLlv9bBM1crVg90H21EOLACvtfcHk0lh55c38hgX6vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVSksbc%253D&md5=6cb366b2e4f647f4c41469bc50de0c7f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DNanus%26aufirst%3DD.%2BM.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DBok%26aufirst%3DD.%26aulast%3DGudas%26aufirst%3DL.%2BJ.%26atitle%3DReduced%2520levels%2520of%2520retinyl%2520esters%2520and%2520vitamin%2520A%2520in%2520human%2520renal%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2774%26epage%3D2781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susanto, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. S.</span></span> <span> </span><span class="NLM_article-title">Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells</span>. <i>J. Gene Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1002/jgm.1276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fjgm.1276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=19065606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1KhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=103-111&author=M.+Kamataauthor=M.+T.+Susantoauthor=I.+S.+Chen&title=Enhanced+transthyretin+tetramer+stability+following+expression+of+an+amyloid+disease+transsuppressor+variant+in+mammalian+cells&doi=10.1002%2Fjgm.1276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells</span></div><div class="casAuthors">Kamata, Masakazu; Susanto, Melisa T.; Chen, Irvin S. Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Gene Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-111</span>CODEN:
                <span class="NLM_cas:coden">JGMEFG</span>;
        ISSN:<span class="NLM_cas:issn">1099-498X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Background: The transthyretin (TTR) amyloidosis is an incurable fatal inherited disease that is characterized by progressive peripheral and autonomic neuropathy.  It is caused by missense amyloidogenic mutations in the TTR gene that destabilize the native tetrameric state and lead to the cytotoxic misfolded monomeric state.  One interesting variant (T119M) stabilizes heterotetramers with amyloidogenic TTR and, in the reported heterozygous individuals, protects the carriers from disease.  In the present study, we characterize in vitro and in vivo the ectopic expression of the human T119M mutant, termed a transsuppressor for TTR amyloid disease.  Methods: Lentiviral vectors encoding wild or mutant forms of human TTR were constructed and transduced to the human hepatocellular carcinoma cell line, HepG2, or mice.  Heterooligomerization between T119M TTR and amyloidogenic variants was analyzed by immunopptn. following western blotting.  Results: T119M TTR was stably expressed in transduced HepG2 cells and was secreted as an oligomer that can interact with its native partner, retinol-binding protein.  Importantly, the T119M TTR formed secreted heterooligomers with amyloidogenic TTR variants, V30M, L55P and V122I, in HepG2 cells that were more stable than the homooligomers of the same amyloidogenic TTR variants.  Human T119M TTR also formed heterooligomers with V30M TTR in transduced mice.  Conclusions: The results obtained in the present study demonstrate the stabilization of heterotetramers by T119M TTR in human cells and suggest that gene transfer of T119M TTR may have potential as a gene therapy for TTR amyloidosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyqbPaieeyX7Vg90H21EOLACvtfcHk0lh55c38hgX6vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1KhsLk%253D&md5=f95f5b0f68180a6caf82c913a5f50a16</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjgm.1276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjgm.1276%26sid%3Dliteratum%253Aachs%26aulast%3DKamata%26aufirst%3DM.%26aulast%3DSusanto%26aufirst%3DM.%2BT.%26aulast%3DChen%26aufirst%3DI.%2BS.%26atitle%3DEnhanced%2520transthyretin%2520tetramer%2520stability%2520following%2520expression%2520of%2520an%2520amyloid%2520disease%2520transsuppressor%2520variant%2520in%2520mammalian%2520cells%26jtitle%3DJ.%2520Gene%2520Med.%26date%3D2009%26volume%3D11%26spage%3D103%26epage%3D111%26doi%3D10.1002%2Fjgm.1276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. K.</span></span> <span> </span><span class="NLM_article-title">Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1525</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S162913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.2147%2FDDDT.S162913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31118583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1515-1525&author=V.+Mathewauthor=A.+K.+Wang&title=Inotersen%3A+new+promise+for+the+treatment+of+hereditary+transthyretin+amyloidosis&doi=10.2147%2FDDDT.S162913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis</span></div><div class="casAuthors">Mathew, Veena; Wang, Annabel K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1515-1525</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract.  Previous treatments using liver transplantation and small mol. stabilizers were not effective in stopping disease progression.  Inotersen, a 2'-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the prodn. of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-mo Phase III study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSK9IbPaT1mrVg90H21EOLACvtfcHk0lghAZZzhB7I9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisrvO&md5=d74cfa639bfb514a97ddafe6118639b1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S162913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S162913%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DA.%2BK.%26atitle%3DInotersen%253A%2520new%2520promise%2520for%2520the%2520treatment%2520of%2520hereditary%2520transthyretin%2520amyloidosis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D1515%26epage%3D1525%26doi%3D10.2147%2FDDDT.S162913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Patisiran: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1631</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0983-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs40265-018-0983-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30251172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslymsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1625-1631&author=S.+M.+Hoy&title=Patisiran%3A+first+global+approval&doi=10.1007%2Fs40265-018-0983-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Patisiran: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1625-1631</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Patisiran (ONPATTRO) is a double-stranded small interfering RNA encapsulated in a lipid nanoparticle for delivery to hepatocytes.  By specifically binding to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type transthyretin (TTR) mRNA, patisiran causes its degrdn. (via RNA interference) and subsequently a redn. in serum TTR protein levels and tissue TTR protein deposits.  Patisiran has been developed by Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and subsequently approved in the EU for the treatment of hATTR in adults with stage 1 or 2 polyneuropathy.  The recommended dosage, administered as a single i.v. infusion over approx. 80 min, is 0.3 mg/kg once every 3 wk for patients weighing < 100 kg and 30 mg once every 3 wk for patients weighing ≥ 100 kg.  This article summarizes the milestones in the development of patisiran leading to these approvals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr69gWrTaxHmLVg90H21EOLACvtfcHk0lghAZZzhB7I9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslymsLfI&md5=94abed01abbe7ba7b679224a42338810</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0983-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0983-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DPatisiran%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1625%26epage%3D1631%26doi%3D10.1007%2Fs40265-018-0983-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulawa, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaudiniere, R.</span></span> <span> </span><span class="NLM_article-title">Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">9629</span>– <span class="NLM_lpage">9634</span>, <span class="refDoi"> DOI: 10.1073/pnas.1121005109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1073%2Fpnas.1121005109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=22645360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=9629-9634&author=C.+E.+Bulawaauthor=S.+Connellyauthor=M.+Devitauthor=L.+Wangauthor=C.+Weigelauthor=J.+A.+Flemingauthor=J.+Packmanauthor=E.+T.+Powersauthor=R.+L.+Wisemanauthor=T.+R.+Fossauthor=I.+A.+Wilsonauthor=J.+W.+Kellyauthor=R.+Labaudiniere&title=Tafamidis%2C+a+potent+and+selective+transthyretin+kinetic+stabilizer+that+inhibits+the+amyloid+cascade&doi=10.1073%2Fpnas.1121005109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade</span></div><div class="casAuthors">Bulawa, Christine E.; Connelly, Stephen; DeVit, Michael; Wang, Lan; Weigel, Charlotte; Fleming, James A.; Packman, Jeff; Powers, Evan T.; Wiseman, R. Luke; Foss, Theodore R.; Wilson, Ian A.; Kelly, Jeffery W.; Labaudiniere, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9629-9634, S9629/1-S9629/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The transthyretin amyloidoses (ATTR) are invariably fatal diseases characterized by progressive neuropathy and/or cardiomyopathy.  ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein complex.  Mutations within TTR that cause autosomal dominant forms of disease facilitate tetramer dissocn., monomer misfolding, and aggregation, although wild-type TTR can also form amyloid fibrils in elderly patients.  Because tetramer dissocn. is the rate-limiting step in TTR amyloidogenesis, targeted therapies have focused on small mols. that kinetically stabilize the tetramer, inhibiting TTR amyloid fibril formation.  One such compd., tafamidis meglumine (Fx-1006A), has recently completed Phase II/111 trials for the treatment of Transthyretin type familial amyloid polyneuropathy (TTR-FAP) and demonstrated a slowing of disease progression in patients heterozygous for the V30M TTR mutation.  Herein we describe the mol. and structural basis of TTR tetramer stabilization by tafamidis.  Tafamidis binds selectively and with neg. cooperativity (KdS ∼2 nM and ∼200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically stabilizes TTR.  Patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants, are also stabilized by tafamidis binding.  The crystal structure of tafamidis-bound TTR suggests that binding stabilizes the weaker dimer-dimer interface against dissocn., the rate-limiting step of amyloidogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfzfMIrqJGHLVg90H21EOLACvtfcHk0lghAZZzhB7I9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWjtb4%253D&md5=05bf9cd644ab6a3dda78bb1620986910</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1121005109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1121005109%26sid%3Dliteratum%253Aachs%26aulast%3DBulawa%26aufirst%3DC.%2BE.%26aulast%3DConnelly%26aufirst%3DS.%26aulast%3DDevit%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeigel%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DJ.%2BA.%26aulast%3DPackman%26aufirst%3DJ.%26aulast%3DPowers%26aufirst%3DE.%2BT.%26aulast%3DWiseman%26aufirst%3DR.%2BL.%26aulast%3DFoss%26aufirst%3DT.%2BR.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DLabaudiniere%26aufirst%3DR.%26atitle%3DTafamidis%252C%2520a%2520potent%2520and%2520selective%2520transthyretin%2520kinetic%2520stabilizer%2520that%2520inhibits%2520the%2520amyloid%2520cascade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D9629%26epage%3D9634%26doi%3D10.1073%2Fpnas.1121005109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulawa, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plante-Bordeneuve, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaudiniere, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundayat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas, P.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis</span>. <i>Neurol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1007/s40120-016-0040-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs40120-016-0040-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=26894299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BC28jit12rtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=1-25&author=T.+Coelhoauthor=G.+Merliniauthor=C.+E.+Bulawaauthor=J.+A.+Flemingauthor=D.+P.+Judgeauthor=J.+W.+Kellyauthor=M.+S.+Maurerauthor=V.+Plante-Bordeneuveauthor=R.+Labaudiniereauthor=R.+Mundayatauthor=S.+Rileyauthor=I.+Lombardoauthor=P.+Huertas&title=Mechanism+of+action+and+clinical+application+of+tafamidis+in+hereditary+transthyretin+amyloidosis&doi=10.1007%2Fs40120-016-0040-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis</span></div><div class="casAuthors">Coelho Teresa; Merlini Giampaolo; Bulawa Christine E; Fleming James A; Judge Daniel P; Kelly Jeffery W; Maurer Mathew S; Plante-Bordeneuve Violaine; Labaudiniere Richard; Mundayat Rajiv; Riley Steve; Lombardo Ilise; Huertas Pedro</div><div class="citationInfo"><span class="NLM_cas:title">Neurology and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-25</span>
        ISSN:<span class="NLM_cas:issn">2193-8253</span>.
    </div><div class="casAbstract">Transthyretin (TTR) transports the retinol-binding protein-vitamin A complex and is a minor transporter of thyroxine in blood.  Its tetrameric structure undergoes rate-limiting dissociation and monomer misfolding, enabling TTR to aggregate or to become amyloidogenic.  Mutations in the TTR gene generally destabilize the tetramer and/or accelerate tetramer dissociation, promoting amyloidogenesis.  TTR-related amyloidoses are rare, fatal, protein-misfolding disorders, characterized by formation of soluble aggregates of variable structure and tissue deposition of amyloid.  The TTR amyloidoses present with a spectrum of manifestations, encompassing progressive neuropathy and/or cardiomyopathy.  Until recently, the only accepted treatment to halt progression of hereditary TTR amyloidosis was liver transplantation, which replaces the hepatic source of mutant TTR with the less amyloidogenic wild-type TTR.  Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis.  Tafamidis is the first pharmacotherapy approved to slow the progression of peripheral neurologic impairment in TTR familial amyloid polyneuropathy.  Here we describe the mechanism of action of tafamidis and review the clinical data, demonstrating that tafamidis treatment slows neurologic deterioration and preserves nutritional status, as well as quality of life in patients with early-stage Val30Met amyloidosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcjwtDHHoc2pQHPYJuLg8TfW6udTcc2ebVUHeiSRKY07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jit12rtA%253D%253D&md5=cbf6666ed975691337c8b2f351036d7f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs40120-016-0040-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40120-016-0040-x%26sid%3Dliteratum%253Aachs%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DMerlini%26aufirst%3DG.%26aulast%3DBulawa%26aufirst%3DC.%2BE.%26aulast%3DFleming%26aufirst%3DJ.%2BA.%26aulast%3DJudge%26aufirst%3DD.%2BP.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DMaurer%26aufirst%3DM.%2BS.%26aulast%3DPlante-Bordeneuve%26aufirst%3DV.%26aulast%3DLabaudiniere%26aufirst%3DR.%26aulast%3DMundayat%26aufirst%3DR.%26aulast%3DRiley%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DI.%26aulast%3DHuertas%26aufirst%3DP.%26atitle%3DMechanism%2520of%2520action%2520and%2520clinical%2520application%2520of%2520tafamidis%2520in%2520hereditary%2520transthyretin%2520amyloidosis%26jtitle%3DNeurol.%2520Ther.%26date%3D2016%26volume%3D5%26spage%3D1%26epage%3D25%26doi%3D10.1007%2Fs40120-016-0040-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maia, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plante-Bordeneuve, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhr, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conceicao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trigo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaudiniere, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, D. R.</span></span> <span> </span><span class="NLM_article-title">Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy</span>. <i>J. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">2802</span>– <span class="NLM_lpage">2814</span>, <span class="refDoi"> DOI: 10.1007/s00415-013-7051-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs00415-013-7051-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23974642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=2013&pages=2802-2814&author=T.+Coelhoauthor=L.+F.+Maiaauthor=A.+M.+da+Silvaauthor=M.+W.+Cruzauthor=V.+Plante-Bordeneuveauthor=O.+B.+Suhrauthor=I.+Conceicaoauthor=H.+H.+Schmidtauthor=P.+Trigoauthor=J.+W.+Kellyauthor=R.+Labaudiniereauthor=J.+Chanauthor=J.+Packmanauthor=D.+R.+Grogan&title=Long-term+effects+of+tafamidis+for+the+treatment+of+transthyretin+familial+amyloid+polyneuropathy&doi=10.1007%2Fs00415-013-7051-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy</span></div><div class="casAuthors">Coelho, Teresa; Maia, Luis F.; Martins da Silva, Ana; Cruz, Marcia W.; Plante-Bordeneuve, Violaine; Suhr, Ole B.; Conceicao, Isabel; Schmidt, Hartmut H.-J.; Trigo, Pedro; Kelly, Jeffery W.; Labaudiniere, Richard; Chan, Jason; Packman, Jeff; Grogan, Donna R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2802-2814</span>CODEN:
                <span class="NLM_cas:coden">JNRYA9</span>;
        ISSN:<span class="NLM_cas:issn">0340-5354</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP) in an 18-mo randomized controlled trial (study Fx-005).  This 12-mo, open-label extension study evaluated the long-term safety, tolerability, and efficacy of tafamidis 20 mg once daily in 86 patients who earlier received blinded treatment with tafamidis or placebo.  Efficacy measures included the Neuropathy Impairment Score in the Lower Limbs (NIS-LL), Norfolk Quality of Life-Diabetic Neuropathy total quality of life (TQOL) score, and changes in neurol. function and nutritional status.  We quantified the monthly rates of change in efficacy measures, and TTR stabilization, and monitored adverse events (AEs).  Patients who continued on tafamidis had stable rates of change in NIS-LL (from 0.08 to 0.11/mo; p = 0.60) and TQOL (from -0.03 to 0.25; p = 0.16).  In patients switched from placebo, the monthly rate of change in NIS-LL declined (from 0.34 to 0.16/mo; p = 0.01), as did TQOL score (from 0.61 to -0.16; p < 0.001).  Patients treated with tafamidis for 30 mo had 55.9 % greater preservation of neurol. function as measured by the NIS-LL than patients in whom tafamidis was initiated later.  Plasma TTR was stabilized in 94.1 % of patients treated with tafamidis for 30 mo.  AEs were similar between groups; no patients discontinued because of an AE.  Long-term tafamidis was well tolerated, with the reduced rate of neurol. deterioration sustained over 30 mo.  Tafamidis also slowed neurol. impairment in patients previously given placebo, but treatment benefits were greater when tafamidis was begun earlier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgr1CkOGcKu7Vg90H21EOLACvtfcHk0lgnYVVWUROPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2jurfI&md5=0168b9b97845a5b89a21e43eb031ab88</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs00415-013-7051-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00415-013-7051-7%26sid%3Dliteratum%253Aachs%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DMaia%26aufirst%3DL.%2BF.%26aulast%3Dda%2BSilva%26aufirst%3DA.%2BM.%26aulast%3DCruz%26aufirst%3DM.%2BW.%26aulast%3DPlante-Bordeneuve%26aufirst%3DV.%26aulast%3DSuhr%26aufirst%3DO.%2BB.%26aulast%3DConceicao%26aufirst%3DI.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DTrigo%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DLabaudiniere%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DPackman%26aufirst%3DJ.%26aulast%3DGrogan%26aufirst%3DD.%2BR.%26atitle%3DLong-term%2520effects%2520of%2520tafamidis%2520for%2520the%2520treatment%2520of%2520transthyretin%2520familial%2520amyloid%2520polyneuropathy%26jtitle%3DJ.%2520Neurol.%26date%3D2013%26volume%3D260%26spage%3D2802%26epage%3D2814%26doi%3D10.1007%2Fs00415-013-7051-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M. W.</span></span> <span> </span><span class="NLM_article-title">Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review</span>. <i>Clin. Auton. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1007/s10286-019-00625-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs10286-019-00625-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31407119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3MvnsVeisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=19-24&author=M.+W.+Cruz&title=Tafamidis+for+autonomic+neuropathy+in+hereditary+transthyretin+%28ATTR%29+amyloidosis%3A+a+review&doi=10.1007%2Fs10286-019-00625-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review</span></div><div class="casAuthors">Cruz Marcia Waddington</div><div class="citationInfo"><span class="NLM_cas:title">Clinical autonomic research : official journal of the Clinical Autonomic Research Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">Suppl 1</span>),
    <span class="NLM_cas:pages">19-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Autonomic dysfunction is a very common, early and distressing aspect of hereditary transthyretin (ATTR) amyloidosis leading to significant loss of quality of life and morbidity for patients.  Although the clinical variability of ATTR has been well characterized as neuropathic, cardiac or mixed phenotype, the extent of autonomic involvement remains poorly understood.  Despite the fact that the autonomic nervous system has not been specifically evaluated in any of the clinical trials of tafamidis, and that, for some primary and secondary endpoints used in these trials, the behavior cannot be separated from non-autonomic items, an attempt was made to use published material to indirectly access the efficacy of tafamidis in treating dysautonomia.  METHODS:  Literature review summarizing the results of primary and secondary endpoints related to the autonomic features used in the original tafamidis trials, the post hoc publications, and real-world data, on the effect of tafamidis on autonomic dysfunction in patients with ATTR amyloidosis.  RESULTS:  There is some evidence that indirectly demonstrates that tafamidis is safe and could slow or arrest the progression of autonomic neuropathy in patients with ATTR amyloidosis, in addition to its well-described effects to ameliorate sensory-motor peripheral neuropathy.  CONCLUSION:  Although the current evidence is scarce, tafamidis might be effective in arresting the progression of autonomic neuropathy in patients with ATTR amyloidosis.  Tafamidis might be more effective at the early stage of the disease; however, individual responses must be monitored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLikgH0XNLR5WtyewyzkyLfW6udTcc2ebEFjk-sd0j9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvnsVeisg%253D%253D&md5=2e656b17da59608e673bcf2e68baab74</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10286-019-00625-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10286-019-00625-9%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DM.%2BW.%26atitle%3DTafamidis%2520for%2520autonomic%2520neuropathy%2520in%2520hereditary%2520transthyretin%2520%2528ATTR%2529%2520amyloidosis%253A%2520a%2520review%26jtitle%3DClin.%2520Auton.%2520Res.%26date%3D2019%26volume%3D29%26spage%3D19%26epage%3D24%26doi%3D10.1007%2Fs10286-019-00625-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Tafamidis: a review in transthyretin amyloidosis with polyneuropathy</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01129-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs40265-019-01129-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31098895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=863-874&author=Y.+N.+Lambauthor=E.+D.+Deeks&title=Tafamidis%3A+a+review+in+transthyretin+amyloidosis+with+polyneuropathy&doi=10.1007%2Fs40265-019-01129-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy</span></div><div class="casAuthors">Lamb, Yvette N.; Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">863-874</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Transthyretin amyloidosis with polyneuropathy (ATTR-PN), a rare and progressive hereditary disorder, results from mutations in the gene coding for the transthyretin (TTR) protein that destabilize the protein's tetrameric structure.  In over 40 countries worldwide, tafamidis (Vyndaqel) is approved for the treatment of TTR amyloidosis in adults with stage 1 symptomatic polyneuropathy, to delay peripheral neurol. impairment.  Tafamidis is administered orally once daily, as a soft capsule.  Evidence from clin. studies, including an 18-mo placebo-controlled trial and subsequent long-term, open-label extension studies (providing data from ≤ 6 years of treatment), indicate that tafamidis slowed deterioration of neurol. function and maintained health-related quality of life in patients with early-stage ATTR-PN and the Val30Met mutation.  TTR tetramers were stabilized in nearly all patients, and nutritional status was generally maintained or improved.  Similar benefit was seen with tafamidis over 12 mo in a noncomparative trial in patients with non-Val30Met ATTR-PN, although disease progression in this population (which was older and had had ATTR-PN for longer than Val30Met patients) became more notable with continued therapy in an extension study.  Data for up to 10 years from large registry and referral center studies support the long-term effectiveness and safety of tafamidis in delaying disease progression and conferring survival benefits in patients with stage 1 ATTR-PN.  Tafamidis was generally well tolerated, with no new safety signals detected during the long-term trial or real-world experience.  Thus, based on up to 10 years' experience, tafamidis continues to be a valuable option in the treatment of early-stage ATTR-PN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMa9d1adtjwLVg90H21EOLACvtfcHk0lgnYVVWUROPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtL3F&md5=4b24681e65dfc76805b1afe0257a58ae</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01129-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01129-6%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DTafamidis%253A%2520a%2520review%2520in%2520transthyretin%2520amyloidosis%2520with%2520polyneuropathy%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D863%26epage%3D874%26doi%3D10.1007%2Fs40265-019-01129-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egolum, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ombengi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, H.</span></span> <span> </span><span class="NLM_article-title">Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1177/1060028019888489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1177%2F1060028019888489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31735059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3MjpvFKltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2020&pages=470-477&author=J.+Parkauthor=U.+Egolumauthor=S.+Parkerauthor=E.+Andrewsauthor=D.+Ombengiauthor=H.+Ling&title=Tafamidis%3A+a+first-in-class+transthyretin+stabilizer+for+transthyretin+amyloid+cardiomyopathy&doi=10.1177%2F1060028019888489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy</span></div><div class="casAuthors">Park Jonathan; Ling Hua; Egolum Ugochukwu; Parker Shanea; Andrews Ebony; Ombengi David</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">470-477</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM).  Data Sources: A PubMed (1966 to October 2019) and ClinicalTrials. gov search was conducted using the keywords tafamidis, Fx-1006A, Vyndaqel, and Vyndamax.  Additional articles were identified from references.  Study Selection and Data Extraction: We included English-language clinical studies evaluating the pharmacology, efficacy, or safety of tafamidis in humans for ATTR-CM.  Data Synthesis: Tafamidis binds to the thyroxine-binding sites of the transthyretin tetramer and inhibits its dissociation into monomers, which is the rate-limiting step in the amyloidogenic process.  Treatment with tafamidis was significantly associated with a significant reduction in mortality, lowered cardiovascular-related hospitalizations, less functional decline, and improved transthyretin stabilization compared with placebo.  Additionally, tafamidis was found to have fewer adverse events, with no difference found compared with placebo.  Relevance to Patient Care and Clinical Practice: Historically, symptomatic management for ATTR-CM was the only option, and the treatment of the underlying disease was limited to liver or heart transplantation.  Tafamidis is the first medication approved for the treatment of ATTR-CM and the only medication that showed a reduction in all-cause mortality and cardiovascular-related hospitalizations in patients with amyloidosis.  However, the role of tafamidis in patients with the New York Heart Association class III/IV heart failure or mutated transthyretin remains unclear.  Conclusion: Tafamidis is an effective and safe oral medication for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMKK_PvoY15e-MdeMhXAHkfW6udTcc2ea2u5ZcUAYdWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjpvFKltA%253D%253D&md5=828d021f03df09f6415b4c24e8f98c88</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1177%2F1060028019888489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028019888489%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DEgolum%26aufirst%3DU.%26aulast%3DParker%26aufirst%3DS.%26aulast%3DAndrews%26aufirst%3DE.%26aulast%3DOmbengi%26aufirst%3DD.%26aulast%3DLing%26aufirst%3DH.%26atitle%3DTafamidis%253A%2520a%2520first-in-class%2520transthyretin%2520stabilizer%2520for%2520transthyretin%2520amyloid%2520cardiomyopathy%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2020%26volume%3D54%26spage%3D470%26epage%3D477%26doi%3D10.1177%2F1060028019888489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alhamadsheh, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reixach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, I. A.</span></span> <span> </span><span class="NLM_article-title">Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">97ra81</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3002473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1126%2Fscitranslmed.3002473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=21865539" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=M.+M.+Alhamadshehauthor=S.+Connellyauthor=A.+Choauthor=N.+Reixachauthor=E.+T.+Powersauthor=D.+W.+Panauthor=I.+A.+Wilsonauthor=J.+W.+Kellyauthor=I.+A.+Graef&title=Potent+kinetic+stabilizers+that+prevent+transthyretin-mediated+cardiomyocyte+proteotoxicity&doi=10.1126%2Fscitranslmed.3002473"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002473%26sid%3Dliteratum%253Aachs%26aulast%3DAlhamadsheh%26aufirst%3DM.%2BM.%26aulast%3DConnelly%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DA.%26aulast%3DReixach%26aufirst%3DN.%26aulast%3DPowers%26aufirst%3DE.%2BT.%26aulast%3DPan%26aufirst%3DD.%2BW.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DGraef%26aufirst%3DI.%2BA.%26atitle%3DPotent%2520kinetic%2520stabilizers%2520that%2520prevent%2520transthyretin-mediated%2520cardiomyocyte%2520proteotoxicity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26doi%3D10.1126%2Fscitranslmed.3002473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albusairi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque Tuhin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jampala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faaij, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhamadsheh, M.</span></span> <span> </span><span class="NLM_article-title">enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7862</span>– <span class="NLM_lpage">7876</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00817</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00817" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGisLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7862-7876&author=M.+Millerauthor=A.+Palauthor=W.+Albusairiauthor=H.+Jooauthor=B.+Pappasauthor=M.+T.+Haque+Tuhinauthor=D.+Liangauthor=R.+Jampalaauthor=F.+Liuauthor=J.+Khanauthor=M.+Faaijauthor=M.+Parkauthor=W.+Chanauthor=I.+Graefauthor=R.+Zamboniauthor=N.+Kumarauthor=J.+Foxauthor=U.+Sinhaauthor=M.+Alhamadsheh&title=enthalpy-driven+stabilization+of+transthyretin+by+AG10+mimics+a+naturally+occurring+genetic+variant+that+protects+from+transthyretin+amyloidosis&doi=10.1021%2Facs.jmedchem.8b00817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis</span></div><div class="casAuthors">Miller, Mark; Pal, Arindom; Albusairi, Wabel; Joo, Hyun; Pappas, Beverly; Haque Tuhin, Md Tariqul; Liang, Dengpan; Jampala, Raghavendra; Liu, Fang; Khan, Jared; Faaij, Marjon; Park, Miki; Chan, William; Graef, Isabella; Zamboni, Robert; Kumar, Neil; Fox, Jonathan; Sinha, Uma; Alhamadsheh, Mamoun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7862-7876</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a fatal disease with no available disease-modifying therapies.  While pathogenic TTR mutations (TTRm) destabilize TTR tetramers, the T119M variant stabilizes TTRm and prevents disease.  A comparison of potency for leading TTR stabilizers in clinic and structural features important for effective TTR stabilization is lacking.  Here, the authors found that mol. interactions reflected in better binding enthalpy may be crit. for development of TTR stabilizers with improved potency and selectivity.  The authors' studies provide mechanistic insights into the unique binding mode of the TTR stabilizer, AG10, which could be attributed to mimicking the stabilizing T119M variant.  Because of the lack of animal models for ATTR-CM, the authors developed an in vivo system in dogs which proved appropriate for assessing the pharmacokinetics-pharmacodynamics profile of TTR stabilizers.  In addn. to stabilizing TTR, the authors hypothesize that optimizing the binding enthalpy could have implications for designing therapeutic agents for other amyloid diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFRxbT_TPMuLVg90H21EOLACvtfcHk0ljwmWB5pgPIJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGisLbF&md5=fb11b83078d797c761397a907b637bbf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00817%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPal%26aufirst%3DA.%26aulast%3DAlbusairi%26aufirst%3DW.%26aulast%3DJoo%26aufirst%3DH.%26aulast%3DPappas%26aufirst%3DB.%26aulast%3DHaque%2BTuhin%26aufirst%3DM.%2BT.%26aulast%3DLiang%26aufirst%3DD.%26aulast%3DJampala%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DFaaij%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DW.%26aulast%3DGraef%26aufirst%3DI.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DFox%26aufirst%3DJ.%26aulast%3DSinha%26aufirst%3DU.%26aulast%3DAlhamadsheh%26aufirst%3DM.%26atitle%3Denthalpy-driven%2520stabilization%2520of%2520transthyretin%2520by%2520AG10%2520mimics%2520a%2520naturally%2520occurring%2520genetic%2520variant%2520that%2520protects%2520from%2520transthyretin%2520amyloidosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7862%26epage%3D7876%26doi%3D10.1021%2Facs.jmedchem.8b00817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penchala, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranczak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappley, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liedtke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witteles, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reixach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhamadsheh, M. M.</span></span> <span> </span><span class="NLM_article-title">AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">9992</span>– <span class="NLM_lpage">9997</span>, <span class="refDoi"> DOI: 10.1073/pnas.1300761110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1073%2Fpnas.1300761110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23716704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOrtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=9992-9997&author=S.+C.+Penchalaauthor=S.+Connellyauthor=Y.+Wangauthor=M.+S.+Parkauthor=L.+Zhaoauthor=A.+Baranczakauthor=I.+Rappleyauthor=H.+Vogelauthor=M.+Liedtkeauthor=R.+M.+Wittelesauthor=E.+T.+Powersauthor=N.+Reixachauthor=W.+K.+Chanauthor=I.+A.+Wilsonauthor=J.+W.+Kellyauthor=I.+A.+Graefauthor=M.+M.+Alhamadsheh&title=AG10+inhibits+amyloidogenesis+and+cellular+toxicity+of+the+familial+amyloid+cardiomyopathy-associated+V122I+transthyretin&doi=10.1073%2Fpnas.1300761110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin</span></div><div class="casAuthors">Penchala, Sravan C.; Connelly, Stephen; Wang, Yu; Park, Miki S.; Zhao, Lei; Baranczak, Aleksandra; Rappley, Irit; Vogel, Hannes; Liedtke, Michaela; Witteles, Ronald M.; Powers, Evan T.; Reixach, Natalia; Chan, William K.; Wilson, Ian A.; Keliy, Jeffery W.; Graef, Isabella A.; Alhamadsheh, Mamoun M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9992-9997, S9992/1-S9992/23</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The misassembly of sol. proteins into toxic aggregates, including amyloid fibrils, underlies a large no. of human degenerative diseases.  Cardiac amyloidoses, which are most commonly caused by aggregation of Ig light chains or transthyretin (TTR) in the cardiac interstitium and conducting system, represent an important and often underdiagnosed cause of heart failure.  Two types of TTR-assocd. amyloid cardiomyopathies are clin. important.  The Val122Ile (V112I) mutation, which alters the kinetic stability of TTR and affects 3% to 4% of African American subjects, can lead to development of familial amyloid cardiomyopathy.  In addn., aggregation of WT TTR in individuals older than age 65 y causes senile systemic amyloidosis.  TTR-mediated amyloid cardiomyopathies are chronic and progressive conditions that lead to arrhythmias, biventricular heart failure, and death.  As no Food and Drug Administration-approved drugs are currently available for treatment of these diseases, the development of therapeutic agents that prevent TTR-mediated cardiotoxicity is desired.  Here, the authors report the development of AG10, a potent and selective kinetic stabilizer of TTR.  AG10 prevents dissocn. of V122I-TTR in serum samples obtained from patients with familial amyloid cardiomyopathy.  In contrast to other TTR stabilizers currently in clin. trials, AG10 stabilizes V122I- and WT-TTR equally well and also exceeds their efficacy to stabilize WT and mutant TTR in whole serum.  Crystallog. studies of AG10 bound to V122I-TTR give valuable insights into how AG10 achieves such effective kinetic stabilization of TTR, which will also aid in designing better TTR stabilizers.  The oral bioavailability of AG10, combined with addnl. desirable drug-like features, makes it a very promising candidate to treat TTR amyloid cardiomyopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOL2rGZR4uzrVg90H21EOLACvtfcHk0ljwmWB5pgPIJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOrtLzE&md5=a7e13a3659bde9c8106bc61f7049ffa5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1300761110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1300761110%26sid%3Dliteratum%253Aachs%26aulast%3DPenchala%26aufirst%3DS.%2BC.%26aulast%3DConnelly%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DM.%2BS.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DBaranczak%26aufirst%3DA.%26aulast%3DRappley%26aufirst%3DI.%26aulast%3DVogel%26aufirst%3DH.%26aulast%3DLiedtke%26aufirst%3DM.%26aulast%3DWitteles%26aufirst%3DR.%2BM.%26aulast%3DPowers%26aufirst%3DE.%2BT.%26aulast%3DReixach%26aufirst%3DN.%26aulast%3DChan%26aufirst%3DW.%2BK.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DGraef%26aufirst%3DI.%2BA.%26aulast%3DAlhamadsheh%26aufirst%3DM.%2BM.%26atitle%3DAG10%2520inhibits%2520amyloidogenesis%2520and%2520cellular%2520toxicity%2520of%2520the%2520familial%2520amyloid%2520cardiomyopathy-associated%2520V122I%2520transthyretin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D9992%26epage%3D9997%26doi%3D10.1073%2Fpnas.1300761110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundapaneni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddington-Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristen, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witteles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsdorf, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapezzi, C.</span></span> <span> </span><span class="NLM_article-title">Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1016</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1805689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1056%2FNEJMoa1805689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30145929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCksLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1007-1016&author=M.+S.+Maurerauthor=J.+H.+Schwartzauthor=B.+Gundapaneniauthor=P.+M.+Elliottauthor=G.+Merliniauthor=M.+Waddington-Cruzauthor=A.+V.+Kristenauthor=M.+Groganauthor=R.+Wittelesauthor=T.+Damyauthor=B.+M.+Drachmanauthor=S.+J.+Shahauthor=M.+Hannaauthor=D.+P.+Judgeauthor=A.+I.+Barsdorfauthor=P.+Huberauthor=T.+A.+Pattersonauthor=S.+Rileyauthor=J.+Schumacherauthor=M.+Stewartauthor=M.+B.+Sultanauthor=C.+Rapezzi&title=Tafamidis+treatment+for+patients+with+transthyretin+amyloid+cardiomyopathy&doi=10.1056%2FNEJMoa1805689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy</span></div><div class="casAuthors">Maurer, Mathew S.; Schwartz, Jeffrey H.; Gundapaneni, Balarama; Elliott, Perry M.; Merlini, Giampaolo; Waddington-Cruz, Marcia; Kristen, Arnt V.; Grogan, Martha; Witteles, Ronald; Damy, Thibaud; Drachman, Brian M.; Shah, Sanjiv J.; Hanna, Mazen; Judge, Daniel P.; Barsdorf, Alexandra I.; Huber, Peter; Patterson, Terrell A.; Riley, Steven; Schumacher, Jennifer; Stewart, Michelle; Sultan, Marla B.; Rapezzi, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1007-1016</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium.  Tafamidis binds to transthyretin, preventing tetramer dissocn. and amyloidogenesis.  In primary anal., we hierarchically assessed all-cause mortality, followed by frequency of cardiovascular-related hospitalizations according to the Finkelstein-Schoenfeld method.  Key secondary end points were the change from baseline to month 30 for the 6-min walk test and the score on the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS), in which higher scores indicate better health status.  In the primary anal., all-cause mortality and rates of cardiovascular-related hospitalizations were lower among the 264 patients who received tafamidis than among the 177 patients who received placebo (P<0.001).  Tafamidis was assocd. with lower all-cause mortality than placebo and a lower rate of cardiovascular-related hospitalizations, with a relative risk ratio of 0.68.  At month 30, tafamidis was also assocd. with a lower rate of decline in distance for the 6-min walk test (P<0.001) and a lower rate of decline in KCCQ-OS score (P<0.001).  The incidence and types of adverse events were similar in the two groups.  In patients with transthyretin amyloid cardiomyopathy, tafamidis was assocd. with redns. in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVh-pvrmMfzLVg90H21EOLACvtfcHk0li7kWV3Eck38g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCksLfP&md5=35f57b7aae8a03914b6882ffb7df7572</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1805689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1805689%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DM.%2BS.%26aulast%3DSchwartz%26aufirst%3DJ.%2BH.%26aulast%3DGundapaneni%26aufirst%3DB.%26aulast%3DElliott%26aufirst%3DP.%2BM.%26aulast%3DMerlini%26aufirst%3DG.%26aulast%3DWaddington-Cruz%26aufirst%3DM.%26aulast%3DKristen%26aufirst%3DA.%2BV.%26aulast%3DGrogan%26aufirst%3DM.%26aulast%3DWitteles%26aufirst%3DR.%26aulast%3DDamy%26aufirst%3DT.%26aulast%3DDrachman%26aufirst%3DB.%2BM.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DJudge%26aufirst%3DD.%2BP.%26aulast%3DBarsdorf%26aufirst%3DA.%2BI.%26aulast%3DHuber%26aufirst%3DP.%26aulast%3DPatterson%26aufirst%3DT.%2BA.%26aulast%3DRiley%26aufirst%3DS.%26aulast%3DSchumacher%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DM.%26aulast%3DSultan%26aufirst%3DM.%2BB.%26aulast%3DRapezzi%26aufirst%3DC.%26atitle%3DTafamidis%2520treatment%2520for%2520patients%2520with%2520transthyretin%2520amyloid%2520cardiomyopathy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1007%26epage%3D1016%26doi%3D10.1056%2FNEJMoa1805689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Judge, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitner, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witteles, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selby, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nativi-Nicolau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtle, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. C.</span></span> <span> </span><span class="NLM_article-title">Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2019.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.jacc.2019.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30885685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyitLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2019&pages=285-295&author=D.+P.+Judgeauthor=S.+B.+Heitnerauthor=R.+H.+Falkauthor=M.+S.+Maurerauthor=S.+J.+Shahauthor=R.+M.+Wittelesauthor=M.+Groganauthor=V.+N.+Selbyauthor=D.+Jacobyauthor=M.+Hannaauthor=J.+Nativi-Nicolauauthor=J.+Patelauthor=S.+Raoauthor=U.+Sinhaauthor=C.+W.+Turtleauthor=J.+C.+Fox&title=Transthyretin+stabilization+by+AG10+in+symptomatic+transthyretin+amyloid+cardiomyopathy&doi=10.1016%2Fj.jacc.2019.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy</span></div><div class="casAuthors">Judge, Daniel P.; Heitner, Stephen B.; Falk, Rodney H.; Maurer, Mathew S.; Shah, Sanjiv J.; Witteles, Ronald M.; Grogan, Martha; Selby, Van N.; Jacoby, Daniel; Hanna, Mazen; Nativi-Nicolau, Jose; Patel, Jignesh; Rao, Satish; Sinha, Uma; Turtle, Cameron W.; Fox, Jonathan C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging.  Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions.  AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation.  This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with symptomatic, chronic heart failure.  ATTR-CM, New York Heart Assocn. functional class II to III subjects (n = 49, mutant or wild-type) were randomized 1:1:1 to AG10 400 mg, AG10 800 mg, or placebo twice daily for 28 days.  Safety and tolerability were assessed by clin. and lab. criteria.  AG10 plasma levels were measured.  TTR stability was assessed by changes in serum TTR, and 2 established ex vivo assays (fluorescent probe exclusion and Western blot).  AG10 treatment was well-tolerated, achieved target plasma concns. and demonstrated near-complete stabilization of TTR.  TTR stabilization was more complete and less variable at the higher dose with stabilization by fluorescent probe exclusion of 92 ± 10% (mean ± SD) at trough and 96 ± 9% at peak (both p < 10-12 vs. placebo).  Av. serum TTR increased by 36 ± 21% and 51 ± 38% at 400 and 800 mg, resp. (both p < 0.0001 vs. placebo).  Baseline serum TTR in treated subjects was below normal in 80% of mutant and 33% of wild-type subjects.  AG10 treatment restored serum TTR to the normal range in all subjects.  AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM.  A phase 3 trial is ongoing.  (Study of AG10 in Amyloid Cardiomyopathy; NCT03458130).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplRqntrbcy8LVg90H21EOLACvtfcHk0ljxZ9ZdxPd6AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyitLvJ&md5=020819a05657af410e927f5b8d3b1477</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2019.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2019.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DJudge%26aufirst%3DD.%2BP.%26aulast%3DHeitner%26aufirst%3DS.%2BB.%26aulast%3DFalk%26aufirst%3DR.%2BH.%26aulast%3DMaurer%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DWitteles%26aufirst%3DR.%2BM.%26aulast%3DGrogan%26aufirst%3DM.%26aulast%3DSelby%26aufirst%3DV.%2BN.%26aulast%3DJacoby%26aufirst%3DD.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DNativi-Nicolau%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DU.%26aulast%3DTurtle%26aufirst%3DC.%2BW.%26aulast%3DFox%26aufirst%3DJ.%2BC.%26atitle%3DTransthyretin%2520stabilization%2520by%2520AG10%2520in%2520symptomatic%2520transthyretin%2520amyloid%2520cardiomyopathy%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2019%26volume%3D74%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.jacc.2019.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesgazardeh, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselmo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novais, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brighty, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span> <span> </span><span class="NLM_article-title">Predictive model of response to tafamidis in hereditary ATTR polyneuropathy</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e126526</span> <span class="refDoi"> DOI: 10.1172/jci.insight.126526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1172%2Fjci.insight.126526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31217346" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&author=C.+Monteiroauthor=J.+S.+Mesgazardehauthor=J.+Anselmoauthor=J.+Fernandesauthor=M.+Novaisauthor=C.+Rodriguesauthor=G.+J.+Brightyauthor=D.+L.+Powersauthor=E.+T.+Powersauthor=T.+Coelhoauthor=J.+W.+Kelly&title=Predictive+model+of+response+to+tafamidis+in+hereditary+ATTR+polyneuropathy&doi=10.1172%2Fjci.insight.126526"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.126526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.126526%26sid%3Dliteratum%253Aachs%26aulast%3DMonteiro%26aufirst%3DC.%26aulast%3DMesgazardeh%26aufirst%3DJ.%2BS.%26aulast%3DAnselmo%26aufirst%3DJ.%26aulast%3DFernandes%26aufirst%3DJ.%26aulast%3DNovais%26aufirst%3DM.%26aulast%3DRodrigues%26aufirst%3DC.%26aulast%3DBrighty%26aufirst%3DG.%2BJ.%26aulast%3DPowers%26aufirst%3DD.%2BL.%26aulast%3DPowers%26aufirst%3DE.%2BT.%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26atitle%3DPredictive%2520model%2520of%2520response%2520to%2520tafamidis%2520in%2520hereditary%2520ATTR%2520polyneuropathy%26jtitle%3DJCI%2520Insight%26date%3D2019%26volume%3D4%26doi%3D10.1172%2Fjci.insight.126526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhr, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obici, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekijima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeldenrust, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heneghan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorevic, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchy, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson-Papp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybin, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisbee, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, P. J.</span></span>; <span class="NLM_contrib-group">Diflunisal Trial Consortium</span> <span> </span><span class="NLM_article-title">Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">2658</span>– <span class="NLM_lpage">2667</span>, <span class="refDoi"> DOI: 10.1001/jama.2013.283815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1001%2Fjama.2013.283815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=24368466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFejur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2013&pages=2658-2667&author=J.+L.+Berkauthor=O.+B.+Suhrauthor=L.+Obiciauthor=Y.+Sekijimaauthor=S.+R.+Zeldenrustauthor=T.+Yamashitaauthor=M.+A.+Heneghanauthor=P.+D.+Gorevicauthor=W.+J.+Litchyauthor=J.+F.+Wiesmanauthor=E.+Nordhauthor=M.+Coratoauthor=A.+Lozzaauthor=A.+Corteseauthor=J.+Robinson-Pappauthor=T.+Coltonauthor=D.+V.+Rybinauthor=A.+B.+Bisbeeauthor=Y.+Andoauthor=S.+Ikedaauthor=D.+C.+Seldinauthor=G.+Merliniauthor=M.+Skinnerauthor=J.+W.+Kellyauthor=P.+J.+Dyckauthor=Diflunisal+Trial+Consortium&title=Repurposing+diflunisal+for+familial+amyloid+polyneuropathy%3A+a+randomized+clinical+trial&doi=10.1001%2Fjama.2013.283815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial</span></div><div class="casAuthors">Berk, John L.; Suhrl, Ole B.; Obici, Laura; Sekijima, Yoshiki; Zeldenrust, Steven R.; Yamashita, Taro; Heneghan, Michael A.; Gorevic, Peter D.; Litchy, William J.; Wiesman, Janice F.; Nordh, Erik; Corato, Manuel; Lozza, Alessandro; Cortese, Andrea; Robinson-Papp, Jessica; Colton, Theodore; Rybin, Denis V.; Bisbee, Alice B.; Ando, Yukio; Ikeda, Shu-ichi; Seldin, David C.; Merlini, Giampaolo; Skinner, Martha; Kelly, Jeffery W.; Dyck, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2658-2667</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">IMPORTANCE Familial amyloid polyneuropathy, a lethal genetic disease caused by aggregation of variant transthyretin, induces progressive peripheral nerve deficits and disability.  Diflunisal, a nonsteroidal anti-inflammatory agent, stabilizes transthyretin tetramers and prevents amyloid fibril formation in vitro.  OBJECTIVE To det. the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy.  DESIGN, SETTING, and PARTICIPANTS International randomized, double-blind, placebo-controlled study conducted among 130 patients with familial amyloid polyneuropathy exhibiting clin. detectable peripheral or autonomic neuropathy at amyloid centers in Sweden (Umea), Italy (Pavia), Japan (Matsumoto and Kumamoto), England (London), and the United States (Boston, Massachusetts; New York, New York; and Rochester, Minnesota) from 2006 through 2012.  INTERVENTION Participants were randomly assigned to receive diflunisal, 250 mg (n = 64), or placebo (n = 66) twice daily for 2 years.  MAIN OUTCOMES AND MEASURES The primary end point, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurol. deficits) to 270 points (no detectable peripheral nerve function).  Secondary outcomes included a quality-of-life questionnaire (36-Item Short-Form Health Survey [SF-36]) and modified body mass index.  Because of attrition, we used likelihood-based modeling and multiple imputation anal. of baseline to 2-yr data.  RESULTS By multiple imputation, the NIS+7 score increased by 25.0 (95% CI, 18.4-31.6) points in the placebo group and by 8.7 (95% CI, 3.3-14.1) points in the diflunisal group, a difference of 16.3 points (95% CI, 8.1-24.5 points; P < .001).  Mean SF-36 phys. scores decreased by 4.9 (95% CI, -7.6 to -2.2) points in the placebo group and increased by 1.5 (95% CI, -0.8 to 3.7) points in the diflunisal group (P < .001).  Mean SF-36 mental scores declined by 1.1 (95% CI, -4.3 to 2.0) points in the placebo group while increasing by 3.7 (95% CI, 1.0-6.4) points in the diflunisal group (P = .02).  By responder anal., 29.7% of the diflunisal group and 9.4% of the placebo group exhibited neurol. stability at 2 years (<2-point increase in NIS+7 score; P = .007).  CONCLUSIONS AND RELEVANCE Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurol. impairment and preserved quality of life.  Although longer-term follow-up studies are needed, these findings suggest benefit of this treatment for familial amyloid polyneuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo12QO7TMUWY7Vg90H21EOLACvtfcHk0lic3gciyl54nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFejur8%253D&md5=4cb486d1fe267e22bbeb14a7c9fe4971</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1001%2Fjama.2013.283815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2013.283815%26sid%3Dliteratum%253Aachs%26aulast%3DBerk%26aufirst%3DJ.%2BL.%26aulast%3DSuhr%26aufirst%3DO.%2BB.%26aulast%3DObici%26aufirst%3DL.%26aulast%3DSekijima%26aufirst%3DY.%26aulast%3DZeldenrust%26aufirst%3DS.%2BR.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DHeneghan%26aufirst%3DM.%2BA.%26aulast%3DGorevic%26aufirst%3DP.%2BD.%26aulast%3DLitchy%26aufirst%3DW.%2BJ.%26aulast%3DWiesman%26aufirst%3DJ.%2BF.%26aulast%3DNordh%26aufirst%3DE.%26aulast%3DCorato%26aufirst%3DM.%26aulast%3DLozza%26aufirst%3DA.%26aulast%3DCortese%26aufirst%3DA.%26aulast%3DRobinson-Papp%26aufirst%3DJ.%26aulast%3DColton%26aufirst%3DT.%26aulast%3DRybin%26aufirst%3DD.%2BV.%26aulast%3DBisbee%26aufirst%3DA.%2BB.%26aulast%3DAndo%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DSeldin%26aufirst%3DD.%2BC.%26aulast%3DMerlini%26aufirst%3DG.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DDyck%26aufirst%3DP.%2BJ.%26aulast%3D%26atitle%3DRepurposing%2520diflunisal%2520for%2520familial%2520amyloid%2520polyneuropathy%253A%2520a%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA%26date%3D2013%26volume%3D310%26spage%3D2658%26epage%3D2667%26doi%3D10.1001%2Fjama.2013.283815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sant’Anna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira-Henriques, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esperante, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reixach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reverter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reig, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, S.</span></span> <span> </span><span class="NLM_article-title">Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">10787</span> <span class="refDoi"> DOI: 10.1038/ncomms10787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2Fncomms10787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=26902880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1ehtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=R.+Sant%E2%80%99Annaauthor=P.+Gallegoauthor=L.+Z.+Robinsonauthor=A.+Pereira-Henriquesauthor=N.+Ferreiraauthor=F.+Pinheiroauthor=S.+Esperanteauthor=I.+Pallaresauthor=O.+Huertasauthor=M.+R.+Almeidaauthor=N.+Reixachauthor=R.+Insaauthor=A.+Velazquez-Campoyauthor=D.+Reverterauthor=N.+Reigauthor=S.+Ventura&title=Repositioning+tolcapone+as+a+potent+inhibitor+of+transthyretin+amyloidogenesis+and+associated+cellular+toxicity&doi=10.1038%2Fncomms10787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity</span></div><div class="casAuthors">Sant'Anna, Ricardo; Gallego, Pablo; Robinson, Lei Z.; Pereira-Henriques, Alda; Ferreira, Nelson; Pinheiro, Francisca; Esperante, Sebastian; Pallares, Irantzu; Huertas, Oscar; Rosario Almeida, Maria; Reixach, Natalia; Insa, Raul; Velazquez-Campoy, Adrian; Reverter, David; Reig, Nuria; Ventura, Salvador</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10787</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses.  TTR tetramer dissocn. precedes pathol. TTR aggregation.  Native state stabilizers are promising drugs to treat TTR amyloidoses.  Here we repurpose tolcapone, an FDA-approved mol. for Parkinson's disease, as a potent TTR aggregation inhibitor.  Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity.  Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-assocd. variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses.  These data indicate that tolcapone, already in clin. trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-mol. therapy exists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptjm7CULfu47Vg90H21EOLACvtfcHk0lic3gciyl54nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1ehtr0%253D&md5=a0a29250b2f01100f5226f092ee8b562</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fncomms10787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10787%26sid%3Dliteratum%253Aachs%26aulast%3DSant%25E2%2580%2599Anna%26aufirst%3DR.%26aulast%3DGallego%26aufirst%3DP.%26aulast%3DRobinson%26aufirst%3DL.%2BZ.%26aulast%3DPereira-Henriques%26aufirst%3DA.%26aulast%3DFerreira%26aufirst%3DN.%26aulast%3DPinheiro%26aufirst%3DF.%26aulast%3DEsperante%26aufirst%3DS.%26aulast%3DPallares%26aufirst%3DI.%26aulast%3DHuertas%26aufirst%3DO.%26aulast%3DAlmeida%26aufirst%3DM.%2BR.%26aulast%3DReixach%26aufirst%3DN.%26aulast%3DInsa%26aufirst%3DR.%26aulast%3DVelazquez-Campoy%26aufirst%3DA.%26aulast%3DReverter%26aufirst%3DD.%26aulast%3DReig%26aufirst%3DN.%26aulast%3DVentura%26aufirst%3DS.%26atitle%3DRepositioning%2520tolcapone%2520as%2520a%2520potent%2520inhibitor%2520of%2520transthyretin%2520amyloidogenesis%2520and%2520associated%2520cellular%2520toxicity%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms10787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilaró, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Parra, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsequell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, G.</span></span> <span> </span><span class="NLM_article-title">Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions</span>. <i>ACS Comb. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1021/co5001234</span> </span><div class="citationLinks">[<a href="/doi/10.1021/co5001234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWns7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=32-38&author=M.+Vilar%C3%B3author=J.+Nietoauthor=J.+R.+La+Parraauthor=M.+R.+Almeidaauthor=A.+Ballesterosauthor=A.+Planasauthor=G.+Arsequellauthor=G.+Valencia&title=Tuning+transthyretin+amyloidosis+inhibition+properties+of+iododiflunisal+by+combinatorial+engineering+of+the+nonsalicylic+ring+substitutions&doi=10.1021%2Fco5001234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions</span></div><div class="casAuthors">Vilaro, Maria; Nieto, Joan; La Parra, Juan Ramon; Almeida, Maria Rosario; Ballesteros, Alfredo; Planas, Antoni; Arsequell, Gemma; Valencia, Gregorio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Combinatorial Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-38</span>CODEN:
                <span class="NLM_cas:coden">ACSCCC</span>;
        ISSN:<span class="NLM_cas:issn">2156-8944</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two series of iododiflunisal and diflunisal analogs have been obtained by using a two step sequential reaction soln.-phase parallel synthesis.  The synthesis combined an aq. Suzuki-Miyaura cross-coupling and a mild electrophilic arom. iodination step using a new polymer-supported iodonium version of Barluenga's reagent.  From a selected set of 77 noniodinated and 77 iodinated diflunisal analogs, a subset of good transthyretin amyloid inhibitors has been obtained with improved turbidimetry inhibition consts., high binding affinity to transthyretin, and good selectivity for TTR compared to other thyroxine binding proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ7MUOzhwOVbVg90H21EOLACvtfcHk0liv__A4Ermhkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWns7fF&md5=bf9221c069bfca42017b3c716ed098b4</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fco5001234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fco5001234%26sid%3Dliteratum%253Aachs%26aulast%3DVilar%25C3%25B3%26aufirst%3DM.%26aulast%3DNieto%26aufirst%3DJ.%26aulast%3DLa%2BParra%26aufirst%3DJ.%2BR.%26aulast%3DAlmeida%26aufirst%3DM.%2BR.%26aulast%3DBallesteros%26aufirst%3DA.%26aulast%3DPlanas%26aufirst%3DA.%26aulast%3DArsequell%26aufirst%3DG.%26aulast%3DValencia%26aufirst%3DG.%26atitle%3DTuning%2520transthyretin%2520amyloidosis%2520inhibition%2520properties%2520of%2520iododiflunisal%2520by%2520combinatorial%2520engineering%2520of%2520the%2520nonsalicylic%2520ring%2520substitutions%26jtitle%3DACS%2520Comb.%2520Sci.%26date%3D2015%26volume%3D17%26spage%3D32%26epage%3D38%26doi%3D10.1021%2Fco5001234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span> <span> </span><span class="NLM_article-title">Lecithin retinol acyltransferase forms functional homodimers</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">6311</span>– <span class="NLM_lpage">6319</span>, <span class="refDoi"> DOI: 10.1021/bi015710b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi015710b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVaitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=6311-6319&author=W.+J.+Jahngauthor=E.+Cheungauthor=R.+R.+Rando&title=Lecithin+retinol+acyltransferase+forms+functional+homodimers&doi=10.1021%2Fbi015710b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Lecithin Retinol Acyltransferase Forms Functional Homodimers</span></div><div class="casAuthors">Jahng, Wan Jin; Cheung, Eric; Rando, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6311-6319</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Membrane-bound lecithin retinol acyltransferase (LRAT), an essential enzyme in vitamin A processing, catalyzes the formation of retinyl esters from vitamin A and lecithin.  Cloned and expressed LRAT has a mol. mass of 25.3 kDa.  The enzyme is not homologous to known enzymes and is, therefore, of substantial interest mechanistically.  Along these lines, the functional protomeric state of LRAT is of importance.  Gel electrophoretic studies on LRAT in the presence of SDS and disulfide reducing agents show the expected 25 kDa monomer.  However, gel electrophoresis in the absence of a reducing agent and/or strong denaturing conditions reveals substantial dimer formation.  LRAT monomers can be efficiently and irreversibly cross-linked by thiol reactive bismaleimides in retinal pigment epithelial (RPE) membranes generating LRAT homodimers.  Cross-linked LRAT homodimers are fully active catalytically.  The expts. suggest that LRAT monomers interact in membranes and form functional homodimers through protein-protein interactions and disulfide bond formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj8AMgDFddXrVg90H21EOLACvtfcHk0liv__A4Ermhkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVaitr0%253D&md5=5cda334049ea226fb4884186ee6732a0</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbi015710b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi015710b%26sid%3Dliteratum%253Aachs%26aulast%3DJahng%26aufirst%3DW.%2BJ.%26aulast%3DCheung%26aufirst%3DE.%26aulast%3DRando%26aufirst%3DR.%2BR.%26atitle%3DLecithin%2520retinol%2520acyltransferase%2520forms%2520functional%2520homodimers%26jtitle%3DBiochemistry%26date%3D2002%26volume%3D41%26spage%3D6311%26epage%3D6319%26doi%3D10.1021%2Fbi015710b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span> <span> </span><span class="NLM_article-title">Models for binding cooperativities of inhibitors with transthyretin</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>466</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2007.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.abb.2007.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=17767913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOlt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=466&publication_year=2007&pages=85-97&author=H.+Wangauthor=Y.+Tangauthor=M.+Lei&title=Models+for+binding+cooperativities+of+inhibitors+with+transthyretin&doi=10.1016%2Fj.abb.2007.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Models for binding cooperativities of inhibitors with transthyretin</span></div><div class="casAuthors">Wang, Houfang; Tang, Yanhui; Lei, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">466</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-97</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Here, mol. dynamics (MD) simulations are performed to study the differences of binding channel shapes of TTR with two inhibitors, flufenamic acid (FLU) and one kind of N-Ph phenoxazine (BPD).  The asymmetries of global structure including the central binding channel are found to be intrinsic.  Moreover, the conformational changes of the binding channel are responsible for neg. cooperativity (NC) or independent cooperativity (IC) of ligands.  The results suggested a possible binding mechanism addressing NC of FLU and IC of BPD.  For FLU, when the first ligand binds with TTR, it leads to expansion of the second binding site which may weaken the interaction of the second FLU with TTR.  But for BPD, the first ligand's binding changes the second site's shape slightly, the second ligand has similar binding ability with TTR in the second site like the first binding event.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2l1Aoyb05NbVg90H21EOLACvtfcHk0liv__A4Ermhkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOlt7zI&md5=78d02824d108fdf4b0cbdfeb837db87e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2007.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2007.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DLei%26aufirst%3DM.%26atitle%3DModels%2520for%2520binding%2520cooperativities%2520of%2520inhibitors%2520with%2520transthyretin%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2007%26volume%3D466%26spage%3D85%26epage%3D97%26doi%3D10.1016%2Fj.abb.2007.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangerter, F. W.</span></span> <span> </span><span class="NLM_article-title">Threshold effects on the concanavalin A-mediated agglutination of modified erythrocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">8318</span>– <span class="NLM_lpage">8323</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(19)86891-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2FS0021-9258%2819%2986891-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=468825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaE1MXlvVOgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=8318-8323&author=R.+R.+Randoauthor=G.+A.+Orrauthor=F.+W.+Bangerter&title=Threshold+effects+on+the+concanavalin+A-mediated+agglutination+of+modified+erythrocytes&doi=10.1016%2FS0021-9258%2819%2986891-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Threshold effects on the concanavalin A-mediated agglutination of modified erythrocytes</span></div><div class="casAuthors">Rando, Robert R.; Orr, George A.; Bangerter, Faan Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8318-23</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Bovine erythrocytes, which were not concanavalin A (ConA)  [11028-71-0]-agglutinable, could be rendered so by attaching α-D-mannose residues to their outer membrane.  The sugars were incorporated by mildly oxidizing the cells with periodate followed by coupling the liberated aldehyde groups with 6-(1'-α-D-thiomannosyl)hexanoyl hydrazide  [71761-09-6].  The rate and extent of ConA-mediated aggregation of the modified cells were not linearly dependent on the amt. of sugar incorporated; the sugar incorporation technique was random, and no functional differences were detected in the receptors introduced at the different periodate concns.  Therefore, the ConA-mediated aggregation of these modified erythrocytes is sensitive to small changes in functionally identical receptor densities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1q7mNendm7Vg90H21EOLACvtfcHk0lhInmmTNiX3Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXlvVOgsr0%253D&md5=8c303cbd53b9cf1a7971909943b3255d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2986891-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252986891-6%26sid%3Dliteratum%253Aachs%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DBangerter%26aufirst%3DF.%2BW.%26atitle%3DThreshold%2520effects%2520on%2520the%2520concanavalin%2520A-mediated%2520agglutination%2520of%2520modified%2520erythrocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D8318%26epage%3D8323%26doi%3D10.1016%2FS0021-9258%2819%2986891-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrassi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaninathan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamedmohaideen, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span> <span> </span><span class="NLM_article-title">Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1587</span>, <span class="refDoi"> DOI: 10.1021/jm049274d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049274d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1576-1587&author=S.+M.+Johnsonauthor=H.+M.+Petrassiauthor=S.+K.+Palaninathanauthor=N.+N.+Mohamedmohaideenauthor=H.+E.+Purkeyauthor=C.+Nicholsauthor=K.+P.+Chiangauthor=T.+Walkupauthor=J.+C.+Sacchettiniauthor=K.+B.+Sharplessauthor=J.+W.+Kelly&title=Bisaryloxime+ethers+as+potent+inhibitors+of+transthyretin+amyloid+fibril+formation&doi=10.1021%2Fjm049274d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bisaryloxime Ethers as Potent Inhibitors of Transthyretin Amyloid Fibril Formation</span></div><div class="casAuthors">Johnson, Steven M.; Petrassi, H. Michael; Palaninathan, Satheesh K.; Mohamedmohaideen, Nilofar N.; Purkey, Hans E.; Nichols, Christopher; Chiang, Kyle P.; Walkup, Traci; Sacchettini, James C.; Sharpless, K. Barry; Kelly, Jeffery W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1576-1587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amyloid fibril formation by the plasma protein transthyretin (TTR), requiring rate-limiting tetramer dissocn. and monomer misfolding, is implicated in several human diseases.  Amyloidogenesis can be inhibited through native state stabilization, mediated by small mol. binding to TTR's primarily unoccupied thyroid hormone binding sites.  New native state stabilizers have been discovered herein by the facile condensation of arylaldehydes R1CHO (R1 = Ph, 3-HO2CC6H4, 2-F3CC6H4, 3,5-Cl2C6H3, etc.) with aryloxyamines R2ONH2 (R2 = Ph, 3-F3CC6H4, 3,5-F2C6H4, etc.) affording a bisarylaldoxime ether R1CH:NOR2 library.  Of the library's 95 compds., 31 were active inhibitors of TTR amyloid formation in vitro.  The bisaryloxime ethers selectively stabilize the native tetrameric state of TTR over the dissociative transition state under amyloidogenic conditions, leading to an increase in the dissocn. activation barrier.  Several bisaryloxime ethers bind selectively to TTR in human blood plasma over the plethora of other plasma proteins, a necessary attribute for efficacy in vivo.  While bisarylaldoxime ethers are susceptible to degrdn. by N-O bond cleavage, this process is slowed by their binding to TTR.  Furthermore, the degrdn. rate of many of the bisarylaldoxime ethers is slow relative to the half-life of plasma TTR.  The bisaryloxime ether library provides valuable structure-activity relationship insight for the development of structurally analogous inhibitors with superior stability profiles, should that prove necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcPw-YPbhoPLVg90H21EOLACvtfcHk0lhInmmTNiX3Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKru7g%253D&md5=019ee482a75f25f841cca7896e99911f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm049274d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049274d%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DS.%2BM.%26aulast%3DPetrassi%26aufirst%3DH.%2BM.%26aulast%3DPalaninathan%26aufirst%3DS.%2BK.%26aulast%3DMohamedmohaideen%26aufirst%3DN.%2BN.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DNichols%26aufirst%3DC.%26aulast%3DChiang%26aufirst%3DK.%2BP.%26aulast%3DWalkup%26aufirst%3DT.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26atitle%3DBisaryloxime%2520ethers%2520as%2520potent%2520inhibitors%2520of%2520transthyretin%2520amyloid%2520fibril%2520formation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1576%26epage%3D1587%26doi%3D10.1021%2Fjm049274d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Tranthyretin ligands capable of inhibitng retinol-dependent RBP4-TTR interaction for treatment of age-related macular degneration, Stargardt disease, and other retinal disease characterized by excessive lipofuscin accumulation</span>. <span class="NLM_patent">US2015/0057320A1</span>, Feb 26, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+Petrukhin&title=Tranthyretin+ligands+capable+of+inhibitng+retinol-dependent+RBP4-TTR+interaction+for+treatment+of+age-related+macular+degneration%2C+Stargardt+disease%2C+and+other+retinal+disease+characterized+by+excessive+lipofuscin+accumulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DTranthyretin%2520ligands%2520capable%2520of%2520inhibitng%2520retinol-dependent%2520RBP4-TTR%2520interaction%2520for%2520treatment%2520of%2520age-related%2520macular%2520degneration%252C%2520Stargardt%2520disease%252C%2520and%2520other%2520retinal%2520disease%2520characterized%2520by%2520excessive%2520lipofuscin%2520accumulation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cotrina, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leite, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsequell, G.</span></span> <span> </span><span class="NLM_article-title">Repurposing benzbromarone for familial amyloid polyneuropathy: a new transthyretin tetramer stabilizer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>, <span class="NLM_elocation-id">7166</span> <span class="refDoi"> DOI: 10.3390/ijms21197166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fijms21197166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWjurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&author=E.+Y.+Cotrinaauthor=A.+Oliveiraauthor=J.+P.+Leiteauthor=J.+Llopauthor=L.+Galesauthor=J.+Quintanaauthor=I.+Cardosoauthor=G.+Arsequell&title=Repurposing+benzbromarone+for+familial+amyloid+polyneuropathy%3A+a+new+transthyretin+tetramer+stabilizer&doi=10.3390%2Fijms21197166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing benzbromarone for familial amyloid polyneuropathy: a new transthyretin tetramer stabilizer</span></div><div class="casAuthors">Cotrina, Ellen Y.; Oliveira, Angela; Leite, Jose Pedro; Llop, Jordi; Gales, Luis; Quintana, Jordi; Cardoso, Isabel; Arsequell, Gemma</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7166</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Transthyretin (TTR) is a homotetrameric protein involved in human amyloidosis, including familial amyloid polyneuropathy (FAP).  Discovering small-mol. stabilizers of the TTR tetramer is a therapeutic strategy for these diseases.  Tafamidis, the only approved drug for FAP treatment, is not effective for all patients.  Herein, we discovered that benzbromarone (BBM), a uricosuric drug, is an effective TTR stabilizer and inhibitor against TTR amyloid fibril formation.  BBM rendered TTR more resistant to urea denaturation, similarly to iododiflunisal (IDIF), a very potent TTR stabilizer.  BBM competes with thyroxine for binding in the TTR central channel, with an IC50 similar to IDIF and tafamidis.  Results obtained by isothermal titrn. calorimetry (ITC) demonstrated that BBM binds TTR with an affinity similar to IDIF, tolcapone and tafamidis, confirming BBM as a potent binder of TTR.  The crystal structure of the BBM-TTR complex shows two mols. binding deeply in the thyroxine binding channel, forming strong intermonomer hydrogen bonds and increasing the stability of the TTR tetramer.  Finally, kinetic anal. of the ability of BBM to inhibit TTR fibrillogenesis at acidic pH and comparison with other stabilizers revealed that benzbromarone is a potent inhibitor of TTR amyloidogenesis, adding a new interesting scaffold for drug design of TTR stabilizers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLQFjgYk8nCrVg90H21EOLACvtfcHk0lj4u2QC37A7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWjurrI&md5=96da0ae4642975c54e62987e5b790d1b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.3390%2Fijms21197166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21197166%26sid%3Dliteratum%253Aachs%26aulast%3DCotrina%26aufirst%3DE.%2BY.%26aulast%3DOliveira%26aufirst%3DA.%26aulast%3DLeite%26aufirst%3DJ.%2BP.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DGales%26aufirst%3DL.%26aulast%3DQuintana%26aufirst%3DJ.%26aulast%3DCardoso%26aufirst%3DI.%26aulast%3DArsequell%26aufirst%3DG.%26atitle%3DRepurposing%2520benzbromarone%2520for%2520familial%2520amyloid%2520polyneuropathy%253A%2520a%2520new%2520transthyretin%2520tetramer%2520stabilizer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26doi%3D10.3390%2Fijms21197166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangerter, F. W.</span></span> <span> </span><span class="NLM_article-title">Threshold effects on the lectin-mediated aggregation of synthetic glycolipid-containing liposomes</span>. <i>J. Supramol. Struct.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1002/jss.400110304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fjss.400110304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=575662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaL3cXkt1WisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1979&pages=295-309&author=R.+R.+Randoauthor=F.+W.+Bangerter&title=Threshold+effects+on+the+lectin-mediated+aggregation+of+synthetic+glycolipid-containing+liposomes&doi=10.1002%2Fjss.400110304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Threshold effects on the lectin-mediated aggregation of synthetic glycolipid-containing liposomes</span></div><div class="casAuthors">Rando, Robert R.; Bangerter, Faan Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Supramolecular Structure</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">JSPMAW</span>;
        ISSN:<span class="NLM_cas:issn">0091-7419</span>.
    </div><div class="casAbstract">Cholesterol analogs contg. sugar residues linked by spacer groups to the cholesterol O were incorporated into egg yolk lecithin small unilamellar liposomes.  The synthetic glycolipid analogs distributed evenly on both sides of the bilayer.  These liposomes were aggregated by the appropriate lectin.  When the sugar residue was a β-galactoside (I) the liposomes were aggregated by ricin and when it was an α-mannoside (II) they were aggregated by concanavalin A.  The lectin-mediated aggregation of these liposomes was reversed by the addn. of the appropriate sugar.  The rates, but not the extents, of aggregation of these liposomes were highly sensitive to the amt. of glycolipid incorporated.  Below ∼5% glycolipid incorporation, the rate of the lectin-mediated aggregation of these liposomes was exceedingly slow, whereas above this level rapid aggregation proceeded.  At all concns. studied the synthetic glycolipids were incorporated in a unimodal fashion, so that the obsd. threshold effects could be based on possible differences in the manner in which the glycolipids were incorporated at different concns.  This conclusion was based on studies with galactose oxidase, which showed that the percentage of galactose oxidn. in a liposome prepd. from a galactosyl-contg. glycolipid is independent of glycolipid concn., and studies on the aggregation of liposomes contg. mixed glycolipids in which the glycolipids behaved independently.  The importance of a crit. d. of membrane-bound receptors for aggregation to occur is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUnbgZw-21LVg90H21EOLACvtfcHk0lj4u2QC37A7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXkt1WisL8%253D&md5=5361dc57bc4c43a9e42c1b4400557337</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fjss.400110304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjss.400110304%26sid%3Dliteratum%253Aachs%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DBangerter%26aufirst%3DF.%2BW.%26atitle%3DThreshold%2520effects%2520on%2520the%2520lectin-mediated%2520aggregation%2520of%2520synthetic%2520glycolipid-containing%2520liposomes%26jtitle%3DJ.%2520Supramol.%2520Struct.%26date%3D1979%26volume%3D11%26spage%3D295%26epage%3D309%26doi%3D10.1002%2Fjss.400110304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangerter, F. W.</span></span> <span> </span><span class="NLM_article-title">Synthetic glycolipids and the lectin-mediated aggregation of liposomes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">4721</span>– <span class="NLM_lpage">4725</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(17)30071-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2FS0021-9258%2817%2930071-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=438211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaE1MXkslaqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=4721-4725&author=G.+A.+Orrauthor=R.+R.+Randoauthor=F.+W.+Bangerter&title=Synthetic+glycolipids+and+the+lectin-mediated+aggregation+of+liposomes&doi=10.1016%2FS0021-9258%2817%2930071-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic glycolipids and the lectin-mediated aggregation of liposomes</span></div><div class="casAuthors">Orr, George A.; Rando, Robert R.; Bangerter, Faan Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4721-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Synthetic mannose-contg. glycolipids (I and II, resp.) utilizing the cholesterol nucleus as a lipid anchor, and either the 6-aminohexyl- or the 6-(6-aminohexanamide)hexyl-1-thio-α-D-mannopyranosides as the carbohydrate ligands, were synthesized and incorporated into small unilamellar liposomes.  Incorporation of these cholesterol-mannoside derivs. at concns. ≤14 mol % apparently did not affect the phys. characteristics of the liposomes.  Addn. of concanavalin A to a suspension of liposomes contg. the long chain cholesterol-mannose deriv. II caused an increase in light-scattering at 360 nm.  Since the increase in absorbance was completely reversed by the addn. of α-methylmannoside, aggregation rather than fusion of the liposomes appeared to occur.  Liposomes contg. 14 mol % of the short chain deriv. I were aggregated by concanavalin A indicating that the lectin can approach to within 10 Å of the lipid bilayer.  The aggregation of vesicles contg. either the long or short chain derivs. was highly dependent on the d. of the sugar in the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGFT9UThuM1bVg90H21EOLACvtfcHk0lj4u2QC37A7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXkslaqtbg%253D&md5=436a072ee66ae60e288a2a776f144b8c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2930071-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252930071-6%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DBangerter%26aufirst%3DF.%2BW.%26atitle%3DSynthetic%2520glycolipids%2520and%2520the%2520lectin-mediated%2520aggregation%2520of%2520liposomes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D4721%26epage%3D4725%26doi%3D10.1016%2FS0021-9258%2817%2930071-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gliubich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berni, R.</span></span> <span> </span><span class="NLM_article-title">Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">5841</span>– <span class="NLM_lpage">5854</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2008.06705.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1111%2Fj.1742-4658.2008.06705.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=19021760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2murrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2008&pages=5841-5854&author=G.+Zanottiauthor=C.+Folliauthor=L.+Cendronauthor=B.+Alfieriauthor=S.+K.+Nishidaauthor=F.+Gliubichauthor=N.+Pasquatoauthor=A.+Negroauthor=R.+Berni&title=Structural+and+mutational+analyses+of+protein-protein+interactions+between+transthyretin+and+retinol-binding+protein&doi=10.1111%2Fj.1742-4658.2008.06705.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein</span></div><div class="casAuthors">Zanotti, Giuseppe; Folli, Claudia; Cendron, Laura; Alfieri, Beatrice; Nishida, Sonia K.; Gliubich, Francesca; Pasquato, Nicola; Negro, Alessandro; Berni, Rodolfo</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5841-5854</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Transthyretin (TTR) is a tetrameric binding protein involved in the transport of thyroid hormones and in the cotransport of retinol by forming a complex in plasma with retinol-binding protein (RBP).  Here, the authors report the crystal structure of a macromol. complex, in which human TTR, human holo-RBP, and a murine anti-RBP Fab are assembled according to a 1:2:2 stoichiometry.  The main interactions, both polar and apolar, between RBP and TTR involved the retinol OH group and a limited no. of solvent exposed residues.  The relevance of TTR residues in complex formation with RBP was by mutational anal., and the structural consequences of some TTR point mutations affecting protein-protein recognition were investigated.  Despite a few exceptions, in general, the substitution of a hydrophilic for a hydrophobic side-chain in contact regions resulted in a decrease or even a loss of binding affinity, thus revealing the importance of interfacial hydrophobic interactions and a high degree of complementarity between RBP and TTR.  The effect was particularly evident when the mutation affected an interacting residue present in 2 distinct subunits of TTR participating simultaneously in 2 interactions with a RBP mol.  This was the case of the amyloidogenic Ser-184 replacement, which abolished the interaction with RBP and was assocd. with altered RBP plasma transport in carriers of this mutation.  Remarkably, some of the residues in mutated human TTR that weakened or abolished the interaction with RBP were present in piscine TTR, consistent with the lack of interaction between RBP and TTR in fish.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQSqcEPxrBcbVg90H21EOLACvtfcHk0lhIh9TMSfeZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2murrM&md5=7b69a87966f10ea134c76f2bcbd5a468</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2008.06705.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2008.06705.x%26sid%3Dliteratum%253Aachs%26aulast%3DZanotti%26aufirst%3DG.%26aulast%3DFolli%26aufirst%3DC.%26aulast%3DCendron%26aufirst%3DL.%26aulast%3DAlfieri%26aufirst%3DB.%26aulast%3DNishida%26aufirst%3DS.%2BK.%26aulast%3DGliubich%26aufirst%3DF.%26aulast%3DPasquato%26aufirst%3DN.%26aulast%3DNegro%26aufirst%3DA.%26aulast%3DBerni%26aufirst%3DR.%26atitle%3DStructural%2520and%2520mutational%2520analyses%2520of%2520protein-protein%2520interactions%2520between%2520transthyretin%2520and%2520retinol-binding%2520protein%26jtitle%3DFEBS%2520J.%26date%3D2008%26volume%3D275%26spage%3D5841%26epage%3D5854%26doi%3D10.1111%2Fj.1742-4658.2008.06705.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span> <span> </span><span class="NLM_article-title">Synthetic concanavalin A receptors and erythrocyte agglutination</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1038/272722a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2F272722a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=76989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaE1cXltVGksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1978&pages=722-725&author=G.+A.+Orrauthor=R.+R.+Rando&title=Synthetic+concanavalin+A+receptors+and+erythrocyte+agglutination&doi=10.1038%2F272722a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic concanavalin A receptors and erythrocyte agglutination</span></div><div class="casAuthors">Orr, George A.; Rando, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">5655</span>),
    <span class="NLM_cas:pages">722</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Introduction of α-D-mannose residues on to the cell surface of bovine erythrocytes rendered them agglutinable by concanavalin A (I) at ≥7.5 μg/mL.  The no. of I binding sites was related to the no. of mannosyl residues incorporated; binding of 6000 addnl. I mols. changing the erythrocytes from being nonagglutinable to agglutinable.  Anal. of the I-binding proteins showed 3 proteins (mol. wts. 15,000-30,000), which showed no periodic acid-Schiff (PAS) reactivity, for normal cells, and 4 PAS-staining proteins (mol. wts. 3.9 × 104, 5 × 104, 1.25 × 105, and 1.8 × 105) for modified cells.  Cell surface α-D-mannose residues seem, therefore, to be the primary specificity determinant for I.  The lectin-induced agglutination of cells may, therefore, provide a model for studying the role of sugars in cell-cell recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAn8dqJhHPY7Vg90H21EOLACvtfcHk0lhIh9TMSfeZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXltVGksb0%253D&md5=bc53c7d093d098075192f132bae6117b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2F272722a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F272722a0%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DRando%26aufirst%3DR.%2BR.%26atitle%3DSynthetic%2520concanavalin%2520A%2520receptors%2520and%2520erythrocyte%2520agglutination%26jtitle%3DNature%26date%3D1978%26volume%3D272%26spage%3D722%26epage%3D725%26doi%3D10.1038%2F272722a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campos-Sandoval, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsella, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyre, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, J. B.</span></span> <span> </span><span class="NLM_article-title">Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4378</span>– <span class="NLM_lpage">4387</span>, <span class="refDoi"> DOI: 10.1021/jm200256g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200256g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1ans7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4378-4387&author=J.+A.+Campos-Sandovalauthor=C.+Redondoauthor=G.+K.+Kinsellaauthor=A.+Palauthor=G.+Jonesauthor=G.+S.+Eyreauthor=S.+C.+Hirstauthor=J.+B.+Findlay&title=Fenretinide+derivatives+act+as+disrupters+of+interactions+of+serum+retinol+binding+protein+%28sRBP%29+with+transthyretin+and+the+sRBP+receptor&doi=10.1021%2Fjm200256g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Fenretinide Derivatives Act as Disrupters of Interactions of Serum Retinol Binding Protein (sRBP) with Transthyretin and the sRBP Receptor</span></div><div class="casAuthors">Campos-Sandoval, Jose Angel; Redondo, Clara; Kinsella, Gemma K.; Pal, Akos; Jones, Geraint; Eyre, Gwen S.; Hirst, Simon C.; Findlay, John B. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4378-4387</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol.  Elevated levels of sRBP may be involved in inhibiting cellular responses to insulin and in generating first insulin resistance and then type 2 diabetes, offering a new target for therapeutic attack for these conditions.  A series of retinoid analogs were synthesized and examd. for their binding to sRBP and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions.  A no. inhibit the sRBP-TTR and sRBP-sRBP receptor interactions as well as or better than Fenretinide (FEN), presenting a potential novel dual mechanism of action and perhaps offering a new therapeutic intervention against type 2 diabetes and its development.  Shortening the chain length of the FEN deriv. substantially abolished binding to sRBP, indicating that the strength of the interaction lies in the polyene chain region.  Differences in potency against the sRBP-TTR and sRBP-sRBP receptor interactions suggest variant effects of the compds. on the two loops of sRBP guarding the entrance of the binding pocket that are responsible for these two protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8mkzc7sp58LVg90H21EOLACvtfcHk0lhNqB_Vpg3lEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1ans7s%253D&md5=cd947368ca8d7bc7e5b1231174748fcc</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm200256g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200256g%26sid%3Dliteratum%253Aachs%26aulast%3DCampos-Sandoval%26aufirst%3DJ.%2BA.%26aulast%3DRedondo%26aufirst%3DC.%26aulast%3DKinsella%26aufirst%3DG.%2BK.%26aulast%3DPal%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DEyre%26aufirst%3DG.%2BS.%26aulast%3DHirst%26aufirst%3DS.%2BC.%26aulast%3DFindlay%26aufirst%3DJ.%2BB.%26atitle%3DFenretinide%2520derivatives%2520act%2520as%2520disrupters%2520of%2520interactions%2520of%2520serum%2520retinol%2520binding%2520protein%2520%2528sRBP%2529%2520with%2520transthyretin%2520and%2520the%2520sRBP%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4378%26epage%3D4387%26doi%3D10.1021%2Fjm200256g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellawell, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumpkin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jernelius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gretler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span> <span> </span><span class="NLM_article-title">First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers</span>. <i>Clin. Pharmacol. Drug Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1002/cpdd.700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fcpdd.700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31172685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFart7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=115-129&author=J.+C.+Foxauthor=J.+L.+Hellawellauthor=S.+Raoauthor=T.+O%E2%80%99Reillyauthor=R.+Lumpkinauthor=J.+Jerneliusauthor=D.+Gretlerauthor=U.+Sinha&title=First-in-human+study+of+AG10%2C+a+novel%2C+oral%2C+specific%2C+selective%2C+and+potent+transthyretin+stabilizer+for+the+treatment+of+transthyretin+amyloidosis%3A+a+phase+1+safety%2C+tolerability%2C+pharmacokinetic%2C+and+pharmacodynamic+study+in+healthy+adult+volunteers&doi=10.1002%2Fcpdd.700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers</span></div><div class="casAuthors">Fox, Jonathan C.; Hellawell, Jennifer L.; Rao, Satish; O'Reilly, Terry; Lumpkin, Rick; Jernelius, Jesper; Gretler, Daniel; Sinha, Uma</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-129</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AG10 is a novel, potent, and selective oral transthyretin (TTR) stabilizer being developed to treat TTR amyloidosis (ATTR).  This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics (ex vivo stabilization) of orally administered AG10 in healthy adult volunteers.  Both mutant and wild-type ATTR are underdiagnosed diseases with limited therapeutic options.  As TTR amyloidogenesis is initiated by dissocn. of TTR tetramers destabilized due to inherited mutations or aging, AG10 is designed to treat the disease at its source.  Four single and three multiple ascending dose levels of AG10 or matching placebo were orally administered.  Pharmacokinetic observations included time to max. concn. <1 h, dose-dependent max. concn. and area under the plasma concn.-time curve, low intersubject variability, and half-life 25 h.  Complete (>90%) stabilization of TTR was obsd. across the entire dosing interval at steady state on the highest dose tested.  Serum TTR levels, an in vivo reflection of TTR stabilization by AG10, increased from baseline following 12 days of dosing.  AG10 appears to be safe and well tolerated in healthy adult volunteers and can completely stabilize TTR across the dosing interval, establishing clin. proof of concept.  Based on these data, AG10 has the potential to be a safe and effective treatment for patients with either mutant or wild-type ATTR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6GTVUHB1QL7Vg90H21EOLACvtfcHk0lhNqB_Vpg3lEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFart7w%253D&md5=8f85dd8126c4a595859cd21fbbcec13a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.700%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DJ.%2BC.%26aulast%3DHellawell%26aufirst%3DJ.%2BL.%26aulast%3DRao%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DLumpkin%26aufirst%3DR.%26aulast%3DJernelius%26aufirst%3DJ.%26aulast%3DGretler%26aufirst%3DD.%26aulast%3DSinha%26aufirst%3DU.%26atitle%3DFirst-in-human%2520study%2520of%2520AG10%252C%2520a%2520novel%252C%2520oral%252C%2520specific%252C%2520selective%252C%2520and%2520potent%2520transthyretin%2520stabilizer%2520for%2520the%2520treatment%2520of%2520transthyretin%2520amyloidosis%253A%2520a%2520phase%25201%2520safety%252C%2520tolerability%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamic%2520study%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Drug%2520Dev.%26date%3D2020%26volume%3D9%26spage%3D115%26epage%3D129%26doi%3D10.1002%2Fcpdd.700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Acyl glucuronides: the good, the bad and the ugly</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1002/bdd.720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fbdd.720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=20830700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2nur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=367-395&author=S.+L.+Reganauthor=J.+L.+Maggsauthor=T.+G.+Hammondauthor=C.+Lambertauthor=D.+P.+Williamsauthor=B.+K.+Park&title=Acyl+glucuronides%3A+the+good%2C+the+bad+and+the+ugly&doi=10.1002%2Fbdd.720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Acyl glucuronides: the good, the bad and the ugly</span></div><div class="casAuthors">Regan, Sophie L.; Maggs, James L.; Hammond, Thomas G.; Lambert, Craig; Williams, Dominic P.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">367-395</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Acyl glucuronidation is the major metabolic conjugation reaction of most carboxylic acid drugs in mammals.  The physiol. consequences of this biotransformation have been investigated incompletely but include effects on drug metab., protein binding, distribution and clearance that impact upon pharmacol. and toxicol. outcomes.  In marked contrast, the exceptional but widely disparate chem. reactivity of acyl glucuronides has attracted far greater attention.  Specifically, the complex transacylation and glycation reactions with proteins have provoked much inconclusive debate over the safety of drugs metabolised to acyl glucuronides.  It has been hypothesised that these covalent modifications could initiate idiosyncratic adverse drug reactions.  However, despite a large body of in vitro data on the reactions of acyl glucuronides with protein, evidence for adduct formation from acyl glucuronides in vivo is limited and potentially ambiguous.  The causal connection of protein adduction to adverse drug reactions remains uncertain.  This review has assessed the intrinsic reactivity, metabolic stability and pharmacokinetic properties of acyl glucuronides in the context of physiol., pharmacol. and toxicol. perspectives.  Although numerous expts. have characterised the reactions of acyl glucuronides with proteins, these might be attenuated substantially in vivo by rapid clearance of the conjugates.  Consequently, to delineate a relationship between acyl glucuronide formation and toxicol. phenomena, detailed pharmacokinetic anal. of systemic exposure to the acyl glucuronide should be undertaken adjacent to detg. protein adduct concns. in vivo.  Further investigation is required to ascertain whether acyl glucuronide clearance is sufficient to prevent covalent modification of endogenous proteins and consequentially a potential immunol. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ1hIcbM_oZ7Vg90H21EOLACvtfcHk0ljk0CIyYkXIhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2nur3L&md5=8c45d4dbb68c12bd128af1dba7a08c16</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fbdd.720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.720%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DAcyl%2520glucuronides%253A%2520the%2520good%252C%2520the%2520bad%2520and%2520the%2520ugly%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2010%26volume%3D31%26spage%3D367%26epage%3D395%26doi%3D10.1002%2Fbdd.720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bäurle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ter Laak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preusse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heldmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bothe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollner, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, G.</span></span> <span> </span><span class="NLM_article-title">Identification of a benzimidazolecarboxylic acid derivative (BAY 1316957) as a potent and selective human prostaglandin e2 receptor subtype 4 (hEP4-R) antagonist for the treatment of endometriosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2541</span>– <span class="NLM_lpage">2563</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01862</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3cjnvVWgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2541-2563&author=S.+B%C3%A4urleauthor=J.+Nagelauthor=O.+Petersauthor=N.+Brauerauthor=A.+Ter+Laakauthor=C.+Preusseauthor=A.+Rottmannauthor=D.+Heldmannauthor=U.+Botheauthor=T.+Blumeauthor=L.+Zornauthor=D.+Walterauthor=T.+M.+Zollnerauthor=A.+Steinmeyerauthor=G.+Langer&title=Identification+of+a+benzimidazolecarboxylic+acid+derivative+%28BAY+1316957%29+as+a+potent+and+selective+human+prostaglandin+e2+receptor+subtype+4+%28hEP4-R%29+antagonist+for+the+treatment+of+endometriosis&doi=10.1021%2Facs.jmedchem.8b01862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis</span></div><div class="casAuthors">Baurle Stefan; Nagel Jens; Peters Olaf; Brauer Nico; Ter Laak Antonius; Preusse Cornelia; Rottmann Antje; Heldmann Dieter; Bothe Ulrich; Blume Thorsten; Zorn Ludwig; Zollner Thomas M; Steinmeyer Andreas; Langer Gernot; Walter Daryl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2541-2563</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The presence and growth of endometrial tissue outside the uterine cavity in endometriosis patients are primarily driven by hormone-dependent and inflammatory processes-the latter being frequently associated with severe, acute, and chronic pelvic pain.  The EP4 subtype of prostaglandin E2 (PGE2) receptors (EP4-R) is a particularly promising anti-inflammatory and antinociceptive target as both this receptor subtype and the pathways forming PGE2 are highly expressed in endometriotic lesions.  High-throughput screening resulted in the identification of benzimidazole derivatives as novel hEP4-R antagonists.  Careful structure-activity relationship investigation guided by rational design identified a methyl substitution adjacent to the carboxylic acid as an appropriate means to accomplish favorable pharmacokinetic properties by reduction of glucuronidation.  Further optimization led to the identification of benzimidazolecarboxylic acid BAY 1316957, a highly potent, specific, and selective hEP4-R antagonist with excellent drug metabolism and pharmacokinetics properties.  Notably, treatment with BAY 1316957 can be expected to lead to prominent and rapid pain relief and significant improvement of the patient's quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAcrUIni_3jw8IxFYvehhofW6udTcc2eYy1U5E-P-Otrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjnvVWgsA%253D%253D&md5=faba2c63669b26b8c2e35aae465056a9</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01862%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A4urle%26aufirst%3DS.%26aulast%3DNagel%26aufirst%3DJ.%26aulast%3DPeters%26aufirst%3DO.%26aulast%3DBrauer%26aufirst%3DN.%26aulast%3DTer%2BLaak%26aufirst%3DA.%26aulast%3DPreusse%26aufirst%3DC.%26aulast%3DRottmann%26aufirst%3DA.%26aulast%3DHeldmann%26aufirst%3DD.%26aulast%3DBothe%26aufirst%3DU.%26aulast%3DBlume%26aufirst%3DT.%26aulast%3DZorn%26aufirst%3DL.%26aulast%3DWalter%26aufirst%3DD.%26aulast%3DZollner%26aufirst%3DT.%2BM.%26aulast%3DSteinmeyer%26aufirst%3DA.%26aulast%3DLanger%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520a%2520benzimidazolecarboxylic%2520acid%2520derivative%2520%2528BAY%25201316957%2529%2520as%2520a%2520potent%2520and%2520selective%2520human%2520prostaglandin%2520e2%2520receptor%2520subtype%25204%2520%2528hEP4-R%2529%2520antagonist%2520for%2520the%2520treatment%2520of%2520endometriosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2541%26epage%3D2563%26doi%3D10.1021%2Facs.jmedchem.8b01862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">PPARgamma signaling and metabolism: the good, the bad and the future</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nm.3159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2Fnm.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23652116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntF2kurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=557-566&author=M.+Ahmadianauthor=J.+M.+Suhauthor=N.+Hahauthor=C.+Liddleauthor=A.+R.+Atkinsauthor=M.+Downesauthor=R.+M.+Evans&title=PPARgamma+signaling+and+metabolism%3A+the+good%2C+the+bad+and+the+future&doi=10.1038%2Fnm.3159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">PPARγ signaling and metabolism: the good, the bad and the future</span></div><div class="casAuthors">Ahmadian, Maryam; Suh, Jae Myoung; Hah, Nasun; Liddle, Christopher; Atkins, Annette R.; Downes, Michael; Evans, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">557-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral medications for type 2 diabetes.  However, their unique benefits are shadowed by the risk for fluid retention, wt. gain, bone loss, and congestive heart failure.  This raises the question as to whether it is possible to build a safer generation of PPARγ-specific drugs that evoke fewer side effects while preserving insulin-sensitizing potential.  Recent studies that have supported the continuing physiol. and therapeutic relevance of the PPARγ pathway also provide opportunities to develop newer classes of mols. that reduce or eliminate adverse effects.  This review highlights key advances in understanding PPARγ signaling in energy homeostasis and metabolic disease and also provides new explanations for adverse events linked to TZD-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYUvLTwYqBIbVg90H21EOLACvtfcHk0lhUjqRwYNcl9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntF2kurs%253D&md5=78ee5d0f4ce5dc5192cd010bb7519ce4</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnm.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3159%26sid%3Dliteratum%253Aachs%26aulast%3DAhmadian%26aufirst%3DM.%26aulast%3DSuh%26aufirst%3DJ.%2BM.%26aulast%3DHah%26aufirst%3DN.%26aulast%3DLiddle%26aufirst%3DC.%26aulast%3DAtkins%26aufirst%3DA.%2BR.%26aulast%3DDownes%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DPPARgamma%2520signaling%2520and%2520metabolism%253A%2520the%2520good%252C%2520the%2520bad%2520and%2520the%2520future%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D557%26epage%3D566%26doi%3D10.1038%2Fnm.3159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niemietz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischhauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandfort, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zibert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte-like cells reveal novel role of SERPINA1 in transthyretin amyloidosis</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>, <span class="NLM_elocation-id">jcs219824</span> <span class="refDoi"> DOI: 10.1242/jcs.219824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1242%2Fjcs.219824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30333144" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&author=C.+Niemietzauthor=L.+Fleischhauerauthor=V.+Sandfortauthor=S.+Guttmannauthor=A.+Zibertauthor=H.+H.+Schmidt&title=Hepatocyte-like+cells+reveal+novel+role+of+SERPINA1+in+transthyretin+amyloidosis&doi=10.1242%2Fjcs.219824"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1242%2Fjcs.219824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.219824%26sid%3Dliteratum%253Aachs%26aulast%3DNiemietz%26aufirst%3DC.%26aulast%3DFleischhauer%26aufirst%3DL.%26aulast%3DSandfort%26aufirst%3DV.%26aulast%3DGuttmann%26aufirst%3DS.%26aulast%3DZibert%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26atitle%3DHepatocyte-like%2520cells%2520reveal%2520novel%2520role%2520of%2520SERPINA1%2520in%2520transthyretin%2520amyloidosis%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2018%26volume%3D131%26doi%3D10.1242%2Fjcs.219824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klabunde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrassi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span> <span> </span><span class="NLM_article-title">Rational design of potent human transthyretin amyloid disease inhibitors</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1038/74082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2F74082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10742177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVSnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=312-321&author=T.+Klabundeauthor=H.+M.+Petrassiauthor=V.+B.+Ozaauthor=P.+Ramanauthor=J.+W.+Kellyauthor=J.+C.+Sacchettini&title=Rational+design+of+potent+human+transthyretin+amyloid+disease+inhibitors&doi=10.1038%2F74082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of potent human transthyretin amyloid disease inhibitors</span></div><div class="casAuthors">Klabunde, Thomas; Petrassi, H. Michael; Oza, Vibha B.; Raman, Prakash; Kelly, Jeffery W.; Sacchettini, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-321</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">The human amyloid disorders, familial amyloid polyneuropathy, familial amyloid cardiomyopathy and senile systemic amyloidosis, are caused by insol. transthyretin (TTR) fibrils, which deposit in the peripheral nerves and heart tissue.  Several nonsteroidal anti-inflammatory drugs and structurally similar compds. have been found to strongly inhibit the formation of TTR amyloid fibrils in vitro.  These include flufenamic acid, diclofenac, flurbiprofen, and resveratrol.  Crystal structures of the protein-drug complexes have been detd. to allow detailed analyses of the protein-drug interactions that stabilize the native tetrameric conformation of TTR and inhibit the formation of amyloidogenic TTR.  Using a structure-based drug design approach ortho-trifluormethylphenyl anthranilic acid and N-(meta-trifluoromethylphenyl)phenoxazine 4,6-dicarboxylic acid have been discovered to be very potent and specific TTR fibril formation inhibitors.  This research provides a rational for a chemotherapeutic approach for the treatment of TTR-assocd. amyloid diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN6c7K6-iktbVg90H21EOLACvtfcHk0lhUjqRwYNcl9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVSnsbo%253D&md5=035be72ca2cf3b266f8933be3fa60bfc</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2F74082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F74082%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DPetrassi%26aufirst%3DH.%2BM.%26aulast%3DOza%26aufirst%3DV.%2BB.%26aulast%3DRaman%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26atitle%3DRational%2520design%2520of%2520potent%2520human%2520transthyretin%2520amyloid%2520disease%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2000%26volume%3D7%26spage%3D312%26epage%3D321%26doi%3D10.1038%2F74082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekijima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarstrom, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawkar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span> <span> </span><span class="NLM_article-title">The biological and chemical basis for tissue-selective amyloid disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2005.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.cell.2005.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=15820680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVaks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2005&pages=73-85&author=Y.+Sekijimaauthor=R.+L.+Wisemanauthor=J.+Mattesonauthor=P.+Hammarstromauthor=S.+R.+Millerauthor=A.+R.+Sawkarauthor=W.+E.+Balchauthor=J.+W.+Kelly&title=The+biological+and+chemical+basis+for+tissue-selective+amyloid+disease&doi=10.1016%2Fj.cell.2005.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The biological and chemical basis for tissue-selective amyloid disease</span></div><div class="casAuthors">Sekijima, Yoshiki; Wiseman, R. Luke; Matteson, Jeanne; Hammarstroem, Per; Miller, Sean R.; Sawkar, Anu R.; Balch, William E.; Kelly, Jeffery W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-85</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Factors controlling the onset and progression of extracellular amyloid diseases remain largely unknown.  Central to disease etiol. is the efficiency of the endoplasmic reticulum (ER) machinery that targets destabilized mutant proteins for degrdn. and the enhanced tendency of these variants to aggregate if secreted.  The authors demonstrate that mammalian cells secrete numerous transthyretin (TTR) disease-assocd. variants with wild-type efficiency in spite of compromised folding energetics.  Only the most highly destabilized TTR variants are subjected to ER-assocd. degrdn. (ERAD) and then only in certain tissues, providing insight into tissue selective amyloidosis.  Rather than a "quality control" std. based on wild-type stability, the authors find that ER-assisted folding (ERAF), based on global protein energetics, dets. the extent of export.  The authors propose that ERAF (influenced by the energetics of the protein fold, chaperone enzyme distributions, and metabolite chaperones) in competition with ERAD defines the unique secretory aptitude of each tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqZgFnMMerqbVg90H21EOLACvtfcHk0ljE48URHVzJ4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVaks7c%253D&md5=1ac8641177cb140b95b898ff108fc543</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DSekijima%26aufirst%3DY.%26aulast%3DWiseman%26aufirst%3DR.%2BL.%26aulast%3DMatteson%26aufirst%3DJ.%26aulast%3DHammarstrom%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DS.%2BR.%26aulast%3DSawkar%26aufirst%3DA.%2BR.%26aulast%3DBalch%26aufirst%3DW.%2BE.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520biological%2520and%2520chemical%2520basis%2520for%2520tissue-selective%2520amyloid%2520disease%26jtitle%3DCell%26date%3D2005%26volume%3D121%26spage%3D73%26epage%3D85%26doi%3D10.1016%2Fj.cell.2005.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radu, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nusinowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata, N. L.</span></span> <span> </span><span class="NLM_article-title">Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4393</span>– <span class="NLM_lpage">4401</span>, <span class="refDoi"> DOI: 10.1167/iovs.05-0820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1167%2Fiovs.05-0820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=16303925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnit1GgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=4393-4401&author=R.+A.+Raduauthor=Y.+Hanauthor=T.+V.+Buiauthor=S.+Nusinowitzauthor=D.+Bokauthor=J.+Lichterauthor=K.+Widderauthor=G.+H.+Travisauthor=N.+L.+Mata&title=Reductions+in+serum+vitamin+A+arrest+accumulation+of+toxic+retinal+fluorophores%3A+a+potential+therapy+for+treatment+of+lipofuscin-based+retinal+diseases&doi=10.1167%2Fiovs.05-0820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases</span></div><div class="casAuthors">Radu Roxana A; Han Yun; Bui Tam V; Nusinowitz Steven; Bok Dean; Lichter Jay; Widder Ken; Travis Gabriel H; Mata Nathan L</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4393-401</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  Excessive accumulation of lipofuscin is observed in numerous degenerative retinal diseases.  A toxic vitamin A-based fluorophore (A2E) present within lipofuscin has been implicated in the death of RPE and photoreceptor cells.  Here, we used an animal model that manifests accelerated lipofuscin accumulation (ABCA4-/- mutant) to evaluate the efficacy of a therapeutic approach based on reduction of serum retinol.  METHODS:  N-(4-hydroxyphenyl)retinamide (HPR) potently and reversibly reduces serum retinol.  The interaction of HPR with retinol binding protein (RBP) and transthyretin was studied by spectrofluorometry and size-exclusion chromatography.  To assess the effects of HPR on visual cycle retinoids and A2E biosynthesis, HPR was chronically administered to ABCA4-/- mice.  Mice were evaluated using biochemical, electrophysiological, and morphologic techniques.  RESULTS:  Administration of HPR to ABCA4-/- mice caused immediate, dose-dependent reductions in serum retinol and RBP.  Chronic administration produced commensurate reductions in visual cycle retinoids and arrested accumulation of A2E and lipofuscin autofluorescence in the RPE.  Physiologically, HPR treatment caused modest delays in dark adaptation.  Chromophore regeneration kinetics, light sensitivity of photoreceptors, and phototransduction processes were normal.  Histologic examinations showed no alteration of retinal cytostructure or morphology.  CONCLUSIONS:  These findings demonstrate the vitamin A-dependent nature of A2E biosynthesis and validate a novel therapeutic approach with potential to halt the accumulation of lipofuscin fluorophores in the eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcST_ie98itsIvcsfMJQC1ZdfW6udTcc2eZSNBuRKLZuc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnit1GgtQ%253D%253D&md5=dc425883e9829eab910c9cf96a9d5fe6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1167%2Fiovs.05-0820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.05-0820%26sid%3Dliteratum%253Aachs%26aulast%3DRadu%26aufirst%3DR.%2BA.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DBui%26aufirst%3DT.%2BV.%26aulast%3DNusinowitz%26aufirst%3DS.%26aulast%3DBok%26aufirst%3DD.%26aulast%3DLichter%26aufirst%3DJ.%26aulast%3DWidder%26aufirst%3DK.%26aulast%3DTravis%26aufirst%3DG.%2BH.%26aulast%3DMata%26aufirst%3DN.%2BL.%26atitle%3DReductions%2520in%2520serum%2520vitamin%2520A%2520arrest%2520accumulation%2520of%2520toxic%2520retinal%2520fluorophores%253A%2520a%2520potential%2520therapy%2520for%2520treatment%2520of%2520lipofuscin-based%2520retinal%2520diseases%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2005%26volume%3D46%26spage%3D4393%26epage%3D4401%26doi%3D10.1167%2Fiovs.05-0820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dobri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moiseyev, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allikmets, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparrow, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">A1120, a Nonretinoid RBP4 Antagonist, Inhibits Formation of Cytotoxic Bisretinoids in the Animal Model of Enhanced Retinal Lipofuscinogenesis</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1167/iovs.12-10050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1167%2Fiovs.12-10050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23211825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjt1eqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=85-95&author=N.+Dobriauthor=Q.+Qinauthor=J.+Kongauthor=K.+Yamamotoauthor=Z.+Liuauthor=G.+Moiseyevauthor=J.-X.+Maauthor=R.+Allikmetsauthor=J.+R.+Sparrowauthor=K.+Petrukhin&title=A1120%2C+a+Nonretinoid+RBP4+Antagonist%2C+Inhibits+Formation+of+Cytotoxic+Bisretinoids+in+the+Animal+Model+of+Enhanced+Retinal+Lipofuscinogenesis&doi=10.1167%2Fiovs.12-10050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis</span></div><div class="casAuthors">Dobri, Nicoleta; Qin, Qiong; Kong, Jian; Yamamoto, Kazunori; Liu, Zhao; Moiseyev, Gennadiy; Ma, Jian-xing; Allikmets, Rando; Sparrow, Janet R.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-95</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">PURPOSE. Excessive accumulation of lipofuscin is assocd. with pathogenesis of atrophic age-related macular degeneration (AMD) and Stargardt disease.  Pharmacol. inhibition of the retinol-induced interaction of retinol-binding protein 4 (RBP4) with transthyretin (TTR) in the serum may decrease the uptake of serum retinol to the retina and reduce formation of lipofuscin bisretinoids.  We evaluated in vitro and in vivo properties of the new nonretinoid RBP4 antagonist, A1120.  METHODS. RBP4 binding potency, ability to antagonize RBP4-TTR interaction, and compd. specificity were analyzed for A1120 and for the prototypic RBP4 antagonist fenretinide.  A1120 ability to inhibit RPE65-mediated isomerohydrolase activity was assessed in the RPE microsomes.  The in vivo effect of A1120 administration on serum RBP4, visual cycle retinoids, lipofuscin bisretinoids, and retinal visual function was evaluated using a combination of biochem. and electrophysiol. techniques.  RESULTS. In comparison to fenretinide, A1120 did not act as a RARα agonist, while exhibiting superior in vitro potency in RBP4 binding and RBP4-TTR interaction assays.  A1120 did not inhibit isomerohydrolase activity in the RPE microsomes.  A1120 dosing in mice induced 75% redn. in serum RBP4, which correlated with redn. in visual cycle retinoids and ocular levels of lipofuscin fluorophores.  A1120 dosing did not induce changes in kinetics of dark adaptation.  CONCLUSIONS. A1120 significantly reduces accumulation of lipofuscin bisretinoids in the Abca4-/- animal model.  This activity correlates with redn. in serum RBP4 and visual cycle retinoids confirming the mechanism of action for A1120.  In contrast to fenretinide, A1120 does not act as a RARα agonist indicating a more favorable safety profile for this nonretinoid compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCuxjzXex7aLVg90H21EOLACvtfcHk0lj65h6iu0n_JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjt1eqs70%253D&md5=3a605e4dc084a06e325ccdd14ec48886</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1167%2Fiovs.12-10050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.12-10050%26sid%3Dliteratum%253Aachs%26aulast%3DDobri%26aufirst%3DN.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMoiseyev%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DJ.-X.%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DSparrow%26aufirst%3DJ.%2BR.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DA1120%252C%2520a%2520Nonretinoid%2520RBP4%2520Antagonist%252C%2520Inhibits%2520Formation%2520of%2520Cytotoxic%2520Bisretinoids%2520in%2520the%2520Animal%2520Model%2520of%2520Enhanced%2520Retinal%2520Lipofuscinogenesis%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2013%26volume%3D54%26spage%3D85%26epage%3D95%26doi%3D10.1167%2Fiovs.12-10050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haselhorst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamerz, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itzstein, M. V.</span></span> <span> </span><span class="NLM_article-title">Saturation transfer difference NMR spectroscopy as a technique to investigate protein-carbohydrate interactions in solution</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1007/978-1-59745-022-5_26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2F978-1-59745-022-5_26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=19277538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFeku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2009&pages=375-386&author=T.+Haselhorstauthor=A.-C.+Lamerzauthor=M.+V.+Itzstein&title=Saturation+transfer+difference+NMR+spectroscopy+as+a+technique+to+investigate+protein-carbohydrate+interactions+in+solution&doi=10.1007%2F978-1-59745-022-5_26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Saturation transfer difference NMR spectroscopy as a technique to investigate protein-carbohydrate interactions in solution</span></div><div class="casAuthors">Haselhorst, Thomas; Lamerz, Anne-Christin; von Itzstein, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">Glycomics</span>),
    <span class="NLM_cas:pages">375-386</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Satn. transfer difference (STD) NMR spectroscopy is a powerful method for studying protein-ligand interactions in soln.  The STD NMR method is capable of identifying the binding epitope of a ligand when bound to its receptor protein.  Ligand protons that are in close contact with the receptor protein receive a higher degree of satn., and as a result stronger STD NMR signals can be obsd.  Protons that are either less or not involved in the binding process reveal no STD NMR signals.  Therefore, the STD NMR method is an excellent tool to investigate how a binding ligand interacts with its receptor mol.  The STD NMR expt. is easy to implement and only small amts. of native protein are required.  This chapter comprises a detailed exptl. protocol to acquire STD NMR spectra and det. the binding epitope of a ligand bound to its target protein.  As representative examples the ligands uridyl-triphosphate (UTP) and uridyl-glucose-diphosphate (UDP-glucose) when bound to the Leishmania major UDP-glucose-pyrophosphorylase (UGP) as target protein are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe28Wu8TS8hLVg90H21EOLACvtfcHk0lj65h6iu0n_JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFeku7w%253D&md5=b14d0ffc34b0ef00fe98d78c99e6032d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2F978-1-59745-022-5_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-59745-022-5_26%26sid%3Dliteratum%253Aachs%26aulast%3DHaselhorst%26aufirst%3DT.%26aulast%3DLamerz%26aufirst%3DA.-C.%26aulast%3DItzstein%26aufirst%3DM.%2BV.%26atitle%3DSaturation%2520transfer%2520difference%2520NMR%2520spectroscopy%2520as%2520a%2520technique%2520to%2520investigate%2520protein-carbohydrate%2520interactions%2520in%2520solution%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2009%26volume%3D534%26spage%3D375%26epage%3D386%26doi%3D10.1007%2F978-1-59745-022-5_26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. All-<i>trans</i>-retinol (vitamin A) (<b>1</b>) and bispecific RBP4 antagonist–TTR tetramer kinetic stabilizer (±)-<b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Thyroid hormone thyroxine (T4) (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative examples of various reported TTR tetramer stabilizer structural classes that bind at the T4 binding site. This sample set of TTR tetramer stabilizers include tafamidis (<b>4</b>),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> AG10 (<b>5</b>),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> diflunisal (<b>6</b>),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> iododiflunisal (<b>7</b>),<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> tolcapone (<b>8</b>),<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> benzbromarone (<b>9</b>), diclofenac (<b>10</b>),<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a><i>N</i>-phenyl phenoxazine (<b>11</b>),<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> dibenzofuran (<b>12</b>),<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and bis-aryloxime ether (<b>13</b>).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The following compounds highlighted in the figure above are registered drugs for various indications: tafamidis (vyndaqel and vyndamax, <b>4</b>) for treating ATTR-PN, diflunisal (dolobid, <b>6</b>), an NSAID also used for ATTR, tolcapone (tasmar, <b>8</b>), a COMT inhibitor for treating Parkinson’s disease, benzbromarone (<b>9</b>), a uricosuric agent and noncompetitive inhibitor of xanthine oxidase previously shown by us to act as a potent TTR ligand,<a onclick="showRef(event, 'ref7 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref7 ref54 ref55">(7,54,55)</a> and diclofenac (voltaren, <b>10</b>), an NSAID to treat pain, inflammatory disorders, and dysmenorrhea.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Quaternary structures of TTR with T4-bound, holo-RBP4, and the holo-RBP4–TTR ternary complexes. (A) Ribbon diagram of the quaternary homotetrameric structure of TTR with T4 (3) bound within its respective binding site (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ROX">2ROX</a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The two dimer subunits are each composed of two individual monomers (labeled A (blue-green), B (orange), C (light blue), and D (pink)). The dimers are associated back-to-back and present two <i>C</i><sub>2</sub> symmetrical T4 binding sites running through the center of the protein. The binding of T4 is shown in a ball and stick format (black). (B) Ribbon diagram of holo-RBP4 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RBP">1RBP</a>). Holo-RBP4 is shown as yellow and all-<i>trans</i>-retinol is depicted in a ball and stick format (black). (C) The holo-RBP4–TTR complex (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB">1QAB</a>) colored by chain and viewed from the front. The TTR tetramer is located at the center of the complex with two holo-RBP4 molecules (one holo-RBP4 molecule is shown as yellow and the other as light green) docked at a twofold axis of symmetry that is perpendicular to the T4 binding sites. All-<i>trans</i>-retinol is depicted in a ball and stick format (black), which is encapsulated by the complex and its binding site is blocked. The T4 binding site is not occluded.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. PPI interaction surfaces between holo-RBP4 and TTR. (A) Close-up view of the holo-RBP4–TTR PPI (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB">1QAB</a>) colored by chain. Holo-RBP4 is shown as yellow and all-<i>trans</i>-retinol is depicted in a ball and stick format (black) and buried in the hydrophobic cavity of the RBP4 β-barrel. The alcohol moiety points toward the EF loop of TTR (subunit B) and engages in a H-bond interaction with Gly83. The TTR monomer subunits are labeled as A (blue-green), B (orange), C (light blue), and D (pink). The image shows how the loops β3−β4 and β5−β6 of holo-RBP4 provide a surface that fits into a crevice formed by the arrangement of three TTR subunits (A–C). (B) Molecular surface representation of holo-RBP4–TTR PPI that more clearly shows holo-RBP4 making contact with three TTR subunits (A–C) (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB">1QAB</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0007.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray crystallographic structure showing AG10 (<b>5</b>) bound to V122I-TTR (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a>). (A) Ribbon diagram of the quaternary homotetrameric structure of TTR with AG10 bound in the T4 binding sites with both symmetry-related binding conformations shown. The TTR dimers are shown as dimer subunits A and B, and each monomer subunit of the tetramer (labeled 1–4) is shown with its secondary structural elements and colored differently. The monomer components of dimer A are shown in cyan (monomer 1) and orange (monomer 2). The monomer components of dimer B are shown in pink (monomer 3) and yellow (monomer 4). The dimers are associated back-to-back creating a large channel through the center of the tetramer that presents two <i>C</i><sub>2</sub> symmetrical T4 binding sites. AG10 is shown in stick format (gray). (B) TTR tetramer kinetic stabilizer AG10 is shown in a ball and stick format (dark gray), with contacting residues labeled and illustrated in stick format (white). The binding pose of AG10 (<b>5</b>) positions the benzoic acid motif bent out of the plane with the rest of the molecule in a nearly orthogonal orientation. (C) Ligand interaction diagram of AG10 (shown as blue) derived from PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a>, which features the HBPs with their associated localized amino acids. The diagram further illustrates key binding interactions observed in the X-ray crystallographic data, including pivotal H-bonds and salt-bridge interactions. The pyrazole head group of AG10 projects deep within the inner binding cavity of the T4 binding pocket where it engages in two H-bond interactions with Ser117 and Ser117′. The pyrazole 3,5-dimethyl groups of AG10 occupy HBP3 and HBP3′. The aliphatic chain of AG10 comes in contact with the residues lining HBP2/HBP2′. The fluorine atom of AG10 projects into a hydrophobic region of HBP1 in the outer T4 binding cavity. The carboxylic acid of AG10 is sandwiched between Lys15 and Lys15′. The H-bond interactions are depicted as blue dashed lines, with the atomic distances labeled in angstrom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0008.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Putative binding mode of piperazine compound <b>14</b> within the T4 binding site. (A) Proposed TTR tetramer kinetic stabilizer <b>14</b>, which contains a piperazine core. (B) Overlay of docked poses of piperazine <b>14</b> (magenta) and AG10 (orange) within the TTR T4 binding cavity using PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a> (obtained from the Protein Data Bank); contacting residues are labeled and illustrated in stick format; H-bond interactions are depicted as blue dashed lines. (C) Molecular surface with the overlay of docked poses of piperazine <b>14</b> (magenta) and AG10 (orange) within the TTR T4 binding cavity using PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ">4HIQ</a>. The protein surface is colored by hydrophobicity (green) and hydrophilicity (purple) using contact preferences; contacting residues are labeled and illustrated in stick format; H-bond interactions are depicted as blue dashed lines. (D) Legend for the ligand interaction diagrams in the binding pose using MOE. (MOE) 2020.09 (Chemical Computing Group, Inc., Montreal, Quebec, Canada, <a href="http://www.chemcomp.com" class="extLink">http://www.chemcomp.com</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0009.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Medicinal chemistry work plan for the identification of novel and conformationally constrained TTR tetramer kinetic stabilizers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0013.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) substituted methyl bromobenzoate, 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos), Tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub>), cesium carbonate (Cs<sub>2</sub>CO<sub>3</sub>), 1,4-dioxane, stirred at reflux for 16 h under an atmosphere of N<sub>2</sub> or heated in a sealed vessel at 110 °C, 16 h; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temperature (rt), 3 h; (c) 3-chloropentane-2,4-dione, <i>N</i>,<i>N</i>-diisopropylethylamine (<i>i</i>-Pr<sub>2</sub>NEt), tetrahydrofuran (THF), 0 °C to rt, 16 h; (d) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (64–65% in H<sub>2</sub>O), THF, rt, 1 h; (e) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 3 h; (ii) 2 N aqueous HCl; (f) 2 N HCl in Et<sub>2</sub>O, 0 °C to rt, 3 h.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0014.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 3-fluoro-4-nitrobenzoate, potassium carbonate (K<sub>2</sub>CO<sub>3</sub>), CH<sub>3</sub>CN, 60 °C, 16 h; (b) H<sub>2</sub> (1 atm pressure), 10%Pd/C, CH<sub>3</sub>OH, rt, 24 h; (c) (i) 0.25 N aqueous H<sub>2</sub>SO<sub>4</sub>, sodium nitrite (NaNO<sub>2</sub>), H<sub>2</sub>O, 0 °C, 30 min; (ii) KI, urea, rt, 1 h; (d) 3-chloropentane-2,4-dione, <i>i</i>-Pr<sub>2</sub>NEt, THF, 0 °C to rt, 16 h; (e) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (64–65% in H<sub>2</sub>O), THF, rt, 1 h; (f) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 3 h; (ii) 2 N aqueous HCl.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0015.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>tert</i>-butyl (3a<i>R</i>,6a<i>S</i>)-hexahydropyrrolo[3,4-<i>c</i>]pyrrole-2(1<i>H</i>)-carboxylate (<b>27</b>), (±)-<i>tert</i>-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate ((±)-<b>33</b>), or <i>tert</i>-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (<b>39</b>), methyl 3-bromo-4-fluorobenzoate, X-Phos, Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, sealed vessel at 110 °C, 16 h; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 3 h; (c) 3-chloropentane-2,4-dione, <i>i</i>-Pr<sub>2</sub>NEt, THF, 0 °C to rt, 16 h; (d) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (64–65% in H<sub>2</sub>O), THF, rt, 1 h; (e) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 3 h; (ii) 2 N aqueous HCl.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0016.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>2</sub>OH·HCl, CH<sub>3</sub>OH, rt, 16 h; (b) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 1 h; (ii) 2 N aqueous HCl.</p></p></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0017.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) CNBr, <i>i</i>-Pr<sub>2</sub>NEt, THF, 0 °C to rt, 1 h, (ii) ammonium chloride (NH<sub>4</sub>Cl), NaN<sub>3</sub>, DMF, 120 °C, 12 h; (b) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 1 h; (ii) 2 N aqueous HCl; (c) 1-bromo-2-(trifluoromethyl)benzene, X-Phos, Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, sealed vessel, 110 °C, 16 h; (d) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 1 h; (ii) 2 N aqueous HCl.</p></p></figure><figure data-id="sch6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0018.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3-methyl-1<i>H</i>-pyrazole-4-carbaldehyde, NaBH(OAc)<sub>3</sub>, acetic acid (HOAc), 1,2-dichloroethane, 60 °C, 12 h; (b) (i) anhydrous LiOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, 3 h; (ii) 2 N aqueous HCl.</p></p></figure><figure data-id="sch7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0019.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NH<sub>4</sub>Cl, HBTU, <i>i</i>-Pr<sub>2</sub>NEt, DMF, rt, 18 h; (b) NaN<sub>3</sub>, tetrachlorosilane, CH<sub>3</sub>CN, 80 °C, 18 h.</p></p></figure><figure data-id="fig9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0010.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Analogue <b>14</b> reduces the formation of high-molecular-weight TTR forms in the acid-induced aggregation assay. TTR protein (5 μg) was aggregated using acetate buffer (pH = 4.0) and incubated for 72 h at 37 °C. TTR tetramer concentration during the incubation was 9 μM. After incubation in the presence of DMSO, 50 μM tafamidis, and 50 μM <b>14</b> and cross-linking with glutaraldehyde, samples were subjected to SDS-PAGE followed by Western blot analysis of TTR. The representative blot of at least three independent experiments is presented (A). Bar graphs represent the pixel volume means ± SD of the scanned bands on the immunoblots in arbitrary units for TTR high-molecular-weight aggregates (B), dimers (C), and monomers (D). Statistical significance was determined by one-way analysis of variance (ANOVA) with the Holm–Šidák <i>post hoc</i> test; *, <i>p</i> ≤ 0.05; **, <i>p</i> ≤ 0.01; ***, <i>p</i> ≤ 0.001; ****, <i>p</i> ≤ 0.0001 compared to TTR aggregation + DMSO group (pH 4.0); <sup>#</sup>, <i>p</i> ≤ 0.05; <sup>##</sup>, <i>p</i> ≤ 0.01; <sup>###</sup>, <i>p</i> ≤ 0.001; <sup>####</sup>, <i>p</i> ≤ 0.0001 compared to TTR without aggregation group (pH = 7.5).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0011.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Pharmacokinetic and pharmacodynamic properties of 14 in mice. (A) Serum RBP4 levels following a single 25 mg/kg oral administration of <b>14</b>. (B) Blood compound levels following administration of a single oral 5 mg/kg dose of <b>14</b>. Data are presented as means ± SD. Three mice per treatment group were used in the PK–PD study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/medium/jm1c00099_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0012.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effect of TTR ligands on circulating levels of serum RBP4 in Balb/c mice. Serum RBP4 levels were measured following a single oral administration of (A) AG10, (B) tafamidis, (C) <b>14a</b>, (D) <b>20e</b>, and (E) <b>20c</b>. Percent changes of serum RBP4 in comparison to the baseline levels (100%) are shown in (F) for test compounds as well as for the dosing vehicle (0.9% NaCl, 2% Tween 80). The oral dose was 25 mg/kg for AG10, <b>14a</b>, <b>20e</b>, and <b>20c</b>; the tafamidis dose was 50 mg/kg. Data represented as the mean ± SD. Three to eight mice per compound treatment group were used in the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00099/20210629/images/large/jm1c00099_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00099&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i119">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 70 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprasadarao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeSousa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, J. B.</span></span> <span> </span><span class="NLM_article-title">The transfer of retinol from serum retinol-binding protein to cellular retinol-binding protein is mediated by a membrane receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">3336</span>– <span class="NLM_lpage">3342</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.6.3336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1074%2Fjbc.273.6.3336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=9452451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVylsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=3336-3342&author=M.+Sundaramauthor=A.+Sivaprasadaraoauthor=M.+M.+DeSousaauthor=J.+B.+Findlay&title=The+transfer+of+retinol+from+serum+retinol-binding+protein+to+cellular+retinol-binding+protein+is+mediated+by+a+membrane+receptor&doi=10.1074%2Fjbc.273.6.3336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The transfer of retinol from serum retinol-binding protein to cellular retinol-binding protein is mediated by a membrane receptor</span></div><div class="casAuthors">Sundaram, Manickavasagam; Sivaprasadarao, Adipu; DeSousa, Monica M.; Findlay, John B. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3336-3342</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The hypothesis that the cellular uptake of retinol involves the specific interaction of a plasma membrane receptor with serum retinol-binding protein (RBP) at the extracellular surface followed by ligand transfer to cytoplasmic cellular retinol-binding protein (CRBP) has been investigated.  The exptl. system consisted of the [3H]retinol-RBP complex, Escherichia coli-expressed recombinant apo-CRBP contg. the 10 amino acid long streptavidin-binding peptide sequence at its C terminus (designated as CRBP-Strep) and permeabilized human placental membranes.  [3H]Retinol transfer from RBP to CRBP-Strep was monitored by measuring the radioactivity assocd. with CRBP-Strep retained by an immobilized streptavidin resin.  Using this assay system, we have demonstrated that optimal retinol uptake is achieved with holo-RBP, the membrane receptor and apo-CRBP.  The effects are specific: other binding proteins, including β-lactoglobulin and serum albumin, despite their ability to bind retinol, failed to substitute for either RBP or apo-CRBP.  The process is facilitated by membranes contg. the native receptor suggesting that this protein is an important component in the transfer mechanism.  Taken together, the data suggest that the RBP receptor, through specific interactions with the binding proteins, participates (either directly or via assocd. proteins) in the mechanism which mediates the transfer of retinol from extracellular RBP to intracellular CRBP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNh_R1TkPFLbVg90H21EOLACvtfcHk0lgxc1kiz6k1qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVylsro%253D&md5=4d9faf55fbd5b90e27d2e7a4c946252a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.6.3336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.6.3336%26sid%3Dliteratum%253Aachs%26aulast%3DSundaram%26aufirst%3DM.%26aulast%3DSivaprasadarao%26aufirst%3DA.%26aulast%3DDeSousa%26aufirst%3DM.%2BM.%26aulast%3DFindlay%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520transfer%2520of%2520retinol%2520from%2520serum%2520retinol-binding%2520protein%2520to%2520cellular%2520retinol-binding%2520protein%2520is%2520mediated%2520by%2520a%2520membrane%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D3336%26epage%3D3342%26doi%3D10.1074%2Fjbc.273.6.3336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ter-Stepanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Vitamin A Transport Mechanism of the Multitransmembrane Cell-Surface Receptor STRA6</span>. <i>Membranes</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.3390/membranes5030425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fmembranes5030425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=26343735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGksrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=425-453&author=R.+Kawaguchiauthor=M.+Zhongauthor=M.+Kassaiauthor=M.+Ter-Stepanianauthor=H.+Sun&title=Vitamin+A+Transport+Mechanism+of+the+Multitransmembrane+Cell-Surface+Receptor+STRA6&doi=10.3390%2Fmembranes5030425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Vitamin A transport mechanism of the multitransmembrane cell-surface receptor STRA6</span></div><div class="casAuthors">Kawaguchi, Riki; Zhong, Ming; Kassai, Miki; Ter-Stepanian, Mariam; Sun, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Membranes (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">425-453</span>CODEN:
                <span class="NLM_cas:coden">MBSEB6</span>;
        ISSN:<span class="NLM_cas:issn">2077-0375</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Vitamin A has biol. functions as diverse as sensing light for vision, regulating stem cell differentiation, maintaining epithelial integrity, promoting immune competency, regulating learning and memory, and acting as a key developmental morphogen.  Vitamin A derivs. have also been used in treating human diseases.  If vitamin A is considered a drug that everyone needs to take to survive, evolution has come up with a natural drug delivery system that combines sustained release with precise and controlled delivery to the cells or tissues that depend on it.  This "drug delivery system" is mediated by plasma retinol binding protein (RBP), the principle and specific vitamin A carrier protein in the blood, and STRA6, the cell-surface receptor for RBP that mediates cellular vitamin A uptake.  The mechanism by which the RBP receptor absorbs vitamin A from the blood is distinct from other known cellular uptake mechanisms.  This review summarizes recent progress in elucidating the fundamental mol. mechanism mediated by the RBP receptor and multiple newly discovered catalytic activities of this receptor, and compares this transport system with retinoid transport independent of RBP/STRA6.  How to target this new type of transmembrane receptor using small mols. in treating diseases is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLm6WqwKJAWbVg90H21EOLACvtfcHk0lgxc1kiz6k1qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGksrbP&md5=331d8bcb759d5565992f3ba9df925fd3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3390%2Fmembranes5030425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmembranes5030425%26sid%3Dliteratum%253Aachs%26aulast%3DKawaguchi%26aufirst%3DR.%26aulast%3DZhong%26aufirst%3DM.%26aulast%3DKassai%26aufirst%3DM.%26aulast%3DTer-Stepanian%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DVitamin%2520A%2520Transport%2520Mechanism%2520of%2520the%2520Multitransmembrane%2520Cell-Surface%2520Receptor%2520STRA6%26jtitle%3DMembranes%26date%3D2015%26volume%3D5%26spage%3D425%26epage%3D453%26doi%3D10.3390%2Fmembranes5030425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coward, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2885</span>– <span class="NLM_lpage">2891</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.04.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.bmcl.2014.04.089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=24835984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotFGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2885-2891&author=Y.+Wangauthor=R.+Connorsauthor=P.+Fanauthor=X.+Wangauthor=Z.+Wangauthor=J.+Liuauthor=F.+Kayserauthor=J.+C.+Medinaauthor=S.+Johnstoneauthor=H.+Xuauthor=S.+Thibaultauthor=N.+Walkerauthor=M.+Connauthor=Y.+Zhangauthor=Q.+Liuauthor=M.+P.+Grilloauthor=A.+Motaniauthor=P.+Cowardauthor=Z.+Wang&title=Structure-assisted+discovery+of+the+first+non-retinoid+ligands+for+Retinol-Binding+Protein+4&doi=10.1016%2Fj.bmcl.2014.04.089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4</span></div><div class="casAuthors">Wang, Yingcai; Connors, Richard; Fan, Pingchen; Wang, Xiaodong; Wang, Zhongyu; Liu, Jiwen; Kayser, Frank; Medina, Julio C.; Johnstone, Sheree; Xu, Haoda; Thibault, Stephen; Walker, Nigel; Conn, Marion; Zhang, Ying; Liu, Qingxiang; Grillo, Mark P.; Motani, Alykhan; Coward, Peter; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2885-2891</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Retinol-Binding Protein 4 (RBP4) is a plasma protein that transports retinol (vitamin A) from the liver to peripheral tissues.  This Letter highlights our efforts in discovering the first, to our knowledge, non-retinoid small mols. that bind to RBP4 at the retinol site and reduce serum RBP4 levels in mice, by disrupting the interaction between RBP4 and transthyretin (TTR), a plasma protein that binds RBP4 and protects it from renal excretion.  Potent compds. were discovered and optimized quickly from high-throughput screen (HTS) hits utilizing a structure-based approach.  Inhibitor co-crystal X-ray structures revealed unique disruptions of RBP4-TTR interactions by our compds. through induced loop conformational changes instead of steric hindrance exemplified by fenretinide.  When administered to mice, A1120, a representative compd. in the series, showed concn.-dependent retinol and RBP4 lowering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq0W6CwH_asbVg90H21EOLACvtfcHk0lgct0IfdrGPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotFGgu74%253D&md5=21bf540e2cc853aa9395f4cfafbec1f0</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.04.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.04.089%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DConnors%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKayser%26aufirst%3DF.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DConn%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGrillo%26aufirst%3DM.%2BP.%26aulast%3DMotani%26aufirst%3DA.%26aulast%3DCoward%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructure-assisted%2520discovery%2520of%2520the%2520first%2520non-retinoid%2520ligands%2520for%2520Retinol-Binding%2520Protein%25204%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2885%26epage%3D2891%26doi%3D10.1016%2Fj.bmcl.2014.04.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cywin, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7731</span>– <span class="NLM_lpage">7757</span>, <span class="refDoi"> DOI: 10.1021/jm5010013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5010013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGht7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7731-7757&author=C.+L.+Cioffiauthor=N.+Dobriauthor=E.+E.+Freemanauthor=M.+P.+Conlonauthor=P.+Chenauthor=D.+G.+Staffordauthor=D.+M.+Schwarzauthor=K.+C.+Goldenauthor=L.+Zhuauthor=D.+B.+Kitchenauthor=K.+D.+Barnesauthor=B.+Raczauthor=Q.+Qinauthor=E.+Michelottiauthor=C.+L.+Cywinauthor=W.+H.+Martinauthor=P.+G.+Pearsonauthor=G.+Johnsonauthor=K.+Petrukhin&title=Design%2C+synthesis%2C+and+evaluation+of+nonretinoid+retinol+binding+protein+4+antagonists+for+the+potential+treatment+of+atrophic+age-related+macular+degeneration+and+Stargardt+disease&doi=10.1021%2Fjm5010013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Nonretinoid Retinol Binding Protein 4 Antagonists for the Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease</span></div><div class="casAuthors">Cioffi, Christopher L.; Dobri, Nicoleta; Freeman, Emily E.; Conlon, Michael P.; Chen, Ping; Stafford, Douglas G.; Schwarz, Daniel M. C.; Golden, Kathy C.; Zhu, Lei; Kitchen, Douglas B.; Barnes, Keith D.; Racz, Boglarka; Qin, Qiong; Michelotti, Enrique; Cywin, Charles L.; Martin, William H.; Pearson, Paul G.; Johnson, Graham; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7731-7757</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Accumulation of lipofuscin in the retina is assocd. with pathogenesis of atrophic age-related macular degeneration and Stargardt disease.  Lipofuscin bisretinoids (exemplified by N-retinylidene-N-retinylethanolamine) seem to mediate lipofuscin toxicity.  Synthesis of lipofuscin bisretinoids depends on the influx of retinol from serum to the retina.  Compds. antagonizing the retinol-dependent interaction of retinol-binding protein 4 (RBP4) with transthyretin in the serum would reduce serum RBP4 and retinol and inhibit bisretinoid formation.  The authors recently showed that I, a potent carboxylic acid based RBP4 antagonist, can significantly reduce lipofuscin bisretinoid formation in the retinas of Abca4-/- mice.  As part of the NIH Blueprint Neurotherapeutics Network project the authors undertook the in vitro exploration to identify novel conformationally flexible and constrained RBP4 antagonists with improved potency and metabolic stability.  The authors also demonstrate that upon acute and chronic dosing in rats, II, a potent cyclopentyl fused pyrrolidine antagonist, reduced circulating plasma RBP4 protein levels by approx. 60%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUF22isGQmYbVg90H21EOLACvtfcHk0lgct0IfdrGPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGht7bF&md5=b1b0f386ddb1766db11e2495e8e1c0b6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm5010013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5010013%26sid%3Dliteratum%253Aachs%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DDobri%26aufirst%3DN.%26aulast%3DFreeman%26aufirst%3DE.%2BE.%26aulast%3DConlon%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DStafford%26aufirst%3DD.%2BG.%26aulast%3DSchwarz%26aufirst%3DD.%2BM.%26aulast%3DGolden%26aufirst%3DK.%2BC.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DBarnes%26aufirst%3DK.%2BD.%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DMichelotti%26aufirst%3DE.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520nonretinoid%2520retinol%2520binding%2520protein%25204%2520antagonists%2520for%2520the%2520potential%2520treatment%2520of%2520atrophic%2520age-related%2520macular%2520degeneration%2520and%2520Stargardt%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7731%26epage%3D7757%26doi%3D10.1021%2Fjm5010013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cywin, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Bicyclic [3.3.0]-octahydrocyclopenta[c]pyrrolo antagonists of retinol binding protein 4: potential treatment of atrophic age-related macular degeneration and Stargardt disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5863</span>– <span class="NLM_lpage">5888</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00423</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyqs7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5863-5888&author=C.+L.+Cioffiauthor=B.+Raczauthor=E.+E.+Freemanauthor=M.+P.+Conlonauthor=P.+Chenauthor=D.+G.+Staffordauthor=D.+M.+Schwarzauthor=L.+Zhuauthor=D.+B.+Kitchenauthor=K.+D.+Barnesauthor=N.+Dobriauthor=E.+Michelottiauthor=C.+L.+Cywinauthor=W.+H.+Martinauthor=P.+G.+Pearsonauthor=G.+Johnsonauthor=K.+Petrukhin&title=Bicyclic+%5B3.3.0%5D-octahydrocyclopenta%5Bc%5Dpyrrolo+antagonists+of+retinol+binding+protein+4%3A+potential+treatment+of+atrophic+age-related+macular+degeneration+and+Stargardt+disease&doi=10.1021%2Facs.jmedchem.5b00423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease</span></div><div class="casAuthors">Cioffi, Christopher L.; Racz, Boglarka; Freeman, Emily E.; Conlon, Michael P.; Chen, Ping; Stafford, Douglas G.; Schwarz, Daniel M. C.; Zhu, Lei; Kitchen, Douglas B.; Barnes, Keith D.; Dobri, Nicoleta; Michelotti, Enrique; Cywin, Charles L.; Martin, William H.; Pearson, Paul G.; Johnson, Graham; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5863-5888</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonists of retinol-binding protein 4 (RBP4) impede ocular uptake of serum all-trans retinol (1) and have been shown to reduce cytotoxic bisretinoid formation in the retinal pigment epithelium (RPE), which is assocd. with the pathogenesis of both dry age-related macular degeneration (AMD) and Stargardt disease.  Thus, these agents show promise as a potential pharmacotherapy by which to stem further neurodegeneration and concomitant vision loss assocd. with geog. atrophy of the macula.  We previously disclosed the discovery of a novel series of nonretinoid RBP4 antagonists, represented by bicyclic [3.3.0]-octahydrocyclopenta[c]pyrrolo analog 4.  We describe herein the utilization of a pyrimidine-4-carboxylic acid fragment as a suitable isostere for the anthranilic acid appendage of 4, which led to the discovery of standout antagonist 33.  Analog 33 possesses exquisite in vitro RBP4 binding affinity and favorable drug-like characteristics and was found to reduce circulating plasma RBP4 levels in vivo in a robust manner (>90%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXHKHv5GfUDrVg90H21EOLACvtfcHk0lgct0IfdrGPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyqs7fL&md5=6360017d9a35d984c99b22be38df8acb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00423%26sid%3Dliteratum%253Aachs%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DFreeman%26aufirst%3DE.%2BE.%26aulast%3DConlon%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DStafford%26aufirst%3DD.%2BG.%26aulast%3DSchwarz%26aufirst%3DD.%2BM.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DBarnes%26aufirst%3DK.%2BD.%26aulast%3DDobri%26aufirst%3DN.%26aulast%3DMichelotti%26aufirst%3DE.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DBicyclic%2520%255B3.3.0%255D-octahydrocyclopenta%255Bc%255Dpyrrolo%2520antagonists%2520of%2520retinol%2520binding%2520protein%25204%253A%2520potential%2520treatment%2520of%2520atrophic%2520age-related%2520macular%2520degeneration%2520and%2520Stargardt%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5863%26epage%3D5888%26doi%3D10.1021%2Facs.jmedchem.5b00423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitchen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaner, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and preclinical efficacy of novel nonretinoid antagonists of retinol-binding protein 4 in the mouse model of hepatic steatosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5470</span>– <span class="NLM_lpage">5500</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00352</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00352" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlKru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5470-5500&author=C.+L.+Cioffiauthor=B.+Raczauthor=A.+Varadiauthor=E.+E.+Freemanauthor=M.+P.+Conlonauthor=P.+Chenauthor=L.+Zhuauthor=D.+B.+Kitchenauthor=K.+D.+Barnesauthor=W.+H.+Martinauthor=P.+G.+Pearsonauthor=G.+Johnsonauthor=W.+S.+Blanerauthor=K.+Petrukhin&title=Design%2C+synthesis%2C+and+preclinical+efficacy+of+novel+nonretinoid+antagonists+of+retinol-binding+protein+4+in+the+mouse+model+of+hepatic+steatosis&doi=10.1021%2Facs.jmedchem.9b00352"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis</span></div><div class="casAuthors">Cioffi, Christopher L.; Racz, Boglarka; Varadi, Andras; Freeman, Emily E.; Conlon, Michael P.; Chen, Ping; Zhu, Lei; Kitchen, Douglas B.; Barnes, Keith D.; Martin, William H.; Pearson, Paul G.; Johnson, Graham; Blaner, William S.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5470-5500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Retinol-binding protein 4 (RBP4) serves as a transporter for all-trans-retinol (1) in the blood, and it has been proposed to act as an adipokine.  Elevated plasma levels of the protein have been linked to diabetes, obesity, cardiovascular diseases, and nonalcoholic fatty liver disease (NAFLD).  Recently, adipocyte-specific overexpression of RBP4 was reported to cause hepatic steatosis in mice.  We previously identified an orally bioavailable RBP4 antagonist that significantly lowered RBP4 serum levels in Abca4-/- knockout mice with concomitant normalization of complement system protein expression and redn. of bisretinoid formation within the retinal pigment epithelium.  We describe herein the discovery of novel RBP4 antagonists 48 and 59, which reduce serum RBP4 levels by >80% in mice upon acute oral dosing.  Furthermore, 59 demonstrated efficacy in the transgenic adi-hRBP4 murine model of hepatic steatosis, suggesting that RBP4 antagonists may also have therapeutic utility for the treatment of NAFLD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqump9JRd0bHrVg90H21EOLACvtfcHk0lidW7map7l20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlKru7Y%253D&md5=26e23f630afb5dacf84b942fcda8a834</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00352%26sid%3Dliteratum%253Aachs%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DFreeman%26aufirst%3DE.%2BE.%26aulast%3DConlon%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DKitchen%26aufirst%3DD.%2BB.%26aulast%3DBarnes%26aufirst%3DK.%2BD.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DBlaner%26aufirst%3DW.%2BS.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520preclinical%2520efficacy%2520of%2520novel%2520nonretinoid%2520antagonists%2520of%2520retinol-binding%2520protein%25204%2520in%2520the%2520mouse%2520model%2520of%2520hepatic%2520steatosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5470%26epage%3D5500%26doi%3D10.1021%2Facs.jmedchem.9b00352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthuraman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of bispecific antagonists of retinol binding protein 4 that stabilize transthyretin tetramers: scaffolding hopping, optimization, and preclinical pharmacological evaluation as a potential therapy for two common age-related comorbidities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11054</span>– <span class="NLM_lpage">11084</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00996</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00996" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11054-11084&author=C.+L.+Cioffiauthor=P.+Muthuramanauthor=A.+Rajaauthor=A.+Varadiauthor=B.+Raczauthor=K.+Petrukhin&title=Discovery+of+bispecific+antagonists+of+retinol+binding+protein+4+that+stabilize+transthyretin+tetramers%3A+scaffolding+hopping%2C+optimization%2C+and+preclinical+pharmacological+evaluation+as+a+potential+therapy+for+two+common+age-related+comorbidities&doi=10.1021%2Facs.jmedchem.0c00996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities</span></div><div class="casAuthors">Cioffi, Christopher L.; Muthuraman, Parthasarathy; Raja, Arun; Varadi, Andras; Racz, Boglarka; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11054-11084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Accumulation of cytotoxic lipofuscin bisretinoids may contribute to atrophic age-related macular degeneration (AMD) pathogenesis.  Retinal bisretinoid synthesis depends on the influx of serum all-trans-retinol delivered via a tertiary retinol binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex.  We previously identified selective RBP4 antagonists that dissoc. circulating RBP4-TTR-retinol complexes, reduce serum RBP4 levels, and inhibit bisretinoid synthesis in models of enhanced retinal lipofuscinogenesis.  However, the release of TTR by selective RBP4 antagonists may be assocd. with TTR tetramer destabilization and, potentially, TTR amyloid formation.  We describe herein the identification of bispecific RBP4 antagonist-TTR tetramer kinetic stabilizers.  Standout analog I possesses suitable potency for both targets, significantly lowers mouse plasma RBP4 levels, and prevents TTR aggregation in a gel-based assay.  This new class of bispecific compds. may be esp. important as a therapy for dry AMD patients who have another common age-related comorbidity, senile systemic amyloidosis, a nongenetic disease assocd. with wild-type TTR misfolding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobBY7AXQ-snrVg90H21EOLACvtfcHk0lidW7map7l20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslCltr7P&md5=2aa161b0000d797b71c4e08f2a6f57f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00996%26sid%3Dliteratum%253Aachs%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DMuthuraman%26aufirst%3DP.%26aulast%3DRaja%26aufirst%3DA.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520bispecific%2520antagonists%2520of%2520retinol%2520binding%2520protein%25204%2520that%2520stabilize%2520transthyretin%2520tetramers%253A%2520scaffolding%2520hopping%252C%2520optimization%252C%2520and%2520preclinical%2520pharmacological%2520evaluation%2520as%2520a%2520potential%2520therapy%2520for%2520two%2520common%2520age-related%2520comorbidities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11054%26epage%3D11084%26doi%3D10.1021%2Facs.jmedchem.0c00996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radu, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nusinowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata, N. L.</span></span> <span> </span><span class="NLM_article-title">Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4393</span>– <span class="NLM_lpage">43401</span>, <span class="refDoi"> DOI: 10.1167/iovs.05-0820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1167%2Fiovs.05-0820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=16303925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnit1GgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=4393-43401&author=R.+A.+Raduauthor=Y.+Hanauthor=T.+V.+Buiauthor=S.+Nusinowitzauthor=D.+Bokauthor=J.+Lichterauthor=K.+Widderauthor=G.+H.+Travisauthor=N.+L.+Mata&title=Reductions+in+serum+vitamin+A+arrest+accumulation+of+toxic+retinal+fluorophores%3A+a+potential+therapy+for+treatment+of+lipofuscin-based+retinal+diseases&doi=10.1167%2Fiovs.05-0820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases</span></div><div class="casAuthors">Radu Roxana A; Han Yun; Bui Tam V; Nusinowitz Steven; Bok Dean; Lichter Jay; Widder Ken; Travis Gabriel H; Mata Nathan L</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4393-401</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  Excessive accumulation of lipofuscin is observed in numerous degenerative retinal diseases.  A toxic vitamin A-based fluorophore (A2E) present within lipofuscin has been implicated in the death of RPE and photoreceptor cells.  Here, we used an animal model that manifests accelerated lipofuscin accumulation (ABCA4-/- mutant) to evaluate the efficacy of a therapeutic approach based on reduction of serum retinol.  METHODS:  N-(4-hydroxyphenyl)retinamide (HPR) potently and reversibly reduces serum retinol.  The interaction of HPR with retinol binding protein (RBP) and transthyretin was studied by spectrofluorometry and size-exclusion chromatography.  To assess the effects of HPR on visual cycle retinoids and A2E biosynthesis, HPR was chronically administered to ABCA4-/- mice.  Mice were evaluated using biochemical, electrophysiological, and morphologic techniques.  RESULTS:  Administration of HPR to ABCA4-/- mice caused immediate, dose-dependent reductions in serum retinol and RBP.  Chronic administration produced commensurate reductions in visual cycle retinoids and arrested accumulation of A2E and lipofuscin autofluorescence in the RPE.  Physiologically, HPR treatment caused modest delays in dark adaptation.  Chromophore regeneration kinetics, light sensitivity of photoreceptors, and phototransduction processes were normal.  Histologic examinations showed no alteration of retinal cytostructure or morphology.  CONCLUSIONS:  These findings demonstrate the vitamin A-dependent nature of A2E biosynthesis and validate a novel therapeutic approach with potential to halt the accumulation of lipofuscin fluorophores in the eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcST_ie98itsIvcsfMJQC1ZdfW6udTcc2ebJt2_zX1q7c7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnit1GgtQ%253D%253D&md5=dc425883e9829eab910c9cf96a9d5fe6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1167%2Fiovs.05-0820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.05-0820%26sid%3Dliteratum%253Aachs%26aulast%3DRadu%26aufirst%3DR.%2BA.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DBui%26aufirst%3DT.%2BV.%26aulast%3DNusinowitz%26aufirst%3DS.%26aulast%3DBok%26aufirst%3DD.%26aulast%3DLichter%26aufirst%3DJ.%26aulast%3DWidder%26aufirst%3DK.%26aulast%3DTravis%26aufirst%3DG.%2BH.%26aulast%3DMata%26aufirst%3DN.%2BL.%26atitle%3DReductions%2520in%2520serum%2520vitamin%2520A%2520arrest%2520accumulation%2520of%2520toxic%2520retinal%2520fluorophores%253A%2520a%2520potential%2520therapy%2520for%2520treatment%2520of%2520lipofuscin-based%2520retinal%2520diseases%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2005%26volume%3D46%26spage%3D4393%26epage%3D43401%26doi%3D10.1167%2Fiovs.05-0820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dobri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moiseyev, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allikmets, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparrow, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1167/iovs.12-10050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1167%2Fiovs.12-10050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23211825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjt1eqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=85-95&author=N.+Dobriauthor=Q.+Qinauthor=J.+Kongauthor=K.+Yamamotoauthor=Z.+Liuauthor=G.+Moiseyevauthor=J.+X.+Maauthor=R.+Allikmetsauthor=J.+R.+Sparrowauthor=K.+Petrukhin&title=A1120%2C+a+nonretinoid+RBP4+antagonist%2C+inhibits+formation+of+cytotoxic+bisretinoids+in+the+animal+model+of+enhanced+retinal+lipofuscinogenesis&doi=10.1167%2Fiovs.12-10050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis</span></div><div class="casAuthors">Dobri, Nicoleta; Qin, Qiong; Kong, Jian; Yamamoto, Kazunori; Liu, Zhao; Moiseyev, Gennadiy; Ma, Jian-xing; Allikmets, Rando; Sparrow, Janet R.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-95</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">PURPOSE. Excessive accumulation of lipofuscin is assocd. with pathogenesis of atrophic age-related macular degeneration (AMD) and Stargardt disease.  Pharmacol. inhibition of the retinol-induced interaction of retinol-binding protein 4 (RBP4) with transthyretin (TTR) in the serum may decrease the uptake of serum retinol to the retina and reduce formation of lipofuscin bisretinoids.  We evaluated in vitro and in vivo properties of the new nonretinoid RBP4 antagonist, A1120.  METHODS. RBP4 binding potency, ability to antagonize RBP4-TTR interaction, and compd. specificity were analyzed for A1120 and for the prototypic RBP4 antagonist fenretinide.  A1120 ability to inhibit RPE65-mediated isomerohydrolase activity was assessed in the RPE microsomes.  The in vivo effect of A1120 administration on serum RBP4, visual cycle retinoids, lipofuscin bisretinoids, and retinal visual function was evaluated using a combination of biochem. and electrophysiol. techniques.  RESULTS. In comparison to fenretinide, A1120 did not act as a RARα agonist, while exhibiting superior in vitro potency in RBP4 binding and RBP4-TTR interaction assays.  A1120 did not inhibit isomerohydrolase activity in the RPE microsomes.  A1120 dosing in mice induced 75% redn. in serum RBP4, which correlated with redn. in visual cycle retinoids and ocular levels of lipofuscin fluorophores.  A1120 dosing did not induce changes in kinetics of dark adaptation.  CONCLUSIONS. A1120 significantly reduces accumulation of lipofuscin bisretinoids in the Abca4-/- animal model.  This activity correlates with redn. in serum RBP4 and visual cycle retinoids confirming the mechanism of action for A1120.  In contrast to fenretinide, A1120 does not act as a RARα agonist indicating a more favorable safety profile for this nonretinoid compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCuxjzXex7aLVg90H21EOLACvtfcHk0lgxuXrcGwtKJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjt1eqs70%253D&md5=3a605e4dc084a06e325ccdd14ec48886</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1167%2Fiovs.12-10050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.12-10050%26sid%3Dliteratum%253Aachs%26aulast%3DDobri%26aufirst%3DN.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMoiseyev%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DJ.%2BX.%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DSparrow%26aufirst%3DJ.%2BR.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DA1120%252C%2520a%2520nonretinoid%2520RBP4%2520antagonist%252C%2520inhibits%2520formation%2520of%2520cytotoxic%2520bisretinoids%2520in%2520the%2520animal%2520model%2520of%2520enhanced%2520retinal%2520lipofuscinogenesis%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2013%26volume%3D54%26spage%3D85%26epage%3D95%26doi%3D10.1167%2Fiovs.12-10050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allikmets, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">11574</span>– <span class="NLM_lpage">11588</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.002062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1074%2Fjbc.RA118.002062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=29871924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGltLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=11574-11588&author=B.+Raczauthor=A.+Varadiauthor=J.+Kongauthor=R.+Allikmetsauthor=P.+G.+Pearsonauthor=G.+Johnsonauthor=C.+L.+Cioffiauthor=K.+Petrukhin&title=A+non-retinoid+antagonist+of+retinol-binding+protein+4+rescues+phenotype+in+a+model+of+Stargardt+disease+without+inhibiting+the+visual+cycle&doi=10.1074%2Fjbc.RA118.002062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle</span></div><div class="casAuthors">Racz, Boglarka; Varadi, Andras; Kong, Jian; Allikmets, Rando; Pearson, Paul G.; Johnson, Graham; Cioffi, Christopher L.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11574-11588</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A primary pathol. defect in the heritable eye disorder Stargardt disease is excessive accumulation of cytotoxic lipofuscin bisretinoids in the retina.  Age-dependent accumulation of lipofuscin in the retinal pigment epithelium (RPE) matches the age-dependent increase in the incidence of the atrophic (dry) form of age-related macular degeneration (AMD) and therefore may be one of several pathogenic factors contributing to AMD progression.  Lipofuscin bisretinoid synthesis in the retina depends on the influx of serum retinol from the circulation into the RPE.  Formation of the tertiary retinol-binding protein 4 (RBP4)-transthyretin-retinol complex in the serum is required for this influx.  Herein, we report the pharmacol. effects of the non-retinoid RBP4 antagonist, BPN-14136.  BPN-14136 dosing in the Abca4-/- mouse model of increased lipofuscinogenesis significantly reduced serum RBP4 levels and inhibited bisretinoid synthesis, and this inhibition correlated with a partial redn. in visual cycle retinoids such as retinaldehydes serving as bisretinoid precursors.  BPN-14136 administration at doses inducing maximal serum RBP4 redn. did not produce changes in the rate of the visual cycle, consistent with minimal changes in dark adaptation.  Abca4-/- mice exhibited dysregulation of the complement system in the retina, and BPN-14136 administration normalized the retinal levels of proinflammatory complement cascade components such as complement factors D and H, C-reactive protein, and C3.  We conclude that BPN-14136 has several beneficial characteristics, combining inhibition of bisretinoid synthesis and redn. in retinaldehydes with normalization of the retinal complement system.  BPN-14136, or a similar compd., may be a promising drug candidate to manage Stargardt disease and dry AMD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCSqbHhwE9BLVg90H21EOLACvtfcHk0lit4dRibRHvLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGltLfE&md5=65f2b1f8433dede41cc2a6c181cc92a9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.002062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.002062%26sid%3Dliteratum%253Aachs%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DJohnson%26aufirst%3DG.%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DA%2520non-retinoid%2520antagonist%2520of%2520retinol-binding%2520protein%25204%2520rescues%2520phenotype%2520in%2520a%2520model%2520of%2520Stargardt%2520disease%2520without%2520inhibiting%2520the%2520visual%2520cycle%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26spage%3D11574%26epage%3D11588%26doi%3D10.1074%2Fjbc.RA118.002062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Racz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Comparative pharmacokinetics and pharmacodynamics of the advanced retinol-binding protein 4 antagonist in dog and cynomolgus monkey</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">e0228291</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0228291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1371%2Fjournal.pone.0228291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31978148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFCqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&author=B.+Raczauthor=A.+Varadiauthor=P.+G.+Pearsonauthor=K.+Petrukhin&title=Comparative+pharmacokinetics+and+pharmacodynamics+of+the+advanced+retinol-binding+protein+4+antagonist+in+dog+and+cynomolgus+monkey&doi=10.1371%2Fjournal.pone.0228291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacokinetics and pharmacodynamics of the advanced Retinol-Binding Protein 4 antagonist in dog and cynomolgus monkey</span></div><div class="casAuthors">Racz, Boglarka; Varadi, Andras; Pearson, Paul G.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0228291</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Accumulation of lipofuscin bisretinoids in the retina contributes to pathogenesis of macular degeneration.  Retinol-Binding Protein 4 (RBP4) antagonists reduce serum retinol concns. thus partially reducing retinol delivery to the retina which decreases bisretinoid synthesis.  BPN-14136 is a novel RBP4 antagonist with good in vitro potency and selectivity and optimal rodent pharmacokinetic (PK) and pharmacodynamic (PD) characteristics.  To select a non-rodent species for regulatory toxicol. studies, we conducted PK and PD evaluation of BPN-14136 in dogs and non-human primates (NHP).  PK properties were detd. following oral and i.v. administration of BPN-14136 in beagle dogs and cynomolgus monkeys.  Dynamics of plasma RBP4 redn. in response to compd. administration was used as a PD marker.  BPN-14136 exhibited favorable PK profile in both species.  Dose-normalized exposure was significantly higher in NHP than in dog.  Baseline concns. of RBP4 were considerably lower in dog than in NHP, reflecting the atypical reliance of canids on non-RBP4 mechanisms of retinoid trafficking.  Oral administration of BPN-14136 to NHP induced a strong 99% serum RBP4 redn.  Dynamics of RBP4 lowering in both species correlated with compd. exposure.  Despite adequate PK and PD characteristics of BPN-14136 in dog, reliance of canids on non-RBP4 mechanisms of retinoid trafficking precludes evaluation of on-target toxicities for RBP4 antagonists in this species.  Strong RBP4 lowering combined with good PK attributes and high BPN-14136 exposure achieved in NHP, along with the biol. of retinoid trafficking that is similar to that of humans, support the choice of NHP as a non-rodent safety species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ufYb9IqvXbVg90H21EOLACvtfcHk0lit4dRibRHvLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFCqtrc%253D&md5=45fb390c994eeb5138a90d33a020afba</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0228291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0228291%26sid%3Dliteratum%253Aachs%26aulast%3DRacz%26aufirst%3DB.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DComparative%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520the%2520advanced%2520retinol-binding%2520protein%25204%2520antagonist%2520in%2520dog%2520and%2520cynomolgus%2520monkey%26jtitle%3DPLoS%2520One%26date%3D2020%26volume%3D15%26doi%3D10.1371%2Fjournal.pone.0228291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotrina, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsequell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Barbero, J.</span></span> <span> </span><span class="NLM_article-title">Insights on the interaction between transthyretin and Aβ in solution. A saturation transfer difference (STD) NMR analysis of the role of iododiflunisal</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5749</span>– <span class="NLM_lpage">5758</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00428</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00428" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Kntrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5749-5758&author=A.+Gimenoauthor=L.+M.+Santosauthor=M.+Alemiauthor=J.+Rivasauthor=D.+Blasiauthor=E.+Y.+Cotrinaauthor=J.+Llopauthor=G.+Valenciaauthor=I.+Cardosoauthor=J.+Quintanaauthor=G.+Arsequellauthor=J.+Jimenez-Barbero&title=Insights+on+the+interaction+between+transthyretin+and+A%CE%B2+in+solution.+A+saturation+transfer+difference+%28STD%29+NMR+analysis+of+the+role+of+iododiflunisal&doi=10.1021%2Facs.jmedchem.7b00428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Insights on the Interaction between Transthyretin and Aβ in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal</span></div><div class="casAuthors">Gimeno, Ana; Santos, Luis M.; Alemi, Mobina; Rivas, Josep; Blasi, Daniel; Cotrina, Ellen Y.; Llop, Jordi; Valencia, Gregorio; Cardoso, Isabel; Quintana, Jordi; Arsequell, Gemma; Jimenez-Barbero, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5749-5758</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several strategies against Alzheimer disease (AD) are directed toward targeting Aβ-peptides.  The ability of transthyretin (TTR) to bind Aβ-peptides and the pos. effect exerted by some TTR stabilizers for modulating the TTR-Aβ interaction have been previously studied.  Here, key structural features of the interaction between TTR and Aβ(12-28) peptide, the essential recognition element of Aβ, have been unraveled by STD-NMR spectroscopy methods in soln.  Mol. aspects related with the role of the TTR stabilizer, iododiflunisal (IDIF), on the TTR-Aβ complex were also examd.  The NMR results, assisted by mol. modeling protocols, provided a structural model for the TTR-Aβ interaction, as well as for the ternary complex formed in the presence of IDIF.  This basic structural information could be relevant for providing light on the mechanisms involved in the ameliorating effects of AD symptoms obsd. in AD/TTR± animal models after IDIF treatment and eventually for designing new mols. toward AD therapeutic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYFHzRMCro1rVg90H21EOLACvtfcHk0lit4dRibRHvLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Kntrw%253D&md5=8e4c5275309c8d1129655c6d30a9c82d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00428%26sid%3Dliteratum%253Aachs%26aulast%3DGimeno%26aufirst%3DA.%26aulast%3DSantos%26aufirst%3DL.%2BM.%26aulast%3DAlemi%26aufirst%3DM.%26aulast%3DRivas%26aufirst%3DJ.%26aulast%3DBlasi%26aufirst%3DD.%26aulast%3DCotrina%26aufirst%3DE.%2BY.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DValencia%26aufirst%3DG.%26aulast%3DCardoso%26aufirst%3DI.%26aulast%3DQuintana%26aufirst%3DJ.%26aulast%3DArsequell%26aufirst%3DG.%26aulast%3DJimenez-Barbero%26aufirst%3DJ.%26atitle%3DInsights%2520on%2520the%2520interaction%2520between%2520transthyretin%2520and%2520A%25CE%25B2%2520in%2520solution.%2520A%2520saturation%2520transfer%2520difference%2520%2528STD%2529%2520NMR%2520analysis%2520of%2520the%2520role%2520of%2520iododiflunisal%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5749%26epage%3D5758%26doi%3D10.1021%2Facs.jmedchem.7b00428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jesus, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaz, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faria, T. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brito, R. M.</span></span> <span> </span><span class="NLM_article-title">A new folding kinetic mechanism for human transthyretin and the influence of the amyloidogenic V30M mutation</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>, <span class="NLM_elocation-id">1428</span> <span class="refDoi"> DOI: 10.3390/ijms17091428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fijms17091428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2qsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&author=C.+S.+Jesusauthor=Z.+L.+Almeidaauthor=D.+C.+Vazauthor=T.+Q.+Fariaauthor=R.+M.+Brito&title=A+new+folding+kinetic+mechanism+for+human+transthyretin+and+the+influence+of+the+amyloidogenic+V30M+mutation&doi=10.3390%2Fijms17091428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A new folding kinetic mechanism for human transthyretin and the influence of the amyloidogenic V30M mutation</span></div><div class="casAuthors">Jesus, Catarina S. H.; Almeida, Zaida L.; Vaz, Daniela C.; Faria, Tiago Q.; Brito, Rui M. M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1428/1-1428/19</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Protein aggregation into insol. amyloid fibrils is the hallmark of several neurodegenerative diseases, chief among them Alzheimer's and Parkinson's.  Although caused by different proteins, these pathologies share some basic mol. mechanisms with familial amyloidotic polyneuropathy (FAP), a rare hereditary neuropathy caused by amyloid formation and deposition by transthyretin (TTR) in the peripheral and autonomic nervous systems.  Among the amyloidogenic TTR mutations known, V30M-TTR is the most common in FAP.  TTR amyloidogenesis (ATTR) is triggered by tetramer dissocn., followed by partial unfolding and aggregation of the low conformational stability monomers formed.  Thus, tetramer dissocn. kinetics, monomer conformational stability and competition between refolding and aggregation pathways do play a crit. role in ATTR.  Here, we propose a new model to analyze the refolding kinetics of WT-TTR and V30M-TTR, showing that at pH and protein concns. close to physiol., a two-step mechanism with a unimol. first step followed by a second-order second step adjusts well to the exptl. data.  Interestingly, although sharing the same kinetic mechanism, V30M-TTR refolds at a much slower rate than WT-TTR, a feature that may favor the formation of transient species leading to kinetic partition into amyloidogenic pathways and, thus, significantly increasing the probability of amyloid formation in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM2hUOB2t2mbVg90H21EOLACvtfcHk0lgpOmyFzRdaSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2qsrfL&md5=298a1ca1f946455376bbccf958d5c69b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3390%2Fijms17091428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms17091428%26sid%3Dliteratum%253Aachs%26aulast%3DJesus%26aufirst%3DC.%2BS.%26aulast%3DAlmeida%26aufirst%3DZ.%2BL.%26aulast%3DVaz%26aufirst%3DD.%2BC.%26aulast%3DFaria%26aufirst%3DT.%2BQ.%26aulast%3DBrito%26aufirst%3DR.%2BM.%26atitle%3DA%2520new%2520folding%2520kinetic%2520mechanism%2520for%2520human%2520transthyretin%2520and%2520the%2520influence%2520of%2520the%2520amyloidogenic%2520V30M%2520mutation%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2016%26volume%3D17%26doi%3D10.3390%2Fijms17091428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damrauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argulian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbyn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerraty, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kember, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vleck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abul-Husn, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirinos, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loos, R. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirugo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadkarni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rader, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, R.</span></span> <span> </span><span class="NLM_article-title">Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of african or hispanic/latino ancestry</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">2191</span>– <span class="NLM_lpage">2202</span>, <span class="refDoi"> DOI: 10.1001/jama.2019.17935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1001%2Fjama.2019.17935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31821430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyqu7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2019&pages=2191-2202&author=S.+M.+Damrauerauthor=K.+Chaudharyauthor=J.+H.+Choauthor=L.+W.+Liangauthor=E.+Argulianauthor=L.+Chanauthor=A.+Dobbynauthor=M.+A.+Guerratyauthor=R.+Judyauthor=J.+Kayauthor=R.+L.+Kemberauthor=M.+G.+Levinauthor=A.+Sahaauthor=T.+Van+Vleckauthor=S.+S.+Vermaauthor=J.+Weaverauthor=N.+S.+Abul-Husnauthor=A.+Barasauthor=J.+A.+Chirinosauthor=B.+Drachmanauthor=E.+E.+Kennyauthor=R.+J.+F.+Loosauthor=J.+Narulaauthor=J.+Overtonauthor=J.+Reidauthor=M.+Ritchieauthor=G.+Sirugoauthor=G.+Nadkarniauthor=D.+J.+Raderauthor=R.+Do&title=Association+of+the+V122I+hereditary+transthyretin+amyloidosis+genetic+variant+with+heart+failure+among+individuals+of+african+or+hispanic%2Flatino+ancestry&doi=10.1001%2Fjama.2019.17935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of Aafrican or Hispanic/Latino ancestry</span></div><div class="casAuthors">Damrauer, Scott M.; Chaudhary, Kumardeep; Cho, Judy H.; Liang, Lusha W.; Argulian, Edgar; Chan, Lili; Dobbyn, Amanda; Guerraty, Marie A.; Judy, Renae; Kay, Jenna; Kember, Rachel L.; Levin, Michael G.; Saha, Aparna; Van Vleck, Tielman; Verma, Shefali S.; Weaver, JoEllen; Abul-Husn, Noura S.; Baras, Aris; Chirinos, Julio A.; Drachman, Brian; Kenny, Eimear E.; Loos, Ruth J. F.; Narula, Jagat; Overton, John; Reid, Jeffrey; Ritchie, Marylyn; Sirugo, Giorgio; Nadkarni, Girish; Rader, Daniel J.; Do, Ron</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2191-2202</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance Hereditary transthyretin (TTR) amyloid cardiomyopathy (hATTR-CM) due to the TTR V122I variant is an autosomal-dominant disorder that causes heart failure in elderly individuals of African ancestry.  The clin. assocns. of carrying the variant, its effect in other African ancestry populations including Hispanic/Latino individuals, and the rates of achieving a clin. diagnosis in carriers are unknown. objective To assess the assocn. between the TTR V122I variant and heart failure and identify rates of hATTR-CM diagnosis among carriers with heart failure. design, setting, and participants Cross-sectional anal. of carriers and noncarriers of TTR V122I of African ancestry aged 50 years or older enrolled in the Penn Medicine Biobank between 2008 and 2017 using electronic health record data from 1996 to 2017.  Case-control study in participants of African and Hispanic/Latino ancestry with and without heart failure in the Mount Sinai BioMe Biobank enrolled between 2007 and 2015 using electronic health record data from 2007 to 2018. exposuresTTR V122I carrier status. main outcomes and measures The primary outcome was prevalent heart failure.  The rate of diagnosis with hATTR-CM among TTR V122I carriers with heart failure was measured. results The cross-sectional cohort included 3724 individuals of African ancestry with a median age of 64 years (interquartile range, 57-71); 1755 (47%) were male, 2896 (78%) had a diagnosis of hypertension, and 753 (20%) had a history of myocardial infarction or coronary revascularization.  There were 116 TTR V122I carriers (3.1%); 1121 participants (30%) had heart failure.  The case-control study consisted of 2307 individuals of African ancestry and 3663 Hispanic/Latino individuals; the median age was 73 years (interquartile range, 68-80), 2271 (38%) were male, 4709 (79%) had a diagnosis of hypertension, and 1008 (17%) had a history of myocardial infarction or coronary revascularization.  There were 1376 cases of heart failure.  TTR V122I was assocd. with higher rates of heart failure (cross-sectional cohort: n = 51/116 TTR V122I carriers [44%], n = 1070/3608 noncarriers [30%], adjusted odds ratio, 1.7 [95% CI, 1.2-2.4], P = .006; case-control study: n = 36/1376 heart failure cases [2.6%], n = 82/4594 controls [1.8%], adjusted odds ratio, 1.8 [95% CI, 1.2-2.7], P = .008).  Ten of 92 TTR V122I carriers with heart failure (11%) were diagnosed as having hATTR-CM; the median time from onset of symptoms to clin. diagnosis was 3 years. conclusions and relevance Among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks, the TTR V122I genetic variant was significantly assocd. with heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJWp0hnVGqZrVg90H21EOLACvtfcHk0lgpOmyFzRdaSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyqu7jN&md5=9f32e51a320407644e54901b78d0c15e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjama.2019.17935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2019.17935%26sid%3Dliteratum%253Aachs%26aulast%3DDamrauer%26aufirst%3DS.%2BM.%26aulast%3DChaudhary%26aufirst%3DK.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DLiang%26aufirst%3DL.%2BW.%26aulast%3DArgulian%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DL.%26aulast%3DDobbyn%26aufirst%3DA.%26aulast%3DGuerraty%26aufirst%3DM.%2BA.%26aulast%3DJudy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DJ.%26aulast%3DKember%26aufirst%3DR.%2BL.%26aulast%3DLevin%26aufirst%3DM.%2BG.%26aulast%3DSaha%26aufirst%3DA.%26aulast%3DVan%2BVleck%26aufirst%3DT.%26aulast%3DVerma%26aufirst%3DS.%2BS.%26aulast%3DWeaver%26aufirst%3DJ.%26aulast%3DAbul-Husn%26aufirst%3DN.%2BS.%26aulast%3DBaras%26aufirst%3DA.%26aulast%3DChirinos%26aufirst%3DJ.%2BA.%26aulast%3DDrachman%26aufirst%3DB.%26aulast%3DKenny%26aufirst%3DE.%2BE.%26aulast%3DLoos%26aufirst%3DR.%2BJ.%2BF.%26aulast%3DNarula%26aufirst%3DJ.%26aulast%3DOverton%26aufirst%3DJ.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DRitchie%26aufirst%3DM.%26aulast%3DSirugo%26aufirst%3DG.%26aulast%3DNadkarni%26aufirst%3DG.%26aulast%3DRader%26aufirst%3DD.%2BJ.%26aulast%3DDo%26aufirst%3DR.%26atitle%3DAssociation%2520of%2520the%2520V122I%2520hereditary%2520transthyretin%2520amyloidosis%2520genetic%2520variant%2520with%2520heart%2520failure%2520among%2520individuals%2520of%2520african%2520or%2520hispanic%252Flatino%2520ancestry%26jtitle%3DJAMA%26date%3D2019%26volume%3D322%26spage%3D2191%26epage%3D2202%26doi%3D10.1001%2Fjama.2019.17935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellotti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Arias, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallaina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obici, L.</span></span> <span> </span><span class="NLM_article-title">A narrative review of the role of transthyretin in health and disease</span>. <i>Neurol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1007/s40120-020-00217-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs40120-020-00217-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=33001386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FlvFOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=395-402&author=M.+A.+Lizauthor=T.+Coelhoauthor=V.+Bellottiauthor=M.+I.+Fernandez-Ariasauthor=P.+Mallainaauthor=L.+Obici&title=A+narrative+review+of+the+role+of+transthyretin+in+health+and+disease&doi=10.1007%2Fs40120-020-00217-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A Narrative Review of the Role of Transthyretin in Health and Disease</span></div><div class="casAuthors">Liz Marcia Almeida; Coelho Teresa; Bellotti Vittorio; Bellotti Vittorio; Fernandez-Arias Maria Isabel; Mallaina Pablo; Obici Laura</div><div class="citationInfo"><span class="NLM_cas:title">Neurology and therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-402</span>
        ISSN:<span class="NLM_cas:issn">2193-8253</span>.
    </div><div class="casAbstract">Transthyretin (TTR) is a tetrameric transport protein highly conserved through vertebrate evolution and synthesized in the liver, choroid plexus, and retinal pigment epithelium.  TTR transports the thyroid hormone thyroxine and the retinol-binding protein (RBP) bound to retinol (vitamin A).  Mutations in TTR are associated with inherited transthyretin amyloidosis (ATTRv), a progressive, debilitating disease that is ultimately fatal and is characterized by misfolding of TTR and aggregation as amyloid fibrils, predominantly leading to cardiomyopathy or polyneuropathy depending on the particular TTR mutation.  Transthyretin amyloid cardiomyopathy can also occur as an age-related disease caused by misfolding of wild-type TTR.  Apart from its transport role, little is known about possible additional physiological functions of TTR.  Evidence from animal model systems in which TTR has been disrupted via gene knockout is adding to our cumulative understanding of TTR function.  There is growing evidence that TTR may have a role in neuroprotection and promotion of neurite outgrowth in response to injury.  Here, we review the literature describing potential roles of TTR in neurobiology and in the pathophysiology of diseases other than ATTR amyloidosis.  A greater understanding of these processes may also contribute to further clarification of the pathology of ATTR and the effects of potential therapies for TTR-related conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUOc90fHQzQae0F5ixvZgXfW6udTcc2eZMhKEUyqnXVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FlvFOkuw%253D%253D&md5=d1d3ee1375a086677381ab96ddf1353a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40120-020-00217-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40120-020-00217-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiz%26aufirst%3DM.%2BA.%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DBellotti%26aufirst%3DV.%26aulast%3DFernandez-Arias%26aufirst%3DM.%2BI.%26aulast%3DMallaina%26aufirst%3DP.%26aulast%3DObici%26aufirst%3DL.%26atitle%3DA%2520narrative%2520review%2520of%2520the%2520role%2520of%2520transthyretin%2520in%2520health%2520and%2520disease%26jtitle%3DNeurol.%2520Ther.%26date%3D2020%26volume%3D9%26spage%3D395%26epage%3D402%26doi%3D10.1007%2Fs40120-020-00217-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taboada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraiva, M. J.</span></span> <span> </span><span class="NLM_article-title">Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Human Transthyretin Leu55Pro</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1935</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)64469-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2FS0002-9440%2810%2964469-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=12414539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD38XptV2gurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2002&pages=1935-1948&author=M.+M.+Sousaauthor=R.+Fernandesauthor=J.+A.+Palhaauthor=A.+Taboadaauthor=P.+Vieiraauthor=M.+J.+Saraiva&title=Evidence+for+Early+Cytotoxic+Aggregates+in+Transgenic+Mice+for+Human+Transthyretin+Leu55Pro&doi=10.1016%2FS0002-9440%2810%2964469-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro</span></div><div class="casAuthors">Sousa, Monica Mendes; Fernandes, Rui; Palha, Joana Almeida; Taboada, Ana; Vieira, Paulo; Saraiva, Joao</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1935-1948</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Familial amyloidotic polyneuropathy (FAP) is a lethal autosomal dominant disorder characterized by systemic extracellular deposition of transthyretin (TTR) amyloid fibrils.  Several groups have generated transgenic mice carrying human TTR Val30Met, the most common mutation in FAP.  To study amyloidogenicity and cytotoxicity of different TTRs, the authors produced transgenic mice expressing human TTR Leu55Pro, one of the most aggressive FAP-related mutations.  TTR deposition and presence of amyloid fibrils was investigated and compared to animals carrying the human TTR Val30Met gene kept under the same conditions.  Deposition in a C57BL/6J background (TTR-Leu55Pro mice) and in a TTR-null background [TTR-Leu55Pro X TTR-knockout (KO) mice] was compared.  Animals in a C57BL/6J background presented early (1 to 3 mo) nonfibrillar TTR deposition but amyloid was absent.  In a TTR-null background, presence of amyloid fibrils was detected starting at 4 to 8 mo with a particular involvement of the gastrointestinal tract and skin.  This data suggested that TTR homotetramers are more prone to fibril formation than TTR murine wild-type/human mutant heterotetramers.  The nature of the deposited material was further investigated by immunocytochem.  Both amorphous aggregates and small TTR fibrils were present in TTR-Leu55Pro X TTR-KO transgenics.  The authors obsd. that these TTR deposits mimic the toxic effect of TTR deposits in FAP: animals with TTR deposition, present approx. twofold increased levels of nitrotyrosine in sites related to deposition.  The TTR-Leu55Pro X TTR-KO mice here described are an important tool for the dual purpose of investigating factors involved in amyloidogenesis and in cytotoxicity of deposited TTR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSteyHj6slmLVg90H21EOLACvtfcHk0lgNp8LWJ7m5oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptV2gurw%253D&md5=5596a3628ee339d3d0b3778ad478cc06</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2964469-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252964469-0%26sid%3Dliteratum%253Aachs%26aulast%3DSousa%26aufirst%3DM.%2BM.%26aulast%3DFernandes%26aufirst%3DR.%26aulast%3DPalha%26aufirst%3DJ.%2BA.%26aulast%3DTaboada%26aufirst%3DA.%26aulast%3DVieira%26aufirst%3DP.%26aulast%3DSaraiva%26aufirst%3DM.%2BJ.%26atitle%3DEvidence%2520for%2520Early%2520Cytotoxic%2520Aggregates%2520in%2520Transgenic%2520Mice%2520for%2520Human%2520Transthyretin%2520Leu55Pro%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2002%26volume%3D161%26spage%3D1935%26epage%3D1948%26doi%3D10.1016%2FS0002-9440%2810%2964469-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connors, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span> <span> </span><span class="NLM_article-title">Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy</span>. <i>Amyloid</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.3109/13506129.2011.574354059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3109%2F13506129.2011.574354059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=21838471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BC3Mjmt1Sqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=157-159&author=L.+H.+Connorsauthor=G.+Dorosauthor=F.+Samauthor=A.+Badieeauthor=D.+C.+Seldinauthor=M.+Skinner&title=Clinical+features+and+survival+in+senile+systemic+amyloidosis%3A+comparison+to+familial+transthyretin+cardiomyopathy&doi=10.3109%2F13506129.2011.574354059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy</span></div><div class="casAuthors">Connors L H; Doros G; Sam F; Badiee A; Seldin D C; Skinner M</div><div class="citationInfo"><span class="NLM_cas:title">Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">157-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0Q70bhE16Pxcr74wzj5o5fW6udTcc2eaHwDanfPV4Drntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mjmt1Sqsg%253D%253D&md5=a5979dec60667c1df1cd9b609be2c148</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3109%2F13506129.2011.574354059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F13506129.2011.574354059%26sid%3Dliteratum%253Aachs%26aulast%3DConnors%26aufirst%3DL.%2BH.%26aulast%3DDoros%26aufirst%3DG.%26aulast%3DSam%26aufirst%3DF.%26aulast%3DBadiee%26aufirst%3DA.%26aulast%3DSeldin%26aufirst%3DD.%2BC.%26aulast%3DSkinner%26aufirst%3DM.%26atitle%3DClinical%2520features%2520and%2520survival%2520in%2520senile%2520systemic%2520amyloidosis%253A%2520comparison%2520to%2520familial%2520transthyretin%2520cardiomyopathy%26jtitle%3DAmyloid%26date%3D2011%26volume%3D18%26spage%3D157%26epage%3D159%26doi%3D10.3109%2F13506129.2011.574354059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buxbaum, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruberg, F. L.</span></span> <span> </span><span class="NLM_article-title">Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1038/gim.2016.200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2Fgim.2016.200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=28102864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFygsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=733-742&author=J.+N.+Buxbaumauthor=F.+L.+Ruberg&title=Transthyretin+V122I+%28pV142I%29*+cardiac+amyloidosis%3A+an+age-dependent+autosomal+dominant+cardiomyopathy+too+common+to+be+overlooked+as+a+cause+of+significant+heart+disease+in+elderly+African+Americans&doi=10.1038%2Fgim.2016.200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans</span></div><div class="casAuthors">Buxbaum, Joel N.; Ruberg, Frederick L.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">733-742</span>CODEN:
                <span class="NLM_cas:coden">GEMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1098-3600</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the identification of a valine-to-isoleucine substitution at position 122 (TTR V122I; pV142I) in the transthyretin (TTR)-derived fibrils extd. from the heart of a patient with late-onset cardiac amyloidosis, it has become clear that the amyloidogenic mutation and the disease occur almost exclusively in individuals of identifiable African descent.  In the United States, the amyloidogenic allele frequency is 0.0173 and is carried by 3.5% of community-dwelling African Americans.  Genotyping across Africa indicates that the origin of the allele is in the West African countries that were the major source of the slave trade to North America.  At autopsy, the allele was found to be assocd. with cardiac TTR amyloid deposition in all the carriers after age 65 years; however, the clin. penetrance varies, resulting in substantial heart disease in some carriers and few symptoms in others.  The allele has been found in 10% of African Americans older than age 65 with severe congestive heart failure.  At this time there are potential forms of therapy in clin. trials.  The combination of a highly accurate genetic test and the potential for specific therapy demands a greater awareness of this autosomal dominant, age-dependent cardiac disease in the cardiol. community.  Genet Med advance online publication 19 Jan. 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMWF8ztYOPfbVg90H21EOLACvtfcHk0lgNp8LWJ7m5oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFygsLfO&md5=edf1f2a43c2c58b8ea6e8e8d35156d05</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fgim.2016.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgim.2016.200%26sid%3Dliteratum%253Aachs%26aulast%3DBuxbaum%26aufirst%3DJ.%2BN.%26aulast%3DRuberg%26aufirst%3DF.%2BL.%26atitle%3DTransthyretin%2520V122I%2520%2528pV142I%2529%252A%2520cardiac%2520amyloidosis%253A%2520an%2520age-dependent%2520autosomal%2520dominant%2520cardiomyopathy%2520too%2520common%2520to%2520be%2520overlooked%2520as%2520a%2520cause%2520of%2520significant%2520heart%2520disease%2520in%2520elderly%2520African%2520Americans%26jtitle%3DGenet.%2520Med.%26date%3D2017%26volume%3D19%26spage%3D733%26epage%3D742%26doi%3D10.1038%2Fgim.2016.200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buxbaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koziol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, L. H.</span></span> <span> </span><span class="NLM_article-title">Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity</span>. <i>Amyloid</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1080/13506120802525285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1080%2F13506120802525285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=19065297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=255-261&author=J.+Buxbaumauthor=J.+Koziolauthor=L.+H.+Connors&title=Serum+transthyretin+levels+in+senile+systemic+amyloidosis%3A+effects+of+age%2C+gender+and+ethnicity&doi=10.1080%2F13506120802525285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity</span></div><div class="casAuthors">Buxbaum, Joel; Koziol, James; Connors, Lawreen H.</div><div class="citationInfo"><span class="NLM_cas:title">Amyloid</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">AIJIET</span>;
        ISSN:<span class="NLM_cas:issn">1350-6129</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Serum transthyretin (TTR) levels are reduced in familial amyloidotic polyneuropathy (FAP).  A single study of patients with senile systemic amyloidosis (SSA) in Sweden found that those individuals also had a significantly lower mean serum TTR concn. than age- and gender-matched controls.  To det. if the same phenomenon prevailed in an ethnically more heterogeneous population, we compared the serum TTR levels, as detd. by ELISA, in 45 documented SSA patients with congestive heart failure, 20 AL patients with congestive heart failure and population controls.  Serum TTR concns. in the controls were influenced in a statistically significant manner by age, gender and ethnicity.  Although it is unlikely that such differences are clin. relevant, they must be considered when assessing the meaning of serum TTR concns. in any clin. defined population.  The serum concns. in patients with SSA did not differ from age, gender and ethnically matched controls or from a group of AL patients with significant clin. cardiac involvement.  We also compared TTR concns. in 12 African-Americans carrying the TTR V122I allele with those in 826 African-Americans who were homozygous wild type at the TTR locus.  The TTR V122I carriers had significantly lower serum TTR concns. than appropriate controls even though the majority of such individuals had not reached the age of clin. or anat. risk, i.e. over 60.  Thus, as in carriers of other TTR mutations the serum TTR level is lower than normal, despite having a much later appearance of clin. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqOXYzo0LtebVg90H21EOLACvtfcHk0lhZ9eMPv2Ehaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7%252FJ&md5=10845b18a6d76cd65b736b7e9b6c6eb0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1080%2F13506120802525285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13506120802525285%26sid%3Dliteratum%253Aachs%26aulast%3DBuxbaum%26aufirst%3DJ.%26aulast%3DKoziol%26aufirst%3DJ.%26aulast%3DConnors%26aufirst%3DL.%2BH.%26atitle%3DSerum%2520transthyretin%2520levels%2520in%2520senile%2520systemic%2520amyloidosis%253A%2520effects%2520of%2520age%252C%2520gender%2520and%2520ethnicity%26jtitle%3DAmyloid%26date%3D2008%26volume%3D15%26spage%3D255%26epage%3D261%26doi%3D10.1080%2F13506120802525285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, D. S.</span></span> <span> </span><span class="NLM_article-title">Retinol-binding protein: the transport protein for vitamin A in human plasma</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2025</span>– <span class="NLM_lpage">2044</span>, <span class="refDoi"> DOI: 10.1172/JCI105889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1172%2FJCI105889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=5675424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaF1cXltVeju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1968&pages=2025-2044&author=M.+Kanaiauthor=A.+Razauthor=D.+S.+Goodman&title=Retinol-binding+protein%3A+the+transport+protein+for+vitamin+A+in+human+plasma&doi=10.1172%2FJCI105889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Retinol-binding protein; the transport protein for vitamin A in human plasma</span></div><div class="casAuthors">Kanai, Masamitsu; Raz, Amiram; Goodman, DeWitt S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2025-44</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">Retinol-binding protein (RBP) was isolated from human plasma following i.v. administration of retinol-15-14C and purified by Cohn fractionation and gel filtration chromatog.  Purified RBP exhibited α1 mobility on electrophoresis and a mol. wt. of 21,000-22,000.  There appeared to be one retinol binding site per RBP mol.  RBP solns. were fluorescent and exhibited uv absorption max. at 330 and 280 mμ.  No fatty acid or fatty acyl chains were present in RBP.  RBP concn. in normal plasma was 3-4 mg./100 ml.  RBP circulated as a complex with another larger protein with prealbumin electrophoretic mobility, separable on gel electrophoresis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBfuGmG0Ac3bVg90H21EOLACvtfcHk0lhZ9eMPv2Ehaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXltVeju7s%253D&md5=61318c230fa0e3d2b625d61ff29207e4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI105889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI105889%26sid%3Dliteratum%253Aachs%26aulast%3DKanai%26aufirst%3DM.%26aulast%3DRaz%26aufirst%3DA.%26aulast%3DGoodman%26aufirst%3DD.%2BS.%26atitle%3DRetinol-binding%2520protein%253A%2520the%2520transport%2520protein%2520for%2520vitamin%2520A%2520in%2520human%2520plasma%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1968%26volume%3D47%26spage%3D2025%26epage%3D2044%26doi%3D10.1172%2FJCI105889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangerter, F. W.</span></span> <span> </span><span class="NLM_article-title">On the labelling of oxidized cell surface membranes by acyl hydrazides</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>557</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1016/0005-2736(79)90333-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2F0005-2736%2879%2990333-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaL3cXltlOmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=557&publication_year=1979&pages=354-362&author=R.+R.+Randoauthor=F.+W.+Bangerter&title=On+the+labelling+of+oxidized+cell+surface+membranes+by+acyl+hydrazides&doi=10.1016%2F0005-2736%2879%2990333-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">On the labeling of oxidized cell surface membranes by acyl hydrazides</span></div><div class="casAuthors">Rando, Robert R.; Bangerter, Faan Wen</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">557</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">354-62</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    </div><div class="casAbstract">The covalent modification of bovine erythrocyte membranes by first oxidizing cell surface sugars followed by the covalent coupling of the oxidized components with hydrazides was investigated.  The aldehydic groups were introduced either chem., by mild periodate oxidn., or enzymically with galactose oxidase.  The periodate (0.1 mM) and galactose oxidase (50 units) oxidns. were complete at 5 and 240 min, resp., in phosphate-buffered saline (pH 7.4) at 30° using 2 × 109 cells/mL.  The rates of hydrazone formation between the oxidatively generated aldehyde groups and α-acethydrazide-3H also were measured (pH 7.4) at 30°.  The reactions with the periodate and galactose oxidase-treated cells went to completion in 1.5 and 6 h, resp.  Aniline had a marked catalytic effect on these rates.  With 5 mM aniline under the same conditions, the periodate-treated cells reacted to completion with acethydrazide in 30 min and the galactose oxidase-treated cells in 40 min.  As expected, although the rates of α-acethydrazide-3H incorporation were increased with aniline, the extents of the reaction were not.  Finally, the stability of the hydrazone linkages were measured.  The hydrazone bonds formed when the galactose oxidase-treated cells were reacted with acethydrazide were completely stable at 30° for 24 h, whereas those formed from the periodate-treated cells were not.  In the latter case roughly 50% of the membrane-bound hydrazone linkages were lost after 6 h at 30°.  The remaining 50%, however, were stable to cleavage.  Thus, these sites are clearly heterogeneous in nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJCs-XBuLGLVg90H21EOLACvtfcHk0lhZ9eMPv2Ehaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXltlOmuw%253D%253D&md5=a85e15cf8071ae57170105918d08e31e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0005-2736%2879%2990333-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2736%252879%252990333-X%26sid%3Dliteratum%253Aachs%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DBangerter%26aufirst%3DF.%2BW.%26atitle%3DOn%2520the%2520labelling%2520of%2520oxidized%2520cell%2520surface%2520membranes%2520by%2520acyl%2520hydrazides%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D1979%26volume%3D557%26spage%3D354%26epage%3D362%26doi%3D10.1016%2F0005-2736%2879%2990333-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraiva, M. J.</span></span> <span> </span><span class="NLM_article-title">Transthyretin: a multifaceted protein</span>. <i>Biomol. Concepts</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1515/bmc-2013-0038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1515%2Fbmc-2013-0038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=25372741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFKmurbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=45-54&author=M.+Vieiraauthor=M.+J.+Saraiva&title=Transthyretin%3A+a+multifaceted+protein&doi=10.1515%2Fbmc-2013-0038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin: a multifaceted protein</span></div><div class="casAuthors">Vieira, Marta; Saraiva, Maria Joao</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecular Concepts</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">BCIOB8</span>;
        ISSN:<span class="NLM_cas:issn">1868-5021</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">A review.  Transthyretin is a highly conserved homotetrameric protein, mainly synthesized by the liver and the choroid plexus of brain.  The carrier role of TTR is well-known; however, many other functions have emerged, namely in the nervous system.  Behavior, cognition, neuropeptide amidation, neurogenesis, nerve regeneration, axonal growth and 14-3-3ζ metab. are some of the processes where TTR has an important role.  TTR aggregates are responsible for many amyloidosis such as familial amyloidotic polyneuropathy and cardiomyopathy.  Normal TTR can also aggregate and deposit in the heart of old people and in preeclampsia placental tissue.  Differences in TTR levels have been found in several neuropathologies, but its neuroprotective role, until now, was described in ischemia and Alzheimer's disease.  The aim of this review is to stress the relevance of TTR, besides its well-known role on transport of thyroxine and retinol-binding protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyXcOGE6oRy7Vg90H21EOLACvtfcHk0lhZ9eMPv2Ehaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFKmurbE&md5=5dfaf06a6cb8a0394d17d1586aa6a1e8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1515%2Fbmc-2013-0038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fbmc-2013-0038%26sid%3Dliteratum%253Aachs%26aulast%3DVieira%26aufirst%3DM.%26aulast%3DSaraiva%26aufirst%3DM.%2BJ.%26atitle%3DTransthyretin%253A%2520a%2520multifaceted%2520protein%26jtitle%3DBiomol.%2520Concepts%26date%3D2014%26volume%3D5%26spage%3D45%26epage%3D54%26doi%3D10.1515%2Fbmc-2013-0038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kassem, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, J. E.</span></span> <span> </span><span class="NLM_article-title">Role of transthyretin in thyroxine transfer from cerebrospinal fluid to brain and choroid plexus</span>. <i>Am. J. Physiol.: Regul., Integr. Comp. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">R1310</span>– <span class="NLM_lpage">R1315</span>, <span class="refDoi"> DOI: 10.1152/ajpregu.00789.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1152%2Fajpregu.00789.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=16825415" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2006&pages=R1310-R1315&author=N.+A.+Kassemauthor=R.+Deaneauthor=M.+B.+Segalauthor=J.+E.+Preston&title=Role+of+transthyretin+in+thyroxine+transfer+from+cerebrospinal+fluid+to+brain+and+choroid+plexus&doi=10.1152%2Fajpregu.00789.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.00789.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.00789.2005%26sid%3Dliteratum%253Aachs%26aulast%3DKassem%26aufirst%3DN.%2BA.%26aulast%3DDeane%26aufirst%3DR.%26aulast%3DSegal%26aufirst%3DM.%2BB.%26aulast%3DPreston%26aufirst%3DJ.%2BE.%26atitle%3DRole%2520of%2520transthyretin%2520in%2520thyroxine%2520transfer%2520from%2520cerebrospinal%2520fluid%2520to%2520brain%2520and%2520choroid%2520plexus%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Regul.%252C%2520Integr.%2520Comp.%2520Physiol.%26date%3D2006%26volume%3D291%26spage%3DR1310%26epage%3DR1315%26doi%3D10.1152%2Fajpregu.00789.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, Â.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liz, M. A.</span></span> <span> </span><span class="NLM_article-title">Transthyretin neuroprotection in Alzheimer’s disease is dependent on proteolysis</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.neurobiolaging.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=28780366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ems7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2017&pages=10-14&author=C.+S.+Silvaauthor=J.+Eiraauthor=C.+A.+Ribeiroauthor=%C3%82.+Oliveiraauthor=M.+M.+Sousaauthor=I.+Cardosoauthor=M.+A.+Liz&title=Transthyretin+neuroprotection+in+Alzheimer%E2%80%99s+disease+is+dependent+on+proteolysis&doi=10.1016%2Fj.neurobiolaging.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin neuroprotection in Alzheimer's disease is dependent on proteolysis</span></div><div class="casAuthors">Silva, Catarina S.; Eira, Jessica; Ribeiro, Carlos A.; Oliveira, Angela; Sousa, Monica M.; Cardoso, Isabel; Liz, Marcia A.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-14</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The deposition of amyloid β peptide (Aβ) in the hippocampus is one of the major hallmarks of Alzheimer's disease, a neurodegenerative disorder characterized by memory loss and cognitive impairment.  The modulation of Aβ levels in the brain results from an equil. between its prodn. from the amyloid precursor protein and removal by amyloid clearance proteins, which might occur via enzymic (Aβ-degrading enzymes) or nonenzymic (binding/transport proteins) reactions.  Transthyretin (TTR) is one of the major Aβ-binding proteins acting as a neuroprotector in AD.  In addn., TTR cleaves Aβ peptide in vitro.  In this work, we show that proteolytically active TTR, and not the inactive form of the protein, impacts on Aβ fibrillogenesis, degrades neuronal-secreted Aβ, and reduces Aβ-induced toxicity in hippocampal neurons.  Our data demonstrate that TTR proteolytic activity is required for the neuroprotective effect of the protein constituting a putative novel therapeutic target for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpThmsCU6e4d7Vg90H21EOLACvtfcHk0liRZjQCwxGBew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ems7%252FM&md5=3fc23516ebc342634546e4a855c15b75</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DC.%2BS.%26aulast%3DEira%26aufirst%3DJ.%26aulast%3DRibeiro%26aufirst%3DC.%2BA.%26aulast%3DOliveira%26aufirst%3D%25C3%2582.%26aulast%3DSousa%26aufirst%3DM.%2BM.%26aulast%3DCardoso%26aufirst%3DI.%26aulast%3DLiz%26aufirst%3DM.%2BA.%26atitle%3DTransthyretin%2520neuroprotection%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520is%2520dependent%2520on%2520proteolysis%26jtitle%3DNeurobiol.%2520Aging%26date%3D2017%26volume%3D59%26spage%3D10%26epage%3D14%26doi%3D10.1016%2Fj.neurobiolaging.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gião, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saavedra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotrina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsequell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, I.</span></span> <span> </span><span class="NLM_article-title">Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for alzheimer’s disease</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>, <span class="NLM_elocation-id">2075</span> <span class="refDoi"> DOI: 10.3390/ijms21062075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fijms21062075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVejsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&author=T.+Gi%C3%A3oauthor=J.+Saavedraauthor=E.+Cotrinaauthor=J.+Quintanaauthor=J.+Llopauthor=G.+Arsequellauthor=I.+Cardoso&title=Undiscovered+roles+for+transthyretin%3A+from+a+transporter+protein+to+a+new+therapeutic+target+for+alzheimer%E2%80%99s+disease&doi=10.3390%2Fijms21062075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Undiscovered roles for transthyretin: from a transporter protein to a new therapeutic target for Alzheimer's disease</span></div><div class="casAuthors">Giao, Tiago; Saavedra, Joana; Cotrina, Ellen; Quintana, Jordi; Llop, Jordi; Arsequell, Gemma; Cardoso, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, resp., has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids.  Still, this protein has managed to stay in the spotlight as it has been assigned new and varied functions.  In this review, we cover knowledge on novel TTR functions and the cellular pathways involved, spanning from neuroprotection to vascular events, while emphasizing its involvement in Alzheimer's disease (AD).  We describe details of TTR as an amyloid binding protein and discuss its interaction with the amyloid Aβ peptides, and the proposed mechanisms underlying TTR neuroprotection in AD.  We also present the importance of translating advances in the knowledge of the TTR neuroprotective role into drug discovery strategies focused on TTR as a new target in AD therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqKLQRIz_CCrVg90H21EOLACvtfcHk0liRZjQCwxGBew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVejsLbP&md5=2c3668a3205d852c73a34efd8df805a8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3390%2Fijms21062075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21062075%26sid%3Dliteratum%253Aachs%26aulast%3DGi%25C3%25A3o%26aufirst%3DT.%26aulast%3DSaavedra%26aufirst%3DJ.%26aulast%3DCotrina%26aufirst%3DE.%26aulast%3DQuintana%26aufirst%3DJ.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DArsequell%26aufirst%3DG.%26aulast%3DCardoso%26aufirst%3DI.%26atitle%3DUndiscovered%2520roles%2520for%2520transthyretin%253A%2520from%2520a%2520transporter%2520protein%2520to%2520a%2520new%2520therapeutic%2520target%2520for%2520alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26doi%3D10.3390%2Fijms21062075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, P. E.</span></span> <span> </span><span class="NLM_article-title">Kinetic analysis of the multistep aggregation pathway of human transthyretin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E6201</span>– <span class="NLM_lpage">E6208</span>, <span class="refDoi"> DOI: 10.1073/pnas.1807024115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1073%2Fpnas.1807024115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=29915031" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E6201-E6208&author=X.+Sunauthor=H.+J.+Dysonauthor=P.+E.+Wright&title=Kinetic+analysis+of+the+multistep+aggregation+pathway+of+human+transthyretin&doi=10.1073%2Fpnas.1807024115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1807024115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1807024115%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DDyson%26aufirst%3DH.%2BJ.%26aulast%3DWright%26aufirst%3DP.%2BE.%26atitle%3DKinetic%2520analysis%2520of%2520the%2520multistep%2520aggregation%2520pathway%2520of%2520human%2520transthyretin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3DE6201%26epage%3DE6208%26doi%3D10.1073%2Fpnas.1807024115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruberg, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M. S.</span></span> <span> </span><span class="NLM_article-title">Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2872</span>– <span class="NLM_lpage">2891</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2019.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.jacc.2019.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31171094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2hs7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=2872-2891&author=F.+L.+Rubergauthor=M.+Groganauthor=M.+Hannaauthor=J.+W.+Kellyauthor=M.+S.+Maurer&title=Transthyretin+amyloid+cardiomyopathy%3A+JACC+state-of-the-art+review&doi=10.1016%2Fj.jacc.2019.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin Amyloid Cardiomyopathy</span></div><div class="casAuthors">Ruberg, Frederick L.; Grogan, Martha; Hanna, Mazen; Kelly, Jeffery W.; Maurer, Mathew S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2872-2891</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin (TTR) or pre-albumin.  Characteristic patterns of echocardiog. and cardiac magnetic resonance can strongly suggest the disease but are not diagnostic.  The diagnosis can be made with noninvasive nuclear imaging when there is no evidence of a monoclonal protein.  Amyloid fibril formation results from a destabilizing mutation in hereditary ATTR amyloidosis (hATTR) or from an aging-linked process in wild-type ATTR amyloidosis (wtATTR).  Recent studies have suggested that up to 10% to 15% of older adults with HF may have unrecognized wtATTR.  Assocd. features, including carpal tunnel syndrome and lumbar spinal stenosis, raise suspicion and may afford a means for early diagnosis.  Previously treatable only by organ transplantation, pharmaceutical therapy that slows or halts ATTR-CM progression and favorably affects clin. outcomes is now available.  Early recognition remains essential to afford the best treatment efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFK5Abf8-PzLVg90H21EOLACvtfcHk0livrmt51MqZDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2hs7nE&md5=451b455f9dff555f9602116d7da03cb1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2019.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2019.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DRuberg%26aufirst%3DF.%2BL.%26aulast%3DGrogan%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DMaurer%26aufirst%3DM.%2BS.%26atitle%3DTransthyretin%2520amyloid%2520cardiomyopathy%253A%2520JACC%2520state-of-the-art%2520review%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2019%26volume%3D73%26spage%3D2872%26epage%3D2891%26doi%3D10.1016%2Fj.jacc.2019.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokochi, T.</span></span> <span> </span><span class="NLM_article-title">Transthyretin cardiac amyloidosis: an update on diagnosis and treatment</span>. <i>ESC Heart Fail.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1139</span>, <span class="refDoi"> DOI: 10.1002/ehf2.12518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fehf2.12518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31553132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvFGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1128-1139&author=H.+Yamamotoauthor=T.+Yokochi&title=Transthyretin+cardiac+amyloidosis%3A+an+update+on+diagnosis+and+treatment&doi=10.1002%2Fehf2.12518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin cardiac amyloidosis: an update on diagnosis and treatment</span></div><div class="casAuthors">Yamamoto Hiroyuki; Yokochi Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">ESC heart failure</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1128-1139</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Transthyretin cardiac amyloidosis (ATTR-CA) demonstrates progressive, potentially fatal, and infiltrative cardiomyopathy caused by extracellular deposition of transthyretin-derived insoluble amyloid fibrils in the myocardium.  Two distinct types of transthyretin (wild type or variant) become unstable, and misfolding forms aggregate, resulting in amyloid fibrils.  ATTR-CA, which has previously been underrecognized and considered to be rare, has been increasingly recognized as a cause of heart failure with preserved ejection fraction among elderly persons.  With the advanced technology, the diagnostic tools have been improving for cardiac amyloidosis.  Recently, the efficacy of several disease-modifying agents focusing on the amyloidogenic process has been demonstrated.  ATTR-CA has been changing from incurable to treatable.  Nevertheless, there are still no prognostic improvements due to diagnostic delay or misdiagnosis because of phenotypic heterogeneity and co-morbidities.  Thus, it is crucial for clinicians to be aware of this clinical entity for early diagnosis and proper treatment.  In this mini-review, we focus on recent advances in diagnosis and treatment of ATTR-CA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAmyb6j8k9Er0AGQpJZWpJfW6udTcc2ebZhQYqYWwRJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvFGlsw%253D%253D&md5=ae2e5096c74f15b8d8b37954cad3d8eb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fehf2.12518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fehf2.12518%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DYokochi%26aufirst%3DT.%26atitle%3DTransthyretin%2520cardiac%2520amyloidosis%253A%2520an%2520update%2520on%2520diagnosis%2520and%2520treatment%26jtitle%3DESC%2520Heart%2520Fail.%26date%3D2019%26volume%3D6%26spage%3D1128%26epage%3D1139%26doi%3D10.1002%2Fehf2.12518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waddington-Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botteman, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amass, L.</span></span> <span> </span><span class="NLM_article-title">Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series</span>. <i>Orphanet J. Rare Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">34</span> <span class="refDoi"> DOI: 10.1186/s13023-019-1000-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1186%2Fs13023-019-1000-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30736835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3cfgslChsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&author=M.+Waddington-Cruzauthor=H.+Schmidtauthor=M.+F.+Bottemanauthor=J.+A.+Carterauthor=M.+Stewartauthor=M.+Hoppsauthor=S.+Falletauthor=L.+Amass&title=Epidemiological+and+clinical+characteristics+of+symptomatic+hereditary+transthyretin+amyloid+polyneuropathy%3A+a+global+case+series&doi=10.1186%2Fs13023-019-1000-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series</span></div><div class="casAuthors">Waddington-Cruz Marcia; Waddington-Cruz Marcia; Schmidt Hartmut; Botteman Marc F; Carter John A; Stewart Michelle; Hopps Markay; Fallet Shari; Amass Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Orphanet journal of rare diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016.  Approximately 18% of the cases were from countries where ATTR-PN is traditionally considered to be endemic (i.e., Portugal, Japan, and Sweden).  East Asia (Japan, China, Taiwan, and South Korea) contributed a sizeable combined proportion (37.0%, n = 200) with Japan (n = 92) and China (n = 71) being the primary contributors.  The most common genotypes among the 65 genotypes represented in the sample were Val30Met (47.6%), Ser77Tyr (10%), Ala97Ser (6.5%), and Phe64Leu (4.4%).  Cases with genotypes other than the aforementioned four had the lowest ages at onset (mean 49.2 [standard deviation {SD} 21.0; inter-quartile range {IQR}14.7]) and diagnosis (mean 53.4 [SD 21.0; IQR 14.7]).  Conversely, Phe64Leu mean age of onset was 67.5 (SD 8.8; IQR 5.2) and mean age of diagnosis was 71.3 (SD 8.8; IQR 5.4).  The prevalence of upper and lower limb involvement at the time of diagnosis (67 and 41%) observed across all cases is consistent with the typical presentation of ATTR-PN.  Other notable findings at the time of diagnosis included a high rate of impotence among the Ala97Ser cases versus all others (67% vs. 21%) and a high rate of non-motor visual symptoms (i.e., visual opacities and glaucoma) in the Ser77Tyr cases versus all others (93% vs. 16%).  Though comparisons were made descriptively and were hindered by inconsistency of reporting across the cases, these findings support the notion that ATTR-PN is a more phenotypically and geographically variable disease than is typically considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR14vDbvZsWtj0SWnHPWbmmfW6udTcc2ebZhQYqYWwRJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfgslChsw%253D%253D&md5=882869e7aea9845f237864c82ecad74d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2Fs13023-019-1000-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13023-019-1000-1%26sid%3Dliteratum%253Aachs%26aulast%3DWaddington-Cruz%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DBotteman%26aufirst%3DM.%2BF.%26aulast%3DCarter%26aufirst%3DJ.%2BA.%26aulast%3DStewart%26aufirst%3DM.%26aulast%3DHopps%26aufirst%3DM.%26aulast%3DFallet%26aufirst%3DS.%26aulast%3DAmass%26aufirst%3DL.%26atitle%3DEpidemiological%2520and%2520clinical%2520characteristics%2520of%2520symptomatic%2520hereditary%2520transthyretin%2520amyloid%2520polyneuropathy%253A%2520a%2520global%2520case%2520series%26jtitle%3DOrphanet%2520J.%2520Rare%2520Dis.%26date%3D2019%26volume%3D14%26doi%3D10.1186%2Fs13023-019-1000-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamerlan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, S. S. A.</span></span> <span> </span><span class="NLM_article-title">Diagnostic and treatment approaches involving transthyretin in amyloidogenic diseases</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">2982</span> <span class="refDoi"> DOI: 10.3390/ijms20122982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fijms20122982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&author=G.+Y.+Parkauthor=A.+Jamerlanauthor=K.+H.+Shimauthor=S.+S.+A.+An&title=Diagnostic+and+treatment+approaches+involving+transthyretin+in+amyloidogenic+diseases&doi=10.3390%2Fijms20122982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnostic and treatment approaches involving transthyretin in amyloidogenic diseases</span></div><div class="casAuthors">Park, Gil Yong; Jamerlan, Angelo; Shim, Kyu Hwan; An, Seong Soo A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2982</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Transthyretin (TTR) is a thyroid hormone-binding protein which transports thyroxine from the bloodstream to the brain.  The structural stability of TTR in tetrameric form is crucial for maintaining its original functions in blood or cerebrospinal fluid (CSF).  The altered structure of TTR due to genetic mutations or its deposits due to aggregation could cause several deadly diseases such as cardiomyopathy and neuropathy in autonomic, motor, and sensory systems.  The early diagnoses for hereditary amyloid TTR with cardiomyopathy (ATTR-CM) and wild-type amyloid TTR (ATTRwt) amyloidosis, which result from amyloid TTR (ATTR) deposition, are difficult to distinguish due to the close similarities of symptoms.  Thus, many researchers investigated the role of ATTR as a biomarker, esp. its potential for differential diagnosis due to its varying pathogenic involvement in hereditary ATTR-CM and ATTRwt amyloidosis.  As a result, the detection of ATTR became valuable in the diagnosis and detn. of the best course of treatment for ATTR amyloidoses.  Assessing the extent of ATTR deposition and genetic anal. could help in detg. disease progression, and thus survival rate could be improved following the detn. of the appropriate course of treatment for the patient.  Here, the perspectives of ATTR in various diseases were presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBFDKPVBDBo7Vg90H21EOLACvtfcHk0ljfslzBXTWCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGlur4%253D&md5=69716e62707a004ec2c260166d6a6154</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3390%2Fijms20122982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20122982%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DG.%2BY.%26aulast%3DJamerlan%26aufirst%3DA.%26aulast%3DShim%26aufirst%3DK.%2BH.%26aulast%3DAn%26aufirst%3DS.%2BS.%2BA.%26atitle%3DDiagnostic%2520and%2520treatment%2520approaches%2520involving%2520transthyretin%2520in%2520amyloidogenic%2520diseases%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26doi%3D10.3390%2Fijms20122982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanus, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudas, L. J.</span></span> <span> </span><span class="NLM_article-title">Reduced levels of retinyl esters and vitamin A in human renal cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2774</span>– <span class="NLM_lpage">2781</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=11289161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVSksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2774-2781&author=X.+Guoauthor=D.+M.+Nanusauthor=A.+Ruizauthor=R.+R.+Randoauthor=D.+Bokauthor=L.+J.+Gudas&title=Reduced+levels+of+retinyl+esters+and+vitamin+A+in+human+renal+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced levels of retinyl esters and vitamin A in human renal cancers</span></div><div class="casAuthors">Guo, Xiaojia; Nanus, David M.; Ruiz, Alberto; Rando, Robert R.; Bok, Dean; Gudas, Lorraine J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2774-2781</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. and preclin. studies suggest that retinoids can inhibit the growth of a small percentage of human renal cancers (RCs), although the majority of RCs both in vitro and in vivo are retinoid resistant.  Our recent studies indicate that the metab. of retinol to retinyl esters is greatly reduced in human carcinoma cell lines of the oral cavity, skin, and breast as compared with their normal epithelial counterparts, suggesting that human carcinoma cells are retinoid deficient relative to normal epithelial cells.  We considered whether retinoid resistance in RCs was related to an abnormality in retinoid metab.  The metab. of [3H]retinol and of [3H]retinoic acid (RA) was examd. in RC cell lines and normal human kidney (NK) epithelial cells cultured in media, in RA, or in RA plus IFN-α.  The expression of LRAT (lecithin:retinol acyltransferase) was assessed by Northern and Western anal.  Retinol and retinyl ester levels were detd. in tissue samples of normal human kidney and renal cell carcinoma.  NK cells esterified all of the 50 nM [3H]retinol in which they were cultured.  In contrast, six of the seven RC cell lines metabolized only trace amts. of [3H]retinol to [3H]retinyl esters.  Consistent with this relative lack of [3H]retinol esterification by the tumor cells, the tumor cells exhibited LRAT transcripts of aberrantly low sizes relative to those in normal epithelial cells.  Moreover, the NK cells expressed abundant levels of LRAT protein by Western anal., whereas the RC cells did not express LRAT protein.  When samples of human kidney tumor tissue were compared with samples of normal kidney tissue from patients who had undergone surgery for primary RC, the normal kidney tissues contained much higher levels of retinol and retinyl esters (approx. 0.5-2 μg/g wet wt.) than the tumor tissues in all seven patients examd.  Culture of the RC lines in IFN-α plus all-trans-RA, a combination therapy used clin., resulted in higher intracellular levels of [3H]retinol and [3H]retinyl esters.  The metab. of [3H]RA was also examd. in these RC lines vs. NK cells.  Although the NK epithelial cells metabolized [3H]RA, the majority of the RC lines metabolized [3H]RA at a much slower rate.  Most of the RC lines metabolized only 10-30% of the 50 nM [3H]RA over 6 h of culture.  These data indicate that RCs both in vitro and in vivo are retinol and retinyl ester deficient relative to the normal human kidney, and they suggest that the aberrant differentiation of the neoplastic renal cells results in part from a defect in retinoid metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtLlv9bBM1crVg90H21EOLACvtfcHk0ljfslzBXTWCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVSksbc%253D&md5=6cb366b2e4f647f4c41469bc50de0c7f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DNanus%26aufirst%3DD.%2BM.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DBok%26aufirst%3DD.%26aulast%3DGudas%26aufirst%3DL.%2BJ.%26atitle%3DReduced%2520levels%2520of%2520retinyl%2520esters%2520and%2520vitamin%2520A%2520in%2520human%2520renal%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2774%26epage%3D2781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Susanto, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. S.</span></span> <span> </span><span class="NLM_article-title">Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells</span>. <i>J. Gene Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1002/jgm.1276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fjgm.1276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=19065606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1KhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=103-111&author=M.+Kamataauthor=M.+T.+Susantoauthor=I.+S.+Chen&title=Enhanced+transthyretin+tetramer+stability+following+expression+of+an+amyloid+disease+transsuppressor+variant+in+mammalian+cells&doi=10.1002%2Fjgm.1276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells</span></div><div class="casAuthors">Kamata, Masakazu; Susanto, Melisa T.; Chen, Irvin S. Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Gene Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-111</span>CODEN:
                <span class="NLM_cas:coden">JGMEFG</span>;
        ISSN:<span class="NLM_cas:issn">1099-498X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Background: The transthyretin (TTR) amyloidosis is an incurable fatal inherited disease that is characterized by progressive peripheral and autonomic neuropathy.  It is caused by missense amyloidogenic mutations in the TTR gene that destabilize the native tetrameric state and lead to the cytotoxic misfolded monomeric state.  One interesting variant (T119M) stabilizes heterotetramers with amyloidogenic TTR and, in the reported heterozygous individuals, protects the carriers from disease.  In the present study, we characterize in vitro and in vivo the ectopic expression of the human T119M mutant, termed a transsuppressor for TTR amyloid disease.  Methods: Lentiviral vectors encoding wild or mutant forms of human TTR were constructed and transduced to the human hepatocellular carcinoma cell line, HepG2, or mice.  Heterooligomerization between T119M TTR and amyloidogenic variants was analyzed by immunopptn. following western blotting.  Results: T119M TTR was stably expressed in transduced HepG2 cells and was secreted as an oligomer that can interact with its native partner, retinol-binding protein.  Importantly, the T119M TTR formed secreted heterooligomers with amyloidogenic TTR variants, V30M, L55P and V122I, in HepG2 cells that were more stable than the homooligomers of the same amyloidogenic TTR variants.  Human T119M TTR also formed heterooligomers with V30M TTR in transduced mice.  Conclusions: The results obtained in the present study demonstrate the stabilization of heterotetramers by T119M TTR in human cells and suggest that gene transfer of T119M TTR may have potential as a gene therapy for TTR amyloidosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyqbPaieeyX7Vg90H21EOLACvtfcHk0ljfslzBXTWCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1KhsLk%253D&md5=f95f5b0f68180a6caf82c913a5f50a16</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjgm.1276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjgm.1276%26sid%3Dliteratum%253Aachs%26aulast%3DKamata%26aufirst%3DM.%26aulast%3DSusanto%26aufirst%3DM.%2BT.%26aulast%3DChen%26aufirst%3DI.%2BS.%26atitle%3DEnhanced%2520transthyretin%2520tetramer%2520stability%2520following%2520expression%2520of%2520an%2520amyloid%2520disease%2520transsuppressor%2520variant%2520in%2520mammalian%2520cells%26jtitle%3DJ.%2520Gene%2520Med.%26date%3D2009%26volume%3D11%26spage%3D103%26epage%3D111%26doi%3D10.1002%2Fjgm.1276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. K.</span></span> <span> </span><span class="NLM_article-title">Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1525</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S162913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.2147%2FDDDT.S162913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31118583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=1515-1525&author=V.+Mathewauthor=A.+K.+Wang&title=Inotersen%3A+new+promise+for+the+treatment+of+hereditary+transthyretin+amyloidosis&doi=10.2147%2FDDDT.S162913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis</span></div><div class="casAuthors">Mathew, Veena; Wang, Annabel K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1515-1525</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract.  Previous treatments using liver transplantation and small mol. stabilizers were not effective in stopping disease progression.  Inotersen, a 2'-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the prodn. of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-mo Phase III study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSK9IbPaT1mrVg90H21EOLACvtfcHk0ljfslzBXTWCqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisrvO&md5=d74cfa639bfb514a97ddafe6118639b1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S162913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S162913%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DA.%2BK.%26atitle%3DInotersen%253A%2520new%2520promise%2520for%2520the%2520treatment%2520of%2520hereditary%2520transthyretin%2520amyloidosis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D1515%26epage%3D1525%26doi%3D10.2147%2FDDDT.S162913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Patisiran: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1625</span>– <span class="NLM_lpage">1631</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0983-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs40265-018-0983-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30251172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslymsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1625-1631&author=S.+M.+Hoy&title=Patisiran%3A+first+global+approval&doi=10.1007%2Fs40265-018-0983-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Patisiran: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1625-1631</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Patisiran (ONPATTRO) is a double-stranded small interfering RNA encapsulated in a lipid nanoparticle for delivery to hepatocytes.  By specifically binding to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type transthyretin (TTR) mRNA, patisiran causes its degrdn. (via RNA interference) and subsequently a redn. in serum TTR protein levels and tissue TTR protein deposits.  Patisiran has been developed by Alnylam Pharmaceuticals; it was recently approved in the USA for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis (hATTR) in adults and subsequently approved in the EU for the treatment of hATTR in adults with stage 1 or 2 polyneuropathy.  The recommended dosage, administered as a single i.v. infusion over approx. 80 min, is 0.3 mg/kg once every 3 wk for patients weighing < 100 kg and 30 mg once every 3 wk for patients weighing ≥ 100 kg.  This article summarizes the milestones in the development of patisiran leading to these approvals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr69gWrTaxHmLVg90H21EOLACvtfcHk0lip4km-NKf83A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslymsLfI&md5=94abed01abbe7ba7b679224a42338810</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0983-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0983-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DPatisiran%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1625%26epage%3D1631%26doi%3D10.1007%2Fs40265-018-0983-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bulawa, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaudiniere, R.</span></span> <span> </span><span class="NLM_article-title">Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">9629</span>– <span class="NLM_lpage">9634</span>, <span class="refDoi"> DOI: 10.1073/pnas.1121005109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1073%2Fpnas.1121005109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=22645360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=9629-9634&author=C.+E.+Bulawaauthor=S.+Connellyauthor=M.+Devitauthor=L.+Wangauthor=C.+Weigelauthor=J.+A.+Flemingauthor=J.+Packmanauthor=E.+T.+Powersauthor=R.+L.+Wisemanauthor=T.+R.+Fossauthor=I.+A.+Wilsonauthor=J.+W.+Kellyauthor=R.+Labaudiniere&title=Tafamidis%2C+a+potent+and+selective+transthyretin+kinetic+stabilizer+that+inhibits+the+amyloid+cascade&doi=10.1073%2Fpnas.1121005109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade</span></div><div class="casAuthors">Bulawa, Christine E.; Connelly, Stephen; DeVit, Michael; Wang, Lan; Weigel, Charlotte; Fleming, James A.; Packman, Jeff; Powers, Evan T.; Wiseman, R. Luke; Foss, Theodore R.; Wilson, Ian A.; Kelly, Jeffery W.; Labaudiniere, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9629-9634, S9629/1-S9629/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The transthyretin amyloidoses (ATTR) are invariably fatal diseases characterized by progressive neuropathy and/or cardiomyopathy.  ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein complex.  Mutations within TTR that cause autosomal dominant forms of disease facilitate tetramer dissocn., monomer misfolding, and aggregation, although wild-type TTR can also form amyloid fibrils in elderly patients.  Because tetramer dissocn. is the rate-limiting step in TTR amyloidogenesis, targeted therapies have focused on small mols. that kinetically stabilize the tetramer, inhibiting TTR amyloid fibril formation.  One such compd., tafamidis meglumine (Fx-1006A), has recently completed Phase II/111 trials for the treatment of Transthyretin type familial amyloid polyneuropathy (TTR-FAP) and demonstrated a slowing of disease progression in patients heterozygous for the V30M TTR mutation.  Herein we describe the mol. and structural basis of TTR tetramer stabilization by tafamidis.  Tafamidis binds selectively and with neg. cooperativity (KdS ∼2 nM and ∼200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically stabilizes TTR.  Patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants, are also stabilized by tafamidis binding.  The crystal structure of tafamidis-bound TTR suggests that binding stabilizes the weaker dimer-dimer interface against dissocn., the rate-limiting step of amyloidogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfzfMIrqJGHLVg90H21EOLACvtfcHk0lip4km-NKf83A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWjtb4%253D&md5=05bf9cd644ab6a3dda78bb1620986910</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1121005109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1121005109%26sid%3Dliteratum%253Aachs%26aulast%3DBulawa%26aufirst%3DC.%2BE.%26aulast%3DConnelly%26aufirst%3DS.%26aulast%3DDevit%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWeigel%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DJ.%2BA.%26aulast%3DPackman%26aufirst%3DJ.%26aulast%3DPowers%26aufirst%3DE.%2BT.%26aulast%3DWiseman%26aufirst%3DR.%2BL.%26aulast%3DFoss%26aufirst%3DT.%2BR.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DLabaudiniere%26aufirst%3DR.%26atitle%3DTafamidis%252C%2520a%2520potent%2520and%2520selective%2520transthyretin%2520kinetic%2520stabilizer%2520that%2520inhibits%2520the%2520amyloid%2520cascade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D9629%26epage%3D9634%26doi%3D10.1073%2Fpnas.1121005109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulawa, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plante-Bordeneuve, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaudiniere, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundayat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas, P.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis</span>. <i>Neurol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1007/s40120-016-0040-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs40120-016-0040-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=26894299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BC28jit12rtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=1-25&author=T.+Coelhoauthor=G.+Merliniauthor=C.+E.+Bulawaauthor=J.+A.+Flemingauthor=D.+P.+Judgeauthor=J.+W.+Kellyauthor=M.+S.+Maurerauthor=V.+Plante-Bordeneuveauthor=R.+Labaudiniereauthor=R.+Mundayatauthor=S.+Rileyauthor=I.+Lombardoauthor=P.+Huertas&title=Mechanism+of+action+and+clinical+application+of+tafamidis+in+hereditary+transthyretin+amyloidosis&doi=10.1007%2Fs40120-016-0040-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis</span></div><div class="casAuthors">Coelho Teresa; Merlini Giampaolo; Bulawa Christine E; Fleming James A; Judge Daniel P; Kelly Jeffery W; Maurer Mathew S; Plante-Bordeneuve Violaine; Labaudiniere Richard; Mundayat Rajiv; Riley Steve; Lombardo Ilise; Huertas Pedro</div><div class="citationInfo"><span class="NLM_cas:title">Neurology and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-25</span>
        ISSN:<span class="NLM_cas:issn">2193-8253</span>.
    </div><div class="casAbstract">Transthyretin (TTR) transports the retinol-binding protein-vitamin A complex and is a minor transporter of thyroxine in blood.  Its tetrameric structure undergoes rate-limiting dissociation and monomer misfolding, enabling TTR to aggregate or to become amyloidogenic.  Mutations in the TTR gene generally destabilize the tetramer and/or accelerate tetramer dissociation, promoting amyloidogenesis.  TTR-related amyloidoses are rare, fatal, protein-misfolding disorders, characterized by formation of soluble aggregates of variable structure and tissue deposition of amyloid.  The TTR amyloidoses present with a spectrum of manifestations, encompassing progressive neuropathy and/or cardiomyopathy.  Until recently, the only accepted treatment to halt progression of hereditary TTR amyloidosis was liver transplantation, which replaces the hepatic source of mutant TTR with the less amyloidogenic wild-type TTR.  Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis.  Tafamidis is the first pharmacotherapy approved to slow the progression of peripheral neurologic impairment in TTR familial amyloid polyneuropathy.  Here we describe the mechanism of action of tafamidis and review the clinical data, demonstrating that tafamidis treatment slows neurologic deterioration and preserves nutritional status, as well as quality of life in patients with early-stage Val30Met amyloidosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcjwtDHHoc2pQHPYJuLg8TfW6udTcc2ebekWIcQ_xdCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jit12rtA%253D%253D&md5=cbf6666ed975691337c8b2f351036d7f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs40120-016-0040-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40120-016-0040-x%26sid%3Dliteratum%253Aachs%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DMerlini%26aufirst%3DG.%26aulast%3DBulawa%26aufirst%3DC.%2BE.%26aulast%3DFleming%26aufirst%3DJ.%2BA.%26aulast%3DJudge%26aufirst%3DD.%2BP.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DMaurer%26aufirst%3DM.%2BS.%26aulast%3DPlante-Bordeneuve%26aufirst%3DV.%26aulast%3DLabaudiniere%26aufirst%3DR.%26aulast%3DMundayat%26aufirst%3DR.%26aulast%3DRiley%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DI.%26aulast%3DHuertas%26aufirst%3DP.%26atitle%3DMechanism%2520of%2520action%2520and%2520clinical%2520application%2520of%2520tafamidis%2520in%2520hereditary%2520transthyretin%2520amyloidosis%26jtitle%3DNeurol.%2520Ther.%26date%3D2016%26volume%3D5%26spage%3D1%26epage%3D25%26doi%3D10.1007%2Fs40120-016-0040-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maia, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plante-Bordeneuve, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhr, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conceicao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trigo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaudiniere, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, D. R.</span></span> <span> </span><span class="NLM_article-title">Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy</span>. <i>J. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">2802</span>– <span class="NLM_lpage">2814</span>, <span class="refDoi"> DOI: 10.1007/s00415-013-7051-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs00415-013-7051-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23974642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=2013&pages=2802-2814&author=T.+Coelhoauthor=L.+F.+Maiaauthor=A.+M.+da+Silvaauthor=M.+W.+Cruzauthor=V.+Plante-Bordeneuveauthor=O.+B.+Suhrauthor=I.+Conceicaoauthor=H.+H.+Schmidtauthor=P.+Trigoauthor=J.+W.+Kellyauthor=R.+Labaudiniereauthor=J.+Chanauthor=J.+Packmanauthor=D.+R.+Grogan&title=Long-term+effects+of+tafamidis+for+the+treatment+of+transthyretin+familial+amyloid+polyneuropathy&doi=10.1007%2Fs00415-013-7051-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy</span></div><div class="casAuthors">Coelho, Teresa; Maia, Luis F.; Martins da Silva, Ana; Cruz, Marcia W.; Plante-Bordeneuve, Violaine; Suhr, Ole B.; Conceicao, Isabel; Schmidt, Hartmut H.-J.; Trigo, Pedro; Kelly, Jeffery W.; Labaudiniere, Richard; Chan, Jason; Packman, Jeff; Grogan, Donna R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2802-2814</span>CODEN:
                <span class="NLM_cas:coden">JNRYA9</span>;
        ISSN:<span class="NLM_cas:issn">0340-5354</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP) in an 18-mo randomized controlled trial (study Fx-005).  This 12-mo, open-label extension study evaluated the long-term safety, tolerability, and efficacy of tafamidis 20 mg once daily in 86 patients who earlier received blinded treatment with tafamidis or placebo.  Efficacy measures included the Neuropathy Impairment Score in the Lower Limbs (NIS-LL), Norfolk Quality of Life-Diabetic Neuropathy total quality of life (TQOL) score, and changes in neurol. function and nutritional status.  We quantified the monthly rates of change in efficacy measures, and TTR stabilization, and monitored adverse events (AEs).  Patients who continued on tafamidis had stable rates of change in NIS-LL (from 0.08 to 0.11/mo; p = 0.60) and TQOL (from -0.03 to 0.25; p = 0.16).  In patients switched from placebo, the monthly rate of change in NIS-LL declined (from 0.34 to 0.16/mo; p = 0.01), as did TQOL score (from 0.61 to -0.16; p < 0.001).  Patients treated with tafamidis for 30 mo had 55.9 % greater preservation of neurol. function as measured by the NIS-LL than patients in whom tafamidis was initiated later.  Plasma TTR was stabilized in 94.1 % of patients treated with tafamidis for 30 mo.  AEs were similar between groups; no patients discontinued because of an AE.  Long-term tafamidis was well tolerated, with the reduced rate of neurol. deterioration sustained over 30 mo.  Tafamidis also slowed neurol. impairment in patients previously given placebo, but treatment benefits were greater when tafamidis was begun earlier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgr1CkOGcKu7Vg90H21EOLACvtfcHk0lg1td07hDIj7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2jurfI&md5=0168b9b97845a5b89a21e43eb031ab88</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs00415-013-7051-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00415-013-7051-7%26sid%3Dliteratum%253Aachs%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DMaia%26aufirst%3DL.%2BF.%26aulast%3Dda%2BSilva%26aufirst%3DA.%2BM.%26aulast%3DCruz%26aufirst%3DM.%2BW.%26aulast%3DPlante-Bordeneuve%26aufirst%3DV.%26aulast%3DSuhr%26aufirst%3DO.%2BB.%26aulast%3DConceicao%26aufirst%3DI.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DTrigo%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DLabaudiniere%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DPackman%26aufirst%3DJ.%26aulast%3DGrogan%26aufirst%3DD.%2BR.%26atitle%3DLong-term%2520effects%2520of%2520tafamidis%2520for%2520the%2520treatment%2520of%2520transthyretin%2520familial%2520amyloid%2520polyneuropathy%26jtitle%3DJ.%2520Neurol.%26date%3D2013%26volume%3D260%26spage%3D2802%26epage%3D2814%26doi%3D10.1007%2Fs00415-013-7051-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M. W.</span></span> <span> </span><span class="NLM_article-title">Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review</span>. <i>Clin. Auton. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1007/s10286-019-00625-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs10286-019-00625-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31407119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3MvnsVeisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=19-24&author=M.+W.+Cruz&title=Tafamidis+for+autonomic+neuropathy+in+hereditary+transthyretin+%28ATTR%29+amyloidosis%3A+a+review&doi=10.1007%2Fs10286-019-00625-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review</span></div><div class="casAuthors">Cruz Marcia Waddington</div><div class="citationInfo"><span class="NLM_cas:title">Clinical autonomic research : official journal of the Clinical Autonomic Research Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">Suppl 1</span>),
    <span class="NLM_cas:pages">19-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Autonomic dysfunction is a very common, early and distressing aspect of hereditary transthyretin (ATTR) amyloidosis leading to significant loss of quality of life and morbidity for patients.  Although the clinical variability of ATTR has been well characterized as neuropathic, cardiac or mixed phenotype, the extent of autonomic involvement remains poorly understood.  Despite the fact that the autonomic nervous system has not been specifically evaluated in any of the clinical trials of tafamidis, and that, for some primary and secondary endpoints used in these trials, the behavior cannot be separated from non-autonomic items, an attempt was made to use published material to indirectly access the efficacy of tafamidis in treating dysautonomia.  METHODS:  Literature review summarizing the results of primary and secondary endpoints related to the autonomic features used in the original tafamidis trials, the post hoc publications, and real-world data, on the effect of tafamidis on autonomic dysfunction in patients with ATTR amyloidosis.  RESULTS:  There is some evidence that indirectly demonstrates that tafamidis is safe and could slow or arrest the progression of autonomic neuropathy in patients with ATTR amyloidosis, in addition to its well-described effects to ameliorate sensory-motor peripheral neuropathy.  CONCLUSION:  Although the current evidence is scarce, tafamidis might be effective in arresting the progression of autonomic neuropathy in patients with ATTR amyloidosis.  Tafamidis might be more effective at the early stage of the disease; however, individual responses must be monitored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLikgH0XNLR5WtyewyzkyLfW6udTcc2ebcM_fp9N-1Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvnsVeisg%253D%253D&md5=2e656b17da59608e673bcf2e68baab74</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10286-019-00625-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10286-019-00625-9%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DM.%2BW.%26atitle%3DTafamidis%2520for%2520autonomic%2520neuropathy%2520in%2520hereditary%2520transthyretin%2520%2528ATTR%2529%2520amyloidosis%253A%2520a%2520review%26jtitle%3DClin.%2520Auton.%2520Res.%26date%3D2019%26volume%3D29%26spage%3D19%26epage%3D24%26doi%3D10.1007%2Fs10286-019-00625-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Tafamidis: a review in transthyretin amyloidosis with polyneuropathy</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01129-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2Fs40265-019-01129-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31098895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=863-874&author=Y.+N.+Lambauthor=E.+D.+Deeks&title=Tafamidis%3A+a+review+in+transthyretin+amyloidosis+with+polyneuropathy&doi=10.1007%2Fs40265-019-01129-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy</span></div><div class="casAuthors">Lamb, Yvette N.; Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">863-874</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Transthyretin amyloidosis with polyneuropathy (ATTR-PN), a rare and progressive hereditary disorder, results from mutations in the gene coding for the transthyretin (TTR) protein that destabilize the protein's tetrameric structure.  In over 40 countries worldwide, tafamidis (Vyndaqel) is approved for the treatment of TTR amyloidosis in adults with stage 1 symptomatic polyneuropathy, to delay peripheral neurol. impairment.  Tafamidis is administered orally once daily, as a soft capsule.  Evidence from clin. studies, including an 18-mo placebo-controlled trial and subsequent long-term, open-label extension studies (providing data from ≤ 6 years of treatment), indicate that tafamidis slowed deterioration of neurol. function and maintained health-related quality of life in patients with early-stage ATTR-PN and the Val30Met mutation.  TTR tetramers were stabilized in nearly all patients, and nutritional status was generally maintained or improved.  Similar benefit was seen with tafamidis over 12 mo in a noncomparative trial in patients with non-Val30Met ATTR-PN, although disease progression in this population (which was older and had had ATTR-PN for longer than Val30Met patients) became more notable with continued therapy in an extension study.  Data for up to 10 years from large registry and referral center studies support the long-term effectiveness and safety of tafamidis in delaying disease progression and conferring survival benefits in patients with stage 1 ATTR-PN.  Tafamidis was generally well tolerated, with no new safety signals detected during the long-term trial or real-world experience.  Thus, based on up to 10 years' experience, tafamidis continues to be a valuable option in the treatment of early-stage ATTR-PN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMa9d1adtjwLVg90H21EOLACvtfcHk0lg1td07hDIj7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtL3F&md5=4b24681e65dfc76805b1afe0257a58ae</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01129-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01129-6%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DTafamidis%253A%2520a%2520review%2520in%2520transthyretin%2520amyloidosis%2520with%2520polyneuropathy%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D863%26epage%3D874%26doi%3D10.1007%2Fs40265-019-01129-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egolum, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ombengi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, H.</span></span> <span> </span><span class="NLM_article-title">Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1177/1060028019888489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1177%2F1060028019888489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31735059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3MjpvFKltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2020&pages=470-477&author=J.+Parkauthor=U.+Egolumauthor=S.+Parkerauthor=E.+Andrewsauthor=D.+Ombengiauthor=H.+Ling&title=Tafamidis%3A+a+first-in-class+transthyretin+stabilizer+for+transthyretin+amyloid+cardiomyopathy&doi=10.1177%2F1060028019888489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy</span></div><div class="casAuthors">Park Jonathan; Ling Hua; Egolum Ugochukwu; Parker Shanea; Andrews Ebony; Ombengi David</div><div class="citationInfo"><span class="NLM_cas:title">The Annals of pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">470-477</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM).  Data Sources: A PubMed (1966 to October 2019) and ClinicalTrials. gov search was conducted using the keywords tafamidis, Fx-1006A, Vyndaqel, and Vyndamax.  Additional articles were identified from references.  Study Selection and Data Extraction: We included English-language clinical studies evaluating the pharmacology, efficacy, or safety of tafamidis in humans for ATTR-CM.  Data Synthesis: Tafamidis binds to the thyroxine-binding sites of the transthyretin tetramer and inhibits its dissociation into monomers, which is the rate-limiting step in the amyloidogenic process.  Treatment with tafamidis was significantly associated with a significant reduction in mortality, lowered cardiovascular-related hospitalizations, less functional decline, and improved transthyretin stabilization compared with placebo.  Additionally, tafamidis was found to have fewer adverse events, with no difference found compared with placebo.  Relevance to Patient Care and Clinical Practice: Historically, symptomatic management for ATTR-CM was the only option, and the treatment of the underlying disease was limited to liver or heart transplantation.  Tafamidis is the first medication approved for the treatment of ATTR-CM and the only medication that showed a reduction in all-cause mortality and cardiovascular-related hospitalizations in patients with amyloidosis.  However, the role of tafamidis in patients with the New York Heart Association class III/IV heart failure or mutated transthyretin remains unclear.  Conclusion: Tafamidis is an effective and safe oral medication for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMKK_PvoY15e-MdeMhXAHkfW6udTcc2eaewHkcCm4aRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjpvFKltA%253D%253D&md5=828d021f03df09f6415b4c24e8f98c88</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1177%2F1060028019888489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028019888489%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DEgolum%26aufirst%3DU.%26aulast%3DParker%26aufirst%3DS.%26aulast%3DAndrews%26aufirst%3DE.%26aulast%3DOmbengi%26aufirst%3DD.%26aulast%3DLing%26aufirst%3DH.%26atitle%3DTafamidis%253A%2520a%2520first-in-class%2520transthyretin%2520stabilizer%2520for%2520transthyretin%2520amyloid%2520cardiomyopathy%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2020%26volume%3D54%26spage%3D470%26epage%3D477%26doi%3D10.1177%2F1060028019888489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alhamadsheh, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reixach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, I. A.</span></span> <span> </span><span class="NLM_article-title">Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">97ra81</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3002473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1126%2Fscitranslmed.3002473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=21865539" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=M.+M.+Alhamadshehauthor=S.+Connellyauthor=A.+Choauthor=N.+Reixachauthor=E.+T.+Powersauthor=D.+W.+Panauthor=I.+A.+Wilsonauthor=J.+W.+Kellyauthor=I.+A.+Graef&title=Potent+kinetic+stabilizers+that+prevent+transthyretin-mediated+cardiomyocyte+proteotoxicity&doi=10.1126%2Fscitranslmed.3002473"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002473%26sid%3Dliteratum%253Aachs%26aulast%3DAlhamadsheh%26aufirst%3DM.%2BM.%26aulast%3DConnelly%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DA.%26aulast%3DReixach%26aufirst%3DN.%26aulast%3DPowers%26aufirst%3DE.%2BT.%26aulast%3DPan%26aufirst%3DD.%2BW.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DGraef%26aufirst%3DI.%2BA.%26atitle%3DPotent%2520kinetic%2520stabilizers%2520that%2520prevent%2520transthyretin-mediated%2520cardiomyocyte%2520proteotoxicity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26doi%3D10.1126%2Fscitranslmed.3002473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albusairi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque Tuhin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jampala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faaij, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamboni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhamadsheh, M.</span></span> <span> </span><span class="NLM_article-title">enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7862</span>– <span class="NLM_lpage">7876</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00817</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00817" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGisLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7862-7876&author=M.+Millerauthor=A.+Palauthor=W.+Albusairiauthor=H.+Jooauthor=B.+Pappasauthor=M.+T.+Haque+Tuhinauthor=D.+Liangauthor=R.+Jampalaauthor=F.+Liuauthor=J.+Khanauthor=M.+Faaijauthor=M.+Parkauthor=W.+Chanauthor=I.+Graefauthor=R.+Zamboniauthor=N.+Kumarauthor=J.+Foxauthor=U.+Sinhaauthor=M.+Alhamadsheh&title=enthalpy-driven+stabilization+of+transthyretin+by+AG10+mimics+a+naturally+occurring+genetic+variant+that+protects+from+transthyretin+amyloidosis&doi=10.1021%2Facs.jmedchem.8b00817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis</span></div><div class="casAuthors">Miller, Mark; Pal, Arindom; Albusairi, Wabel; Joo, Hyun; Pappas, Beverly; Haque Tuhin, Md Tariqul; Liang, Dengpan; Jampala, Raghavendra; Liu, Fang; Khan, Jared; Faaij, Marjon; Park, Miki; Chan, William; Graef, Isabella; Zamboni, Robert; Kumar, Neil; Fox, Jonathan; Sinha, Uma; Alhamadsheh, Mamoun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7862-7876</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a fatal disease with no available disease-modifying therapies.  While pathogenic TTR mutations (TTRm) destabilize TTR tetramers, the T119M variant stabilizes TTRm and prevents disease.  A comparison of potency for leading TTR stabilizers in clinic and structural features important for effective TTR stabilization is lacking.  Here, the authors found that mol. interactions reflected in better binding enthalpy may be crit. for development of TTR stabilizers with improved potency and selectivity.  The authors' studies provide mechanistic insights into the unique binding mode of the TTR stabilizer, AG10, which could be attributed to mimicking the stabilizing T119M variant.  Because of the lack of animal models for ATTR-CM, the authors developed an in vivo system in dogs which proved appropriate for assessing the pharmacokinetics-pharmacodynamics profile of TTR stabilizers.  In addn. to stabilizing TTR, the authors hypothesize that optimizing the binding enthalpy could have implications for designing therapeutic agents for other amyloid diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFRxbT_TPMuLVg90H21EOLACvtfcHk0lhj-6p26fMNmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGisLbF&md5=fb11b83078d797c761397a907b637bbf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00817%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPal%26aufirst%3DA.%26aulast%3DAlbusairi%26aufirst%3DW.%26aulast%3DJoo%26aufirst%3DH.%26aulast%3DPappas%26aufirst%3DB.%26aulast%3DHaque%2BTuhin%26aufirst%3DM.%2BT.%26aulast%3DLiang%26aufirst%3DD.%26aulast%3DJampala%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DKhan%26aufirst%3DJ.%26aulast%3DFaaij%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DW.%26aulast%3DGraef%26aufirst%3DI.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DFox%26aufirst%3DJ.%26aulast%3DSinha%26aufirst%3DU.%26aulast%3DAlhamadsheh%26aufirst%3DM.%26atitle%3Denthalpy-driven%2520stabilization%2520of%2520transthyretin%2520by%2520AG10%2520mimics%2520a%2520naturally%2520occurring%2520genetic%2520variant%2520that%2520protects%2520from%2520transthyretin%2520amyloidosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7862%26epage%3D7876%26doi%3D10.1021%2Facs.jmedchem.8b00817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penchala, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranczak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappley, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liedtke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witteles, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reixach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhamadsheh, M. M.</span></span> <span> </span><span class="NLM_article-title">AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">9992</span>– <span class="NLM_lpage">9997</span>, <span class="refDoi"> DOI: 10.1073/pnas.1300761110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1073%2Fpnas.1300761110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23716704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOrtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=9992-9997&author=S.+C.+Penchalaauthor=S.+Connellyauthor=Y.+Wangauthor=M.+S.+Parkauthor=L.+Zhaoauthor=A.+Baranczakauthor=I.+Rappleyauthor=H.+Vogelauthor=M.+Liedtkeauthor=R.+M.+Wittelesauthor=E.+T.+Powersauthor=N.+Reixachauthor=W.+K.+Chanauthor=I.+A.+Wilsonauthor=J.+W.+Kellyauthor=I.+A.+Graefauthor=M.+M.+Alhamadsheh&title=AG10+inhibits+amyloidogenesis+and+cellular+toxicity+of+the+familial+amyloid+cardiomyopathy-associated+V122I+transthyretin&doi=10.1073%2Fpnas.1300761110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin</span></div><div class="casAuthors">Penchala, Sravan C.; Connelly, Stephen; Wang, Yu; Park, Miki S.; Zhao, Lei; Baranczak, Aleksandra; Rappley, Irit; Vogel, Hannes; Liedtke, Michaela; Witteles, Ronald M.; Powers, Evan T.; Reixach, Natalia; Chan, William K.; Wilson, Ian A.; Keliy, Jeffery W.; Graef, Isabella A.; Alhamadsheh, Mamoun M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9992-9997, S9992/1-S9992/23</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The misassembly of sol. proteins into toxic aggregates, including amyloid fibrils, underlies a large no. of human degenerative diseases.  Cardiac amyloidoses, which are most commonly caused by aggregation of Ig light chains or transthyretin (TTR) in the cardiac interstitium and conducting system, represent an important and often underdiagnosed cause of heart failure.  Two types of TTR-assocd. amyloid cardiomyopathies are clin. important.  The Val122Ile (V112I) mutation, which alters the kinetic stability of TTR and affects 3% to 4% of African American subjects, can lead to development of familial amyloid cardiomyopathy.  In addn., aggregation of WT TTR in individuals older than age 65 y causes senile systemic amyloidosis.  TTR-mediated amyloid cardiomyopathies are chronic and progressive conditions that lead to arrhythmias, biventricular heart failure, and death.  As no Food and Drug Administration-approved drugs are currently available for treatment of these diseases, the development of therapeutic agents that prevent TTR-mediated cardiotoxicity is desired.  Here, the authors report the development of AG10, a potent and selective kinetic stabilizer of TTR.  AG10 prevents dissocn. of V122I-TTR in serum samples obtained from patients with familial amyloid cardiomyopathy.  In contrast to other TTR stabilizers currently in clin. trials, AG10 stabilizes V122I- and WT-TTR equally well and also exceeds their efficacy to stabilize WT and mutant TTR in whole serum.  Crystallog. studies of AG10 bound to V122I-TTR give valuable insights into how AG10 achieves such effective kinetic stabilization of TTR, which will also aid in designing better TTR stabilizers.  The oral bioavailability of AG10, combined with addnl. desirable drug-like features, makes it a very promising candidate to treat TTR amyloid cardiomyopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOL2rGZR4uzrVg90H21EOLACvtfcHk0lhj-6p26fMNmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOrtLzE&md5=a7e13a3659bde9c8106bc61f7049ffa5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1300761110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1300761110%26sid%3Dliteratum%253Aachs%26aulast%3DPenchala%26aufirst%3DS.%2BC.%26aulast%3DConnelly%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DM.%2BS.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DBaranczak%26aufirst%3DA.%26aulast%3DRappley%26aufirst%3DI.%26aulast%3DVogel%26aufirst%3DH.%26aulast%3DLiedtke%26aufirst%3DM.%26aulast%3DWitteles%26aufirst%3DR.%2BM.%26aulast%3DPowers%26aufirst%3DE.%2BT.%26aulast%3DReixach%26aufirst%3DN.%26aulast%3DChan%26aufirst%3DW.%2BK.%26aulast%3DWilson%26aufirst%3DI.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DGraef%26aufirst%3DI.%2BA.%26aulast%3DAlhamadsheh%26aufirst%3DM.%2BM.%26atitle%3DAG10%2520inhibits%2520amyloidogenesis%2520and%2520cellular%2520toxicity%2520of%2520the%2520familial%2520amyloid%2520cardiomyopathy-associated%2520V122I%2520transthyretin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D9992%26epage%3D9997%26doi%3D10.1073%2Fpnas.1300761110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundapaneni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waddington-Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristen, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witteles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsdorf, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapezzi, C.</span></span> <span> </span><span class="NLM_article-title">Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1016</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1805689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1056%2FNEJMoa1805689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30145929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCksLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1007-1016&author=M.+S.+Maurerauthor=J.+H.+Schwartzauthor=B.+Gundapaneniauthor=P.+M.+Elliottauthor=G.+Merliniauthor=M.+Waddington-Cruzauthor=A.+V.+Kristenauthor=M.+Groganauthor=R.+Wittelesauthor=T.+Damyauthor=B.+M.+Drachmanauthor=S.+J.+Shahauthor=M.+Hannaauthor=D.+P.+Judgeauthor=A.+I.+Barsdorfauthor=P.+Huberauthor=T.+A.+Pattersonauthor=S.+Rileyauthor=J.+Schumacherauthor=M.+Stewartauthor=M.+B.+Sultanauthor=C.+Rapezzi&title=Tafamidis+treatment+for+patients+with+transthyretin+amyloid+cardiomyopathy&doi=10.1056%2FNEJMoa1805689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy</span></div><div class="casAuthors">Maurer, Mathew S.; Schwartz, Jeffrey H.; Gundapaneni, Balarama; Elliott, Perry M.; Merlini, Giampaolo; Waddington-Cruz, Marcia; Kristen, Arnt V.; Grogan, Martha; Witteles, Ronald; Damy, Thibaud; Drachman, Brian M.; Shah, Sanjiv J.; Hanna, Mazen; Judge, Daniel P.; Barsdorf, Alexandra I.; Huber, Peter; Patterson, Terrell A.; Riley, Steven; Schumacher, Jennifer; Stewart, Michelle; Sultan, Marla B.; Rapezzi, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1007-1016</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium.  Tafamidis binds to transthyretin, preventing tetramer dissocn. and amyloidogenesis.  In primary anal., we hierarchically assessed all-cause mortality, followed by frequency of cardiovascular-related hospitalizations according to the Finkelstein-Schoenfeld method.  Key secondary end points were the change from baseline to month 30 for the 6-min walk test and the score on the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS), in which higher scores indicate better health status.  In the primary anal., all-cause mortality and rates of cardiovascular-related hospitalizations were lower among the 264 patients who received tafamidis than among the 177 patients who received placebo (P<0.001).  Tafamidis was assocd. with lower all-cause mortality than placebo and a lower rate of cardiovascular-related hospitalizations, with a relative risk ratio of 0.68.  At month 30, tafamidis was also assocd. with a lower rate of decline in distance for the 6-min walk test (P<0.001) and a lower rate of decline in KCCQ-OS score (P<0.001).  The incidence and types of adverse events were similar in the two groups.  In patients with transthyretin amyloid cardiomyopathy, tafamidis was assocd. with redns. in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVh-pvrmMfzLVg90H21EOLACvtfcHk0ljs4jvvVdtjgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCksLfP&md5=35f57b7aae8a03914b6882ffb7df7572</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1805689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1805689%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DM.%2BS.%26aulast%3DSchwartz%26aufirst%3DJ.%2BH.%26aulast%3DGundapaneni%26aufirst%3DB.%26aulast%3DElliott%26aufirst%3DP.%2BM.%26aulast%3DMerlini%26aufirst%3DG.%26aulast%3DWaddington-Cruz%26aufirst%3DM.%26aulast%3DKristen%26aufirst%3DA.%2BV.%26aulast%3DGrogan%26aufirst%3DM.%26aulast%3DWitteles%26aufirst%3DR.%26aulast%3DDamy%26aufirst%3DT.%26aulast%3DDrachman%26aufirst%3DB.%2BM.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DJudge%26aufirst%3DD.%2BP.%26aulast%3DBarsdorf%26aufirst%3DA.%2BI.%26aulast%3DHuber%26aufirst%3DP.%26aulast%3DPatterson%26aufirst%3DT.%2BA.%26aulast%3DRiley%26aufirst%3DS.%26aulast%3DSchumacher%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DM.%26aulast%3DSultan%26aufirst%3DM.%2BB.%26aulast%3DRapezzi%26aufirst%3DC.%26atitle%3DTafamidis%2520treatment%2520for%2520patients%2520with%2520transthyretin%2520amyloid%2520cardiomyopathy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1007%26epage%3D1016%26doi%3D10.1056%2FNEJMoa1805689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Judge, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitner, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witteles, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selby, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nativi-Nicolau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turtle, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. C.</span></span> <span> </span><span class="NLM_article-title">Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2019.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.jacc.2019.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30885685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyitLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2019&pages=285-295&author=D.+P.+Judgeauthor=S.+B.+Heitnerauthor=R.+H.+Falkauthor=M.+S.+Maurerauthor=S.+J.+Shahauthor=R.+M.+Wittelesauthor=M.+Groganauthor=V.+N.+Selbyauthor=D.+Jacobyauthor=M.+Hannaauthor=J.+Nativi-Nicolauauthor=J.+Patelauthor=S.+Raoauthor=U.+Sinhaauthor=C.+W.+Turtleauthor=J.+C.+Fox&title=Transthyretin+stabilization+by+AG10+in+symptomatic+transthyretin+amyloid+cardiomyopathy&doi=10.1016%2Fj.jacc.2019.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy</span></div><div class="casAuthors">Judge, Daniel P.; Heitner, Stephen B.; Falk, Rodney H.; Maurer, Mathew S.; Shah, Sanjiv J.; Witteles, Ronald M.; Grogan, Martha; Selby, Van N.; Jacoby, Daniel; Hanna, Mazen; Nativi-Nicolau, Jose; Patel, Jignesh; Rao, Satish; Sinha, Uma; Turtle, Cameron W.; Fox, Jonathan C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging.  Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions.  AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation.  This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with symptomatic, chronic heart failure.  ATTR-CM, New York Heart Assocn. functional class II to III subjects (n = 49, mutant or wild-type) were randomized 1:1:1 to AG10 400 mg, AG10 800 mg, or placebo twice daily for 28 days.  Safety and tolerability were assessed by clin. and lab. criteria.  AG10 plasma levels were measured.  TTR stability was assessed by changes in serum TTR, and 2 established ex vivo assays (fluorescent probe exclusion and Western blot).  AG10 treatment was well-tolerated, achieved target plasma concns. and demonstrated near-complete stabilization of TTR.  TTR stabilization was more complete and less variable at the higher dose with stabilization by fluorescent probe exclusion of 92 ± 10% (mean ± SD) at trough and 96 ± 9% at peak (both p < 10-12 vs. placebo).  Av. serum TTR increased by 36 ± 21% and 51 ± 38% at 400 and 800 mg, resp. (both p < 0.0001 vs. placebo).  Baseline serum TTR in treated subjects was below normal in 80% of mutant and 33% of wild-type subjects.  AG10 treatment restored serum TTR to the normal range in all subjects.  AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM.  A phase 3 trial is ongoing.  (Study of AG10 in Amyloid Cardiomyopathy; NCT03458130).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplRqntrbcy8LVg90H21EOLACvtfcHk0ljs4jvvVdtjgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyitLvJ&md5=020819a05657af410e927f5b8d3b1477</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2019.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2019.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DJudge%26aufirst%3DD.%2BP.%26aulast%3DHeitner%26aufirst%3DS.%2BB.%26aulast%3DFalk%26aufirst%3DR.%2BH.%26aulast%3DMaurer%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DWitteles%26aufirst%3DR.%2BM.%26aulast%3DGrogan%26aufirst%3DM.%26aulast%3DSelby%26aufirst%3DV.%2BN.%26aulast%3DJacoby%26aufirst%3DD.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DNativi-Nicolau%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DU.%26aulast%3DTurtle%26aufirst%3DC.%2BW.%26aulast%3DFox%26aufirst%3DJ.%2BC.%26atitle%3DTransthyretin%2520stabilization%2520by%2520AG10%2520in%2520symptomatic%2520transthyretin%2520amyloid%2520cardiomyopathy%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2019%26volume%3D74%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.jacc.2019.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monteiro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesgazardeh, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anselmo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novais, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brighty, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span> <span> </span><span class="NLM_article-title">Predictive model of response to tafamidis in hereditary ATTR polyneuropathy</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e126526</span> <span class="refDoi"> DOI: 10.1172/jci.insight.126526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1172%2Fjci.insight.126526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31217346" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&author=C.+Monteiroauthor=J.+S.+Mesgazardehauthor=J.+Anselmoauthor=J.+Fernandesauthor=M.+Novaisauthor=C.+Rodriguesauthor=G.+J.+Brightyauthor=D.+L.+Powersauthor=E.+T.+Powersauthor=T.+Coelhoauthor=J.+W.+Kelly&title=Predictive+model+of+response+to+tafamidis+in+hereditary+ATTR+polyneuropathy&doi=10.1172%2Fjci.insight.126526"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.126526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.126526%26sid%3Dliteratum%253Aachs%26aulast%3DMonteiro%26aufirst%3DC.%26aulast%3DMesgazardeh%26aufirst%3DJ.%2BS.%26aulast%3DAnselmo%26aufirst%3DJ.%26aulast%3DFernandes%26aufirst%3DJ.%26aulast%3DNovais%26aufirst%3DM.%26aulast%3DRodrigues%26aufirst%3DC.%26aulast%3DBrighty%26aufirst%3DG.%2BJ.%26aulast%3DPowers%26aufirst%3DD.%2BL.%26aulast%3DPowers%26aufirst%3DE.%2BT.%26aulast%3DCoelho%26aufirst%3DT.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26atitle%3DPredictive%2520model%2520of%2520response%2520to%2520tafamidis%2520in%2520hereditary%2520ATTR%2520polyneuropathy%26jtitle%3DJCI%2520Insight%26date%3D2019%26volume%3D4%26doi%3D10.1172%2Fjci.insight.126526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suhr, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obici, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekijima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeldenrust, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heneghan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorevic, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchy, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson-Papp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybin, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisbee, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seldin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, P. J.</span></span>; <span class="NLM_contrib-group">Diflunisal Trial Consortium</span> <span> </span><span class="NLM_article-title">Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">2658</span>– <span class="NLM_lpage">2667</span>, <span class="refDoi"> DOI: 10.1001/jama.2013.283815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1001%2Fjama.2013.283815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=24368466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFejur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2013&pages=2658-2667&author=J.+L.+Berkauthor=O.+B.+Suhrauthor=L.+Obiciauthor=Y.+Sekijimaauthor=S.+R.+Zeldenrustauthor=T.+Yamashitaauthor=M.+A.+Heneghanauthor=P.+D.+Gorevicauthor=W.+J.+Litchyauthor=J.+F.+Wiesmanauthor=E.+Nordhauthor=M.+Coratoauthor=A.+Lozzaauthor=A.+Corteseauthor=J.+Robinson-Pappauthor=T.+Coltonauthor=D.+V.+Rybinauthor=A.+B.+Bisbeeauthor=Y.+Andoauthor=S.+Ikedaauthor=D.+C.+Seldinauthor=G.+Merliniauthor=M.+Skinnerauthor=J.+W.+Kellyauthor=P.+J.+Dyckauthor=Diflunisal+Trial+Consortium&title=Repurposing+diflunisal+for+familial+amyloid+polyneuropathy%3A+a+randomized+clinical+trial&doi=10.1001%2Fjama.2013.283815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial</span></div><div class="casAuthors">Berk, John L.; Suhrl, Ole B.; Obici, Laura; Sekijima, Yoshiki; Zeldenrust, Steven R.; Yamashita, Taro; Heneghan, Michael A.; Gorevic, Peter D.; Litchy, William J.; Wiesman, Janice F.; Nordh, Erik; Corato, Manuel; Lozza, Alessandro; Cortese, Andrea; Robinson-Papp, Jessica; Colton, Theodore; Rybin, Denis V.; Bisbee, Alice B.; Ando, Yukio; Ikeda, Shu-ichi; Seldin, David C.; Merlini, Giampaolo; Skinner, Martha; Kelly, Jeffery W.; Dyck, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2658-2667</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">IMPORTANCE Familial amyloid polyneuropathy, a lethal genetic disease caused by aggregation of variant transthyretin, induces progressive peripheral nerve deficits and disability.  Diflunisal, a nonsteroidal anti-inflammatory agent, stabilizes transthyretin tetramers and prevents amyloid fibril formation in vitro.  OBJECTIVE To det. the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy.  DESIGN, SETTING, and PARTICIPANTS International randomized, double-blind, placebo-controlled study conducted among 130 patients with familial amyloid polyneuropathy exhibiting clin. detectable peripheral or autonomic neuropathy at amyloid centers in Sweden (Umea), Italy (Pavia), Japan (Matsumoto and Kumamoto), England (London), and the United States (Boston, Massachusetts; New York, New York; and Rochester, Minnesota) from 2006 through 2012.  INTERVENTION Participants were randomly assigned to receive diflunisal, 250 mg (n = 64), or placebo (n = 66) twice daily for 2 years.  MAIN OUTCOMES AND MEASURES The primary end point, the difference in polyneuropathy progression between treatments, was measured by the Neuropathy Impairment Score plus 7 nerve tests (NIS+7) which ranges from 0 (no neurol. deficits) to 270 points (no detectable peripheral nerve function).  Secondary outcomes included a quality-of-life questionnaire (36-Item Short-Form Health Survey [SF-36]) and modified body mass index.  Because of attrition, we used likelihood-based modeling and multiple imputation anal. of baseline to 2-yr data.  RESULTS By multiple imputation, the NIS+7 score increased by 25.0 (95% CI, 18.4-31.6) points in the placebo group and by 8.7 (95% CI, 3.3-14.1) points in the diflunisal group, a difference of 16.3 points (95% CI, 8.1-24.5 points; P < .001).  Mean SF-36 phys. scores decreased by 4.9 (95% CI, -7.6 to -2.2) points in the placebo group and increased by 1.5 (95% CI, -0.8 to 3.7) points in the diflunisal group (P < .001).  Mean SF-36 mental scores declined by 1.1 (95% CI, -4.3 to 2.0) points in the placebo group while increasing by 3.7 (95% CI, 1.0-6.4) points in the diflunisal group (P = .02).  By responder anal., 29.7% of the diflunisal group and 9.4% of the placebo group exhibited neurol. stability at 2 years (<2-point increase in NIS+7 score; P = .007).  CONCLUSIONS AND RELEVANCE Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurol. impairment and preserved quality of life.  Although longer-term follow-up studies are needed, these findings suggest benefit of this treatment for familial amyloid polyneuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo12QO7TMUWY7Vg90H21EOLACvtfcHk0lhTue_HJIbYLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFejur8%253D&md5=4cb486d1fe267e22bbeb14a7c9fe4971</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1001%2Fjama.2013.283815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2013.283815%26sid%3Dliteratum%253Aachs%26aulast%3DBerk%26aufirst%3DJ.%2BL.%26aulast%3DSuhr%26aufirst%3DO.%2BB.%26aulast%3DObici%26aufirst%3DL.%26aulast%3DSekijima%26aufirst%3DY.%26aulast%3DZeldenrust%26aufirst%3DS.%2BR.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DHeneghan%26aufirst%3DM.%2BA.%26aulast%3DGorevic%26aufirst%3DP.%2BD.%26aulast%3DLitchy%26aufirst%3DW.%2BJ.%26aulast%3DWiesman%26aufirst%3DJ.%2BF.%26aulast%3DNordh%26aufirst%3DE.%26aulast%3DCorato%26aufirst%3DM.%26aulast%3DLozza%26aufirst%3DA.%26aulast%3DCortese%26aufirst%3DA.%26aulast%3DRobinson-Papp%26aufirst%3DJ.%26aulast%3DColton%26aufirst%3DT.%26aulast%3DRybin%26aufirst%3DD.%2BV.%26aulast%3DBisbee%26aufirst%3DA.%2BB.%26aulast%3DAndo%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DSeldin%26aufirst%3DD.%2BC.%26aulast%3DMerlini%26aufirst%3DG.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DDyck%26aufirst%3DP.%2BJ.%26aulast%3D%26atitle%3DRepurposing%2520diflunisal%2520for%2520familial%2520amyloid%2520polyneuropathy%253A%2520a%2520randomized%2520clinical%2520trial%26jtitle%3DJAMA%26date%3D2013%26volume%3D310%26spage%3D2658%26epage%3D2667%26doi%3D10.1001%2Fjama.2013.283815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sant’Anna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira-Henriques, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esperante, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reixach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reverter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reig, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, S.</span></span> <span> </span><span class="NLM_article-title">Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">10787</span> <span class="refDoi"> DOI: 10.1038/ncomms10787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2Fncomms10787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=26902880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1ehtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=R.+Sant%E2%80%99Annaauthor=P.+Gallegoauthor=L.+Z.+Robinsonauthor=A.+Pereira-Henriquesauthor=N.+Ferreiraauthor=F.+Pinheiroauthor=S.+Esperanteauthor=I.+Pallaresauthor=O.+Huertasauthor=M.+R.+Almeidaauthor=N.+Reixachauthor=R.+Insaauthor=A.+Velazquez-Campoyauthor=D.+Reverterauthor=N.+Reigauthor=S.+Ventura&title=Repositioning+tolcapone+as+a+potent+inhibitor+of+transthyretin+amyloidogenesis+and+associated+cellular+toxicity&doi=10.1038%2Fncomms10787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity</span></div><div class="casAuthors">Sant'Anna, Ricardo; Gallego, Pablo; Robinson, Lei Z.; Pereira-Henriques, Alda; Ferreira, Nelson; Pinheiro, Francisca; Esperante, Sebastian; Pallares, Irantzu; Huertas, Oscar; Rosario Almeida, Maria; Reixach, Natalia; Insa, Raul; Velazquez-Campoy, Adrian; Reverter, David; Reig, Nuria; Ventura, Salvador</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10787</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses.  TTR tetramer dissocn. precedes pathol. TTR aggregation.  Native state stabilizers are promising drugs to treat TTR amyloidoses.  Here we repurpose tolcapone, an FDA-approved mol. for Parkinson's disease, as a potent TTR aggregation inhibitor.  Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity.  Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-assocd. variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses.  These data indicate that tolcapone, already in clin. trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-mol. therapy exists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptjm7CULfu47Vg90H21EOLACvtfcHk0lhTue_HJIbYLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1ehtr0%253D&md5=a0a29250b2f01100f5226f092ee8b562</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fncomms10787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10787%26sid%3Dliteratum%253Aachs%26aulast%3DSant%25E2%2580%2599Anna%26aufirst%3DR.%26aulast%3DGallego%26aufirst%3DP.%26aulast%3DRobinson%26aufirst%3DL.%2BZ.%26aulast%3DPereira-Henriques%26aufirst%3DA.%26aulast%3DFerreira%26aufirst%3DN.%26aulast%3DPinheiro%26aufirst%3DF.%26aulast%3DEsperante%26aufirst%3DS.%26aulast%3DPallares%26aufirst%3DI.%26aulast%3DHuertas%26aufirst%3DO.%26aulast%3DAlmeida%26aufirst%3DM.%2BR.%26aulast%3DReixach%26aufirst%3DN.%26aulast%3DInsa%26aufirst%3DR.%26aulast%3DVelazquez-Campoy%26aufirst%3DA.%26aulast%3DReverter%26aufirst%3DD.%26aulast%3DReig%26aufirst%3DN.%26aulast%3DVentura%26aufirst%3DS.%26atitle%3DRepositioning%2520tolcapone%2520as%2520a%2520potent%2520inhibitor%2520of%2520transthyretin%2520amyloidogenesis%2520and%2520associated%2520cellular%2520toxicity%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms10787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilaró, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Parra, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsequell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valencia, G.</span></span> <span> </span><span class="NLM_article-title">Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions</span>. <i>ACS Comb. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1021/co5001234</span> </span><div class="citationLinks">[<a href="/doi/10.1021/co5001234" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWns7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=32-38&author=M.+Vilar%C3%B3author=J.+Nietoauthor=J.+R.+La+Parraauthor=M.+R.+Almeidaauthor=A.+Ballesterosauthor=A.+Planasauthor=G.+Arsequellauthor=G.+Valencia&title=Tuning+transthyretin+amyloidosis+inhibition+properties+of+iododiflunisal+by+combinatorial+engineering+of+the+nonsalicylic+ring+substitutions&doi=10.1021%2Fco5001234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning transthyretin amyloidosis inhibition properties of iododiflunisal by combinatorial engineering of the nonsalicylic ring substitutions</span></div><div class="casAuthors">Vilaro, Maria; Nieto, Joan; La Parra, Juan Ramon; Almeida, Maria Rosario; Ballesteros, Alfredo; Planas, Antoni; Arsequell, Gemma; Valencia, Gregorio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Combinatorial Science</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-38</span>CODEN:
                <span class="NLM_cas:coden">ACSCCC</span>;
        ISSN:<span class="NLM_cas:issn">2156-8944</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two series of iododiflunisal and diflunisal analogs have been obtained by using a two step sequential reaction soln.-phase parallel synthesis.  The synthesis combined an aq. Suzuki-Miyaura cross-coupling and a mild electrophilic arom. iodination step using a new polymer-supported iodonium version of Barluenga's reagent.  From a selected set of 77 noniodinated and 77 iodinated diflunisal analogs, a subset of good transthyretin amyloid inhibitors has been obtained with improved turbidimetry inhibition consts., high binding affinity to transthyretin, and good selectivity for TTR compared to other thyroxine binding proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ7MUOzhwOVbVg90H21EOLACvtfcHk0lgxn3rf42cl-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWns7fF&md5=bf9221c069bfca42017b3c716ed098b4</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fco5001234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fco5001234%26sid%3Dliteratum%253Aachs%26aulast%3DVilar%25C3%25B3%26aufirst%3DM.%26aulast%3DNieto%26aufirst%3DJ.%26aulast%3DLa%2BParra%26aufirst%3DJ.%2BR.%26aulast%3DAlmeida%26aufirst%3DM.%2BR.%26aulast%3DBallesteros%26aufirst%3DA.%26aulast%3DPlanas%26aufirst%3DA.%26aulast%3DArsequell%26aufirst%3DG.%26aulast%3DValencia%26aufirst%3DG.%26atitle%3DTuning%2520transthyretin%2520amyloidosis%2520inhibition%2520properties%2520of%2520iododiflunisal%2520by%2520combinatorial%2520engineering%2520of%2520the%2520nonsalicylic%2520ring%2520substitutions%26jtitle%3DACS%2520Comb.%2520Sci.%26date%3D2015%26volume%3D17%26spage%3D32%26epage%3D38%26doi%3D10.1021%2Fco5001234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span> <span> </span><span class="NLM_article-title">Lecithin retinol acyltransferase forms functional homodimers</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">6311</span>– <span class="NLM_lpage">6319</span>, <span class="refDoi"> DOI: 10.1021/bi015710b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi015710b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVaitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=6311-6319&author=W.+J.+Jahngauthor=E.+Cheungauthor=R.+R.+Rando&title=Lecithin+retinol+acyltransferase+forms+functional+homodimers&doi=10.1021%2Fbi015710b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Lecithin Retinol Acyltransferase Forms Functional Homodimers</span></div><div class="casAuthors">Jahng, Wan Jin; Cheung, Eric; Rando, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6311-6319</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Membrane-bound lecithin retinol acyltransferase (LRAT), an essential enzyme in vitamin A processing, catalyzes the formation of retinyl esters from vitamin A and lecithin.  Cloned and expressed LRAT has a mol. mass of 25.3 kDa.  The enzyme is not homologous to known enzymes and is, therefore, of substantial interest mechanistically.  Along these lines, the functional protomeric state of LRAT is of importance.  Gel electrophoretic studies on LRAT in the presence of SDS and disulfide reducing agents show the expected 25 kDa monomer.  However, gel electrophoresis in the absence of a reducing agent and/or strong denaturing conditions reveals substantial dimer formation.  LRAT monomers can be efficiently and irreversibly cross-linked by thiol reactive bismaleimides in retinal pigment epithelial (RPE) membranes generating LRAT homodimers.  Cross-linked LRAT homodimers are fully active catalytically.  The expts. suggest that LRAT monomers interact in membranes and form functional homodimers through protein-protein interactions and disulfide bond formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj8AMgDFddXrVg90H21EOLACvtfcHk0lgxn3rf42cl-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVaitr0%253D&md5=5cda334049ea226fb4884186ee6732a0</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbi015710b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi015710b%26sid%3Dliteratum%253Aachs%26aulast%3DJahng%26aufirst%3DW.%2BJ.%26aulast%3DCheung%26aufirst%3DE.%26aulast%3DRando%26aufirst%3DR.%2BR.%26atitle%3DLecithin%2520retinol%2520acyltransferase%2520forms%2520functional%2520homodimers%26jtitle%3DBiochemistry%26date%3D2002%26volume%3D41%26spage%3D6311%26epage%3D6319%26doi%3D10.1021%2Fbi015710b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span> <span> </span><span class="NLM_article-title">Models for binding cooperativities of inhibitors with transthyretin</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>466</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2007.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.abb.2007.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=17767913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVOlt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=466&publication_year=2007&pages=85-97&author=H.+Wangauthor=Y.+Tangauthor=M.+Lei&title=Models+for+binding+cooperativities+of+inhibitors+with+transthyretin&doi=10.1016%2Fj.abb.2007.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Models for binding cooperativities of inhibitors with transthyretin</span></div><div class="casAuthors">Wang, Houfang; Tang, Yanhui; Lei, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">466</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-97</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Here, mol. dynamics (MD) simulations are performed to study the differences of binding channel shapes of TTR with two inhibitors, flufenamic acid (FLU) and one kind of N-Ph phenoxazine (BPD).  The asymmetries of global structure including the central binding channel are found to be intrinsic.  Moreover, the conformational changes of the binding channel are responsible for neg. cooperativity (NC) or independent cooperativity (IC) of ligands.  The results suggested a possible binding mechanism addressing NC of FLU and IC of BPD.  For FLU, when the first ligand binds with TTR, it leads to expansion of the second binding site which may weaken the interaction of the second FLU with TTR.  But for BPD, the first ligand's binding changes the second site's shape slightly, the second ligand has similar binding ability with TTR in the second site like the first binding event.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2l1Aoyb05NbVg90H21EOLACvtfcHk0lgxn3rf42cl-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVOlt7zI&md5=78d02824d108fdf4b0cbdfeb837db87e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2007.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2007.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DLei%26aufirst%3DM.%26atitle%3DModels%2520for%2520binding%2520cooperativities%2520of%2520inhibitors%2520with%2520transthyretin%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2007%26volume%3D466%26spage%3D85%26epage%3D97%26doi%3D10.1016%2Fj.abb.2007.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangerter, F. W.</span></span> <span> </span><span class="NLM_article-title">Threshold effects on the concanavalin A-mediated agglutination of modified erythrocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">8318</span>– <span class="NLM_lpage">8323</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(19)86891-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2FS0021-9258%2819%2986891-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=468825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaE1MXlvVOgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=8318-8323&author=R.+R.+Randoauthor=G.+A.+Orrauthor=F.+W.+Bangerter&title=Threshold+effects+on+the+concanavalin+A-mediated+agglutination+of+modified+erythrocytes&doi=10.1016%2FS0021-9258%2819%2986891-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Threshold effects on the concanavalin A-mediated agglutination of modified erythrocytes</span></div><div class="casAuthors">Rando, Robert R.; Orr, George A.; Bangerter, Faan Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8318-23</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Bovine erythrocytes, which were not concanavalin A (ConA)  [11028-71-0]-agglutinable, could be rendered so by attaching α-D-mannose residues to their outer membrane.  The sugars were incorporated by mildly oxidizing the cells with periodate followed by coupling the liberated aldehyde groups with 6-(1'-α-D-thiomannosyl)hexanoyl hydrazide  [71761-09-6].  The rate and extent of ConA-mediated aggregation of the modified cells were not linearly dependent on the amt. of sugar incorporated; the sugar incorporation technique was random, and no functional differences were detected in the receptors introduced at the different periodate concns.  Therefore, the ConA-mediated aggregation of these modified erythrocytes is sensitive to small changes in functionally identical receptor densities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1q7mNendm7Vg90H21EOLACvtfcHk0lj3c6-V8RrvUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXlvVOgsr0%253D&md5=8c303cbd53b9cf1a7971909943b3255d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2986891-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252986891-6%26sid%3Dliteratum%253Aachs%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DBangerter%26aufirst%3DF.%2BW.%26atitle%3DThreshold%2520effects%2520on%2520the%2520concanavalin%2520A-mediated%2520agglutination%2520of%2520modified%2520erythrocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D8318%26epage%3D8323%26doi%3D10.1016%2FS0021-9258%2819%2986891-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrassi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaninathan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamedmohaideen, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span> <span> </span><span class="NLM_article-title">Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1587</span>, <span class="refDoi"> DOI: 10.1021/jm049274d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049274d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1576-1587&author=S.+M.+Johnsonauthor=H.+M.+Petrassiauthor=S.+K.+Palaninathanauthor=N.+N.+Mohamedmohaideenauthor=H.+E.+Purkeyauthor=C.+Nicholsauthor=K.+P.+Chiangauthor=T.+Walkupauthor=J.+C.+Sacchettiniauthor=K.+B.+Sharplessauthor=J.+W.+Kelly&title=Bisaryloxime+ethers+as+potent+inhibitors+of+transthyretin+amyloid+fibril+formation&doi=10.1021%2Fjm049274d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bisaryloxime Ethers as Potent Inhibitors of Transthyretin Amyloid Fibril Formation</span></div><div class="casAuthors">Johnson, Steven M.; Petrassi, H. Michael; Palaninathan, Satheesh K.; Mohamedmohaideen, Nilofar N.; Purkey, Hans E.; Nichols, Christopher; Chiang, Kyle P.; Walkup, Traci; Sacchettini, James C.; Sharpless, K. Barry; Kelly, Jeffery W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1576-1587</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amyloid fibril formation by the plasma protein transthyretin (TTR), requiring rate-limiting tetramer dissocn. and monomer misfolding, is implicated in several human diseases.  Amyloidogenesis can be inhibited through native state stabilization, mediated by small mol. binding to TTR's primarily unoccupied thyroid hormone binding sites.  New native state stabilizers have been discovered herein by the facile condensation of arylaldehydes R1CHO (R1 = Ph, 3-HO2CC6H4, 2-F3CC6H4, 3,5-Cl2C6H3, etc.) with aryloxyamines R2ONH2 (R2 = Ph, 3-F3CC6H4, 3,5-F2C6H4, etc.) affording a bisarylaldoxime ether R1CH:NOR2 library.  Of the library's 95 compds., 31 were active inhibitors of TTR amyloid formation in vitro.  The bisaryloxime ethers selectively stabilize the native tetrameric state of TTR over the dissociative transition state under amyloidogenic conditions, leading to an increase in the dissocn. activation barrier.  Several bisaryloxime ethers bind selectively to TTR in human blood plasma over the plethora of other plasma proteins, a necessary attribute for efficacy in vivo.  While bisarylaldoxime ethers are susceptible to degrdn. by N-O bond cleavage, this process is slowed by their binding to TTR.  Furthermore, the degrdn. rate of many of the bisarylaldoxime ethers is slow relative to the half-life of plasma TTR.  The bisaryloxime ether library provides valuable structure-activity relationship insight for the development of structurally analogous inhibitors with superior stability profiles, should that prove necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcPw-YPbhoPLVg90H21EOLACvtfcHk0lj3c6-V8RrvUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKru7g%253D&md5=019ee482a75f25f841cca7896e99911f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm049274d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049274d%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DS.%2BM.%26aulast%3DPetrassi%26aufirst%3DH.%2BM.%26aulast%3DPalaninathan%26aufirst%3DS.%2BK.%26aulast%3DMohamedmohaideen%26aufirst%3DN.%2BN.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DNichols%26aufirst%3DC.%26aulast%3DChiang%26aufirst%3DK.%2BP.%26aulast%3DWalkup%26aufirst%3DT.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26atitle%3DBisaryloxime%2520ethers%2520as%2520potent%2520inhibitors%2520of%2520transthyretin%2520amyloid%2520fibril%2520formation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1576%26epage%3D1587%26doi%3D10.1021%2Fjm049274d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">Tranthyretin ligands capable of inhibitng retinol-dependent RBP4-TTR interaction for treatment of age-related macular degneration, Stargardt disease, and other retinal disease characterized by excessive lipofuscin accumulation</span>. <span class="NLM_patent">US2015/0057320A1</span>, Feb 26, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+Petrukhin&title=Tranthyretin+ligands+capable+of+inhibitng+retinol-dependent+RBP4-TTR+interaction+for+treatment+of+age-related+macular+degneration%2C+Stargardt+disease%2C+and+other+retinal+disease+characterized+by+excessive+lipofuscin+accumulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DTranthyretin%2520ligands%2520capable%2520of%2520inhibitng%2520retinol-dependent%2520RBP4-TTR%2520interaction%2520for%2520treatment%2520of%2520age-related%2520macular%2520degneration%252C%2520Stargardt%2520disease%252C%2520and%2520other%2520retinal%2520disease%2520characterized%2520by%2520excessive%2520lipofuscin%2520accumulation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cotrina, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leite, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llop, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gales, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arsequell, G.</span></span> <span> </span><span class="NLM_article-title">Repurposing benzbromarone for familial amyloid polyneuropathy: a new transthyretin tetramer stabilizer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>, <span class="NLM_elocation-id">7166</span> <span class="refDoi"> DOI: 10.3390/ijms21197166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.3390%2Fijms21197166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWjurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&author=E.+Y.+Cotrinaauthor=A.+Oliveiraauthor=J.+P.+Leiteauthor=J.+Llopauthor=L.+Galesauthor=J.+Quintanaauthor=I.+Cardosoauthor=G.+Arsequell&title=Repurposing+benzbromarone+for+familial+amyloid+polyneuropathy%3A+a+new+transthyretin+tetramer+stabilizer&doi=10.3390%2Fijms21197166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing benzbromarone for familial amyloid polyneuropathy: a new transthyretin tetramer stabilizer</span></div><div class="casAuthors">Cotrina, Ellen Y.; Oliveira, Angela; Leite, Jose Pedro; Llop, Jordi; Gales, Luis; Quintana, Jordi; Cardoso, Isabel; Arsequell, Gemma</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7166</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Transthyretin (TTR) is a homotetrameric protein involved in human amyloidosis, including familial amyloid polyneuropathy (FAP).  Discovering small-mol. stabilizers of the TTR tetramer is a therapeutic strategy for these diseases.  Tafamidis, the only approved drug for FAP treatment, is not effective for all patients.  Herein, we discovered that benzbromarone (BBM), a uricosuric drug, is an effective TTR stabilizer and inhibitor against TTR amyloid fibril formation.  BBM rendered TTR more resistant to urea denaturation, similarly to iododiflunisal (IDIF), a very potent TTR stabilizer.  BBM competes with thyroxine for binding in the TTR central channel, with an IC50 similar to IDIF and tafamidis.  Results obtained by isothermal titrn. calorimetry (ITC) demonstrated that BBM binds TTR with an affinity similar to IDIF, tolcapone and tafamidis, confirming BBM as a potent binder of TTR.  The crystal structure of the BBM-TTR complex shows two mols. binding deeply in the thyroxine binding channel, forming strong intermonomer hydrogen bonds and increasing the stability of the TTR tetramer.  Finally, kinetic anal. of the ability of BBM to inhibit TTR fibrillogenesis at acidic pH and comparison with other stabilizers revealed that benzbromarone is a potent inhibitor of TTR amyloidogenesis, adding a new interesting scaffold for drug design of TTR stabilizers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLQFjgYk8nCrVg90H21EOLACvtfcHk0lhizckM96sGnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWjurrI&md5=96da0ae4642975c54e62987e5b790d1b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.3390%2Fijms21197166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21197166%26sid%3Dliteratum%253Aachs%26aulast%3DCotrina%26aufirst%3DE.%2BY.%26aulast%3DOliveira%26aufirst%3DA.%26aulast%3DLeite%26aufirst%3DJ.%2BP.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DGales%26aufirst%3DL.%26aulast%3DQuintana%26aufirst%3DJ.%26aulast%3DCardoso%26aufirst%3DI.%26aulast%3DArsequell%26aufirst%3DG.%26atitle%3DRepurposing%2520benzbromarone%2520for%2520familial%2520amyloid%2520polyneuropathy%253A%2520a%2520new%2520transthyretin%2520tetramer%2520stabilizer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26doi%3D10.3390%2Fijms21197166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangerter, F. W.</span></span> <span> </span><span class="NLM_article-title">Threshold effects on the lectin-mediated aggregation of synthetic glycolipid-containing liposomes</span>. <i>J. Supramol. Struct.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1002/jss.400110304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fjss.400110304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=575662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaL3cXkt1WisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1979&pages=295-309&author=R.+R.+Randoauthor=F.+W.+Bangerter&title=Threshold+effects+on+the+lectin-mediated+aggregation+of+synthetic+glycolipid-containing+liposomes&doi=10.1002%2Fjss.400110304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Threshold effects on the lectin-mediated aggregation of synthetic glycolipid-containing liposomes</span></div><div class="casAuthors">Rando, Robert R.; Bangerter, Faan Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Supramolecular Structure</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">295-309</span>CODEN:
                <span class="NLM_cas:coden">JSPMAW</span>;
        ISSN:<span class="NLM_cas:issn">0091-7419</span>.
    </div><div class="casAbstract">Cholesterol analogs contg. sugar residues linked by spacer groups to the cholesterol O were incorporated into egg yolk lecithin small unilamellar liposomes.  The synthetic glycolipid analogs distributed evenly on both sides of the bilayer.  These liposomes were aggregated by the appropriate lectin.  When the sugar residue was a β-galactoside (I) the liposomes were aggregated by ricin and when it was an α-mannoside (II) they were aggregated by concanavalin A.  The lectin-mediated aggregation of these liposomes was reversed by the addn. of the appropriate sugar.  The rates, but not the extents, of aggregation of these liposomes were highly sensitive to the amt. of glycolipid incorporated.  Below ∼5% glycolipid incorporation, the rate of the lectin-mediated aggregation of these liposomes was exceedingly slow, whereas above this level rapid aggregation proceeded.  At all concns. studied the synthetic glycolipids were incorporated in a unimodal fashion, so that the obsd. threshold effects could be based on possible differences in the manner in which the glycolipids were incorporated at different concns.  This conclusion was based on studies with galactose oxidase, which showed that the percentage of galactose oxidn. in a liposome prepd. from a galactosyl-contg. glycolipid is independent of glycolipid concn., and studies on the aggregation of liposomes contg. mixed glycolipids in which the glycolipids behaved independently.  The importance of a crit. d. of membrane-bound receptors for aggregation to occur is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUnbgZw-21LVg90H21EOLACvtfcHk0lhizckM96sGnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXkt1WisL8%253D&md5=5361dc57bc4c43a9e42c1b4400557337</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fjss.400110304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjss.400110304%26sid%3Dliteratum%253Aachs%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DBangerter%26aufirst%3DF.%2BW.%26atitle%3DThreshold%2520effects%2520on%2520the%2520lectin-mediated%2520aggregation%2520of%2520synthetic%2520glycolipid-containing%2520liposomes%26jtitle%3DJ.%2520Supramol.%2520Struct.%26date%3D1979%26volume%3D11%26spage%3D295%26epage%3D309%26doi%3D10.1002%2Fjss.400110304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangerter, F. W.</span></span> <span> </span><span class="NLM_article-title">Synthetic glycolipids and the lectin-mediated aggregation of liposomes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">4721</span>– <span class="NLM_lpage">4725</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(17)30071-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2FS0021-9258%2817%2930071-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=438211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaE1MXkslaqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=4721-4725&author=G.+A.+Orrauthor=R.+R.+Randoauthor=F.+W.+Bangerter&title=Synthetic+glycolipids+and+the+lectin-mediated+aggregation+of+liposomes&doi=10.1016%2FS0021-9258%2817%2930071-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic glycolipids and the lectin-mediated aggregation of liposomes</span></div><div class="casAuthors">Orr, George A.; Rando, Robert R.; Bangerter, Faan Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4721-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Synthetic mannose-contg. glycolipids (I and II, resp.) utilizing the cholesterol nucleus as a lipid anchor, and either the 6-aminohexyl- or the 6-(6-aminohexanamide)hexyl-1-thio-α-D-mannopyranosides as the carbohydrate ligands, were synthesized and incorporated into small unilamellar liposomes.  Incorporation of these cholesterol-mannoside derivs. at concns. ≤14 mol % apparently did not affect the phys. characteristics of the liposomes.  Addn. of concanavalin A to a suspension of liposomes contg. the long chain cholesterol-mannose deriv. II caused an increase in light-scattering at 360 nm.  Since the increase in absorbance was completely reversed by the addn. of α-methylmannoside, aggregation rather than fusion of the liposomes appeared to occur.  Liposomes contg. 14 mol % of the short chain deriv. I were aggregated by concanavalin A indicating that the lectin can approach to within 10 Å of the lipid bilayer.  The aggregation of vesicles contg. either the long or short chain derivs. was highly dependent on the d. of the sugar in the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGFT9UThuM1bVg90H21EOLACvtfcHk0lhizckM96sGnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXkslaqtbg%253D&md5=436a072ee66ae60e288a2a776f144b8c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2930071-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252930071-6%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DRando%26aufirst%3DR.%2BR.%26aulast%3DBangerter%26aufirst%3DF.%2BW.%26atitle%3DSynthetic%2520glycolipids%2520and%2520the%2520lectin-mediated%2520aggregation%2520of%2520liposomes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D4721%26epage%3D4725%26doi%3D10.1016%2FS0021-9258%2817%2930071-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gliubich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berni, R.</span></span> <span> </span><span class="NLM_article-title">Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">5841</span>– <span class="NLM_lpage">5854</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2008.06705.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1111%2Fj.1742-4658.2008.06705.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=19021760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2murrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2008&pages=5841-5854&author=G.+Zanottiauthor=C.+Folliauthor=L.+Cendronauthor=B.+Alfieriauthor=S.+K.+Nishidaauthor=F.+Gliubichauthor=N.+Pasquatoauthor=A.+Negroauthor=R.+Berni&title=Structural+and+mutational+analyses+of+protein-protein+interactions+between+transthyretin+and+retinol-binding+protein&doi=10.1111%2Fj.1742-4658.2008.06705.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein</span></div><div class="casAuthors">Zanotti, Giuseppe; Folli, Claudia; Cendron, Laura; Alfieri, Beatrice; Nishida, Sonia K.; Gliubich, Francesca; Pasquato, Nicola; Negro, Alessandro; Berni, Rodolfo</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5841-5854</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Transthyretin (TTR) is a tetrameric binding protein involved in the transport of thyroid hormones and in the cotransport of retinol by forming a complex in plasma with retinol-binding protein (RBP).  Here, the authors report the crystal structure of a macromol. complex, in which human TTR, human holo-RBP, and a murine anti-RBP Fab are assembled according to a 1:2:2 stoichiometry.  The main interactions, both polar and apolar, between RBP and TTR involved the retinol OH group and a limited no. of solvent exposed residues.  The relevance of TTR residues in complex formation with RBP was by mutational anal., and the structural consequences of some TTR point mutations affecting protein-protein recognition were investigated.  Despite a few exceptions, in general, the substitution of a hydrophilic for a hydrophobic side-chain in contact regions resulted in a decrease or even a loss of binding affinity, thus revealing the importance of interfacial hydrophobic interactions and a high degree of complementarity between RBP and TTR.  The effect was particularly evident when the mutation affected an interacting residue present in 2 distinct subunits of TTR participating simultaneously in 2 interactions with a RBP mol.  This was the case of the amyloidogenic Ser-184 replacement, which abolished the interaction with RBP and was assocd. with altered RBP plasma transport in carriers of this mutation.  Remarkably, some of the residues in mutated human TTR that weakened or abolished the interaction with RBP were present in piscine TTR, consistent with the lack of interaction between RBP and TTR in fish.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQSqcEPxrBcbVg90H21EOLACvtfcHk0lhizckM96sGnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2murrM&md5=7b69a87966f10ea134c76f2bcbd5a468</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2008.06705.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2008.06705.x%26sid%3Dliteratum%253Aachs%26aulast%3DZanotti%26aufirst%3DG.%26aulast%3DFolli%26aufirst%3DC.%26aulast%3DCendron%26aufirst%3DL.%26aulast%3DAlfieri%26aufirst%3DB.%26aulast%3DNishida%26aufirst%3DS.%2BK.%26aulast%3DGliubich%26aufirst%3DF.%26aulast%3DPasquato%26aufirst%3DN.%26aulast%3DNegro%26aufirst%3DA.%26aulast%3DBerni%26aufirst%3DR.%26atitle%3DStructural%2520and%2520mutational%2520analyses%2520of%2520protein-protein%2520interactions%2520between%2520transthyretin%2520and%2520retinol-binding%2520protein%26jtitle%3DFEBS%2520J.%26date%3D2008%26volume%3D275%26spage%3D5841%26epage%3D5854%26doi%3D10.1111%2Fj.1742-4658.2008.06705.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, R. R.</span></span> <span> </span><span class="NLM_article-title">Synthetic concanavalin A receptors and erythrocyte agglutination</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1038/272722a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2F272722a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=76989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADyaE1cXltVGksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1978&pages=722-725&author=G.+A.+Orrauthor=R.+R.+Rando&title=Synthetic+concanavalin+A+receptors+and+erythrocyte+agglutination&doi=10.1038%2F272722a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic concanavalin A receptors and erythrocyte agglutination</span></div><div class="casAuthors">Orr, George A.; Rando, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">5655</span>),
    <span class="NLM_cas:pages">722</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Introduction of α-D-mannose residues on to the cell surface of bovine erythrocytes rendered them agglutinable by concanavalin A (I) at ≥7.5 μg/mL.  The no. of I binding sites was related to the no. of mannosyl residues incorporated; binding of 6000 addnl. I mols. changing the erythrocytes from being nonagglutinable to agglutinable.  Anal. of the I-binding proteins showed 3 proteins (mol. wts. 15,000-30,000), which showed no periodic acid-Schiff (PAS) reactivity, for normal cells, and 4 PAS-staining proteins (mol. wts. 3.9 × 104, 5 × 104, 1.25 × 105, and 1.8 × 105) for modified cells.  Cell surface α-D-mannose residues seem, therefore, to be the primary specificity determinant for I.  The lectin-induced agglutination of cells may, therefore, provide a model for studying the role of sugars in cell-cell recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAn8dqJhHPY7Vg90H21EOLACvtfcHk0lhHnuGGtVU9Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXltVGksb0%253D&md5=bc53c7d093d098075192f132bae6117b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2F272722a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F272722a0%26sid%3Dliteratum%253Aachs%26aulast%3DOrr%26aufirst%3DG.%2BA.%26aulast%3DRando%26aufirst%3DR.%2BR.%26atitle%3DSynthetic%2520concanavalin%2520A%2520receptors%2520and%2520erythrocyte%2520agglutination%26jtitle%3DNature%26date%3D1978%26volume%3D272%26spage%3D722%26epage%3D725%26doi%3D10.1038%2F272722a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campos-Sandoval, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsella, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyre, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, J. B.</span></span> <span> </span><span class="NLM_article-title">Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4378</span>– <span class="NLM_lpage">4387</span>, <span class="refDoi"> DOI: 10.1021/jm200256g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200256g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1ans7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4378-4387&author=J.+A.+Campos-Sandovalauthor=C.+Redondoauthor=G.+K.+Kinsellaauthor=A.+Palauthor=G.+Jonesauthor=G.+S.+Eyreauthor=S.+C.+Hirstauthor=J.+B.+Findlay&title=Fenretinide+derivatives+act+as+disrupters+of+interactions+of+serum+retinol+binding+protein+%28sRBP%29+with+transthyretin+and+the+sRBP+receptor&doi=10.1021%2Fjm200256g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Fenretinide Derivatives Act as Disrupters of Interactions of Serum Retinol Binding Protein (sRBP) with Transthyretin and the sRBP Receptor</span></div><div class="casAuthors">Campos-Sandoval, Jose Angel; Redondo, Clara; Kinsella, Gemma K.; Pal, Akos; Jones, Geraint; Eyre, Gwen S.; Hirst, Simon C.; Findlay, John B. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4378-4387</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol.  Elevated levels of sRBP may be involved in inhibiting cellular responses to insulin and in generating first insulin resistance and then type 2 diabetes, offering a new target for therapeutic attack for these conditions.  A series of retinoid analogs were synthesized and examd. for their binding to sRBP and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions.  A no. inhibit the sRBP-TTR and sRBP-sRBP receptor interactions as well as or better than Fenretinide (FEN), presenting a potential novel dual mechanism of action and perhaps offering a new therapeutic intervention against type 2 diabetes and its development.  Shortening the chain length of the FEN deriv. substantially abolished binding to sRBP, indicating that the strength of the interaction lies in the polyene chain region.  Differences in potency against the sRBP-TTR and sRBP-sRBP receptor interactions suggest variant effects of the compds. on the two loops of sRBP guarding the entrance of the binding pocket that are responsible for these two protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8mkzc7sp58LVg90H21EOLACvtfcHk0lhHnuGGtVU9Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1ans7s%253D&md5=cd947368ca8d7bc7e5b1231174748fcc</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm200256g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200256g%26sid%3Dliteratum%253Aachs%26aulast%3DCampos-Sandoval%26aufirst%3DJ.%2BA.%26aulast%3DRedondo%26aufirst%3DC.%26aulast%3DKinsella%26aufirst%3DG.%2BK.%26aulast%3DPal%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DEyre%26aufirst%3DG.%2BS.%26aulast%3DHirst%26aufirst%3DS.%2BC.%26aulast%3DFindlay%26aufirst%3DJ.%2BB.%26atitle%3DFenretinide%2520derivatives%2520act%2520as%2520disrupters%2520of%2520interactions%2520of%2520serum%2520retinol%2520binding%2520protein%2520%2528sRBP%2529%2520with%2520transthyretin%2520and%2520the%2520sRBP%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4378%26epage%3D4387%26doi%3D10.1021%2Fjm200256g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellawell, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumpkin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jernelius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gretler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span> <span> </span><span class="NLM_article-title">First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers</span>. <i>Clin. Pharmacol. Drug Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1002/cpdd.700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fcpdd.700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=31172685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFart7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=115-129&author=J.+C.+Foxauthor=J.+L.+Hellawellauthor=S.+Raoauthor=T.+O%E2%80%99Reillyauthor=R.+Lumpkinauthor=J.+Jerneliusauthor=D.+Gretlerauthor=U.+Sinha&title=First-in-human+study+of+AG10%2C+a+novel%2C+oral%2C+specific%2C+selective%2C+and+potent+transthyretin+stabilizer+for+the+treatment+of+transthyretin+amyloidosis%3A+a+phase+1+safety%2C+tolerability%2C+pharmacokinetic%2C+and+pharmacodynamic+study+in+healthy+adult+volunteers&doi=10.1002%2Fcpdd.700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers</span></div><div class="casAuthors">Fox, Jonathan C.; Hellawell, Jennifer L.; Rao, Satish; O'Reilly, Terry; Lumpkin, Rick; Jernelius, Jesper; Gretler, Daniel; Sinha, Uma</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-129</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AG10 is a novel, potent, and selective oral transthyretin (TTR) stabilizer being developed to treat TTR amyloidosis (ATTR).  This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics (ex vivo stabilization) of orally administered AG10 in healthy adult volunteers.  Both mutant and wild-type ATTR are underdiagnosed diseases with limited therapeutic options.  As TTR amyloidogenesis is initiated by dissocn. of TTR tetramers destabilized due to inherited mutations or aging, AG10 is designed to treat the disease at its source.  Four single and three multiple ascending dose levels of AG10 or matching placebo were orally administered.  Pharmacokinetic observations included time to max. concn. <1 h, dose-dependent max. concn. and area under the plasma concn.-time curve, low intersubject variability, and half-life 25 h.  Complete (>90%) stabilization of TTR was obsd. across the entire dosing interval at steady state on the highest dose tested.  Serum TTR levels, an in vivo reflection of TTR stabilization by AG10, increased from baseline following 12 days of dosing.  AG10 appears to be safe and well tolerated in healthy adult volunteers and can completely stabilize TTR across the dosing interval, establishing clin. proof of concept.  Based on these data, AG10 has the potential to be a safe and effective treatment for patients with either mutant or wild-type ATTR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6GTVUHB1QL7Vg90H21EOLACvtfcHk0lhvA0iGLwe30Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFart7w%253D&md5=8f85dd8126c4a595859cd21fbbcec13a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.700%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DJ.%2BC.%26aulast%3DHellawell%26aufirst%3DJ.%2BL.%26aulast%3DRao%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DLumpkin%26aufirst%3DR.%26aulast%3DJernelius%26aufirst%3DJ.%26aulast%3DGretler%26aufirst%3DD.%26aulast%3DSinha%26aufirst%3DU.%26atitle%3DFirst-in-human%2520study%2520of%2520AG10%252C%2520a%2520novel%252C%2520oral%252C%2520specific%252C%2520selective%252C%2520and%2520potent%2520transthyretin%2520stabilizer%2520for%2520the%2520treatment%2520of%2520transthyretin%2520amyloidosis%253A%2520a%2520phase%25201%2520safety%252C%2520tolerability%252C%2520pharmacokinetic%252C%2520and%2520pharmacodynamic%2520study%2520in%2520healthy%2520adult%2520volunteers%26jtitle%3DClin.%2520Pharmacol.%2520Drug%2520Dev.%26date%3D2020%26volume%3D9%26spage%3D115%26epage%3D129%26doi%3D10.1002%2Fcpdd.700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Acyl glucuronides: the good, the bad and the ugly</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1002/bdd.720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1002%2Fbdd.720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=20830700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2nur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=367-395&author=S.+L.+Reganauthor=J.+L.+Maggsauthor=T.+G.+Hammondauthor=C.+Lambertauthor=D.+P.+Williamsauthor=B.+K.+Park&title=Acyl+glucuronides%3A+the+good%2C+the+bad+and+the+ugly&doi=10.1002%2Fbdd.720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Acyl glucuronides: the good, the bad and the ugly</span></div><div class="casAuthors">Regan, Sophie L.; Maggs, James L.; Hammond, Thomas G.; Lambert, Craig; Williams, Dominic P.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">367-395</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Acyl glucuronidation is the major metabolic conjugation reaction of most carboxylic acid drugs in mammals.  The physiol. consequences of this biotransformation have been investigated incompletely but include effects on drug metab., protein binding, distribution and clearance that impact upon pharmacol. and toxicol. outcomes.  In marked contrast, the exceptional but widely disparate chem. reactivity of acyl glucuronides has attracted far greater attention.  Specifically, the complex transacylation and glycation reactions with proteins have provoked much inconclusive debate over the safety of drugs metabolised to acyl glucuronides.  It has been hypothesised that these covalent modifications could initiate idiosyncratic adverse drug reactions.  However, despite a large body of in vitro data on the reactions of acyl glucuronides with protein, evidence for adduct formation from acyl glucuronides in vivo is limited and potentially ambiguous.  The causal connection of protein adduction to adverse drug reactions remains uncertain.  This review has assessed the intrinsic reactivity, metabolic stability and pharmacokinetic properties of acyl glucuronides in the context of physiol., pharmacol. and toxicol. perspectives.  Although numerous expts. have characterised the reactions of acyl glucuronides with proteins, these might be attenuated substantially in vivo by rapid clearance of the conjugates.  Consequently, to delineate a relationship between acyl glucuronide formation and toxicol. phenomena, detailed pharmacokinetic anal. of systemic exposure to the acyl glucuronide should be undertaken adjacent to detg. protein adduct concns. in vivo.  Further investigation is required to ascertain whether acyl glucuronide clearance is sufficient to prevent covalent modification of endogenous proteins and consequentially a potential immunol. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ1hIcbM_oZ7Vg90H21EOLACvtfcHk0lgHFVdBqW-EyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2nur3L&md5=8c45d4dbb68c12bd128af1dba7a08c16</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fbdd.720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.720%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DAcyl%2520glucuronides%253A%2520the%2520good%252C%2520the%2520bad%2520and%2520the%2520ugly%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2010%26volume%3D31%26spage%3D367%26epage%3D395%26doi%3D10.1002%2Fbdd.720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bäurle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ter Laak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preusse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heldmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bothe, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollner, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, G.</span></span> <span> </span><span class="NLM_article-title">Identification of a benzimidazolecarboxylic acid derivative (BAY 1316957) as a potent and selective human prostaglandin e2 receptor subtype 4 (hEP4-R) antagonist for the treatment of endometriosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2541</span>– <span class="NLM_lpage">2563</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01862</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BB3cjnvVWgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2541-2563&author=S.+B%C3%A4urleauthor=J.+Nagelauthor=O.+Petersauthor=N.+Brauerauthor=A.+Ter+Laakauthor=C.+Preusseauthor=A.+Rottmannauthor=D.+Heldmannauthor=U.+Botheauthor=T.+Blumeauthor=L.+Zornauthor=D.+Walterauthor=T.+M.+Zollnerauthor=A.+Steinmeyerauthor=G.+Langer&title=Identification+of+a+benzimidazolecarboxylic+acid+derivative+%28BAY+1316957%29+as+a+potent+and+selective+human+prostaglandin+e2+receptor+subtype+4+%28hEP4-R%29+antagonist+for+the+treatment+of+endometriosis&doi=10.1021%2Facs.jmedchem.8b01862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis</span></div><div class="casAuthors">Baurle Stefan; Nagel Jens; Peters Olaf; Brauer Nico; Ter Laak Antonius; Preusse Cornelia; Rottmann Antje; Heldmann Dieter; Bothe Ulrich; Blume Thorsten; Zorn Ludwig; Zollner Thomas M; Steinmeyer Andreas; Langer Gernot; Walter Daryl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2541-2563</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The presence and growth of endometrial tissue outside the uterine cavity in endometriosis patients are primarily driven by hormone-dependent and inflammatory processes-the latter being frequently associated with severe, acute, and chronic pelvic pain.  The EP4 subtype of prostaglandin E2 (PGE2) receptors (EP4-R) is a particularly promising anti-inflammatory and antinociceptive target as both this receptor subtype and the pathways forming PGE2 are highly expressed in endometriotic lesions.  High-throughput screening resulted in the identification of benzimidazole derivatives as novel hEP4-R antagonists.  Careful structure-activity relationship investigation guided by rational design identified a methyl substitution adjacent to the carboxylic acid as an appropriate means to accomplish favorable pharmacokinetic properties by reduction of glucuronidation.  Further optimization led to the identification of benzimidazolecarboxylic acid BAY 1316957, a highly potent, specific, and selective hEP4-R antagonist with excellent drug metabolism and pharmacokinetics properties.  Notably, treatment with BAY 1316957 can be expected to lead to prominent and rapid pain relief and significant improvement of the patient's quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAcrUIni_3jw8IxFYvehhofW6udTcc2ebI9NStrJUB3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjnvVWgsA%253D%253D&md5=faba2c63669b26b8c2e35aae465056a9</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01862%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A4urle%26aufirst%3DS.%26aulast%3DNagel%26aufirst%3DJ.%26aulast%3DPeters%26aufirst%3DO.%26aulast%3DBrauer%26aufirst%3DN.%26aulast%3DTer%2BLaak%26aufirst%3DA.%26aulast%3DPreusse%26aufirst%3DC.%26aulast%3DRottmann%26aufirst%3DA.%26aulast%3DHeldmann%26aufirst%3DD.%26aulast%3DBothe%26aufirst%3DU.%26aulast%3DBlume%26aufirst%3DT.%26aulast%3DZorn%26aufirst%3DL.%26aulast%3DWalter%26aufirst%3DD.%26aulast%3DZollner%26aufirst%3DT.%2BM.%26aulast%3DSteinmeyer%26aufirst%3DA.%26aulast%3DLanger%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520a%2520benzimidazolecarboxylic%2520acid%2520derivative%2520%2528BAY%25201316957%2529%2520as%2520a%2520potent%2520and%2520selective%2520human%2520prostaglandin%2520e2%2520receptor%2520subtype%25204%2520%2528hEP4-R%2529%2520antagonist%2520for%2520the%2520treatment%2520of%2520endometriosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2541%26epage%3D2563%26doi%3D10.1021%2Facs.jmedchem.8b01862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. M.</span></span> <span> </span><span class="NLM_article-title">PPARgamma signaling and metabolism: the good, the bad and the future</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nm.3159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2Fnm.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23652116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntF2kurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=557-566&author=M.+Ahmadianauthor=J.+M.+Suhauthor=N.+Hahauthor=C.+Liddleauthor=A.+R.+Atkinsauthor=M.+Downesauthor=R.+M.+Evans&title=PPARgamma+signaling+and+metabolism%3A+the+good%2C+the+bad+and+the+future&doi=10.1038%2Fnm.3159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">PPARγ signaling and metabolism: the good, the bad and the future</span></div><div class="casAuthors">Ahmadian, Maryam; Suh, Jae Myoung; Hah, Nasun; Liddle, Christopher; Atkins, Annette R.; Downes, Michael; Evans, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">557-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral medications for type 2 diabetes.  However, their unique benefits are shadowed by the risk for fluid retention, wt. gain, bone loss, and congestive heart failure.  This raises the question as to whether it is possible to build a safer generation of PPARγ-specific drugs that evoke fewer side effects while preserving insulin-sensitizing potential.  Recent studies that have supported the continuing physiol. and therapeutic relevance of the PPARγ pathway also provide opportunities to develop newer classes of mols. that reduce or eliminate adverse effects.  This review highlights key advances in understanding PPARγ signaling in energy homeostasis and metabolic disease and also provides new explanations for adverse events linked to TZD-based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYUvLTwYqBIbVg90H21EOLACvtfcHk0liuhr_cg_UNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntF2kurs%253D&md5=78ee5d0f4ce5dc5192cd010bb7519ce4</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnm.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3159%26sid%3Dliteratum%253Aachs%26aulast%3DAhmadian%26aufirst%3DM.%26aulast%3DSuh%26aufirst%3DJ.%2BM.%26aulast%3DHah%26aufirst%3DN.%26aulast%3DLiddle%26aufirst%3DC.%26aulast%3DAtkins%26aufirst%3DA.%2BR.%26aulast%3DDownes%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26atitle%3DPPARgamma%2520signaling%2520and%2520metabolism%253A%2520the%2520good%252C%2520the%2520bad%2520and%2520the%2520future%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D557%26epage%3D566%26doi%3D10.1038%2Fnm.3159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niemietz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischhauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandfort, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zibert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte-like cells reveal novel role of SERPINA1 in transthyretin amyloidosis</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>, <span class="NLM_elocation-id">jcs219824</span> <span class="refDoi"> DOI: 10.1242/jcs.219824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1242%2Fjcs.219824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=30333144" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&author=C.+Niemietzauthor=L.+Fleischhauerauthor=V.+Sandfortauthor=S.+Guttmannauthor=A.+Zibertauthor=H.+H.+Schmidt&title=Hepatocyte-like+cells+reveal+novel+role+of+SERPINA1+in+transthyretin+amyloidosis&doi=10.1242%2Fjcs.219824"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1242%2Fjcs.219824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.219824%26sid%3Dliteratum%253Aachs%26aulast%3DNiemietz%26aufirst%3DC.%26aulast%3DFleischhauer%26aufirst%3DL.%26aulast%3DSandfort%26aufirst%3DV.%26aulast%3DGuttmann%26aufirst%3DS.%26aulast%3DZibert%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26atitle%3DHepatocyte-like%2520cells%2520reveal%2520novel%2520role%2520of%2520SERPINA1%2520in%2520transthyretin%2520amyloidosis%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2018%26volume%3D131%26doi%3D10.1242%2Fjcs.219824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klabunde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrassi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J. C.</span></span> <span> </span><span class="NLM_article-title">Rational design of potent human transthyretin amyloid disease inhibitors</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1038/74082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1038%2F74082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10742177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVSnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=312-321&author=T.+Klabundeauthor=H.+M.+Petrassiauthor=V.+B.+Ozaauthor=P.+Ramanauthor=J.+W.+Kellyauthor=J.+C.+Sacchettini&title=Rational+design+of+potent+human+transthyretin+amyloid+disease+inhibitors&doi=10.1038%2F74082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of potent human transthyretin amyloid disease inhibitors</span></div><div class="casAuthors">Klabunde, Thomas; Petrassi, H. Michael; Oza, Vibha B.; Raman, Prakash; Kelly, Jeffery W.; Sacchettini, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-321</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">The human amyloid disorders, familial amyloid polyneuropathy, familial amyloid cardiomyopathy and senile systemic amyloidosis, are caused by insol. transthyretin (TTR) fibrils, which deposit in the peripheral nerves and heart tissue.  Several nonsteroidal anti-inflammatory drugs and structurally similar compds. have been found to strongly inhibit the formation of TTR amyloid fibrils in vitro.  These include flufenamic acid, diclofenac, flurbiprofen, and resveratrol.  Crystal structures of the protein-drug complexes have been detd. to allow detailed analyses of the protein-drug interactions that stabilize the native tetrameric conformation of TTR and inhibit the formation of amyloidogenic TTR.  Using a structure-based drug design approach ortho-trifluormethylphenyl anthranilic acid and N-(meta-trifluoromethylphenyl)phenoxazine 4,6-dicarboxylic acid have been discovered to be very potent and specific TTR fibril formation inhibitors.  This research provides a rational for a chemotherapeutic approach for the treatment of TTR-assocd. amyloid diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN6c7K6-iktbVg90H21EOLACvtfcHk0liuhr_cg_UNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVSnsbo%253D&md5=035be72ca2cf3b266f8933be3fa60bfc</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2F74082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F74082%26sid%3Dliteratum%253Aachs%26aulast%3DKlabunde%26aufirst%3DT.%26aulast%3DPetrassi%26aufirst%3DH.%2BM.%26aulast%3DOza%26aufirst%3DV.%2BB.%26aulast%3DRaman%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26aulast%3DSacchettini%26aufirst%3DJ.%2BC.%26atitle%3DRational%2520design%2520of%2520potent%2520human%2520transthyretin%2520amyloid%2520disease%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2000%26volume%3D7%26spage%3D312%26epage%3D321%26doi%3D10.1038%2F74082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekijima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarstrom, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawkar, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. W.</span></span> <span> </span><span class="NLM_article-title">The biological and chemical basis for tissue-selective amyloid disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2005.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1016%2Fj.cell.2005.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=15820680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVaks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2005&pages=73-85&author=Y.+Sekijimaauthor=R.+L.+Wisemanauthor=J.+Mattesonauthor=P.+Hammarstromauthor=S.+R.+Millerauthor=A.+R.+Sawkarauthor=W.+E.+Balchauthor=J.+W.+Kelly&title=The+biological+and+chemical+basis+for+tissue-selective+amyloid+disease&doi=10.1016%2Fj.cell.2005.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The biological and chemical basis for tissue-selective amyloid disease</span></div><div class="casAuthors">Sekijima, Yoshiki; Wiseman, R. Luke; Matteson, Jeanne; Hammarstroem, Per; Miller, Sean R.; Sawkar, Anu R.; Balch, William E.; Kelly, Jeffery W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-85</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Factors controlling the onset and progression of extracellular amyloid diseases remain largely unknown.  Central to disease etiol. is the efficiency of the endoplasmic reticulum (ER) machinery that targets destabilized mutant proteins for degrdn. and the enhanced tendency of these variants to aggregate if secreted.  The authors demonstrate that mammalian cells secrete numerous transthyretin (TTR) disease-assocd. variants with wild-type efficiency in spite of compromised folding energetics.  Only the most highly destabilized TTR variants are subjected to ER-assocd. degrdn. (ERAD) and then only in certain tissues, providing insight into tissue selective amyloidosis.  Rather than a "quality control" std. based on wild-type stability, the authors find that ER-assisted folding (ERAF), based on global protein energetics, dets. the extent of export.  The authors propose that ERAF (influenced by the energetics of the protein fold, chaperone enzyme distributions, and metabolite chaperones) in competition with ERAD defines the unique secretory aptitude of each tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqZgFnMMerqbVg90H21EOLACvtfcHk0liuhr_cg_UNeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVaks7c%253D&md5=1ac8641177cb140b95b898ff108fc543</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DSekijima%26aufirst%3DY.%26aulast%3DWiseman%26aufirst%3DR.%2BL.%26aulast%3DMatteson%26aufirst%3DJ.%26aulast%3DHammarstrom%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DS.%2BR.%26aulast%3DSawkar%26aufirst%3DA.%2BR.%26aulast%3DBalch%26aufirst%3DW.%2BE.%26aulast%3DKelly%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520biological%2520and%2520chemical%2520basis%2520for%2520tissue-selective%2520amyloid%2520disease%26jtitle%3DCell%26date%3D2005%26volume%3D121%26spage%3D73%26epage%3D85%26doi%3D10.1016%2Fj.cell.2005.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radu, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nusinowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bok, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata, N. L.</span></span> <span> </span><span class="NLM_article-title">Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4393</span>– <span class="NLM_lpage">4401</span>, <span class="refDoi"> DOI: 10.1167/iovs.05-0820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1167%2Fiovs.05-0820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=16303925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnit1GgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=4393-4401&author=R.+A.+Raduauthor=Y.+Hanauthor=T.+V.+Buiauthor=S.+Nusinowitzauthor=D.+Bokauthor=J.+Lichterauthor=K.+Widderauthor=G.+H.+Travisauthor=N.+L.+Mata&title=Reductions+in+serum+vitamin+A+arrest+accumulation+of+toxic+retinal+fluorophores%3A+a+potential+therapy+for+treatment+of+lipofuscin-based+retinal+diseases&doi=10.1167%2Fiovs.05-0820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases</span></div><div class="casAuthors">Radu Roxana A; Han Yun; Bui Tam V; Nusinowitz Steven; Bok Dean; Lichter Jay; Widder Ken; Travis Gabriel H; Mata Nathan L</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4393-401</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  Excessive accumulation of lipofuscin is observed in numerous degenerative retinal diseases.  A toxic vitamin A-based fluorophore (A2E) present within lipofuscin has been implicated in the death of RPE and photoreceptor cells.  Here, we used an animal model that manifests accelerated lipofuscin accumulation (ABCA4-/- mutant) to evaluate the efficacy of a therapeutic approach based on reduction of serum retinol.  METHODS:  N-(4-hydroxyphenyl)retinamide (HPR) potently and reversibly reduces serum retinol.  The interaction of HPR with retinol binding protein (RBP) and transthyretin was studied by spectrofluorometry and size-exclusion chromatography.  To assess the effects of HPR on visual cycle retinoids and A2E biosynthesis, HPR was chronically administered to ABCA4-/- mice.  Mice were evaluated using biochemical, electrophysiological, and morphologic techniques.  RESULTS:  Administration of HPR to ABCA4-/- mice caused immediate, dose-dependent reductions in serum retinol and RBP.  Chronic administration produced commensurate reductions in visual cycle retinoids and arrested accumulation of A2E and lipofuscin autofluorescence in the RPE.  Physiologically, HPR treatment caused modest delays in dark adaptation.  Chromophore regeneration kinetics, light sensitivity of photoreceptors, and phototransduction processes were normal.  Histologic examinations showed no alteration of retinal cytostructure or morphology.  CONCLUSIONS:  These findings demonstrate the vitamin A-dependent nature of A2E biosynthesis and validate a novel therapeutic approach with potential to halt the accumulation of lipofuscin fluorophores in the eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcST_ie98itsIvcsfMJQC1ZdfW6udTcc2eZ9EcCEv2mXKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnit1GgtQ%253D%253D&md5=dc425883e9829eab910c9cf96a9d5fe6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1167%2Fiovs.05-0820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.05-0820%26sid%3Dliteratum%253Aachs%26aulast%3DRadu%26aufirst%3DR.%2BA.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DBui%26aufirst%3DT.%2BV.%26aulast%3DNusinowitz%26aufirst%3DS.%26aulast%3DBok%26aufirst%3DD.%26aulast%3DLichter%26aufirst%3DJ.%26aulast%3DWidder%26aufirst%3DK.%26aulast%3DTravis%26aufirst%3DG.%2BH.%26aulast%3DMata%26aufirst%3DN.%2BL.%26atitle%3DReductions%2520in%2520serum%2520vitamin%2520A%2520arrest%2520accumulation%2520of%2520toxic%2520retinal%2520fluorophores%253A%2520a%2520potential%2520therapy%2520for%2520treatment%2520of%2520lipofuscin-based%2520retinal%2520diseases%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2005%26volume%3D46%26spage%3D4393%26epage%3D4401%26doi%3D10.1167%2Fiovs.05-0820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dobri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moiseyev, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allikmets, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparrow, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrukhin, K.</span></span> <span> </span><span class="NLM_article-title">A1120, a Nonretinoid RBP4 Antagonist, Inhibits Formation of Cytotoxic Bisretinoids in the Animal Model of Enhanced Retinal Lipofuscinogenesis</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1167/iovs.12-10050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1167%2Fiovs.12-10050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=23211825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjt1eqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=85-95&author=N.+Dobriauthor=Q.+Qinauthor=J.+Kongauthor=K.+Yamamotoauthor=Z.+Liuauthor=G.+Moiseyevauthor=J.-X.+Maauthor=R.+Allikmetsauthor=J.+R.+Sparrowauthor=K.+Petrukhin&title=A1120%2C+a+Nonretinoid+RBP4+Antagonist%2C+Inhibits+Formation+of+Cytotoxic+Bisretinoids+in+the+Animal+Model+of+Enhanced+Retinal+Lipofuscinogenesis&doi=10.1167%2Fiovs.12-10050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis</span></div><div class="casAuthors">Dobri, Nicoleta; Qin, Qiong; Kong, Jian; Yamamoto, Kazunori; Liu, Zhao; Moiseyev, Gennadiy; Ma, Jian-xing; Allikmets, Rando; Sparrow, Janet R.; Petrukhin, Konstantin</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-95</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">PURPOSE. Excessive accumulation of lipofuscin is assocd. with pathogenesis of atrophic age-related macular degeneration (AMD) and Stargardt disease.  Pharmacol. inhibition of the retinol-induced interaction of retinol-binding protein 4 (RBP4) with transthyretin (TTR) in the serum may decrease the uptake of serum retinol to the retina and reduce formation of lipofuscin bisretinoids.  We evaluated in vitro and in vivo properties of the new nonretinoid RBP4 antagonist, A1120.  METHODS. RBP4 binding potency, ability to antagonize RBP4-TTR interaction, and compd. specificity were analyzed for A1120 and for the prototypic RBP4 antagonist fenretinide.  A1120 ability to inhibit RPE65-mediated isomerohydrolase activity was assessed in the RPE microsomes.  The in vivo effect of A1120 administration on serum RBP4, visual cycle retinoids, lipofuscin bisretinoids, and retinal visual function was evaluated using a combination of biochem. and electrophysiol. techniques.  RESULTS. In comparison to fenretinide, A1120 did not act as a RARα agonist, while exhibiting superior in vitro potency in RBP4 binding and RBP4-TTR interaction assays.  A1120 did not inhibit isomerohydrolase activity in the RPE microsomes.  A1120 dosing in mice induced 75% redn. in serum RBP4, which correlated with redn. in visual cycle retinoids and ocular levels of lipofuscin fluorophores.  A1120 dosing did not induce changes in kinetics of dark adaptation.  CONCLUSIONS. A1120 significantly reduces accumulation of lipofuscin bisretinoids in the Abca4-/- animal model.  This activity correlates with redn. in serum RBP4 and visual cycle retinoids confirming the mechanism of action for A1120.  In contrast to fenretinide, A1120 does not act as a RARα agonist indicating a more favorable safety profile for this nonretinoid compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCuxjzXex7aLVg90H21EOLACvtfcHk0lgVABqX5yNmKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjt1eqs70%253D&md5=3a605e4dc084a06e325ccdd14ec48886</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1167%2Fiovs.12-10050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.12-10050%26sid%3Dliteratum%253Aachs%26aulast%3DDobri%26aufirst%3DN.%26aulast%3DQin%26aufirst%3DQ.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMoiseyev%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DJ.-X.%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DSparrow%26aufirst%3DJ.%2BR.%26aulast%3DPetrukhin%26aufirst%3DK.%26atitle%3DA1120%252C%2520a%2520Nonretinoid%2520RBP4%2520Antagonist%252C%2520Inhibits%2520Formation%2520of%2520Cytotoxic%2520Bisretinoids%2520in%2520the%2520Animal%2520Model%2520of%2520Enhanced%2520Retinal%2520Lipofuscinogenesis%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2013%26volume%3D54%26spage%3D85%26epage%3D95%26doi%3D10.1167%2Fiovs.12-10050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haselhorst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamerz, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itzstein, M. V.</span></span> <span> </span><span class="NLM_article-title">Saturation transfer difference NMR spectroscopy as a technique to investigate protein-carbohydrate interactions in solution</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1007/978-1-59745-022-5_26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=10.1007%2F978-1-59745-022-5_26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=19277538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFeku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2009&pages=375-386&author=T.+Haselhorstauthor=A.-C.+Lamerzauthor=M.+V.+Itzstein&title=Saturation+transfer+difference+NMR+spectroscopy+as+a+technique+to+investigate+protein-carbohydrate+interactions+in+solution&doi=10.1007%2F978-1-59745-022-5_26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Saturation transfer difference NMR spectroscopy as a technique to investigate protein-carbohydrate interactions in solution</span></div><div class="casAuthors">Haselhorst, Thomas; Lamerz, Anne-Christin; von Itzstein, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">Glycomics</span>),
    <span class="NLM_cas:pages">375-386</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Satn. transfer difference (STD) NMR spectroscopy is a powerful method for studying protein-ligand interactions in soln.  The STD NMR method is capable of identifying the binding epitope of a ligand when bound to its receptor protein.  Ligand protons that are in close contact with the receptor protein receive a higher degree of satn., and as a result stronger STD NMR signals can be obsd.  Protons that are either less or not involved in the binding process reveal no STD NMR signals.  Therefore, the STD NMR method is an excellent tool to investigate how a binding ligand interacts with its receptor mol.  The STD NMR expt. is easy to implement and only small amts. of native protein are required.  This chapter comprises a detailed exptl. protocol to acquire STD NMR spectra and det. the binding epitope of a ligand bound to its target protein.  As representative examples the ligands uridyl-triphosphate (UTP) and uridyl-glucose-diphosphate (UDP-glucose) when bound to the Leishmania major UDP-glucose-pyrophosphorylase (UGP) as target protein are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe28Wu8TS8hLVg90H21EOLACvtfcHk0lgVABqX5yNmKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFeku7w%253D&md5=b14d0ffc34b0ef00fe98d78c99e6032d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2F978-1-59745-022-5_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-59745-022-5_26%26sid%3Dliteratum%253Aachs%26aulast%3DHaselhorst%26aufirst%3DT.%26aulast%3DLamerz%26aufirst%3DA.-C.%26aulast%3DItzstein%26aufirst%3DM.%2BV.%26atitle%3DSaturation%2520transfer%2520difference%2520NMR%2520spectroscopy%2520as%2520a%2520technique%2520to%2520investigate%2520protein-carbohydrate%2520interactions%2520in%2520solution%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2009%26volume%3D534%26spage%3D375%26epage%3D386%26doi%3D10.1007%2F978-1-59745-022-5_26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1QAB','PDB','1QAB'); return false;">PDB: 1QAB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BSZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BSZ','PDB','3BSZ'); return false;">PDB: 3BSZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ROX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ROX','PDB','2ROX'); return false;">PDB: 2ROX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RBP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RBP','PDB','1RBP'); return false;">PDB: 1RBP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4HIQ','PDB','4HIQ'); return false;">PDB: 4HIQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i116"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00099">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_78061"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00099?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00099</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">TTR in vitro assay information, RBP4 <i>in vitro</i> assay information, mouse PK information, serum RBP4 measurement information, <i>in vitro</i> ADME assay information, general chemistry information, and spectroscopic and analytical data for compounds <b>14</b> (<sup>1</sup>H NMR, <sup>13</sup>C NMR, <sup>19</sup>F NMR, MS, HRMS, and HPLC), <b>20c</b>, and <b>20e</b> (<sup>1</sup>H NMR, MS, and HPLC) and all of the remaining biologically tested compounds (HPLC), and molecular formula strings for biologically tested compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00099/suppl_file/jm1c00099_si_004.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00099/suppl_file/jm1c00099_si_004.pdf">jm1c00099_si_004.pdf (2.93 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00099&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-13%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00099%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00099" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c73c52a9cc3cee","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
